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Abstract 
Currently, most preventive vaccine strategies against the human immunodeficiency virus-1 
(HIV-1) focus on the induction of broadly neutralizing antibodies (bNAbs) targeting the viral 
envelope glycoprotein (Env). However, all attempts to elicit bNAbs by vaccination remained 
unsuccessful so far. The development of stabilized Env trimers is considered as first success 
on the road towards broader neutralizing antibody responses. Characterized by a favorable 
antigenicity profile, meaning the efficient presentation of bNAb epitopes and occlusion of 
non-neutralizing epitopes, these trimers for the first time elicited autologous tier 2 
neutralization in animal models. Novel approaches, including particle-based Env delivery and 
development of improved Env immunogens are considered important steps to broaden 
humoral immune responses. This thesis investigated methods for the characterization and 
development of improved Env immunogens. The first project of this thesis investigated the 
potential of the biophysical in-solution method MicroScale Thermophoresis (MST) for the 
analysis of soluble and particle-presented Env proteins under artificial (buffer) and 
physiological conditions (serum). Using two model systems, 1) a five-member Env/V3 
chimeric library with distinct binding capacities towards the monoclonal antibody 447-52D, 
and 2) stabilized BG505 SOSIP.664 trimers and a panel of quaternary structure-characterizing 
antibodies, it has been demonstrated that MST is useful tool for the analysis of soluble and 
particle-presented Env immunogens under artificial and near-physiological conditions (50 % 
serum). Thereby, results were in general agreement with data obtained from enzyme-linked 
immunosorbent assay (ELISA), validating MST as a fast, low-sample consuming method for 
the analysis of Env immunogens. The second project focused on the development of a 
mammalian cell display approach for mapping of bNAb epitopes, providing valuable 
information for rational vaccine design. For this purpose, a BG505 SOSIP gp160 based 
alanine substitution library was developed and applied to proof-of-principle screenings with 
well-characterized bNAbs. Here, the library demonstrated its capacity for epitope mapping. 
However, further improvements are necessary to turn the library into a powerful mapping 
tool. The third project aimed to investigate the influence of single glycan deletions on binding 
of bNAbs. For this purpose, a cellular BG505 SOSIP gp145 glycan-knockout library was 
generated and applied to fluorescence-activated cell sorting (FACS). An initial screening with 
the glycan-dependent bNAb PGT135 resulted in a 35-fold enrichment of the Env variant 
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N332A in the applied low-affinity gate. This demonstrates that the library could be a useful to 
tool to identify glycans that contribute to binding of bNAbs. 
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Zusammenfassung 
Aktuell zielen die meisten präventiven Impfstrategien gegen das humane Immundefizienz-
Virus 1 (HIV-1) darauf ab breit-neutralisierende Antikörper (bNAbs) gegen das virale 
Hüllprotein (Env) zu induzieren. Trotz aller Anstrengungen die diesbezüglich unternommen 
wurden, blieb die Entwicklung eines Schutz-vermittelnden Vakzins bisher erfolglos. Die 
Entwicklung von stabilisierten Env Trimeren, welche sich durch ein vorteilhaftes 
Immunogenitätsprofil auszeichnen – effektive Präsentation von bNAb Epitopen bei 
gleichzeitiger Vermeidung der Exposition von nicht-neutralisierenden Antikörper Epitopen – 
wird als erster Erfolg auf dem Weg zu einem schützenden Vakzin angesehen. In Tierstudien, 
in denen stabilisierte Env Trimere als Immunogene verabreicht wurden, konnte erstmals eine 
Neutralisation von autologen tier 2 Viren erreicht werden. Basierend auf diesen Erkenntnissen 
sollen neue innovative Ansätze, wie beispielsweise eine Partikel-vermittelte Env Präsentation 
und die Entwicklung von neuartigen Env Immunogenen, dazu beitragen eine breitere 
humorale Immunantwort zu induzieren. Die Ziele dieser Arbeit waren, zu untersuchen 
welchen Beitrag biophysikalische und Zytometer-basierte Methoden zur Charakterisierung 
und Entwicklung von verbesserten Env Immunogenen leisten können. Im ersten Teil der 
Arbeit sollte untersucht werden, ob sich die biophysikalische Messmethode Microscale 
Thermophoresis (MST) für die Charakterisierung von Antikörper-Env Interaktionen eignet. 
Hierbei sollte insbesondere überprüft werden, ob die MST zur Analyse von Partikel-
präsentierten Env Proteinen herangezogen werden kann. Zudem sollte die Anwendbarkeit der 
MST unter physiologischen Bedingungen (Serum) getestet werden. Hierzu wurden zwei 
Modellsysteme verwendet: 1) Eine Modell-Bibliothek bestehend aus fünf chimären Env 
Proteinen (Env/V3) mit definiertem Bindungsprofil zum monoklonalen Antikörper 447-52D 
und 2) stabilisierte BG505 SOSIP.664 Trimere und ein Set von Quartärstruktur-
charakterisierenden Antikörpern. Die Ergebnisse zeigten, dass die MST in der Lage ist 
Interaktionen zwischen löslichen und Partikel-präsentierten Env Proteinen und Antikörpern zu 
analysieren. Dies gilt sowohl für Messungen unter artifiziellen Bedingungen (Puffer) als auch 
für Messungen unter nahezu physiologischen Bedingungen (50 % Serum). Die Ergebnisse aus 
den MST Analysen stimmten dabei im Großen und Ganzen mit Ergebnissen aus enzyme-
linked immunosorbent assay (ELISA) Experimenten überein, wodurch die MST als schnelle 
und zugleich sparsame Methode zur Analyse von Env Immunogenen validiert werden konnte. 
Der zweite Teil der Arbeit konzentrierte sich auf die Entwicklung eines auf Säugetierzellen 
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basierenden Display Verfahrens zu Kartierung von bNAb Epitopen. Zu diesem Zweck wurde 
eine auf dem BG505 SOSIP gp160 Env basierende Alanin-Substitutionsbibliothek entwickelt, 
welche mit einem Set von bekannten bNAbs charakterisiert wurde. Hierbei zeigte sich 
sowohl, dass die Bibliothek prinzipiell für Kartierungsexperimente herangezogen werden 
kann, als auch, dass noch einige Verbesserungen nötig sind, um aus der Bibliothek in ein 
robustes und präzises Instrument zur Antikörperkartierung zu generieren. Der dritte Teil der 
Arbeit zielte darauf ab, den Einfluss einzelner Glykan-Deletionen auf die Bindung von bNAbs 
zu untersuchen. Zu diesem Zweck wurde eine zelluläre BG505 SOSIP gp145-Glykan-
Knockout-Bibliothek generiert. Diese wurde mittels fluoreszenz-aktivierter Zellsortierung 
(FACS) auf ihre Bindung zum glykan-abhängigen bNAb PGT135 hin untersucht. Hierbei 
konnte eine 35-fache Anreicherung der Env Variante N332A im gate mit niedriger Affinität 
zum PGT135 Antikörper beobachtet werden. Dieses Ergebnis zeigt, dass die Bibliothek 
zukünftig dazu verwendet werden könnte, Glykane zu identifieren die einen Beitrag zur 
Bindung von bNAbs leisten. 
 _________________________________________________________________ Introduction 
14 
 
1. Introduction 
1.1 The HIV-1 pandemic 
Since its identification in the 1980`s HIV-1, a retrovirus in the genus Lentiviridae and 
causative agent of the acquired immunodeficiency syndrome (AIDS), spread all over the 
world and became one of the most devastating infectious diseases in recent history1,2. The 
HIV-1 infection is characterized by a progressive depletion of T lymphocytes, carrying the 
cluster of differentiation 4 (CD4) receptor. The loss of CD4+ T lymphocytes, impairing the 
cellular immune response, is in close association with an increased susceptibility of infected 
individuals to opportunistic infections, defining AIDS3.  
The origins of the pandemic are located in west central Africa, were HIV-1 emerged from 
four cross-species transmission events of simian immunodeficiency viruses (SIVs) to humans, 
most likely by exposure to infected ape body fluids. The four independent transmission events 
resulted in four HIV-1 linages, termed groups M (major), N (non-M/non-O), O (outlier) and P 
(pending). Phylogenetic tree analysis showed, that group M and N are closely related with 
SIVcpzPtt strains, indicating that they are of chimpanzee origin. Origins of groups P and O 
are not fully understood, but phylogenetic data support a gorilla origin of both, group P and 
O1,4. Out of the four groups described above, M is responsible for the HIV-1 pandemic. 
Phylogenetic and statistical analyses indicate that group M emerged in the beginning of the 
twentieth century, most likely in the area around Kinshasa and it is assumed that early 
diversification of group M also took place in this area, from which the infection spread 
globally. Currently, group M lineages are classified by nine subtypes (A–D, F–H, J, K), 
nowadays predominating in different geographic areas, resulting from a number of founder 
events1, see Figure 1. Furthermore, there exists a growing number of currently about 100 
circulating recombinant forms (CRFs), resulting from multiple infections with different 
subtypes in the same population5,1. Within group M, subtype C accounts for almost 50% of 
the infections, and thus represents the dominant subtype in the actual HIV-1 pandemic, 
followed by subtypes A (12 %) and B (11 %), CRF02_AG (8 %), CRF01_AE (5 %), subtypes 
G (5 %) and D (2 %)6, as shown in Figure 1. 
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Figure 1. Geographic distribution of HIV-1 subtypes and recombinants. Pei charts illustrate the regional percentage 
distribution of HIV-1 subtypes, circulating recombinant forms (CRFs) and unique recombinant forms (URFs), represented by 
different colors. The distribution was calculated according to data collected from 2004-2007. Figure adapted from Hemelaar, 
J. The origin and diversity of the HIV-1 pandemic. Trends Mol. Med. 18, 182–92 (2012)7, with permission from Elsevier, 
license number 4536020267052. 
 
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) 77.3 million 
[59.9–100 million] people have become infected with HIV-1 since the start of the epidemic 
from who 35.4 million [25.0–49.9 million] died due to AIDS-related illness. In 2017, there 
were 36.9 million [31.1 million–43.9 million] people living with HIV, with sub-Saharan 
Africa accounting for about 70 % of the global burden of infection. With major efforts, the 
number of new infections has been steadily reduced from 3.4 million [2.6–4.4 million] in 
1996 (peak of new infections) to 1.8 million [1.4–2.4 million] in 2017, meaning a reduction of 
47 %. Furthermore, AIDS-related deaths have been reduced by more than 51 % since the peak 
in 20048, see Figure 2. 
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Figure 2. Number of new HIV infections and deaths among the HIV population. Global data from 1990-2017, adapted 
from UNAIDS9. 
 
Ambitious prevention programs, significant progress in the development of antiretroviral 
drugs and modern treatment strategies went hand in hand and contributed to this success. 
However, the story of success in anti-retroviral therapy included three important therapeutic 
revolutions. The first revolution was the introduction of new classes of antiretroviral drugs in 
1995/1996, including protease inhibitors and non-nucleoside reverse-transcriptase inhibitors. 
These newly introduced anti-retroviral drugs in combination with nucleoside-analog reverse-
transcriptase inhibitors, which until then were the only treatment option available, greatly 
improved the prognosis of an otherwise lethal disease. The combined antiretroviral therapy is 
nowadays referred to as cART and in 2018 there were about 40 antiretroviral drugs available, 
including 7 drug classes, which were approved by the US Food and Drug Administration 
(FDA)10,11,12. The second revolution was marked by the realization that HIV-1 treatment 
contributes to prevention, since studies showed that treatment in serodiscordant couples (one 
HIV seronegative and one HIV seropositive partner) reduced the risk of sexual transmission 
by 96 %. The third revolution arised when first studies showed that early cART treatment, 
also if the number CD4+ cells is more than 500 cells per cubic millimeter, is associated with a 
significant clinical benefit in terms of a 57 % reduced risk in AIDS and non-AIDS morbidity 
and mortality13,14,11. The findings of these studies had a lasting impact on treatment 
guidelines. For example, while in the 2013 World Health Organisation (WHO) guidelines a 
CD4+ cell count of less than or equal to 500 cells per cubic millimeter was one of the criteria 
for starting therapy, recommendations changed in the 2016 WHO guidelines where therapy 
for all infected individuals is recommended, regardless of the CD4+ cell count. This is known 
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as the test and treat strategy15,16,11. Further, in 2014 UNAIDS launched the 90-90-90 targets 
meaning that by 2020 90 % of all people living with HIV know their HIV status, 90 % of 
people with diagnosed HIV infection will receive sustained cART, and 90% of those on 
cART will be virally suppressed. These targets were extended to 95-95-95 by 2030. Modeling 
analyses suggest that achieving these ambitious goals by 2020, enables ending of the 
epidemic in 203017,18. However, another study predicts that if current diagnosis, treatment and 
suppression levels are maintained (53-75-77, when the study was published in 2017) a global 
median of 49 million new infections will occur between 2015 and 2035. The same study 
predicts that from the 49 million infections 22 million can be averted by reaching 90-90-90 
and a further 3.3 million by reaching 95-95-95 targets. Furthermore, the study predicted that a 
50 % efficacy vaccine alone, rolled out in 2020 with an annual scale-up of 25 % coverage to a 
maximum coverage of 70 %, and under current diagnosis and treatment levels, would avert 17 
million new infections19, see Figure 3. This highlights that even a moderate efficacy vaccine 
could significantly contribute to the end the HIV-1 pandemic. 
 
 
 
Figure 3. Calculated averted infections between 2015 
and 2030 compared with maintaining status quo 
diagnosis, treatment and viral suppression levels. 
Averted infections by reaching UNAIDS 95-95-95 targets 
(95 % of infected people know their HIV status, 95 % with 
diagnosed infection receive cART, 95% of people receiving 
cART are virally suppressed) (Top), rollout of a vaccine in 
2020 (Middle) and 95-95-95 targets combined with vaccine 
enrollment in 2020 (Bottom). Data are based on diagnosis, 
treatment and viral suppression levels of 53-75-77. Figure 
from Medlock, J. et al. Effectiveness of UNAIDS targets 
and HIV vaccination across 127 countries. Proc. Natl. 
Acad. Sci. U. S. A. 114, 4017–4022 (2017)19. 
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In summary, major efforts in prevention programs and significant progress in anti-retroviral 
therapy contributed reduce the number of new infections and AIDS-related death. This is also 
reflected by the current UNAIDS global data, since in 2017 75 % of people living with HIV 
know their status, 79 % of people living with HIV who know their status are accessing 
antiretroviral therapy and 81 % of people accessing treatment had suppressed viral loads8. 
However, a strategy with focus on anti-retroviral therapy has some drawbacks since it 
requires daily medication, a high level of compliance and medical monitoring, still 
representing major challenges in low-income countries. As described above, a prophylactic 
vaccine could significantly contribute to prevent further infections with a still not curable 
disease and therefore the development of such a vaccine is of utmost importance. 
1.2 HIV-1 vaccine clinical trials 
Soon after the discovery of HIV it was expected that an effective vaccine would be rapidly 
developed but so far only six HIV-1 vaccine candidates have been tested in clinical efficacy 
trials, with no liscenced vaccine yet, see Figure 4. However the story of vaccine paradigms 
and clinical trials can be separated in three overlapping “waves“20,21. 
The first wave of HIV vaccines was based on the concept that neutralizing antibody responses 
would be sufficient to protect from infection. Since the viral envelope glycoprotein is the 
mediator of host cell infection and therefore a main target of a neutralizing antibody response, 
vaccine development in late 1980s to mid-1990s focused on recombinant Env immunogens. 
These first recombinant Env immunogens were primarily produced as glycoprotein (gp) 120 
proteins, representing soluble monomeric subunits of the Env protein, that is naturally present 
as trimer of heterodimers on the surface HIV virions, see 1.3.120,22. From 1998 to 2003, two 
phase 3 efficacy trials with recombinant bivalent gp120 vaccines were carried out. However, 
these studies known as VAX004 (gp120 subtype B/B) and VAX003 (gp120 subtype B/E) 
failed to show efficacy, see Figure 4. Although both vaccines induced high titers of 
neutralizing antibodies (NAbs), these were of limited specificity and therefore could not 
prevent HIV infection20,21,23,24.  
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Figure 4. HIV vaccine clinical trials conducted until today. Abbreviations: recombinant (r), men who have sex with men 
(MSM), broadly neutralizing antibodies (bNAbs), prime-boost regimen (*), antibodies (Ab). Freely reproduced from Trovato, 
M. et al. HIV Vaccination: A Roadmap among Advancements and Concerns. Int. J. Mol. Sci. 19, 1241 (2018)21. 
 
The second wave of HIV vaccines started in the early 2000s when the failure of recombinant 
Env vaccines and new findings, supporting the importance of CD8+ T-cells in controlling 
viral replication, focused the field towards cytotoxic T-lymphocytes (CTLs)20. Two phase 2b 
vaccine efficacy trials were conducted to explore if cell-mediated immune responses can 
confer protection from infection or reduce plasma viral load after infection. In both, the Step 
study (HIV Vaccine Trials Network (HVTN) 502, started in 2004) and the Phambili trial 
(HVTN503, started in January 2007), see Figure 4, vaccinees were immunized with the 
MRKAd5 HIV-1 vaccine. This vaccine, consisting of a mixture of replication-defective 
recombinant adenovirus type 5 (Ad5) vectors expressing HIV-1 group-specific antigen (gag), 
polymerase (pol) and negative regulatory factor (nef) subtype B genes, induced cell-mediated 
immune responses in a phase I clinical trial25,26,27. However, after the first interim analysis of 
the Step study in September 2007 both studies were stopped, since, despite of eliciting 
interferon (IFN)-γ enzyme-linked immuno spot assay (ELISPOT) responses in 75 % of the 
vaccinees, the vaccine did no prevent HIV infection. Instead, analysis of available data 
revealed an increased risk of infection for male vaccinees who were uncircumsized or Ad5 
seropositive pre-vaccination21,28,29,30. 
The third wave began with vaccine efficacy trials that attempted to stimulate both arms of the 
immune response to ideally induce both, protective antibody and protective cell-mediated 
immune responses. Until today, two of those studies were conducted and evaluated. From 
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2009 to 2013 the HVTN enrolled a phase 2b efficacy trial called HVTN505, see Figure 4. To 
adress the viral diversity, the vaccine regimen was based on a heterologous prime/boost 
approach including immunogens from multiple HIV-1 subtypes. The vaccine regimen 
consisted of a DNA prime (six DNA plasmids expressing HIV-1 clade B Gag, Pol, and Nef 
and Env proteins from clades A, B, and C) and a rAd5 boost (four rAd5 vectors  expressing a 
HIV-1 clade B Gag-Pol fusion protein and Env proteins from clades A, B, and C). However, 
despite of inducing both, cellular and humoral immune responses, the vaccine regimen did not 
show efficacy in preventing HIV infection21,31,32. The RV144 phase 3 clinical trial, conducted 
in Thailand between 2003 and 2005 and enrolling a total of 16,402 volunteers, was the only 
clinical trial that demonstrated an, albeit modest, efficacy in preventing HIV infection, see 
Figure 4. The study tested a heterologous prime/boost regimen consisting of two vaccines, 
matching the in Thailand predominantly circulating HIV-1 subtypes B and CRF01_AE: 1) 
ALVAC-HIV (vCP1521), a canarypox vector expressing HIV-1 CRF01_AE gp120 Env 
(linked to the transmembrane-anchoring portion of subtype B gp41) and HIV-1 subtype B 
Gag and protease was used for priming; and 2) AIDSVAX B/E (same vaccine as in the 
VAX003 study) formulated with alum adjuvant was used for boosting. Prior to RV144 study, 
this prime/boost regimen was tested in a phase 2 trial were it induced both, cellular and 
humoral immune responses and was therefore qualified for advanced testing in the RV144 
trial33,34. The results of the RV144 trial, published in 2009, demonstrated 31.2 % vaccine 
efficacy in preventing HIV aquisition after 3.5 years. Further, post-hoc analyses reported that 
even higher vaccine efficacies (60.5 %) occurred in the first year following vaccination and 
declined over time33,35,36. Analysis of immune correlates, reviewed in36,37, revealed that the 
protective effect primarily correlated with non-neutralizing immunoglobulin G (IgG) 
antibodies targeting the variable 1/variable 2 (V1/V2) regions of the Env protein (see 1.3.1). 
The protective effect of the antibody response was most likely mediated by Fc-receptor 
functions, including antibody-dependent cellular cytotoxicity (ADCC)38,37. Further, Env-
specific IgG3 immune responses correlated with a decreased risk of HIV transmission. 
Recently, a study comparing matched Env IgG1 and Env IgG3 antibodies reported that the 
IgG3 subclass is more potent than the IgG1subclass in mediating virion internalization. This 
maybe a mechanism by which non-neutralizing Env-specific IgG1 and IgG3 antibody 
responses contributed to vaccine efficacy in the RV144 trial39,36. Polyfunctional CD4+ T-cell 
responses also correlated with a decreased risk of HIV infection. Two T-cell subsets were 
identified, significantly correlating with a decreased risk of infection. One subset expressed 
CD40 ligand (CD40L), interleukin (IL)-2, IL-4, IFN-γ and tumor necrosis factor (TNF)-α, 
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while the other expressed CD40L, IL-2 and IL-4. Notably, both subsets include CD40L and 
IL4, which are involved CD4+ T-cell/B-cell interactions, indicating that these T-cell subsets 
may contribute T-cell help necessary for antibody production40,36. Next to correlates of 
protection in RV144 described above, there was also a strong direct correlate increasing risk 
of infection. Studies reported that high levels of serum IgGA, binding to specific envelopes 
increased risk of infection. Further, it has been shown that the Env-specific IgA/IgG ratio 
directly correlates with infection risk, most likely due to interfering events, since the same 
study reported that Env specific IgA can do both, inhibit Env binding and block ADCC 
activity of vaccine-induced IgG targeting the same epitope41,42,37,36. Based on the promising 
results from the RV144 trial a number of follow-on trials were designed, to test if the RV144 
regimen can induce protective immune responses in South Africa. For this purpose the RV144 
regimen was adapted to subtype C using ALVAC-HIV (vCP2438) in combination with 
recombinant bivalent subtype C gp120 formulated in MF59 adjuvant. This combination is 
currently tested in a phase 2b/3 efficacy trial (HVTN702) which was launched in 2016 in 
South Africa43,21. 
When the results of the RV144 study were published in 2009, the focus of vaccine design was 
redirected from cell-mediated immune responses towards the humoral immune response, 
since antibodies, although not neutralizing, were correlated with protection from HIV 
infection. In parallel, studies of humoral immune responses of HIV-positive individuals using 
novel high-throughput screening methods resulted in the identification of scores of Env-
directed broadly neutralizing antibodies (bNAbs) since beginning of 200944. BNAbs are 
characterized by potent and broad neutralizing activity (described in detail in 1.4.2), and the 
attempts to induce a bNAb response by vaccination further focused vaccine design towards 
the Env protein and dominate the field until today.  
1.3 The HIV-1 envelope glycoprotein 
The viral envelope glycoprotein (Env) plays a key role in HIV-1 infection, since it mediates 
the infection of CD4+ host cells, and thus enables viral replication. In addition, Env is the only 
viral protein on the surface of HIV virions and therefore the only target of the humoral 
immune response. Thus, the Env protein represents a key component in HIV-1 vaccine 
design45,46,47. 
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1.3.1 Biosynthesis and structure of the HIV-1 envelope protein 
The HIV-1 Env protein is expressed as gp160 precursor polypeptide that gets extensively 
glycosylated during synthesis in the endoplasmatic reticulum (ER). Thereby, glycans account 
for about the half of the molecular mass of the protein. Glycosylation of Env proteins occurs 
as N-linked glycosylation at the asparagine of NXT/S sequons, with X being any amino acid 
(AA) except possibly proline or aspartic acid48,49. In addition, there are studies reporting some 
rare O-linked glycosylations of Env proteins, which can occur at serine or threonine residues. 
But contrary to N-linked glycosylation sites, there is no clear-cut motif in the amino acid 
sequence which defines their glycosylation50,51,52. The gp160 precursor is proteolytically 
processed by Golgi-associated serin proteases of the Furin family, cleaving at the C-terminus 
of the amino acid consensus sequence REKR, into non-covalently linked gp120/gp41 
subunits, called protomers53,54. Three gp120 / gp41 protomers assemble into Env trimers that 
are transported to the plasma membrane, and thus incorporated into virions. From there, they 
can mediate host cell entry by a series of complex receptor-triggered conformational 
changes55,56, see 1.3.2. 
During the infection of host cells, gp120 and gp41 have different functions, which are defined 
by their structure. The gp120 subunit, including CD4 and co-receptor binding sites, is heavily 
glycosylated and has a highly variable surface that can be subdivided in five variable loops 
(V1-V5) and five constant regions (C1-C5), see Figure 5A to C 46,57,58. Structurally, gp120 
can be separated in an inner- and outer domain that are connected by the bridging sheet, 
consisting of four anti-parallel β-sheets. While the inner domain non-covalently connects 
gp120 to the gp41 subunit, the outer domain is involved in receptor binding58. The gp41 
subunit anchors the Env protein in the viral membrane and contains the fusion machinery, 
required for fusion of host and viral membranes. In comparison to gp120, the gp41 subunit is 
more conserved in its amino acid sequence. The gp41 subunit consists of the fusion peptide 
(FP), two heptad repeats (HR1, HR2), a conserved disulfide loop (DSL), the membrane-
proximal external region (MPER), the transmembrane domain (TM) and the cytoplasmic tail 
(CT), see Figure 5A to C46,59,60.  
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Figure 5. Schematic representation and overall architecture of the HIV-1 Env trimer. (A) Schematic view of the BG505 
full-length gp160 consisting of gp120 and gp41 subunits. Gp120 includes constant regions 1-5 (C1-C5) and variable loops 1-
5 (V1-V5), while gp41 contains the fusion peptide (FP), heptad repeats 1 and 2 (HR1/HR2), the disulfide loop (DSL), the 
membrane-proximal external region (MPER), the transmembrane domain (TM) and the cytoplasmic tail (CT). Glycan trees 
and the Furin cleavage site are also indicated. (B), (C) Structure of the soluble, cleaved, recombinant HIV-1 Env BG505 
SOSIP.664, representing a soluble native-like Env trimer61. Note, since the BG505 SOSIP.664 is a soluble, MPER deleted 
protein, ending at amino acid position 664 (HXB2 numbering), the MPER, TM, and CT are not part of the crystal structure. 
(B) Side view of the Env trimer. For one out of the three protomers, the gp120 core is highlighted in yellow while V3 and 
V1/V2 loops are colored in red and orange, respectively. Gp41 HR1 and HR2 are labeled in different shades of green. Protein 
components are depicted according to their secondary structure, while glycans are shown as spheres and are numbered 
according to their asparagine (N) residues (HXB2 numbering). (C) Top view on the Env trimer with variable loops V1-V5 
projecting into the periphery. The localizations of V2 and V4 loops are indicated by dashed lines as they are disordered in the 
structure. Figure adapted from Julien, J.-P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (80-. 
). 342, (2013)60, reprinted with permission from AAAS, license number 4536030553645. 
 
1.3.2 Function of the HIV-1 envelope 
HIV-1 can infect all cells that express its primary receptor CD4 and co-receptors of the 
chemokine receptor family, including the C-C chemokine receptor type 5 (CCR5) or C-X-C 
chemokine receptor type 4 (CXCR4). Thus, CD4+ T-cells as well as macrophages are 
susceptible to HIV infection47,62. The metastable nature of the pre-fusion state of the protein 
plays a crucial role in host cell infection, since it allows the protein to undergo irreversible 
conformational changes required for the fusion process63.  
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Figure 6. HIV entry into host cells. HIV entry into host cells involves two major events, receptor binding and membrane 
fusion. In the first step, the HIV Env trimer, consisting of three gp120 (blue spheres) and three gp41 (blue bars) subunits 
comes in proximity to host cells (A). After engagement of the CD4 receptor (green spheres) by the gp120 subunit, containing 
the CD4 binding site (CD4bs), structural rearrangements result in the exposure of the co-receptor binding site (B). Followed 
by co-receptor binding (C), resulting in further structural rearrangements, the fusion peptide (FP) is inserted into the host cell 
membrane (D). The formation of a stable six-helix bundle (6HB) brings the viral and host cell membrane in close proximity. 
This process is mediated by N and C-terminal α-helical regions of the gp41 subunits, termed heptad repeats 1 and 2 
(HR1/HR2), shown in blue and red. During this process, the N-terminal heptad repeats of the three gp41 subunits fold into a 
central triple-stranded coiled coil and the three C-terminal heptad repeats pack antiparallel into the three groves of the coiled-
coil. The process involves a prefusion intermediate (E) and results in the formation of the 6HB and the establishment of the 
fusion pore (F), required to release the viral core into the cytoplasm. Figure from Lobritz, M. A., Ratcliff, A. N. & Arts, E. J. 
HIV-1 Entry, Inhibitors, and Resistance. Viruses 2, 1069–105 (2010)47. 
 
The initial contact is mediated by the gp120 subunit that binds with its CD4 binding site 
(CD4bs), consisting of discontinuous residues in the constant regions of gp120, to the N-
terminus of CD4, Figure 6A, and B. This results in the rearrangement of the gp120 subunit 
and exposure of the highly conserved co-receptor binding site, consisting of regions of C4, β-
sheets of V1/V2 and residues of the V3 loop, see Figure 6B. The interaction of the co-
receptor binding site with CCR5 or CXCR4 co-receptors leads to further structural 
rearrangements, resulting in the exposure of the FP. The FP, consisting of 15 hydrophobic 
amino acids located at the N-terminus of gp41, inserts into and destabilizes the host cell 
membrane (Figure 6C and D). After insertion of the FP, viral and host cell membrane are 
brought in close proximity and membrane fusion occurs. This process involves a re-folding 
event within gp41 that is mediated by N and C-terminal α-helical regions, termed heptad 
repeat 1 and 2 (HR1/HR2). HR1 and HR2 of each gp41 subunit fold into each other, forming 
a stable six-helix bundle (6HB). In this configuration, the FP and the transmembrane domain 
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of gp41 are located at the same end of the molecule. The re-folding event and release of free 
energy finally results in membrane fusion and formation of a fusion pore (Figure 6E and F). 
Lipid mixing results in enlargement of the fusion pore and when a critical size is reached the 
viral core is released into the cytoplasm47,64,65. From there, subsequent steps in HIV 
replication cycle occur, reviewed in2,66. 
1.3.3 Immune evasion mechanisms of the HIV-1 envelope 
The viral Env protein is the only viral component on the surface of HIV-1virions, and thus 
exposed to the selection pressure of the humoral immune response. In order to avoid 
antibody-mediated neutralization, HIV has evolved a number of escape mechanisms: 
1) HIV-1 variability (Figure 7B): The high replication rate (~109 virions are generated per 
day in an infected individual) and the error-prone reverse transcriptase HIV-1( approximately 
one nucleotide substitution per genome during a single replication cycle) are responsible for 
the extensive genetic diversity of HIV-1 and contribute to the adaptation of both, 
antiretroviral therapy and immune responses67. Thereby the envelope is the most variable of 
all HIV-1 genes68. Studies have shown that Env proteins can exhibit 35 % amino acid 
diversity between subtypes and 20 % within a subtype. Thereby most sequence variation 
occurs in the gp120 subunit, including variable loops69,70. The high variability in these 
domains is driven by the need of the virus to continuously escape hosts neutralizing antibody 
responses. The Env variable loops 1-5 (V1-V5) contribute to masking of more conserved Env 
g120 regions lying underneath, and can tolerate high mutation rates, including insertions and 
deletions. For example, the length of the most variable loop V1/V2 can range from 50 to 99 
amino acids, while V4 and V5 loop lengths range from 19 to 44 and 14 to 36 amino acids, 
respectively. The length of the V3 loop is more or less constant (34-35 amino acids), since V3 
is involved in important trimer stabilizing contacts and in co-receptor engagement. Next to 
their diversity in amino acid composition and length, variable loops exhibit also high levels of 
glycosylation and flexibility, and thus contribute to the viral defense to protect conserved Env 
regions from neutralizing antibody responses 46,71,72,73. 2) Env glycanshield (Figure 7A): 
HIV-1 Env trimers contain a median of 93 N-linked glycans, comprised of a mixture of 
mainly high-mannose-type and further processed complex-type glycans that account for 
approximately 50 % of the mass of the protein. The glycan shield consists of a network of 
interlocked oligosaccharides that occludes most of the polypeptide surface of Env. Thus, it 
enables HIV-1 to avoid most antibody-mediated neutralization. The glycan shield appears to 
be evolving by coupling the high HIV mutation rate with high numbers of N-linked glycans 
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on the surface of Env trimers. This seems to be the primary mechanism by which HIV escapes 
humoral immune responses since despite of high titers of HIV-reactive antibodies, a sustained 
viremia is frequently observed during chronic infection74,75,76,77. 
 
 
Figure 7. HIV-1 envelope glycan shield and 
sequence variability. (A) N-linked glycans 
on the pre-fusion closed Env strucure of 
BG505 SOSIP.664 (PDB ID: 4TVP), shown 
in top (left) and side view (right). Glycans 
with a conservation of more than 90 % are 
shown in light green, while glycans with 
greater variability (less than 90 % 
conservation) are depicted in dark green. A 
conserved glycan residue, not present in 
BG505, is shown in yellow. (B) Sequence 
variability shown from conserved to variable 
(white to purple). Figure adapted from 
Pancera, M. et al. Structure and immune 
recognition of trimeric pre-fusion HIV-1 Env. 
Nature 514, 455–61 (2014)78, with permission 
of Springer Nature, license number 
4536050168052. 
 
 
3) Conformational masking: Immune evasion is also mediated by conformational masking 
of Env conserved functional sites such as the co-receptor binding site in gp120 that is not 
fully exposed until the CD4 binding site has bound to the CD4 receptor. Similarly, the fusion 
machinery in the MPER of gp41 becomes only accessible when the co-receptor binding site is 
occupied and viral fusion is already initiated. Thus, conformational masking restricts the 
access of antibodies to these relatively conserved regions of Env and therefore contributes to 
immune evasion79,80,81. 4) Conformational flexibility (Figure 8): HIV Env pre-fusion trimers 
are highly dynamic metastable fusion machineries that alternate between closed and more 
open conformations. This is referred to as “breathing”. It has been shown that trimer opening 
results in the exposure of some non-neutralizing epitopes, possibly misleading humoral 
immune responses. However, the relative proportion of pre-fusion conformational states 
varies within different isolates. For example, in easy-to-neutralize tier 1 isolates a larger 
proportion of trimers adopt an open conformation, compared to neutralization-resistant tier 2 
isolates. In addition, CD4 engagement of the gp120 subunit results in dissociation of the Env 
trimer, and thus to exposure of epitopes that induce non-neutralizing antibody responses, 
since these epitopes are occluded in pre-fusion state trimers82,83,84. 
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Figure 8. Conformational states of HIV-1 pre-fusion 
trimers. Biophysical data suggest that pre-fusion Env 
trimers can fluctuate between closed (left) and more 
open states (right) in a dynamic equilibrium. This is 
referred to as trimer breathing. Figure adapted with 
modifications from Ozorowski, G. et al. Open and 
Closed Structures Reveal Allostery and Pliability in the 
HIV-1 Envelope Spike. Nature 547, 360–363 (2017)85, 
with permission of Springer Nature, license number 
4536060148887. 
 
 
5) Low spike density: HIV presents only a low number of Env proteins on its surface 
(~14/per virion), thereby impeding bivalent antibody binding by inter-spike crosslinking. The 
primarily monovalent binding suffers from reduced potency, compared to bivalent binding. 
Thus, the low spike density contributes to immune evasion of Env86. In addition, virions bear 
non-functional gp120-gp41 monomers, most likely resulting from trimer dissociation along 
the axis of trimerization, and gp41 stumps that result from shedding of non-covalently linked 
gp120 subunits. Both, gp120-gp41 monomers and gp41 stumps expose non-functional Env 
epitopes, and thus contribute to immune evasion by misleading antibody responses87,88.  
The features and mechanisms described above enable HIV-1 to continuously escape from host 
humoral immune response. Further, they represent major hurdles that have to be considered 
within the development of a protective vaccine targeting the HIV-1 Env protein, see 1.5. 
1.4 Env directed antibody responses 
1.4.1 Antibody responses during acute and chronic infection 
Env-directed antibody responses can be classified into three groups that occur at different 
timepoints during the course of HIV infection89. The first group includes Env-binding but 
non-neutralizing antibodies that arise within weeks after transmission. Virion-antibody 
immune complexes are the first form of detectable B-cell responses that occur about one week 
after plasma virus detection, followed by first free plasma anti-gp41 antibodies a few days 
later. In contrast, anti-gp120 antibodies primarily targeting V3 can be detected about four 
weeks after onset of viremia. However, these early antibodies have no detectable effect on 
plasma viral load and there is also no evidence of antibody-induced Env selection90. The 
antibodies described above, typically bind to immunodominant Env epitopes on HIV virions 
that are not present on native functional trimers, such as gp41 stumps, resulting from gp120 
shedding. Therefore, they are not able to neutralize functional trimers. Nevertheless, the may 
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have some antiviral activity, since antiviral activity is not restricted to neutralization (meaning 
viral inactivation by binding and blocking of functional Env trimers, and thus preventing 
infection of host cells) but also includes other antibody functions such as ADCC or antibody-
dependent cell-mediated virus inhibition (ADCVI)89,91. 
The second group includes antibodies that can neutralize HIV-1 in a strain specific manner 
(NAbs). These antibodies typically arise after several weeks to months after infection. The 
reasons for the slow development of neutralizing antibodies remain elusive. Presentation of 
immunodominant epitopes (for example gp41 stumps) that divert antibody responses towards 
non-neutralizing epitopes, and impaired CD4+ T cell help may contribute to the delayed 
induction of neutralizing responses. As their name implies NAbs are capable to neutralize the 
infecting (autologous) strain but cannot neutralize most other (heterologous) strains. NAbs 
typically target epitopes in variable loops or other regions with relatively high sequence 
variation, which is also the reason why HIV can easily escape by amino acid substitution, 
insertions/deletions or an evolving glycan shield, see 1.3.3 89,91.  
However, in some individuals the sustained co-evolution between NAbs and viral escape after 
years results in the development antibodies with increased neutralization breadth and potency. 
These antibodies are termed broadly neutralizing antibodies and represent the third group of 
Env-directed antibody responses, which is described separately in the following chapter. 
1.4.2 Broadly neutralizing antibodies 
During HIV-1 infection between 10 % and 50 % of all infected individuals develop broadly 
neutralizing antibodies that can neutralize diverse viral isolates. A much smaller fraction 
(around 1 %), referred to as elite neutralizers, develops bNAbs with exceptional breadth and 
potency (bNAbs in the context of this thesis). Some of these bNAbs were capable to 
neutralize over 90 % of isolates tested in pseudovirus assays92,93. However, even infected 
individuals with broadly neutralizing serum activity do not benefit from the existing bNAbs as 
the autologous virus continues to escape from neutralization94.The reasons why only a small 
proportion of infected individuals develop potent broadly neutralizing responses are rather 
complex and involve a number of factors. For example, high viral loads, low CD4+ counts, a 
higher frequency of T-follicular helper (Tfh) cells in the periphery and the duration of 
infection have been associated with the development of bNAb responses92,93,95.  
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Typically, bNAbs arise between two and four years after infection in the chronic phase of 
disease and display a number of unusual features96,95. 1) High degree of somatic 
hypermutation: A high level of somatic hypermutation (SHM) is a common feature shared 
by bNAbs. Whereas most affinity matured human antibodies carry about 15-20 somatic 
mutations, bNAbs are more extensively mutated with up to 40-110 somatic mutations. 
Typically, mutations accumulate in the complementarity determining region (CDR) loops of 
the antibodies since they usually contact the antigen. In addition, mutations in the canonical 
framework regions (FWRs), required for scaffolding of CDRs and commonly less tolerant to 
mutations, seem to play a critical role in both, breadth and potency of most bNAbs79,97. 2) 
Long HCDR3 loops: Some, but not all bNAbs exhibit an unusual long heavy chain 
complementarity-determining region 3 (HCDR3) with loop lengths between 20 to 34 amino 
acids (average in humans: 16 amino acids). Long HCDR3 loops are typical features that 
enable V1/V2 and V3 directed bNAbs to penetrate the Env glycan shield. Similar is observed 
for MPER directed bNAbs, where long HCDR3 loops help to reach highly conserved 
hydrophobic residues of gp41. However, the lower frequency of human B-cells encodes for 
long HCDR3s. In addition, antibodies with long HCDR3s have the potential of auto-
reactivity, thus B-cells encoding for this antibodies are frequently deleted by negative 
selection. Taken together, it is seen as challenging to induce antibodies with long HCDR3s by 
vaccination98,79. 3) Poly-/Autoreactivity: Despite poly-/autoreactivity is normally associated 
with negative B-cell selection, some bNAbs also display poly-/autoreactivity. Polyreactivity 
likely contributes to increase the overall affinity via heteroligation. In addition, lipid binding 
seems to essentially contribute to the general neutralization mechanism of MPER-directed 
bNAbs. Thereby, the initial low affinity contact to the viral lipid membrane seems to result in 
the exposure of lipid-immersed MPER epitopes that are subsequently bound with high 
affinity79,99. 
Until 2009 only a limited amount of bNAbs was described in literature. The first generation 
bNAbs were isolated in the 1990s by phage display and from human hybridomas and resulted 
in the identification of conserved Env epitopes (see Figure 9), such as the CD4bs (bNAb: 
b12100,85), the MPER region (bNAbs: 4E10101,102, 2F5101,103,104) and a glycan epitope at the 
outer domain (OD) of gp120 (bNAb: 2G12101,105). However, all epitopes of the bNAbs 
described above are present within a single gp120/gp41 protomer, resulting from monomeric 
antigens used for selection and screening79,92. Since 2009, the development of new screening 
procedures and technologies, including single B-cell culture and functional screenings with 
tier 2 neutralization as primary selection criterion, resulted in the identification of scores of 
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bNAbs, which reflect the second generation of bNAbs. Compared to first generation bNAbs, 
second generation bNAbs were in general of greater breadth and potency44,92. Since a 
screening with neutralization as primary selection criterion is not restricted to antibody-
binding to already existing antigens, like phage display or B-cell sorting, some of the isolated 
antibodies defined new bNAb epitopes (see Figure 9). These include the gp120 V2-glycan 
site at the trimer apex, a region at the gp120/gp41 interface and the gp120 V3-glycan epitope, 
overlapping the 2G12 epitope. Since the V3-glycan epitope has a central glycan at position 
332 it is also referred to as N332-glycan supersite44,92,89,106. Notably, multiple epitopes of the 
newly identified bNAbs were characterized/identified using BG505 SOSIP.664 trimers61,56 
(described in detail in 1.5.1). BG505 SOSIP.664 trimers have been proven valuable for 
structural studies since using these trimers in cryo electron microscopy and x-ray 
crystallography approaches resulted in the first authentic high-resolution structures of a HIV-1 
Env trimer. For example, a new cluster of quaternary structure-specific antibodies (including 
PGT151107,108) was mapped to the gp120-gp41 interface of BG505 SOSIP.664 trimers56.  
 
 
Figure 9. bNAb epitopes on the 
Env trimer. Major epitopes of 
broadly neutralizing antibodies 
(bNAbs) on the surface of BG505 
SOSIP.664 (PDB ID: 4TVP. 
Epitopes are shown in different 
colors:  CD4 binding site (red); 
V1/V2 (V2-glycan) (blue); V3-
glycan (green); gp120/gp41 interface 
(wheat); MPER (illustrated as grey 
rectangle). Unspecified regions of 
gp120 and gp41 moieties are shown 
in light and dark grey, respectively. 
Representative bNAbs for each 
epitope are listed in boxes (right). 
Figure from Zhang, Z. et al. Antiviral 
Therapy by HIV-1 Broadly 
Neutralizing and Inhibitory 
Antibodies. Int. J. Mol. Sci. 17, 1901 
(2016)109. 
 
In summary, several findings described above greatly impacted HIV vaccine design and 
focused vaccine design towards the Env protein. These findings include that 10 % to 50 % of 
all infected individuals can develop a broadly neutralizing antibody response, with a smaller 
number developing bNAbs with the capacity to neutralize over 90 % of tested isolates. This 
shows that the human immune system is basically able to generate broadly neutralizing 
antibody responses91. Further, a large number of bNAbs have been isolated since 2009 and 
mapping of these antibodies to newly available immunogens, such as the BG505 SOSIP.664, 
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resulted in the discovery of new bNAb epitopes. The knowledge, gained from the discovery 
and mapping bNAbs, was and is of utmost importance in development of next generation Env 
immunogens, described in 1.5. That the induction of bNAbs is a desirable goal in HIV 
vaccine development is highlighted by passive immunization and challenge experiments. It 
has been shown that passive immunization of bNAbs can protect macaques from infection 
with chimeric simian-human immunodeficiency viruses (SHIVs) encoding HIV-1 envelope 
genes in an SIV backbone110,111,112. This indicates that bNAbs, if present in sufficient titers 
prior to infection, can protect from infection. 
1.5 Advanced Env vaccine design and efforts towards 
the induction of cross-neutralizing antibody responses 
The first HIV vaccines were monomeric gp120 subunit vaccines that failed to confer 
protection by neutralization in phase 3 efficacy trials23,24, see 1.2. Although gp120 monomers 
may display epitopes of potent bNAbs such as the CD4 binding site, they failed to induce 
neutralizing antibody responses. The presentation of immunodominat non-neutralizing 
epitopes, such as gp120 epitopes normally occluded by inter-subunit interaction, and the 
inability to present potent quaternary structure and gp41 epitopes may have contributed to this 
outcome56. However, the only efficacy trial demonstrating modest efficacy (RV14433) was 
based on a gp120 subunit vaccine. Notably, a primary correlate of protection was a non-
neutralizing antibody response directed against V1/V2, see 1.2. However, to overcome 
limitations of gp120 described above, HIV Env vaccine design focused on the production of 
soluble trimeric proteins. A general strategy for the production of soluble trimers involved a 
stop codon before the gp41 transmembrane domain to generate soluble proteins consisting of 
the ectodomain of gp41 (gp41ECTO) and gp120 subunits. Further, they included the 
inactivation of the Furin cleavage site (e.g. REKR to SEKS) to produce covalently linked 
gp120 and gp41 subunits that otherwise would rapidly dissociate into gp120 subunits and a 
trimerized form of gp41. When tested in humans, these Env trimers elicited only weak 
neutralizing antibody responses, limited to easy-to-neutralize tier 1 strains56,113,114,115. The 
limitations of the first soluble Env trimers were revealed more than a decade after their 
development, when studies have shown that these trimers adopt non-native conformations 
with gp120 subunits dangling from trimerized gp41 thereby exposing non-neutralizing 
epitopes56,116,117. 
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1.5.1 Stabilized trimers to focus immune responses towards bNAb 
epitopes 
A hallmark in HIV Env vaccine design was the development of the soluble cleaved BG505 
SOSIP.66461 trimer, based on the clade A transmitted/founder isolate BG505118. Many 
modifications in the wild-type BG505 sequence (see Figure 10), resulted in BG505 
SOSIP.664 gp140, representing trimers with improved stability, homogeneity and solubility. 
The sequence modifications included an optimized Furin cleavage site, REKR to RRRRRR 
(R6), to enhance cleavage and therefor proper protein folding, disulfide-bond forming 
cysteines at amino acid positions 501 and 605 (referred to as “SOS”) for covalent linkage of 
gp120-gp41ECTO subunits and a helix-breaking point substitution isoleucine to proline at 
amino acid position 559 (I559P), allowing gp41ECTO subunits to remain in the pre-fusion 
ground state. Furthermore, the MPER region was deleted to improve homogeneity and 
solubility (C-terminal residue at amino acid position 664) and a glycan was introduced at 
amino acid position 332 (T332N), since the binding of several bNAbs is depending on the 
presence of this glycan. Negative stain electron microscopy confirmed that affinity and size 
exclusion chromatography (SEC) purified BG505 SOSIP.664 trimers were highly 
homogeneous with more than 95 % adopting a tri-lobed propeller shape, nowadays defining 
the characteristics of native-like soluble trimers56,61. With melting temperatures of about 67 
⁰C, the trimers were highly stable and different biochemical and biophysical assays (ELISA, 
surface plasmon resonance spectroscopy (SPR), biolayer interferometry (BLI), isothermal 
titration calorimetry (ITC)) confirmed that the BG505 SOSIP.664 trimers have desirable 
antigenic properties since they show binding to all known bNAbs (with the exception of 
MPER directed bNAbs) but no or very poor binding to non-neutralizing antibodies61,119,120,56. 
In an immunization study with rabbits, BG505 SOSIP.664 trimers elicited strong and 
consistent NAb responses against the autologous tier 2 virus BG505.T332N, whereas BG505 
gp120 monomers and uncleaved gp140 trimers induced weaker or undetectable NAb 
responses. Notably, autologous neutralization was observed the first time for Env-based 
immunogens. In an immunization study with rhesus macaques BG505 SOSIP.664 trimers also 
induced a NAb response against the autologous virus but antibody titers were lower than in 
rabbits. However, heterologous neutralization of a tier 2 clade C isolate was not 
achieved121,122. Although both, rabbits and macaques, developed autologous neutralization, 
the epitopes mainly contributing to autologous neutralization differed between the species as 
it was reported in a very recent published study123. According to the study, a previously 
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described glycan-hole site in BG505 SOSIP.664 (amino acid positions 241/289) accounts for 
about 50 % of autologous neutralization in rabbits. However, the study identified another 
important epitope in the C3 region of Env (termed C3/465) that accounts for about 25 % of 
the neutralizing responses in rabbits. Remarkably, the same study was able to show that the 
neutralizing response in macaques is dominated by the newly identified C3/465 epitope123,124. 
Meanwhile, the SOSIP.664 design was successfully transferred to other isolates with 
properties similar to BG505. In addition, different strategies were applied to further stabilize 
BG505 SOSIP trimers and to reduce the conformational flexibility in order to avoid/reduce 
undesired exposure of non-neutralizing epitopes related to trimer breathing (for example non-
neutralizing V3 epitopes) and CD4-induced open conformations56. These strategies include 
chemical crosslinking of trimers as well as further stabilization by applying further stabilizing 
modifications125,56. Further, findings from the SOSIP design resulted in alternative designs for 
trimer stabilization, like the native-flexible linker design (NFL). The NFL design essentially 
reflects the SOSIP design, with the major difference that gp120 and gp41 subunits are 
covalently linked by a flexible glycine-serine (GS) linker instead of a disulfide bond. Thus, 
NFL trimers do not require Furin cleavage to adopt a native-like conformation126,127. By direct 
comparison in an immunization study with macaques, BG505 NFL trimers and BG505 
SOSIP.664 trimers induced approximately equivalent neutralizing antibody responses128. In 
addition, the same study investigated the immunogenicity of advanced BG505 SOSIP.664 
trimers designed for further stabilization, reduced V3 loop exposure and minimized CD4 
reactivity/CD4-induced non-nAb epitope exposure129,130,131. Interestingly, despite of reduced 
V3 responses, there was no difference in absolute tier 2 NAb responses between further 
modified versions and the basis version of BG505.SOSIP.664 trimers128. 
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Figure 10. Schematic presentation of BG505 gp160 wildtype (WT), BG505 SOSIP.664 and native flexible linker (NFL) 
Env variants. Top: BG505 gp160 wildtype. Constant regions (C1-C5), variable loops (V1-V5) as well as heptad repeats 1 
and 2 (HR1, HR2), membrane-proximal external region (MPER), transmembrane domain (TM) and cytoplasmic tail (CT) are 
shown in grey. Glycan trees are depicted in green (oligomannose-type), purple (complex-type), orange (hybrid- or mixed-
types) and grey (unknown composition). The REKR cleavage site is also indicated. Middle: BG505 SOSIP.664. MPER, TM 
and CT are truncated to enable expression of a soluble trimer. SOSIP modifications include the helix-breaking isoleucine to 
proline substitution at amino acid position 559 (I559P) to stabilize the pre-fusion ground state of gp41ECTO subunits, and 
further disulfide-bond forming cysteine substitutions at positions 501 (A501C) and 605 (T605C) to covalently link gp120 and 
gp41 subunits. Further modifications include the replacement of the original REKR Furin cleavage site by six arginine (R6) 
to enhance Furin cleavage and the introduction of a glycan site at amino acid position 332 (T332N) to restore the central 
glycan of the V3-glycan bNAb epitope. Bottom: NFL design. The Furin cleavage site is substituted by two flexible glycine-
serine linkers (2x G4S, in purple) that covalently link gp120 and gp41 subunits and allow a cleavage-independent folding into 
native-like trimers. Importantly, the NFL design also includes the I559P substitution. Figure adapted with modifications from 
Sanders, R. W. & Moore, J. P. Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol. Rev. 275, 161–182 
(2017)56. 
 
Although stabilized trimers were designed to focus the humoral immune response towards 
bNAb epitopes, the induction of bNAbs remained unsuccessful so far. Nevertheless, stabilized 
trimers are worth to be tested in human trials since, as learned from the RV144 trial, 
protection from infection is not limited to the (although highly desirable) induction of bNAbs. 
Native-like trimers, such as BG505 SOSIP.664, expose V1/V2 loops that were the target of 
one correlate of protection, non-neutralizing antibodies mediating ADCC, in the RV144 trial. 
However, they do not expose immunogenic epitopes such as the “backside” of gp120, like the 
gp120 immunogens in RV144 probably did. Thus, stabilized trimers maybe useful to focus 
immune responses towards protective epitopes (in context of ADCC) by avoiding distraction 
of antibody responses to immunodominant sites not correlated with ADCC. However, if this 
theory holds true has to be shown in future clinical studies. 
1.5.2 Sequential immunization to guide B-cells towards bNAb 
responses 
In infected patients the development of bNAbs usually takes years of co-evolution between 
the immune system and viral escape, see 1.4.2. Sequential immunization strategies basically 
aim to mimic this process by using suitable Env immunogens. For this purpose, rational 
vaccine design focuses on the development of germline-targeting Env immunogens that are 
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able to activate naive B-cells, expressing receptors of bNAb germline precursors. Once 
activated and expanded, sequentially immunized intermediate Env variants should guide B-
cells towards bNAb responses132,133,121. Adressing B-cell receptors of bNAb germline 
precursors by specially designed antigens became from particular interest since immunization 
studies with (stabilized) trimers as only immunogens (e.g. BG505 SOSIP.664 in rabbits and 
macaques122) failed to induce bNAb responses. A reason that maybe contributed to the 
outcome of such studies is that BG505 SOSIP.664 (and maybe also other Env immunogens) 
does not react with most germline reverted precursors of bNAbs121,134, and thus failed to 
efficiently stimulate B-cell receptors of bNAb germline precursors. However, sequential 
immunization studies once may help to solve this problem. The potential of these approaches 
were highlighted in a recent study that aimed for the induction VRC01 class antibodies, 
targeting the CD4 binding site and representing highly potent bNAbs. In the study, an 
engineered outer domain (eOD) construct GT8135,136, based on gp120 and containing 
modifications that enable binding of multiple predicted germline precursors of VRC01 class 
antibodies, was used to prime transgenic mice expressing germline VRC01 heavy chains. 
Boosting with an intermediate Env (BG505-GT3) and then with BG505 SOSIP.664 
containing a glycan deletion at amino acid position 276 (N276D) resulted in the elicitation of 
highly mutated antibodies. Analyses revealed that a significant part of the mutations were 
shared with mature VRC01 class antibodies. Interestingly, the elicited antibodies were able to 
broadly neutralize a panel of near-native tier 2 isolates (lacking the glycan at amino acid 
position 276). However, heterologous neutralization of fully-native viruses containing the 
N276 glycan was limited to one isolate137. Similar results were obtained in a study in which 
transgenic mice, expressing the germline reverted version of the PGT121 family precursor 
(epitope: V3-glycan), were primed and sequentially boosted with a set of successive mutated 
Env antigens133. In addition, a recent study published the design of a germline antibody 
binding variant of BG505 SOSIP.664. 17 individual point substitutions, including the deletion 
of several glycans (also the glycan at position 276), and the deletion of seven amino acids in 
the V2 loop resulted in a stabilized trimer termed BG505 SOSIP.v4.1-GT1. This trimer can 
bind multiple germline reverted bNAb precursors in vitro and activate B-cells in transgenic 
mice, expressing germline VRC01 and PGT121 precursors138. Future sequential immunization 
studies have to prove the suitability of this protein as germline priming antigen for the 
induction of bNAbs. 
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1.5.3 Approaches to improve durability and quality of Env-directed 
antibody responses 
One important observation in the RV144 trial was that the initial vaccine efficacy of 60.5 % 
during the first 12 months after vaccination, declined to 31.2 % in the follow-up time of 42 
months. Further, the initial vaccine efficacy corresponded to a time when most immune 
responses, including Env IgG/IgG3 and ADCC responses (correlates of protection, see 1.2) 
were higher36. The observations highlight that the magnitude of Env-directed immune 
responses were critical for vaccine efficacy, and further that Env-directed immune responses 
are limited in their durability. Thus, a general aim in HIV vaccine development is to induce 
durable Env-directed immune responses of high magnitude that ideally also contribute to the 
development of bNAbs. Formulation of Env immunogens in potent adjuvants is a likely way 
to address the limitations described above. In the RV144 trial proteins for boosting were 
administered in alum (see 1.2), representing one of the oldest (discovered in the 1920s) and 
most widely used adjuvants139. Although alum failed to induce long-lasting antibody titers in 
the RV144 trial, it is a highly safe adjuvant, normally known to generate high and long-lasting 
antibody titers via type 2 T-helper (Th) cell immune responses. However, there are also other 
types of adjuvants available, like for example the squalene based oil-in-water emulsion MF59 
(improves humoral and cell-mediated immunity, generates high antibody titers), 
monophosphoryl lipid A (toll-like receptor 4 agonist, generates Th1 immune responses), 
ISCOMATRIX (lipid-based adjuvant formation containing immunostimulatory saponin 
QS21, generates high and long-lasting antibody titers, induction of balanced Th1 and  Th2 
responses as well as cell-mediated immunity) and many others 139. For example, MF59 is 
currently tested in the phase 2b/3 efficacy trial HVTN702, see 1.2 and ISCOMATRIX is 
widely used is in studies analyzing humoral immune responses induced by stabilized 
trimers140. Presentation of Env proteins on the surface of particles is another possibility that is 
expected to improve the durability and quality of antibody responses, since they offer several 
advantages over soluble proteins, including: 1) Delivery of many antigen copies to an antigen-
presenting cell at once, possibly resulting in enhanced T-cell priming; 2) crosslinking of B-
cell receptors by higher avidity interactions, and thus enhanced B-cell activation. Enhanced 
B-cell activation supported by Tfh-cells is expected to result in improved germinal center 
(GC) reactions, including affinity maturation by somatic hypermutation, which in turn lead to 
antibody responses with increased durability and breadth141,142. The potential of particle-based 
approaches is highlighted in a recent immunization study where macaques were immunized 
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with clade C 16055 NFL trimers, arrayed in a well-ordered manner on the surface liposomes. 
Interestingly, trimer exposing liposomes were generated by capturing histidine-tagged 16055 
NFL trimers to liposomes with incorporated Ni+2 lipids. The results of the study showed that 
liposome-presented Env induced superior GC responses (larger GCs, greater content of Tfh 
cells in GCs of liposome immunized animals) and higher autologous tier 2 neutralizing 
antibody titers compared to the soluble version of the proteins143. However, there exist also 
other approaches to present Env on particles, including for example virus-like particles 
(VLPs) and poly(lactic acid) particles (PLA particles)141,56,144. Generation of Env-carrying 
VLPs, produced by coexpression of HIVs group-specific antigen (Gag) and Env proteins in 
mammalian cells, represents one of the initial efforts to present Env trimers on the surface of 
particles. The advantages of VLPs are that Env proteins are presented in their membrane-
bound state, and further that the Gag protein itself is immunogenic and elicits cytotoxic T 
lymphocyte responses. However, there are also some challenges with VLPs. These include 
low Env density and presentation of a mixture of native and non-native forms of Env, as 
known from HIV virions (see 1.3.3). Both problems have been addressed. Proteases for 
example were successfully used to digest non-functional Env molecules (greater protease 
vulnerability) from the surface of JRFL Env-carrying VLPs, while Env with native 
conformation remained intact. The amount of VLP incorporated Env can be increased by 
truncation of the CT141,56. However, experiments with cell-surface expressed Env molecules 
showed that the deletion of the CT diminishes binding of trimer-specific bNAbs and results in 
the exposure of non-neutralizing epitopes145. PLA particles consist of biodegradable polymers 
that have been licensed for human use and offer features which makes them interesting for 
vaccine design in general. For example, PLA particles allow the adsorption of antigens to the 
surface of the particles via electrostatic interactions or encapsulation of compounds into the 
particles or a combination of both146. Several studies reviewed in146, highlight the potential of 
PLA particles as vaccine carriers. For example, PLA-adsorbed HIV p24 protein induced high 
antibody titers in mice, rabbits and macaques147. Further, in an immunization study with 
rabbits, PLA-adsorbed p24 induced similar antibody titers as MF59-formulated p24148. In 
conclusion, the immunogenic properties of Env can be greatly enhanced by potent adjuvant 
formulations and particle presentation or a combination of both.  
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1.6 Biophysical and biochemical characterization of Env 
proteins 
Characterizing the antigenicity profile of Env immunogens is of great importance in HIV 
vaccine design, especially in case of native-like Env immunogens. Usually two important 
components are involved in the characterization of (native-like) Env immunogens: 1) methods 
and technologies that allow the precise quantification of Env-antibody interactions and 2) a 
set of quaternary structure-characterizing antibodies, including bNAbs and non-neutralizing 
antibodies. Commonly used assays for example are ELISA, SPR, BLI and less often also 
ITC56,61,119,120. Each of the methods named above has its individual benefits and drawbacks. 
ELISA for example is an easy to establish, widely used and robust method that enables 
measurement of equilibrium binding affinities but it requires surface immobilization. 
Depending on the assay setup, surface immobilization can affect the structure and thereby the 
antigenicity profile of the immobilized ligand125. Establishment of SPR assays is quite labor-
intensive and, like ELISA, requires surface immobilization of one interaction partner. 
However, when successfully established the method provides valuable data about on- and off-
rates of an interaction149. Similar is true for BLI assays.  The benefits of ITC are that the 
method is label-free and measurement takes place in solution. By measuring the reaction 
enthalpy, this method provides information about dissociation constants and stoichiometry of 
an interaction. Drawbacks of the method include preparation time, high concentration and 
amount of sample material and buffer limitations149.  
MicroScale Thermophoresis represents a relatively new and powerful technique for the 
analysis of molecular interactions (explained in detail in 4.1.1)149,150. MST can measure 
equilibrium binding affinities and provides several advantages, including low sample 
consumption, essentially no limitation in respect to molecule size, and the ability to measure 
affinities in solution and under physiological conditions, such as serum149. Thus, the method 
offers great opportunities for the analysis of Env-antibody interactions that could be only 
limitedly applicable in some of the methods described above. These include particularly the 
potential to characterize the antigenicity profile of particle-presented Env proteins and to 
analyze Env-antibody interactions in the presence of serum. Both aspects play essential roles 
in vaccine design. For example, native-like trimers immobilized to particles should retain 
their native-like structure and favorable antigenicity profile, which therefore has to be 
analyzed by suitable methods. Another, often neglected question is how the presence of serum 
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affects the antigenicity profile of native-like Env trimers since in most studies the antigenicity 
profile is assessed under artificial conditions in buffer. However, it is well documented that a 
stabilized soluble Env protein from subtype B (B41) can suffer from proteolytical damage of 
the V3 region, mediated by serum proteases in the medium of producer cells151. Since 
proteolytical damage may influence the favorable antigenicity profile of native-like trimers 
and with the possibility that this may also happen in the presence of human serum, it is 
reasonable to address this question. Thus, one objective of this thesis was to test if MST can 
meet the requirements to investigate Env-antibody interaction under these rather complex 
conditions described above. 
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2. Objectives 
The induction of broadly neutralizing antibodies by Env immunogens is a highly desirable 
goal in HIV-1 vaccine design that remained unsuccessful so far152. The development of 
stabilized native-like trimers with desired antigenic properties (binding to bNAbs, no/reduced 
binding to non-neutralizing antibodies) represented a hallmark in HIV-1 Env vaccine 
design61. Tested in animal models, these trimers for the first time induced neutralizing 
antibody responses against the autologous tier 2 virus121,122. With the intention to elicit more 
durable and broader NAb responses Env immunogens have been presented on different kinds 
of particles141,143,56,144,153. However, it is essential that the antigenicity profile of particle-
presented Env is preserved and comparable to the corresponding soluble protein. Further, it is 
reasonable to test if Env immunogens, soluble or particle-presented, retain their antigenicity 
profile under physiological conditions, such as serum. One objective of this thesis was to test 
if MicroScale Thermophoresis, allowing affinity measurements in solution, is a useful 
technique for the characterization of soluble and particle-presented Env proteins in buffer and 
under physiological conditions. Therefore, a five-member Env/V3 chimeric model library and 
the monoclonal antibody (mAb) 447-52D as well as native-like BG505.SOSIP.664 trimers 
and a panel of quaternary structure-characterizing antibodies were used to establish protocols 
for MST analysis of soluble and particle-presented Env proteins. Thereby, MST results were 
compared to ELISA data that were collected in parallel.  
The design of Env immunogens requires knowledge about amino acid residues that are critical 
for antibody binding. A mammalian cell display of Env libraries containing Env variants with 
consecutive alanine substitutions is one approach that can be used for identification of such 
amino acid residues and the generation of such a library reflects the second objective of this 
thesis. The reliability of the results of an Env cell-surface display mapping technology is 
strongly dependent on a homogeneous well-ordered Env trimer population on the cell 
membrane. Thus, the library was generated based on the BG505 isolate that is known to 
benefit from intrinsic trimer enhancing propensities127. In addition, a part of the library 
containing all variants with alanine substitutions that result in the knockout of N-linked 
glycosylation sites was used to for the generation of a stable cell line based BG505 SOSIP 
gp145 glycan-knockout library. This library should be used to investigate antibody-glycan 
interactions via a previously described cell sorting based approach154 allowing the isolation of 
Env antigens according to their antibody binding properties. 
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3. Materials and methods 
Unless stated otherwise, all chemicals used in this work were purchased from Sigma-Aldrich, 
Merck or Carl Roth. General plastic material was purchased from BD Falcon, Eppendorf and 
Sarstedt. 
3.1 Human codon optimization 
All HIV-1 envelope variants used in this work were optimized for human codon usage using 
the online tool “GeneArt GeneOptimizer”155,156 (GeneArt/ThermoFisher Scientific). 
3.2 Molecular biology 
3.2.1 General molecular biology 
Unless stated otherwise, cloning of all DNA constructs was performed using standard cloning 
protocols157. Restriction digestions of vectors and inserts were carried out using restriction 
endonucleases from New England Biolabs (NEB) or Fermentas according to manufacturer`s 
instructions. Inserts for cloning were generated either by digestion of plasmids with restriction 
endonucleases or polymerase chain reaction (PCR) amplification using the Phusion High 
Fidelity Polymerase. Briefly, primer extension PCR with appropriate oligonucleotides was 
used for the attachment of restriction sites and sequences encoding for protein tags, whereas 
overlap extension PCR was used to introduce additional mutations. Amplified inserts as well 
as digested vectors and inserts were purified via agarose gel electrophoresis, followed by gel 
extraction of desired DNA fragments using the QIAquick Gel Extraction Kit. Ligation of 
digested vectors and inserts (molar ratio 1:3 vector to insert) was performed using the T4 
DNA ligase according to manufacturer`s recommendations. The ligation mixture was 
transformed into chemically competent Escherichia coli (E. coli)  DH10B or DH5α according 
to standard protocols158. Insert containing colonies were identified by an analytical PCR using 
GoTaq® Green Master Mix and subsequently used to inoculate LB medium containing the 
appropriate antibiotic. Plasmid DNA was purified from LB cultures using the GeneJET™ 
Plasmid Miniprep Kit and DNA concentration and purity were determined by photometric 
quantification (absorbance at 260 and 280 nm) using a NanoDrop ND-1000 photometer. 
Finally, DNA was verified by Sanger sequencing (Seqlab, Göttingen, Germany or GATC, 
Konstanz, Germany). Cloning inserts into QuickLigation (QL) vectors containing a control of 
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cell death toxin B (CcdB) cassette159 was carried out by golden gate cloning as described 
previously160. Briefly, a reaction mixture containing the pQL13 plasmid, the insert of interest 
and the type IIs endonuclease Esp3I was incubated for 45 min at 37 ⁰C in a PCR cycler. After 
incubation, a ligation mixture containing T4 DNA ligase was added and the reaction was 
incubated at alternating temperatures (25 C⁰, 37 C⁰, 25 C⁰) for 45 min, each. The reaction 
mixture was transformed into chemically competent E. coli and further analysis was carried 
out as described above. All oligonucleotides used for cloning and sequencing are listed in 
Appendix Table 2. A detailed catalogue of all vectors used in this thesis is shown in 
Appendix Table 3. Oligonucleotides and elements used for cloning of the BG505 alanine 
substitution library are separately listed, see 3.2.3. 
 
Phusion® High-Fidelity DNA Polymerase New England Biolabs, Ipswich, USA, # 
M0530 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany, # 28706 
T4 DNA Ligase New England Biolabs, # M0202 
E. coli DH10B F- mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80dlacZΔM15 ΔlacX74 endA1 recA1 deoR 
Δ(ara, leu)7697 araD139 galU galK nupG 
rpsL λ-161 
E. coli DH5α F- supE44 ΔlacU169 (φ80 lacZΔM15) hsdR1 
recA1 endA1 gyrA96 thi-1 relA1158 
Lysogeny broth (LB) medium 1 % (w/v) NaCl, 1 % (w/v) tryptone, 0.5 % 
(w/v) yeast extract, pH 7.5 
GoTaq® Green Master Mix Promega, Fitchburg, USA, # M712 
GeneJET™ Plasmid Miniprep Kit ThermoFisher Scientific, Waltham, USA, # 
K0503 
NanoDrop ND-1000 photometer PEQLAB Biotechnologie GmbH, Erlangen, 
Germany 
Endonuclease Esp3I ThermoFisher Scientific, # ER0452 
 
3.2.2 Preparation of plasmid DNA for transfection of human cells 
Depending on the amount needed, plasmid DNA was isolated from LB cultures using 
QIAGEN Midi, Maxi or Mega Kits according to manufacturer`s instructions. Concentration 
and purity of isolated plasmid DNA was determined by photometric quantification 
(absorbance at 260 and 280 nm) using a NanoDrop ND-1000 photometer. 
 
QIAGEN Plasmid Midi, Maxi, Mega Kit Qiagen, # 12143, # 12163, # 12183 
 
 _________________________________________________________ Materials and methods 
43 
 
3.2.3 Cloning of the BG505 SOSIP alanine substitution library 
The BG505 SOSIP alanine substitution library was cloned based on the full-length BG505 
sequence (GenBank # DQ208458.1), which was adapted to human codon usage and further 
modified by adding the previously described SOSIP modifications, the R6 cleavage site and 
the T332N substitution61. Starting with amino acid position 34 (HXB2 numbering), every 
amino acid (except SOSIP modifications, R6 cleavage site and natural occurring alanines and 
cysteines) of the extracellular part of the protein, including the transmembrane domain 
(gp145, AA 34-712) was consecutively substituted for an alanine, while the intracellular part 
of the protein, represented by the cytoplasmic tail remained unmodified. Besides, for being 
able to quickly transform the BG505 SOSIP gp160 alanine substitution library into either a 
gp145 or a gp140 library, elements were implemented to allow this switching by simple and 
robust molecular biology tools. The cloning procedure of the library included five major 
steps, which will be described in detail in the sections below: 1) cloning of the library 
template, encoding for the extracellular part of the protein; 2) cloning of sequence segment 
exchange cassettes into the library template which were later on substituted by double 
stranded linker oligos including the alanine substitutions; 3) cloning of the CT encoding 
sequence into the target expression vector; 4) cloning of the sequence segment exchange 
cassettes into the target expression vector; 5) linker ligation of linker oligos into cloning 
cassettes to introduce alanine substitutions, thereby generating 615 BG505 SOSIP gp160 
variants encoding for consecutive alanine substitutions in the extracellular part of the protein. 
All elements, including oligonucleotides, gBlock sequences and DNA linkers required for 
cloning and sequencing of the BG505 SOSIP gp160 alanine substitution library are listed in 
Appendix Table 4, Appendix Table 5 and Appendix Table 6, respectively. 
 
Cloning of the BG505 SOSIP R6 library template 
The library template was cloned in the pSEVA silent vector (see Appendix Table 3). In a 
first step, a KpnI site in the multiple cloning site (MCS) of the vector was removed to later on 
enable cloning of library cassettes. To generate the library template, the 3´ part of the 
extracellular BG505 SOSIP sequence was synthesized as gBlock sequence, (gBlockXhoI, 
obtained from GeneArt/ThermoFisher) including NcoI, XhoI, SfiI and AarI (type IIs 
endonuclease) restriction sites, and cloned into pSEVA silent via HindIII/NheI. To complete 
the BG505 SOSIP library template, the 5´ part of the BG505 SOSIP sequence was cloned into 
the pSEVA silent vector via HindIII/NcoI (see Figure 11). 
 
 _________________________________________________________ Materials and methods 
44 
 
 
Figure 11. Cloning of the library template encoding for the extracellular part of BG505 SOSIP R6. The gBlockXhoI 
sequence, encoding for the 3´ part of the BG505 SOSIP sequence and including NcoI, XhoI, SfiI and AarI restriction sites, 
was cloned into pSEVA silent via HindIII and NheI. In the next step, HindIII and NcoI were used to clone the 5´ part of the 
BG505 SOSIP sequence into the pSEVA silent vector, thereby completing the library template. 
 
Cloning of exchange cassettes  
The BG505 SOSIP R6 library template in pSEVA silent was used to generate exchange 
cassettes to later on enable linker ligation in the pLib1.1 vector. Starting 3´ to the signal 
peptide (SP) encoding sequence, oligonucleotide pairs (see Appendix Table 5) were used in 
vector PCRs to generate 38 vectors containing 38 consecutive exchange cassettes. The 
exchange cassettes were designed to allow the exchange of 54 bp, each, thereby together 
covering the entire BG505 SOSIP sequence encoding for the extracellular part of the protein, 
see Figure 12A. It is important to note that sequences flanking a particular exchange cassette 
correspond to the initial BG505 SOSIP library template. During the vector PCR, the 
oligonucleotides introduced BsaI (type IIs endonuclease) and KpnI restriction sites (see 
Figure 12B). The latter, were used to digest and re-ligate the amplified vectors, whereas the 
BsaI sites were required for later on linker ligation in the pLib1.1 expression vector. 
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Figure 12. Cloning of exchange cassettes based on the BG505 SOSIP R6 library template in pSEVA silent. (A) Starting 
3´ to the signal peptide (SP) encoding sequence, oligonucleotide pairs were used in vector PCRs to generate 38 vectors, 
containing 38 consecutive exchange cassettes. Each cassette was designed to allow the exchange of 54 bp, thereby together 
covering the entire of the BG505 SOSIP sequence, encoding for the extracellular part of the protein. (B) Cloning and design 
of the exchange cassettes. Exchange cassettes contained KpnI and BsaI restriction sites for digestion and re-ligation of 
vectors (KpnI) and later on linker ligation in the pLib1.1 expression vector (BsaI). 
 
Cloning of expression vector pLib1.1 
First, a BsaI site in the ampicillin resistance of the pcDNA5/FRT/TO vector was removed by 
introducing a silent mutation and a KpnI site in the MCS of the vector was also removed. The 
sequence encoding for the CT and the 3´ part of gp140 was synthesized as a gBlock sequence 
(gBlockCT) including XhoI, KpnI and AarI restriction sites. PCR was used to extend the 3´ 
part of gp140 with sequences encoding for a glycine-serine linker, a hexa histidine-tag (His6-
tag) and stop codons to enable purification of soluble proteins. The modified gBlockCT was 
cloned into pcDNA5/FRT/TO ΔBsaIΔKpnI via NotI/ApaI and the KpnI and XhoI sites in the 
gBlockCT sequence were used to introduce a SfiI restriction site, the 3´ part of gp145 and 
stop codons. The resulting vector was further referred to as pLib1.1 see Figure 13. Next, the 
BG505 SOSIP R6 library template in pSEVA silent, containing the exchange cassettes were 
cloned into the pLib1.1 vector via HindIII and AarI, resulting in a total number of 38 pLib1.1 
vectors containing exchange cassettes for linker ligation, the CT sequence and the 3´ prime 
parts of gp145 and gp140, respectively. The SfiI and XhoI sites together with the 3´ parts of 
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gp145 and gp140 offer the option to easily switch the gp160 into gp145 or gp140 constructs, 
since corresponding restriction sites are also present in the BG505 SOSIP R6 library template. 
 
 
 
Figure 13. Cloning of expression vector pLib1.1 with exchange cassettes. BsaI and KpnI sites in the ampicillin resistance 
and the MCS of the pcDNA5/FRT/TO vector were removed by mutation. The gBlockCT sequence encoding for the Env 
cytoplasmic tail (CT) and the 3´ part of gp140, including XhoI, KpnI and AarI restriction sites, was further modified by 
extending the 3´ part of gp140 with sequences encoding for a glycine-serine (GS) linker a hexa histidine-tag (His6-tag) and 
stop codons. NotI and ApaI were used to clone the modified gBlockCT into the pcDNA5/FRT/TO ΔBsaIΔKpnI vector. The 
KpnI and XhoI sites in the gBlockCT were then used to introduce the 3´ part of gp145 and a SfiI site and the resulting vector 
was further referred to as pLib1.1. HindIII and AarI were used to clone the BG505 SOSIP R6 library template with exchange 
cassettes (in pSEVA silent) into pLib1.1, like it is exemplarily shown for exchange cassette 1. In total, 38 pLib1.1 vectors 
were generated, containing exchange cassettes for linker ligation, the CT sequence and the 3´ parts of gp140 and gp145, 
respectively. 
 
Insertion of alanine substitutions via linker ligation 
The final step in generating the BG505 SOSIP alanine substitution library was the integration 
of codons encoding for alanine substitutions into pLib.1.1 vectors with exchange cassettes. 
This was achieved via BsaI digestion of the corresponding pLib.1.1 vectors and subsequent 
ligation of DNA linkers (see Appendix Table 6), encoding for the respective BG505 SOSIP 
sequence with an alanine substitution at a particular position, see Figure 14. The linker 
sequences, representing annealed oligonucleotides with appropriate overlaps for particular 
BsaI digested exchange cassettes, were obtained from GeneArt/ThermoFisher. Taken 
together, BsaI digestion and linker ligation were used for seamless cloning of 615 BG505 
SOSIP R6 variants in which amino acid positions 34 - 712 (according to HXB2 numbering) 
were consecutively substituted for an alanine with exception of SOSIP modifications, the R6 
cleavage site and naturally occurring alanines and cysteines. Finally, plasmid DNA was 
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purified and verified by Sanger sequencing (Seqlab, Göttingen, Germany or GATC, 
Konstanz, Germany). 
 
 
 
Figure 14. Insertion of alanine substitutions via linker ligation. To complete cloning of the BG505 SOSIP alanine 
substitution library, DNA linkers encoding for the respective BG505 SOSIP sequence with an alanine substitution at a 
particular position were cloned into pLib1.1 vectors. For this purpose, pLib1.1 vectors with exchange cassettes were digested 
with BsaI and DNA linkers (annealed oligonucleotides with appropriate overlaps for BsaI digested exchange cassettes) were 
ligated into the respective pLib1.1 vectors. The cloning procedure is exemplarily shown for pLib.1.1 with exchange cassette 
1 and DNA linker 1, which encodes for the BG505 SOSIP sequence with an alanine substitution at amino acid (AA) position 
34 (first amino acid after the Env signal peptide (SP), according to HXB2 numbering). 
 
3.2.4 Magnetic beads purification 
PCR fragments, generated during next generation sequencing (NGS) sample preparation were 
purified by using AMPure XP magnetic beads. To maximize DNA yield, all steps were 
performed in 1.5 ml DNA LoBind Tubes. Briefly, 1.8 times the sample volume of magnetic 
beads was added to DNA samples in H2O and thoroughly mixed by pipetting. After 
incubation for 5 min at room temperature (RT), samples were placed in a magnetic rack until 
the solution turned clear. Next, the supernatant was removed and the pellets were washed two 
times with 500 μl freshly prepared 70 % ethanol. To this end, the ethanol was added to the 
pellet and incubated for 30 sec while turning the cups in the magnetic rack. Subsequently, the 
supernatant was discarded without disturbing the pellet and the washing procedure was 
repeated. After the second washing step, the ethanol was carefully aspirated by pipetting and 
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the pellets were air-dried for 3 min. To elute DNA, 30 μl H2O were added, pellets were 
vortexed for 15 sec, centrifuged and placed in the magnetic rack for 1 min. Finally, the 
supernatant was transferred into a new tube. 
 
Agencourt AMPure XP  Beckman Coulter, # A63881 
1.5 ml DNA LoBind Tubes Eppendorf, Hamburg, Germany, # 
0030108051 
 
3.2.5 Next generation sequencing 
NGS was used to quality control the BG505 SOSIP gp145 glycan-knockout library (see 
3.3.5), and further to identify Env variants, which were enriched during FACS analysis (see 
3.3.8). In total, env genes isolated from four different genomic DNA (gDNA) samples were 
simultaneously analyzed in one experiment using the Illumina MiSeq platform162,163. The 
preparation of the NGS experiment required several steps, which are described in the 
following sections.  
 
Generation of the amplicon library 
Two consecutive PCR reactions (PCR1 and PCR2) were used to generate an amplicon library, 
consisting of PCR fragments about 300 bp in size (amplicons), including NGS-specific primer 
binding sites, indices and adapter sequences required for NGS. PCR reactions were performed 
based on the protocols described in detail in the PhD thesis of Julia Koop164. PCR1 was used 
to amplify env genes from the gDNA templates (for gDNA preparation see 3.3.8). Briefly, 12 
primer pairs (see Appendix Table 7) were used to generate overlapping PCR amplicons 
about 300 bp in size, together covering the entire BG505 SOSIP gp145 sequence and 
containing NGS-specific primer binding sites. Since PCR1 was performed on four different 
gDNA templates this resulted in a total number of 48 amplicons (12 amplicons per gDNA 
template). The resulting amplicons were purified from agarose gels using the QIAquick Gel 
Extraction Kit and further purified by magnetic beads purification, see 3.2.4. During PCR2 
TruSeq Small RNA PCR Index Primers (see Appendix Table 8) were used to add index and 
adapter sequences to the amplicons generated in PCR1. Adapter sequences are required to 
hybridize samples to the surface of the Illumina flow cell, whereas indices are needed to 
differentiate between the analyzed samples. To this end, all 12 amplicons generated during 
PCR1, using a particular gDNA template, were barcoded with the very same index sequence. 
In total, four different indices were used (1 index per 12 related amplicons), resulting in a 
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total number of 48 barcoded amplicons. After gel and magnetic bead purification, the 
concentration of each of the amplicons was quantified using the Agilent 2100 Bioanalyzer and 
the Agilent High Sensitivity DNA Kit and an amplicon library was generated by pooling all 
48 amplicons in an equimolar ratio to a final concentration of 30 nM. 
 
QIAquick Gel Extraction Kit Qiagen, # 28706 
Agilent High Sensitivity DNA Kit Agilent, Santa Clara, USA, # 5067-4626 
Agilent 2100 Bioanalyzer Instrument Agilent 
 
Next generation sequencing of the amplicon library 
Prior to loading samples on the NGS flow cell, the amplicon library was diluted and 
subsequently denatured. Since the utilized amplicon library is characterized by low sequence 
diversity, 30 % PhiX control were spiked-in during library dilution to mitigate sequencing 
challenges. Briefly, a mixture composed of the amplicon library (70 %) and PhiX control (30 
%) with a final concentration of 2 nM in 10 μl H2O was created and subsequently denatured 
by adding 10 μl freshly prepared 0.2 N NaOH solution. After incubation for 5 min at RT, the 
mixture was diluted with chilled HT1 hybridization buffer to a final concentration of 10 pM in 
a total volume of 2 ml. Next, 1 ml of the 10 pM dilution was loaded on the flow cell and the 
NGS run was started using a previously designed MiSeq control software sample sheet with 
following parameter settings: 1) FastQ only; 2) sample prep kit: TruSeq Small RNA. The 
number of cycles in the sample sheet were manually adjusted for 2x 151 reads to enable 
sequencing from both the 5´and 3´end. The NGS run was performed at the laboratory of Prof. 
Dr. Gunter Meister under instruction of Norbert Eichner. 
 
MiSeq Reagent Kit v2 (300 cycles) Illumina, San Diego, USA, # MS-102-2002 
PhiX Control v3 Illumina, # FC-110-3001 
MiSeq NGS platform Illumina 
 
Analysis of NGS data 
Sequence analysis of NGS results was performed using CLC Genomics Workbench 7. After 
importing FastQ files into CLC, files containing corresponding forward and reverse reads 
were paired. Overlapping pairs were merged into one file without altering the predefined 
settings of the program and subsequently aligned with a reference sequence. Next, results 
were exported as SAM files and further investigated using an analyzer tool (programmed by 
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Dr. Benedikt Asbach) that was designed to count every codon at each position, delivering a 
table with the absolute numbers of amino acids. 
 
CLC Genomics Workbench Version 7.0.3  Qiagen 
3.3 Cell biology 
3.3.1 Cultivation of human cells 
Adherent cells 
All adherent cell lines were cultivated at 37 °C and 5 % CO2 in cell culture flasks with culture 
medium DMEM, supplemented with additives listed in Table 1. Cells were grown to a 
confluency of 80 % and subcultured in a 1:10 ratio twice a week. For subculturing cells were 
washed with PBS and detached with Trypsin/EDTA solution, followed by resuspension in the 
respective culture medium. 
 
Cell culture flasks T25, T75, T175 Sarstedt, Nümbrecht, Germany, # 
83.3910.002, # 83.3911.002, # 83.3912.002 
Dulbecco`s Modified Eagle`s Medium 
(DMEM) 
Gibco/ThermoFisher Scientific, # 11995-065 
Phosphate buffered saline (PBS) 
 
137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.47 mM KH2PO4, pH 7.4 
Trypsin/EDTA PAN-Biotech, Aidenbach, Germany, # P10-
023500 
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Table 1. Cell lines and culture media. 
Cell line Culture medium 
Human Embryonic Kidney (HEK) 293T, 
(ATCC, # CRL-11268) 
DMEM + 10 % FBS + 1 % Pen/Strep 
Flp-In™ T-REx™ 293, (ThermoFisher 
Scientific, # R78007) 
DMEM + 10 % FBSΔtet + 1 % Pen/Strep + 
100 μg/ml zeocin + 15 μg/ml blasticidin 
Flp-In™ T-REx™ 293 CMV_Furin+, clone 
[4_2]165 
DMEM + 10 % FBSΔtet + 1 % Pen/Strep + 
100 μg/ml zeocin + 15 μg/ml blasticidin + 400 
μg/ml geniticin sulfate 
Stable cell lines generated from Flp-In™ T-
REx™ 293 cells 
DMEM + 10 % FBSΔtet + 1 % Pen/Strep + 
100 μg/ml hygromycin B + 15 μg/ml 
blasticidin  
Stable cell lines generated from Flp-In™ T-
REx™ 293 CMV_Furin+ clone [4_2] cells 
DMEM + 10 % FBSΔtet + 1 % Pen/Strep + 
100 μg/ml hygromycin B + 15 μg/ml 
blasticidin + 400 μg/ml geniticin sulfate 
Additives Supplier 
Fetal bovine serum (FBS) for HEK293T cell 
cultivation 
Gibco/ThermoFisher Scientific, # 10270-106 
Tetracycline free FBS for Flp-In™ T-REx™ 
293 cell cultivation (FBSΔtet) 
Biochrom, Berlin, Germany, # S0115 
Penicillin/Streptomycin (Pen/Strep) 10,000 U/ml penicillin, 10 mg/ml 
streptomycin, PAN Biotech, # P06-07100 
Zeocin 100 mg/ml, InvivoGen, San Diego, USA, # 
ant-zn 
Blasticidin 10 mg/ml, InvivoGen, # ant-bl 
Hygromycin B 100 mg/ml, InvivoGen, # ant-hg 
Geniticin sulfate (G418) 100 mg/ml, InvivoGen, # ant-gn 
 
293-F suspension cells 
FreeStyle™ 293-F suspension cells (293F-cells) were cultured at 37 °C, 8 % CO2 and 90 rpm 
in 1 L Corning® Erlenmeyer cell culture flasks containing 300 ml FreeStyle™ 293 expression 
medium supplemented with 0.5 % Pen/Strep. For maintenance, cells were subcultured 
between cell densities of 0.1-1.6 Mio/ml. For subculturing, the respective amount of cells was 
centrifuged for 5 min at 100 g and RT, the supernatant was discarded and the cell pellet was 
resuspended in fresh medium. 
 
FreeStyle™ 293-F suspension cells ThermoFisher Scientific, # R79007 
FreeStyle™ 293 expression medium ThermoFisher Scientific, # 12338018 
Corning® Erlenmeyer cell culture flasks Sigma-Aldrich, St. Louis, USA, # CLS431147 
Penicillin/Streptomycin (Pen/Strep) PAN Biotech, # P06-07100 
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3.3.2 Transient transfection of human cells 
HEK293T cells 
HEK293T cells were transiently transfected using polyethyleneimine (PEI). Depending on the 
experiment, different transfection scales were used to obtain the desired amount of transfected 
cells, see Table 2. Cells were seeded one day before transfection to reach a confluency of 
about 80 % at the day of transfection. Prior to transfection, the medium was exchanged to 
DMEM, free of serum and antibiotics (see Table 2, volume DMEM for transfection). The 
transfection mix was prepared by dissolving DNA containing plasmids and PEI (dissolved in 
H2O to a final concentration of 1 mg/ml, adjusted to pH 7 with NaOH) in a 1:4 (w/w) ratio in 
DMEM without supplements. After incubation for 20 min at RT, the transfection mix was 
added to the cells. Five to six hours post transfection, the medium was exchanged to 
HEK293T culture medium, see Table 1. In case of BG505 SOSIP transfections, plasmids 
encoding for Env (pcDNA5/FRT/TO, pLib1.1) and Furin (pcDNA3.1(+)QL) were 
cotransfected at a ratio of 3:1 (w/w). 
 
Polyethyleneimine (PEI) Max linear, MW 
40,000 
Polysciences, Warrington, USA, # 24765 
6-well, 96-well tissue culture plates Sarstedt, Nümbrecht, Germany, # 83.3920, # 
83.3924 
 
 
Table 2. Transfection of different cell culture scales. 
Culture 
vessel 
Vol. culture 
medium (ml) 
Number of 
seeded cells 
per well/flask 
Vol. DMEM for 
transfection 
reaction (ml) 
DNA 
(μg) 
PEI 
(μg) 
Vol. 
transfection 
mix (ml) 
96-well 0.1 3 x 104 0.03 0.24 0.96 0.03 
6-well 2 5 x 105 1 2 8 0.1 
T175 30 1.2 x 107 30 30 120 3 
 
293-F suspension cells 
FreeStyle™ 293-F suspension cells were cultivated at 37 °C, 8 % CO2 and 90 rpm in 1 L 
Corning® Erlenmeyer cell culture flasks containing 300 ml FreeStyle™ 293 expression 
medium supplemented with 0.5 % Pen/Strep. For transfection, cells were grown to a cell 
concentration of 1 Mio/ml at the day of transfection. Prior to transfection, cells were 
harvested by centrifugation (5 min at 100 g and RT). The supernatant was discarded and the 
pellet was resuspended in 300 ml FreeStyle™ 293 expression medium without supplements. 
The transfection mix was prepared by dissolving 300 μg plasmid DNA in 6.5 ml DMEM, free 
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of serum and antibiotics. Simultaneously 1.2 ml PEI solution (PEI diluted to a final 
concentration of 1 mg/ml in PEI buffer, pH 7.5) was added to 6.5 ml DMEM without 
supplements. After incubation for 5 min at RT, PEI and DNA solutions were mixed, 
incubated for 20 min at RT and then added to the cells. Five to six hours post transfection, the 
medium was exchanged to FreeStyle™ 293 expression medium supplemented with 0.5 % 
Pen/Strep. 
 
Polyethyleneimine (PEI), linear, MW 25,000 Polysciences, Warrington, USA, # 23966 
PEI buffer 25 mM HEPES pH 7.5, 150 mM NACl 
 
3.3.3 Stable transfection of Flp-In™ T-REx™ 293 CMV_Furin+ 
cells 
The constitutive Furin overexpressing cell line Flp-In™ T-REx™ 293 CMV_Furin+ [clone 
4_2], which was previously established in our lab (master`s thesis Dominik Fiegle165), was 
used to generate stable cell lines with inducible Env expression regulated by the Tet 
operator/repressor system. Flp-In™ T-REx™ 293 CMV_Furin+ cells were transfected as 
described for HEK293T cells in 3.3.2, with the difference that the plasmid mixture contained 
the respective env variant in pLib1.1 and the pOG44 helper plasmid, encoding for the 
recombinase, in a pLib1.1/pOG44 ratio of 4:1 (w/w). Five to six hours post transfection the 
medium was exchanged to DMEM + 10 % FBSΔtet + 1 % Pen/Strep. 24 h post transfection 
the medium was refreshed. 48 h post transfection the cells were detached by pipetting and 
directly transferred into cell culture flasks containing selection medium to select for cells with 
stable integration events. In case of 6-well transfections, cells were transferred to T75 flasks. 
After 24 hours the selection medium was refreshed and selection was carried out for 24 days 
with medium being refreshed every 4 days. 
 
Selection/culture medium DMEM + 10 % FBSΔtet + 1 % Pen/Strep + 
100 μg/ml hygromycin B + 15 μg/ml 
blasticidin + 400 μg/ml geniticin sulfate 
 
3.3.4 Induction of Env expression in stable cell lines 
Cells were seeded one day before induction to reach a confluency of about 80 % at the day of 
induction. Depending on the experiment, different amounts of cells were seeded to obtain the 
 _________________________________________________________ Materials and methods 
54 
 
desired amount of cells. For the amount of seeded cells in different cell culture scales, see 
Table 2. To induce Env expression, the medium was refreshed to the respective cell culture 
medium (see Table 1) containing 1 μg/ml doxycycline. 
 
Doxycycline Sigma-Aldrich, # D9891 
 
3.3.5 Generation of the BG505 SOSIP gp145 glycan-knockout 
library expressed by stable cell lines 
The BG505 SOSIP contains 28 N-linked potential glycosylation sites per gp145 protomer (84 
glycosylation sites per trimer) which are defined by (NXT/S) sequons in the amino acid 
sequence, with X being any amino acid except possibly proline or aspartic acid48,49. The 
BG505 SOSIP gp160 alanine substitution library (see 3.2.3) was used as a template to 
generate a BG505 SOSIP gp145 glycan-knockout library, including all variants which encode 
for alanine substitutions in the glycosylation sequons. Since the alanine substitution of N and 
T/S should prevent the glycosylation of the asparagine in the sequon, both knockout variants 
were included into the library, resulting in two BG505 SOSIP glycan-knockout variants for a 
particular glycosylation site and a total number of 56 BG505 SOSIP glycan-knockout 
variants. Further, alanine variants were included which knockout two potential O-linked 
glycosylation sites at positions T499 and T606 (HXB2 numbering), respectively50,51. O-linked 
glycosylation can take place on serine or threonine residues and, contrary to N-linked 
glycosylation sites, there is no clear-cut motif in the amino acid sequence which defines their 
glycosylation52. Using the respective BG505 SOSIP gp160 alanine substitution variants as 
starting material, each of the 58 Env variants described above was cloned from gp160 to 
gp145 constructs by simple restriction digest with SfiI and subsequent re-ligation as described 
in 3.2.3. The resulting BG505 SOSIP gp145 constructs were stably transfected into the 
constitutive Furin overexpressing cell line Flp-In™ T-REx™ 293 CMV_Furin+ (see 3.3.3), 
thereby generating  stable cell lines with doxycycline inducible Env expression, each 
expressing a particular Env variant with a single glycan deletion in the gp145 protomer (3 
deletions per trimer). After completing the generation of cell lines, cells of each cell line were 
cryopreserved and stored in liquid nitrogen according to manufacturer`s recommendations for 
Flp-In™ T-REx™ 293 cells (see 3.3.1, Table 1). Furthermore, cells of all cell lines were 
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pooled to equal numbers and the resulting pool was further referred to as BG505 SOSIP 
gp145 glycan-knockout library. 
3.3.6 Flow cytometry 
Transiently transfected cells (see 3.3.2, HEK293T cells) or doxycycline induced stable cell 
lines (see 3.3.4) were analyzed by flow cytometry 48 h post transfection/induction. Briefly, 
cells were washed and detached with an appropriate amount of chilled FACS buffer and 7 x 
104 to 1 x 105 cells were transferred to a 96-well round bottom plate and centrifuged for 5 min 
at 500 g and 4 °C. After removal of the supernatant, cells were stained with the respective 
Alexa647- or Alexa488-labeled antibodies (for antibody labeling see 3.4.7). For this purpose, 
antibodies were diluted in FACS buffer to desired concentrations and cells were stained with 
30 μl antibody dilution per well for 30 min at 4 °C. Experiments with the antibody 17b, in 
some cases, required pre-incubation of cells with the soluble CD4 receptor (sCD4) to trigger 
the CD4-induced (CD4i) state of cell-surface presented Env molecules. For this purpose, cells 
were incubated with 25 μl sCD4, diluted in FACS buffer to a final concentration of 8.6 μg/ml, 
for 30 min at 4 °C. Next, 5 μl of 17b were added at desired concentrations and the cells were 
incubated for another 30 min at 4 °C. After antibody incubation, three washing cycles were 
performed to remove unbound antibody. Washing was performed by adding 200 μl FACS 
buffer per well to the cells, followed by centrifugation for 5 min at 500 g and 4 °C. 
Subsequently, cells were resuspended in 200 μl FACS buffer and analyzed using the Attune 
NxT flow cytometer. Cells were gated for single (FSC-A/FSC-H plot), living cells (FSC-
A/SSC-A plot) as shown in Figure 15. 
 
FACS buffer PBS, 1 % (v/v) heat inactivated FBS, 2 mM 
EDTA, 0.1 % (w/v) NaN3 
Fetal bovine serum (FBS) Gibco/ThermoFisher Scientific, # 10270-106 
Soluble CD4 receptor (sCD4) National Institutes of Health (NIH) AIDS 
Reagent Program, Germantown, Maryland, 
USA, # 4615 
96-well tissue culture plates (round bottom) Sarstedt, Nümbrecht, Germany, # 83.3925 
Attune NxT flow cytometer ThermoFisher Scientific 
Anti-Env antibodies See 3.4.6, Table 4 
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Figure 15. Gating strategy for single (FSC-A/FSC-H plot, left panel), living cells (FSC-A/SSC-A plot, right panel). 
 
3.3.7 Flow cytometry-based antibody titration 
For flow cytometry-based titration experiments, HEK293T cells transiently transfected with 
plasmids encoding for BG505 SOSIP gp145/160 (see 3.3.2) or doxycycline induced stable 
cell lines expressing BG505 SOSIP gp145/160 (see 3.3.4), were stained with fluorescent-
labeled antibodies at desired concentrations and analyzed as described in 3.3.6. Mock 
transfected HEK293T cells (pcDNA5/FRT/TO without env + pcDNA3.1(+) QL with furin) 
and the constitutive Furin overexpressing cell line Flp-In™ T-REx™ 293 CMV_Furin+ 
(doxycycline induced, without integrated env gene) were used as negative controls for 
transiently transfected cells and stable cell lines, respectively. The mean fluorescence 
intensity (MFI) of Env expressing cells stained with the titration antibody was corrected for 
the antibody background signal by subtracting the respective negative control signals 
(negative controls were titrated with the very same antibody concentrations) and is further 
referred to as “referenced” MFI. In addition, to compare antibody binding with regard to 
varying Env surface expression levels (between transiently transfected cells, stable cell lines 
and Env variants) the referenced MFI was further normalized for Env surface expression. To 
this end, cells of each variant were stained in separate wells with 250 nM mAb 2G12 which 
was used as reference antibody and the respective referenced MFI signal of the titration 
antibody was divided by the respective referenced MFI signal of 2G12 and is further referred 
to as “relative MFI”. For curve fit, MFI values described above were fitted using non-linear 
least squares regression (one site binding, hyperbola; GraphPad Prism 5). 
 
GraphPad Prism, version 5.04 GraphPad Software, La Jolla, USA 
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3.3.8 FACS analysis of the BG505 SOSIP gp145 glycan-knockout 
library  
1.2 x 107 cells of the BG505 SOSIP gp145 glycan-knockout library (pool of single cell lines, 
see 3.3.5) were seeded in a T175 flask and induced with doxycycline the following day (see 
3.3.4). 48 h post induction, cells were washed with chilled FACS buffer, subsequently 
detached with 10 ml chilled FACS buffer and centrifuged for 5 min at 500 g and 4 °C. After 
removal of the supernatant, cells were co-stained with Alexa488-labeled PGT135 (screening 
antibody) and Alexa647-labeled VRC01 (reference antibody for normalization of Env surface 
expression). Briefly, 1 ml staining solution containing 100 nM PGT135 and 250 nM VRC01 
diluted in FACS buffer was prepared and cells were gently resuspended in the staining 
solution and incubated for 30 min at 4 °C. After incubation, three washing cycles were 
performed. For this purpose, 10 ml FACS buffer was added to the cells and after gentle 
resuspension cells were centrifuged for 5 min at 500 g and 4 °C. After the last washing step, 
cells were resuspended in 600 μl PBS (optimal concentration for sorting 2 x 107 cells/ml) and 
singularized by passing cells through a 30 μm pre-separation filter. 50 μl of the sample 
material was collected to serve as input control and the remaining sample was sorted at the 
Regensburg Center for Interventional Immunology (RCI) using the FACS Aria IIu device. 
The instrument was set to “single cell mode” to discard two-target-events and obtain the most 
accurate counts of the sorting procedure160. The following gating strategy was applied: 1) 
FSC-A/SSC-A plot to gate for living cells (P1); 2) FSC-A/FSC-W plot to gate for single cells 
(P2); 3) FITC-A/APC-A plot with sorting gate P3, allowing the sorting of cells with the 
lowest PGT135 signal in relation to their VRC01 signal, and thus the selection of cells with 
lowest affinity to PGT135 in relation to their Env surface expression; 4) FSC-A/SSC-A plot 
with gate P4, representing the sorted, living cells that were collected in 100 μl PBS. In total, 
about 1.5 x 107 cells were sorted from which about 3 x 105cells were sorted into gate P4. The 
genomic DNA from about 2-3 x 105 cells of the input control and sorted cells was recovered 
using the QIAamp DNA Mini Kit (protocol for DNA purification from blood and body fluids) 
according to manufacturer`s instructions. Finally, the genomic DNA was further analyzed by 
NGS, see 3.2.5. 
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FACS buffer PBS, 1 % (v/v) heat inactivated FBS, 2 mM 
EDTA, 0.1 % (w/v) NaN3 
Anti-Env antibodies See 3.4.6, Table 4 
Antibody labeling See 3.4.7  
Pre-Separation Filters (30 µm) Miltenyi Biotec, Bergisch Gladbach, 
Germany, # 130-041-407 
FACS Aria IIu Becton Dickinson (BD), Franklin Lakes, USA 
QIAamp DNA Mini Kit Qiagen, # 51306 
 
3.4 Protein biochemistry 
3.4.1 Env constructs 
Gp140 Env/V3 constructs were generated by deleting the transmembrane domain from the 
respective gp145 containing plasmids via PCR. Additionally, gp140 Env/V3 variants were 
engineered via PCR to contain a flexible glycine-serine linker and Flag/hexa histidine-tag 
(Flag/His6-tag) at the C-terminus of gp41 by adding amino acid sequence 
SGGGGSDYKDDDDKHHHHHH and the stop codon. Furthermore, the Furin cleavage site 
was altered from REKR to REKS via overlap extension PCR. For generation of gp120 
constructs, gp41 was deleted by PCR and in contrast to gp140 constructs no tag was added. 
Env constructs were re-cloned into the pQL13 vector by golden gate cloning, see 3.2.1. The 
previously described BG505 SOSIP.664 gp14061 was engineered to contain a glycine-serine 
linker and a His6-tag at the C-terminus of the gp41 ectodomain (gp41ECTO) by adding amino 
acid sequence GSHHHHHH and the stop codon. Cloning was performed by XhoI digestion 
and subsequent re-ligation of membrane-bound BG505 SOSIP gp145 in pLib1.1 as described 
in 3.2.3. 
3.4.2 Expression and purification of soluble Env proteins 
Soluble gp120 and gp140 proteins were expressed into the supernatant of 293-F suspension 
cells. For this purpose, 293-F suspension cells were transiently transfected with plasmids 
encoding for gp120 or gp140 Env/V3 chimeras (pQL13) or BG505 SOSIP.664 (pLib1.1) (see 
3.4.1), as described in 3.3.2. In case of BG505 SOSIP.664 transfection, plasmids encoding for 
Env (pLib1.1) and Furin (pcDNA3.1(+)QL) were cotransfected at a ratio of 3:1 (w/w) to 
confer proper gp120-gp41ECTO cleavage. 72 h post transfection, culture supernatants were 
harvested by centrifugation for 10 min at 1,000 g and 4 ⁰C, followed by filtration with 
Filtropur 0.22 μm filters. For affinity purification of gp120, culture supernatants were loaded 
onto a 5 ml lectin affinity column at a constant flow rate of 1 ml/min at 4 ⁰C. Unbound 
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protein was washed out with 5 column volumes (CV) PBS, 1 mM EDTA, 1 mM EGTA. Env 
proteins were eluted with PBS, 1 mM EDTA, 1 mM EGTA, 1 M methyl-α-D-
mannopyranoside and protein containing fractions were subsequently concentrated to a 
volume of 0.5 to 1.0 ml using 30 kDa Amicon® Ultra-4 centrifugal filters. Affinity 
purification of His-tagged gp140 was performed in a similar way with the exceptions of using 
a 5 ml Ni-sepharose column with corresponding buffers for washing (PBS, 0.5 M NaCl, 0.03 
M imidazole, pH 7.4) and elution (PBS, 0.5 M NaCl, 0.5 M imidazole, pH 7.4) and 100 kDa 
Amicon® Ultra-15 centrifugal filters for concentration. Env proteins were purified to 
monomer (gp120) or trimer size homogeneity (gp140) using a HiPrep 16/60 Sephacryl S-300 
HR size exclusion chromatography column at a constant flowrate of 0.5 ml/min with running 
buffer HBS-EP or PBS for gp120 and gp140, respectively. Gp120 monomer or gp140 trimer 
containing fractions were pooled, concentrated (only in case of gp140 trimers) using 30 kDa 
Amicon® Ultra-4 centrifugal filters and stored at -80 ⁰C. Protein concentrations were 
determined by photometric quantification (absorbance at 280 nm) using a NanoDrop ND-
1000 photometer. Photometric quantification was performed in consideration of extinction 
coefficients and molecular weights of gp120 monomers and gp140 trimers (see Table 3) 
which were calculated based on the corresponding amino acid sequences using the ExPASy 
protParam tool166. 
 
Filtropur 0.22 μm filters Filtropur L 0.2 LS, Sarstedt, Nümbrecht, 
Germany, # 83.1827.001 
Agarose-bound Galanthus nivalis lectin for 5 
ml affinity column 
Vector Laboratories, Burlingame, USA, # AL-
1243 
Methyl-α-D-mannopyranoside Merck Millipore, # 462711 
30 kDa Amicon® Ultra-4 centrifugal filters Merck Millipore, # UFC803024 
5 ml Ni-sepharose column, HisTrap™ High 
Performance 5 ml 
GE Healthcare Life Sciences, # 17-5248-01 
100 kDa Amicon® Ultra-15 centrifugal filters Merck Millipore, # UFC910024 
Size exclusion chromatography column, 
HiPrep 16/60 Sephacryl S-300 HR 
GE Healthcare Life Sciences, # 17116701 
HBS-EP 0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM 
EDTA, 0.005 % (v/v) Surfactant P20 
 
  
 _________________________________________________________ Materials and methods 
60 
 
Table 3. Extinction coefficients and molecular weights of Env proteins calculated using ExPASy protParam tool. 
Env Protein Extinction 
coefficient 
gp120 monomer 
Molecular 
weight (Da) 
gp120 monomer 
Extinction 
coefficient 
gp140 trimer 
Molecular 
weight (Da) 
gp140 trimer 
     
MN 68965 54582 427620 229559 
HXB2 65985 54618 418680 229668 
CDC42 72975 54503 439650 229322 
RF  67475 54337 423150 228823 
SF33 68965 54477 427620 229244 
BG505 
SOSIP.664 
  335175 215306 
 
3.4.3 Production and purification of HIV-1 Gag VLPs 
VLPs were produced by transient transfection of 293-F cells, see 3.3.2, with plasmids 
encoding for optimized HIV-1 Gag (TeeGag1167 in pcDNA3.1(+)) and cleavage competent 
gp145 versions of the Env/V3 chimeras (in pQL13) at a ratio of 2:1 (w/w). 48 h post-
transfection VLP containing supernatants were cleared from cells by centrifugation for 15 min 
at 3,000 g and 4 ⁰C. To concentrate VLPs, 30 ml of supernatants were loaded onto 5 ml 30 % 
(w/w) sucrose in PBS cushion and ultra-centrifuged for 2 h at 100,000 g and 4 ⁰C. The pellets 
were resuspended in an appropriate amount of PBS overnight at 4 ⁰C. To separate VLPs 
according to their density, VLPs were loaded onto a 10 to 50 % (w/w) sucrose in PBS 
gradient (2 ml of each, 10 %, 20 %, 30 %, 40% and 50 %) and centrifuged for 2.5 h at 
100,000 g and 4 ⁰C. 22 fractions of 550 μl each were collected and analyzed for their density 
(weighing each fraction, using an electronic analytical balance) and co-banding of Gag and 
Env (analyzing 10 μl of each fraction by Western blot, see 3.4.5). VLP containing fractions 
were pooled, diluted in 35 ml PBS and centrifuged for 2 h at 100,000 g and 4 ⁰C. Finally, 
VLP pellets were resuspended in 400 μl PBS containing 15 % (w/w) trehalose over night at 4 
⁰C and stored at - 80 ⁰C. To approximately quantify the amount of Gag in the VLP 
preparations a densitometric analysis was performed. For this purpose, 3 μl of the VLP 
preparations and BSA reference samples were analyzed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), see 3.4.5. After coomassie staining, see 
3.4.4, the band intensities were densitometrically analyzed using ImageJ. Further, to semi-
quantitavely analyze the Env concentrations in the VLP preparations a slot blot experiment 
was performed. Briefly, 0.25 – 2 μl of the VLP preparations and a serial dilution of a soluble 
gp140 standard protein (96ZM651) were loaded onto a slot blot, see 3.4.5, and the band 
intensities were analyzed by densitometric analysis, using ImageJ168. 
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Centrifuge tubes for sucrose cushion: 38.5 ml, 
25 x 89 mm 
Beckman Coulter, Brea, USA, # 326823 
Centrifuge tubes for sucrose in PBS gradient: 
14 ml, 14 x 95 mm 
Beckman Coulter, # 344060 
Ultracentrifuge: Optima™ L-90K with rotors 
SW 32 Ti and SW 40 Ti for 38.5 ml and 14 ml 
tubes, respectively 
Beckman Coulter 
Electronic analytical balance: A200S Sartorius AG, Göttingen, Germany 
Bovine serum albumin (BSA), fraction V Biomol, Hamburg, Germany, # 01400 
ImageJ 1.48v National Institutes of Health (NIH), Bethesda, 
USA 
 
3.4.4 Blue Native PAGE  
The purity of gp120 monomers and gp140 trimers was analyzed by Blue native 
polyacrylamide gel electrophoresis (BN-PAGE). In brief, 3 μg Env proteins were mixed with 
2x loading dye and directly loaded on precast SERVAGelTM N 4-16 native Gels. BN-PAGEs 
were performed in running buffers for 2 h at 200 V, followed by staining with Coomassie blue 
solution. 
 
2x loading dye 100 mM MOPS, 100 mM Tris-HCl, pH 7.7, 
40 % glycerol, 0.2 % Coomassie Brilliant 
Blue R-250 
Coomassie Brilliant Blue R-250 AppliChem GmbH, Darmstadt, Germany, # 
A1092 
SERVAGelTM N 4-16, Vertical Native Gels 4-
16 % 
SERVA Electrophoresis, Heidelberg, 
Germany, # 43253 
Anode buffer 50 mM Bis Tris-HCl pH 7.0 
Cathode buffer 50 mM Tricine, 15 mM Bis Tris 
Coomassie blue solution 0.125 % (w/v) Coomassie Brilliant Blue R-
250, 50 % (v/v) ethanol, 7 % (v/v) acetic acid 
 
3.4.5 SDS-PAGE, Western Blot and Slot blot analysis 
Proteins were separated according to their size via SDS-PAGE, as described previously169. 
Prior to loading on SDS gels (12.5 %), samples were mixed with 2x Laemmli buffer and 
incubated for 5 min at 95 ⁰C. PageRulerTM Plus Prestained Protein Ladder was used as 
molecular weight marker. Electrophoresis was started by applying 90 V for 30 min (pre-run). 
Afterwards, the voltage was adjusted to 140 V, until the tracking dye reached the bottom of 
the gel. Western Blot transfer of SDS-PAGE separated proteins to nitrocellulose membranes 
was performed using the BlueFlash-L semi-dry blotting unit (SERVA Electrophoresis, 
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Heidelberg, Germany), according to manufacturer`s instructions (1.5 mA/cm2 gel for 1 h). For 
slot blots, protein solutions were transferred to nitrocellulose membranes using the Bio-Dot® 
SF microfiltration apparatus (Bio-Rad, Hercules, USA). Briefly, the membrane was incubated 
for 10 min in transfer buffer and placed in the Bio-Dot apparatus, including five layers of 
transfer-buffer-moistened Whatman blotting papers. A vacuum of 800 mbar was applied and 
after a washing step with 250 μl transfer buffer protein samples, diluted to a final volume of 
200 μl in PBS, were absorbed onto the membrane, followed by a further washing step with 
transfer buffer. Both, nitrocellulose membranes from Western Blot and slot blot experiments, 
were blocked in TBS-M5 overnight at 4 °C. For immunodetection, membranes were washed 
four times with TBS-T, followed by incubation with primary antibodies in TBS-M1 for 1h at 
RT. After washing with TBS-T, membranes were incubated with secondary antibodies (in 
TBS-M1) for 1 h at RT. Membranes were washed with TBS-T, followed by incubation with 
ECL substrate solution for 5 min at RT. After removal of the substrate solution the 
chemiluminescent signal of the peroxidase reaction was detected with a ChemiluxPro device 
(Intas, Göttingen, Germany). 
 
2x Laemmli buffer 125 mM Tris, 2 % (w/v) SDS, 10 % (v/v) β-
mercaptoethanol, 1 mM EDTA, 10 % (w/v) 
glycerol, 0.01 % (w/v) bromophenol blue, pH 
6.8 
PageRulerTM Plus Prestained Protein Ladder ThermoFisher Scientific, # 26620 
Nitrocellulose membranes, Amersham™ 
Protran® 0.2 μm 
GE Healthcare Life Sciences, # 10600001 
Transfer buffer 25 mM Tris, 150 mM glycine, 10 % (v/v) 
methanol 
WhatmanTM 3MM Chr Blotting Paper GE Healthcare Life Sciences, # 3030-917 
Tris buffered saline (TBS) 150 mM NaCl, 50 mM Tris/HCl, pH 7.4 
TBS-M5 TBS, 5 % (w/v) skim milk powder 
TBS-M1 TBS, 1 % (w/v) skim milk powder 
TBS-T TBS, 0.3 % (v/v) Tween-20 
ECL substrate solution 100 mM Tris/HCl pH 8.5, 12.5 mM luminol, 
1.98 mM coumaric acid, 305 μl/l 30 % (v/v) 
H2O2 
Primary α-gp41antibody cocktail for Env 
detection 
Human monoclonal antibodies10E8, 2F5, 
4E10 and 5F3, see Table 4, each at 1 μg/ml  
Primary antibody for p24/p55 detection Clone CB-13/5170,171, monoclonal mouse IgG1 
from hybridoma cell line, dilution 1:1,000. 
Secondary antibodies Polyclonal horseradish peroxidase (HRP)-
conjugated rabbit anti-human and rabbit anti-
mouse immunoglobulin (Ig) fractions (1:2,000 
each), Dako, Agilent, Santa Clara, USA, # 
P0214, # P0260) 
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3.4.6 Anti-Env antibodies 
All human monoclonal antibodies targeting the HIV-1 Env protein that were used in this work 
are listed in Table 4. Monoclonal antibodies PG9, PGT145, PGT135, PGT151, VRC01, 17b, 
F105, and 10E8 were produced in house. Briefly, 293-F cells were transfected with the 
corresponding heavy and light chain genes (both in CMVR expression vectors) in a 1:1 (w/w) 
ratio, using PEI transfection, see 3.3.2. 72 h post transfection, culture supernatants were 
harvested by centrifugation for 10 min at 1,000 g and 4 ⁰C, followed by filtration with 
Filtropur 0.22 μm filters. The supernatants were loaded onto a 1 ml HiTrap® rProtein A FF 
column at a constant flowrate of 1ml/min. After washing with 5 CV PBS, antibodies were 
eluted with 5 CV 0.1 M glycine pH 3.2, followed by neutralization with 1 M Tris-HCl pH 9. 
In case of PGT145 elution was performed with 0.1 M glycine pH 3.2, 0.1 M fructose. Purified 
mAbs were buffer exchanged to PBS or 0.1 M NaHCO3, 0.5 M NaCl, pH 8.3 in case of 
PGT145, using PD-10 columns. Antibody concentrations were determined by photometric 
quantification (absorbance at 280 nm) using a NanoDrop ND-1000 photometer. For MST and 
ELISAs antibody concentrations were recorded in nM with the assumption that the average 
size of an IgG molecule is approximately 150 kDa. 
 
CMVR VRC01 mAb heavy chain and light 
chain expression vectors 
NIH AIDS Reagent Program, Germantown, 
Maryland, USA, # 12035, # 12036 
Filtropur 0.22 μm filters Filtropur L 0.2 LS, Sarstedt, Nümbrecht, 
Germany, # 83.1827.001 
HiTrap® rProtein A FF, 1 ml GE Healthcare Life Sciences, # 17-5079-01 
PD-10 Columns GE Healthcare Life Sciences, # 17-0851-01 
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Table 4. Human monoclonal antibodies targeting the HIV-1 Env protein. 
Antibody Specificity Supplier  
10E8172,173  gp41 MPER In house production 
4E10101,102  gp41MPER Polymun Scientific, 
Klosterneuburg, Austria, # 
AB004 
2F5101,104,103 gp41 MPER Polymun Scientific, 
Klosterneuburg, Austria, # 
AB001 
5F3101,174 gp41 Polymun Scientific, 
Klosterneuburg, Austria, # 
AB010 
PGT151107,108 gp41-gp120 interface In house production 
PG9175,176,177 V1/V2  In house production 
PGT145178,179 V1/V2 In house production 
PGT135178,180 N332 glycan supersite In house production 
2G12101,105 N332 glycan supersite Polymun Scientific, 
Klosterneuburg, Austria, # 
AB002 
VRC01181,182 CD4 binding site In house production 
F105183,184 CD4 binding site In house production 
17b185,186 CD4 induced In house production 
447-52D187,188  V3 loop Polymun Scientific, 
Klosterneuburg, Austria, # 
AB014 
 
3.4.7 Protein labeling 
Antibodies used in MST, flow cytometry or FACS analysis were labeled with fluorescent 
dyes Alexa Fluor™ 647 or Alexa Fluor™ 488 according to manufacturer`s instructions. For 
MST analysis VLPs were labeled using the Monolith NT™ Protein Labeling Kit RED-NHS 
according to manufacturer`s instructions, except for step B in which 10 µl of VLPs were 
mixed with 190 µl of 10.9 µM DY-647P1-NHS-Ester in PBS pH 7.4 containing 2.6 % 
(v/v) DMSO. After an incubation time of 30 min at RT in the dark, VLPs were eluted into 
HBS-EP buffer. Antibodies used in serum ELISAs were biotinylated using the EZ-Link™  
NHS-LC-Biotin reagent. Briefly, EZ-Link™ NHS-LC-Biotin was dissolved in 
dimethylformamide to a final concentration of 10 mM, followed by adding the biotin reagent 
in a 75 molar excess to the antibodies in PBS (40.5 μl 10 mM EZ-Link™ NHS-LC-Biotin per 
1 mg antibody). After an incubation time for 1 h at RT, the buffer was exchanged to PBS 
using NAP™-5 gelfiltration columns and the antibody concentration was determined using a 
NanoDrop ND-1000 photometer (absorbance at 280 nm). 
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Alexa Fluor™ 647 Protein Labeling Kit ThermoFisher Scientific, # A20173 
Alexa Fluor™ 488 Protein Labeling Kit ThermoFisher Scientific, # A10235 
Monolith NT™ Protein Labeling Kit RED-
NHS 
NanoTemper Technologies, Munich, 
Germany, # MO-L001 
DY-647P1-NHS-Ester Dyomics, Jena, Germany, # 647P1-01 
HBS-EP 0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM 
EDTA, 0.005 % (v/v) Surfactant P20 
EZ-Link™ NHS-LC-Biotin ThermoFisher Scientific, # 21336 
NAP™-5 gelfiltration columns GE Healthcare Life Sciences, # 17-0853-01 
  
3.4.8 Poly(lactic acid) particles  
Poly(lactic acid) particles (PLA particles) with adsorbed BG505 SOSIP.664 trimers were 
produced and characterized in the lab of our cooperation partner Bernard Verrier as described 
below. Empty PLA particles, prepared by nanoprecipitation method without any surfactant or 
stabilizer, were purchased from Adjuvatis. For adsorption of BG505 SOSIP.664 trimers, the 
protein was diluted in Dulbecco`s phosphate-buffered saline (DPBS) to final a concentration 
of 100 μg/ml and incubated with PLA particles (10 mg/ml in DPBS) at a 1:1 v/v ratio for 2 h 
at RT under moderate end-overhead stirring. To calculate the amount of adsorbed BG505 
SOSIP.664 trimers, unbound protein was collected in the supernatant by centrifugation at 
10,000 g for 10 min and quantified using the Micro BCA™ Protein Assay Kit. The 
absorbance was measured at 562 nm using a microplate reader. To further characterize the 
particle preparations, the hydrodynamic diameter and size distribution (polydispersity index) 
were determined by dynamic light scattering (DLS). For this purpose, particle preparations 
were diluted in 1 mM NaCl, 0.33 µm filtered, and analyzed using the Zetasizer Nano ZS 
(measurement at 25 °C, scattering angle of 173°). Each particle preparation was analyzed in 
four independent measurements and the mean value was calculated. Furthermore, the 
electrophoretic mobilities (zeta potential) were measured using the Zetasizer Nano ZS but at 
an angle of 12.8°. In summary, two batches of PLA particles with adsorbed BG505 
SOSIP.664 trimers were produced. The average hydrodynamic diameter in the two 
independent preparations was 175 ± 12 nm in size (average size of two batches of empty 
control particles: 136 ± 2 nm) and the average polydispersity index was 0.197 ± 0.028, 
indicating a relatively homogeneous size distribution (control particles: 0.091 ± 0.011). The 
average zeta potential of the two particle preparations was -50 ± 5 mV (control particles: -45 
± 10 mV) and the amount of BG505 SOSIP.664 trimers was calculated about around 47 ± 3 
trimers per particle. 
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PLA particles (i-Particles®) Adjuvatis, Lyon, France 
Dulbecco`s phosphate-buffered saline (DPBS) Gibco/ThermoFisher Scientific, # 14190-086 
Micro BCA™ Protein Assay Kit ThermoFisher Scientific, # 23235 
Multiskan™ FC microplate photometer ThermoFisher Scientific 
Zetasizer Nano ZS Malvern Panalytical, Malvern, UK 
 
3.4.9 ELISA 
ELISA with soluble gp120 and gp140 Env/V3 chimeras 
Nunc MaxiSorp® flat-bottom 96-well plates were coated with 200 ng Galanthus nivalis lectin 
(GNL) in PBS per well over night at 4 °C. After coating, plates were washed with  three well-
volumes PBS-T using the Tecan HydroFlex microplate washer and subsequently blocked with 
200 μl blocking buffer per well for 2 h at RT. Plates were washed with three well-volumes 
PBS-T and incubated with 50 ng Env in PBS per well for 1h at RT. After washing with six 
well-volumes PBS-T, 50 μl mAb 447-52D in binding buffer per well was titrated and 
incubated for 1h at RT. Plates were washed with ten well-volumes PBS-T to remove unbound 
antibodies and antibody binding was detected by incubating plates with 50 μl polyclonal 
horseradish peroxidase (HRP)-conjugated rabbit anti-human Ig (1:5,000 in binding buffer) per 
well for 30 min at RT. After washing with ten well-volumes PBS-T, plates were developed 
with 50 μl 3,3′,5,5′-tetramethylbenzidine (TMB) substrate per well, which was freshly 
prepared by mixing TMB A and TMB B in a 20:1 ratio. The colorimetric reaction was 
stopped by adding 25 μl 1 M H2SO4 per well and the absorbance was measured at 450 nm 
using a microplate reader. The resulting data were corrected by subtracting negative control 
signals (wells without Env proteins, titrated with the very same antibody concentrations) and 
fitted using non-linear least squares regression (one site binding, hyperbola), GraphPad Prism 
5. 
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Nunc MaxiSorp® flat-bottom 96-well plates ThermoFisher Scientific, # 442404 
Galanthus nivalis lectin (GNL) Sigma-Aldrich, # L8275 
PBS-T PBS, 0.05 % (v/v) Tween-20 
Blocking buffer PBS, 5 % (w/v) skim milk powder, 0.1 % 
(v/v) Tween-20 
Binding buffer PBS, 1 % (w/v) BSA 
Anti-Env antibody 447-52D See 3.4.6, Table 4 
Detection antibody Polyclonal HRP-conjugated rabbit anti-human 
Ig fraction, Dako, Agilent, Santa Clara, USA, 
# P0214 
TMB A 30 mM tri-potassium citrate-monohydrate 
adjusted to pH 4.1 with 10 % (w/v) citric acid 
TMB B 0.24 % (w/v) TMB, 10 % (v/v) acetone, 90 % 
(v/v) ethanol, 80 mM H2O2 
HydroFlex microplate washer Tecan, Männedorf, Switzerland 
Microplate reader Model 680 Bio-Rad Laboratories, Hercules, USA 
GraphPad Prism, version 5.04 GraphPad Software, La Jolla, USA 
 
 
His-capture and direct-ELISA with BG505 SOSIP.664 trimers 
His-capture ELISAs with BG505 SOSIP.664 trimers were performed as described above for 
ELISAs with Env/V3 chimeras, with the difference that ELISA plates were coated with 100 
ng 6x-His tag antibody in PBS per well for capturing of His-tagged BG505 SOSIP.664 
trimers. Furthermore, a different antibody panel was titrated, including VRC01, PGT145, 
PGT151, F105 and 2G12. For direct-ELISAs, 50 ng Env in PBS per well were coated to 
ELISA plates over night at 4 °C and after washing with three well-volumes PBS-T, plates 
were blocked with 200 μl blocking buffer per well for 2 h at RT. Next, plates were washed 
with three well-volumes PBS-T, followed by titration of 50 μl mAbs in binding buffer per 
well. MAbs were incubated for 1 h at RT and all subsequent steps were carried out as 
described for ELISAs with Env/V3 chimeras. 
 
6x-His Tag Monoclonal Antibody (HIS.H8) ThermoFisher Scientific, # MA1-21315 
Anti-Env antibodies See 3.4.6, Table 4 
 
PLA and VLP-ELISA 
PLA and VLP-ELISAs were essentially performed as described for direct-ELISAs. For PLA 
ELISAs, plates were coated with 50 ng PLA-adsorbed BG505 SOSIP.664 trimers in PBS per 
well over night at 4 °C and subsequent steps were carried out as described for direct-ELISAs. 
In case of ELISAs with VLP-presented gp145 Env/V3 chimeras, plates were coated with 
VLPs in PBS, containing a total amount of 25 ng Env per well (Env concentrations 
determined by slot blot titration, see 3.4.3). All subsequent steps were performed as described 
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for direct-ELISAs with the differences that all washing steps were performed with three well-
volumes PBS instead of PBS-T and the blocking buffer did not contain Tween-20. 
 
PLA-adsorbed BG505 SOSIP.664 trimers See 3.4.8 
VLP-presented gp145 Env/V3 chimeras See 3.4.3 
 
Serum ELISA 
Serum ELISAs of Env proteins and VLPs were performed as described for the respective 
ELISAs in buffer, with the difference that biotinylated mAbs were incubated in presence of 
50 % human serum (100 % serum mixed v/v with PBS). Further, HRP-conjugated 
streptavidin (1:10,000 in binding buffer) was used for detection. 
 
Antibody biotinylation See 3.4.7 
Human serum Sigma-Aldrich, # H4522 
Streptavidin-POD conjugate Roche, Basel, Switzerland, # 11 089 153 001 
 
3.5 MicroScale Thermophoresis 
MST experiments were performed at 25 °C in premium coated glass capillaries on a Monolith 
NT.115Pico device. The measurement conditions for the analysis of the Env/V3 chimeras 
(gp120 monomers, gp140 trimers and VLP-presented gp145) in buffer or 50 % human serum 
are shown in Table 5 and Table 6, respectively. BG505 SOSIP.664 trimers (soluble or 
adsorbed to PLA particles) were analyzed in buffer or 50 % human serum under conditions 
described in Table 7. For measurement, the fluorescent-labeled interaction partner was kept at 
constant concentration in reaction buffer and the unlabeled interaction partner was used as 
titrant in a 1:2 dilution series. Measurement results were analyzed using the NT Analysis 
software (analysis from best signal to noise ratio). To calculate the fraction bound ratio, the 
baseline corrected normalized fluorescence (ΔFNorm) value of each point was divided by the 
amplitude of the fitted curve. The resulting values, ranging from 0 to 1 (0=unbound, 
1=bound), were processed with KaleidaGraph and fitted using the KD fit formula, derived 
from the law of mass action. 
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Monolith NT.115Pico NanoTemper Technologies, Munich, Germany 
Monolith™ NT.115 MST Premium Coated 
Capillaries 
NanoTemper, # MO-K005 
NT Analysis software, version 1.5.41 NanoTemper Technologies 
KaleidaGraph, version 4.5 Synergy Software, Reading, Pennsylvania, 
USA 
Human serum Sigma-Aldrich, # H4522 
HBS-EP 0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM 
EDTA, 0.005 % (v/v) Surfactant P20 
Anti-Env antibodies and protein labeling See 3.4.6, Table 4 and 3.4.7 
 
Table 5. MST measurement conditions for Env/V3 chimeras in buffer. 
 gp120 monomers gp140 trimers VLP-presented gp145 
Fluorescent-labeled 
interaction partner 
Alexa647-labeled 447-
52D at 0.25 - 0.5 nM 
Alexa647-labeled 447-
52D at 0.05 nM 
DY-647P1-labeled VLPs with 
Env concentrations < 1 ng/μl 
Titrant 
MN: 50 nM - 2 pM 
HXB2: 1556 nM - 50 pM 
CDC42: 826 nM - 25 pM 
RF: 920 nM - 28 pM 
SF33: 1101 nM - 34 pM 
MN: 25 nM - 1 pM 
HXB2: 100 nM  - 3 pM 
CDC42: 100 nM  - 3 pM 
RF: 100 nM -  3 pM 
SF33: 2569 nM  - 78 pM 
447-52D: 1803 nM - 55 pM 
Reaction buffer HBS-EP 
MST power 80 % 
LED power 30 - 85 % 100 % 2 – 20 % 
 
Table 6. MST measurement conditions for Env/V3 chimeras in 50 % human serum. 
 gp120 monomers gp140 trimers VLP-presented gp145 
Fluorescent-labeled 
interaction partner 
Alexa647-labeled 447-52D at 0.5 nM 
DY-647P1-labeled VLPs with 
Env concentrations < 1 ng/μl 
Titrant 
MN: 800 nM - 24 pM 
HXB2: 1556 nM - 50 pM 
CDC42: 800 nM - 24 pM 
RF: 800 nM - 24 pM 
SF33: 800 nM - 24 pM 
MN: 25 nM - 1 pM 
HXB2: 100 nM - 3 pM 
CDC42: 100 nM - 3 pM 
RF: 100 nM - 3 pM 
SF33: 100 nM - 3 pM 
447-52D: 900 nM  - 27 pM 
Reaction buffer 50 % HBS-EP, 50 % human serum (v/v) 
MST power 80 % 
LED power 5 - 7 % 10 - 15 % 10 – 20 % 
 
Table 7. MST measurement conditions for soluble and PLA-adsorbed BG505 SOSIP.664 trimers in buffer and 50 % 
human serum. 
 
BG505 SOSIP.664 trimers 
PLA-adsorbed 
BG505 SOSIP.664 trimers 
 
Buffer 
50 % human 
serum 
Buffer 
50 % human 
serum 
Fluorescent-labeled 
interaction partner 
Alexa647-labeled mAbs VRC01, PGT145, PGT151, F105 and 2G12 at 0.25 nM 
Titrant BG505 SOSIP.664: 150 nM - 5 pM 
PLA-adsorbed BG505 SOSIP.664 trimers: 
96 nM - 3 pM 
Reaction buffer HBS-EP 
50 % HBS-EP, 
50 % human serum 
(v/v) 
50 % HBS-EP, 
50 % PBS (v/v) 
50 % PBS, 
50 % human serum 
(v/v) 
MST power 80 % 
LED power 15 - 30 % 12 - 20 % 30 % 15 % 
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4. Results 
4.1 MicroScale Thermophoresis and ELISA analysis of 
Env proteins 
One objective of this thesis was to explore the opportunities of MST to analyze Env-antibody 
interactions of soluble and particle-presented Env proteins in buffer and presence of serum. 
Using two different model systems, a comprehensive and detailed analysis of Env-antibody 
interactions was performed. The first model system included a five-member Env/V3 chimeric 
model library with distinct binding capacities to monoclonal antibody 447-52D (see 4.1.2). 
This model system was used to step-by-step establish MST measurements of different 
oligomeric and particle-presented forms of Env, including gp120 monomers, gp140 trimers 
and VLP-presented gp145 variants. Thereby, Env proteins were analyzed in both, buffer and 
human serum. In order to test if MST measurements affect the structure of stabilized trimers 
and, as well to include a relevant Env immunogen in MST analyses, BG505 SOSIP.664 
trimers and set of quaternary structure-characterizing antibodies were used as a second model 
system (see 4.1.12). Further, based on promising results, MST was utilized to characterize 
PLA particle-presented BG505 SOSIP trimers. Like for experiments with Env/V3 chimeras, 
all experiments were performed in buffer and human serum. In addition, ELISA experiments 
were performed in parallel to benchmark results obtained from MST measurements. 
4.1.1 MicroScale Thermophoresis 
The optical based in solution method MST utilizes the physical phenomenon of 
thermophoresis, describing the directed movement of molecules in a temperature gradient, 
which is in this case established by an infrared laser (see Figure 16A). Thermophoresis 
depends on molecule size, charge, and the hydration shell. Since at least one of these 
parameters is affected by the binding of an interaction partner, this technique can be used to 
distinguish unbound and bound states and hence determine the equilibrium binding affinities 
of molecular interaction partners at microliter scale189,190. As a detection prerequisite, 
molecules either have to be fluorescently labeled or intrinsically fluorescent, such as proteins 
with one or several tryptophan residues. The fluorescence within the observation window is 
monitored over time (see Figure 16B). The initial fluorescence is typically monitored over 
five seconds before laser activation. Switching on the laser initializes a steep drop of the 
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fluorescence signal, reflecting temperature dependent changes in the quantum yield of the 
fluorophore. After this phase, called Temperature Jump or T-Jump, thermophoresis forces 
molecules to leave the observation window, leading to a decrease of overall fluorescence until 
thermophoresis is counterbalanced by mass diffusion. Thermophoresis is terminated upon 
deactivation of the laser. Ultimately, back-diffusion of molecules and reverse T-Jump result in 
increase of fluorescence in the observation window. In a typical MST experiment, a serial 
dilution of the ligand is prepared and mixed with a constant concentration of labeled target 
molecule to establish different ratios of the binding partners. The samples are loaded into 
capillaries and analyzed in the instrument by subsequent scanning of each capillary. The 
resulting movement profiles (MST time traces) of the different ratios of interaction partners 
are plotted in one graph (see Figure 16C). The normalized fluorescence (FNorm) is 
calculated from the ratio between the fluorescence after heating (Fhot) and before heating 
(Fcold). Plotting the baseline corrected FNorm (ΔFNorm) against ligand concentrations and 
subsequent curve fitting results in binding graphs and corresponding affinity values (see 
Figure 16D).  
 
 
Figure 16. (A) Technical setup of MicroScale Thermophoresis (MST). Thin glass capillaries are filled with sample 
molecules. Fluorescence signals originating from the optically visible interaction partner in the sample are monitored via 
optics. A thermal gradient is applied by a laser source. Changes in fluorescence can be used to monitor thermophoretic 
movement of the molecules in solution. (B) MST time trace – movement profile of molecules in a temperature gradient. 
Fluorescence is monitored over time. After an initial 5 sec cold phase (laser off), the laser is switched on and establishes the 
temperature gradient. After the T-Jump phase, in which the fluorescent dye decreases its signal yield upon heat induction, the 
thermophoretic movement takes place. After 30 sec the laser is turned off and the molecules diffuse back. (C) Results of a 
typical MST experiment: The MST time traces of 16 capillaries containing the same concentration of optical visible 
interaction partner and an increasing concentration of the unlabeled ligand are recorded and plotted on one graph. (D) The 
normalized fluorescence (FNorm) of the MST traces is calculated from the ratio between the fluorescence after heating (Fhot) 
and before heating (Fcold). Finally, the baseline corrected FNorm (ΔFNorm) is plotted against the concentration of the ligand 
and data points are fitted to obtain binding parameters such as the binding affinity. The figure was kindly provided by 2bind. 
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4.1.2 The Env/V3 model system 
To investigate Env-antibody interactions by MST and ELISA a previously described model 
system consisting of five Env/V3 chimeras and the mAb 447-52D187,188 (Core epitope: amino 
acid motif GPGR in the V3 crown) was used. The five Env/V3 chimeras are based on the 
backbone of the subtype C isolate 96ZM651 (GenBank # AF286224.1), with the autologous 
V3 loop substituted by the V3 loops of the isolates MN, HXB2, CDC42, RF and SF33 (see 
Figure 17). It has been shown recently that 447-52D binds with distinct binding capacities to 
membrane-bound gp145 versions of the Env/V3 chimeras in cytometer-based titration assays. 
Furthermore, ELISA titrations have shown that the affinity ranking, with variant MN 
depicting the best binding, closely followed by HXB2 and CDC42, while variant RF exhibits 
only low binding and SF33 no binding, is transferable from membrane-bound to soluble 
trimeric gp140 versions of the Env/V3 chimeras154. Thus, this model system represents a 
valuable tool to investigate Env-antibody interactions by MST and ELISA. 
 
Figure 17. Schematic presentation of soluble monomeric gp120, trimeric gp140 and membrane-bound gp145 Env/V3 
chimeras. Constant regions (C1-C5), variable loops (V1-V5) as well as heptad repeats 1 and 2 (HR1, HR2), membrane-
proximal external region (MPER) and transmembrane domain (TM) are indicated. The intrinsic V3 loop of the HIV-1 isolate 
96ZM651 was substituted by the V3 loops of the isolates MN, HXB2, CDC42, RF and SF33, resulting in five chimeric Env 
variants with distinct binding affinities to the antibody 447-52D. To create soluble gp140 versions of the proteins the gp41 
TM was deleted and a C-terminal Flag/His6-tag was added for affinity purification. Furthermore, the natural cleavage site was 
changed from REKR to REKS to prevent cleavage. To create monomeric gp120 versions of the protein the gp41 domain was 
completely deleted. 
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4.1.3 Production of soluble and VLP-presented Env/V3 chimeras 
for MST and ELISA analysis 
For the step-by-step analysis of Env-antibody interactions by MST and ELISA, Env/V3 
chimeras were produced in different oligomerization states (gp120 monomers, gp140 trimers) 
and as HIV-1 Gag VLP-presented gp145 Env/V3 chimeras. Soluble gp120 and gp140 Env/V3 
(inactivated cleavage site, REKS) chimeras were produced by transient transfection of 293F 
suspension cells with the respective Env expressing plasmids and purified to monomer/trimer 
homogeneity using affinity and size exclusion chromatography, as described in 3.4.2. SEC 
profiles with indicated monomer and trimer fractions are shown in Appendix Figure 1. 
Pooled monomer and trimer fractions were quality controlled by BN-PAGE (see 3.4.4). As 
shown in Figure 18, Env/V3 chimeras of gp120 and gp140 trimers have been successfully 
purified. However, both, gp120 and gp140 preparations contained some dimer/aggregate 
contaminations that could not be separated. As depicted in Appendix Figure 1, the protein 
peaks flowed smoothly into each other, which did not allow a clear-cut fractionation of 
monomers and trimers without substantial loss of protein. Of note, contrary to gp140 Env/V3 
chimeras, it was not possible to purify tagged gp120 Env/V3 chimeras since addition of the 
Flag/His6-tag in this case resulted in aggregation of the proteins. 
 
 
Figure 18. BN-PAGE analysis of affinity/SEC 
purified gp120 and gp140 Env/V3 chimeras. 
Molecular weight (MW) markers are indicated. 
VLPs were produced by cotransfection of 293F cells with Gag and cleavage competent 
(REKR) gp145 Env/V3 chimeras expressing plasmids and purified from cell culture 
supernatants using sucrose cushion and sucrose density gradient ultracentrifugation (3.4.3). 
Gag and Env concentrations in the VLP preparations were semi-quantitatively assessed by 
densitometric quantification of SDS-gel and slot blot analyses (3.4.3). For quality control of 
final VLP preparations a Western blot was performed. In the Western blot an α-gp41 antibody 
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cocktail and an α-p24/p55 antibody were used for Env and Gag detection, respectively (3.4.5). 
As shown in Figure 19, all Env/V3 chimeras-carrying VLPs showed a signal for Gag and 
Env, indicating the successful incorporation of Env into membrane of VLPs. Blank VLPs 
(Gag w/o, no cotransfection of Env) that were used as control exhibited a Gag, but no Env 
signal. The supernatant of cells that were transfected with an Env but without a Gag 
expressing plasmid (Env w/o) was purified according the VLP purification protocol and used 
as additional control. As expected, this control resulted in neither, an Env nor a Gag signal. 
Further, a strong signal at 35 kDa compared to the signal at 130 kDa indicates that the bulk of 
Env protein in VLP-presented Env/V3 chimeras was cleaved into gp120 (not visible since 
anti-gp41 antibodies were used for detection) and gp41 subunits. 
 
 
 
 
Figure 19. Analysis of Env/V3 pseudotyped VLPs. 
VLP samples were loaded on a reducing SDS gel 
(loading amount: ~ 200 ng Gag, according to 
densitometrical analysis) and analyzed by 
immunoblotting for presence of Gag (α-p24/p55 
antibody CB-13/5) and Env (α-gp41 mix). Co-
banding of Gag and Env in Env/V3 VLPs (lane 4-8) 
indicates incorporation of Env into the membrane of 
VLPs. A strong gp41 signal at 35 kDa, compared to 
the signal at 130 kDa, indicates that the bulk of 
protein is cleaved. A soluble gp140 standard protein 
(96ZM651) (lane 1), Env without cotranfected Gag 
(Env w/o) (lane 2) and blank Gag VLPs without 
cotransfected Env (Gag w/o) (lane 3) were used as 
positive and negative controls, respectively. Data 
were generated during the doctoral thesis of Tobias 
Fischer under my experimental supervision. 
 
In summary, Env/V3 chimeras of gp120 monomers, gp140 trimers and VLP-presented gp145 
Env have been successfully purified and were subsequently used for MST and ELISA 
analyses. 
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4.1.4 Interactions between mAb 447-52D and soluble, monomeric 
gp120 Env/V3 chimeras in buffer 
In the first step, interactions between mAb 447-52D and monomeric gp120 Env/V3 chimeras 
were analyzed in buffer, since these interactions represent the most simple in the Env/V3 
model system. For MST analyses, the Alexa647-labeled 447-52D was kept at constant 
nanomolar concentrations and monomeric Env/V3 chimeras were used as titrants, see 3.5 with 
measurement conditions in Table 5. In order to avoid labeling of Env proteins, this 
experimental setup was chosen for MST analyses of soluble Env proteins in general. Using 
common protocols, labeling takes place statistically, mainly at lysine residues of a protein. 
This in turn can affect antibody epitopes either by blocking lysines required for antibody 
binding or maybe by sterical hindrance due to lysines carrying a fluorescent dye close to 
antibody epitopes. In addition, general experiences in our group with fluorescent-labeled 
antibodies (flow cytometry, FACS) showed that antibodies commonly well-tolerate labeling 
with fluorescent dyes. MST data from titrations were processed as following: In order to 
calculate a fraction that relates the amount of bound antibodies to the amount of unbound 
antibodies, the ΔFNorm value of each point was divided by the amplitude of the fitted curve, 
resulting in values from 0 to 1 (0=unbound, 1=bound), processed using the KaleidaGraph 4.5 
software and fitted using the KD fit formula derived from the law of mass action (3.5). The 
resulting binding curves (see Figure 20A) with corresponding equilibrium dissociation 
constants (KD)s, see Table 8, showed that 447-52D bound with distinct binding affinities to 
the gp120 Env/V3 chimeras, with MN being the best binding variant, followed by CDC42 and 
HXB2 which bound with similar affinity. Both, RF and SF33 exhibited marginal/no binding. 
Next, gp120 Env/V3-447-52D interactions were analyzed by ELISA. In general, following 
typical ELISA setups for the analyses Env-antibody interactions described in 
literature61,127,125, soluble Env proteins were immobilized by capturing of Env proteins, 
whereas antibodies were used as titrants. For the analysis of gp120 Env/V3-447-52D 
interactions, gp120 Env/V3 chimeras were captured via GNL while 447-52D was titrated 
(3.4.9). GNL was used for capturing since gp120 Env/V3 chimeras were expressed without a 
His-tag, representing one of the commonly used tags for protein capturing (e.g. via coated 
anti-His antibodies). However, as shown in Figure 20B with corresponding KD-values in 
Table 8, ELISA results validated affinity data measured by MST since the results were highly 
comparable. In both, MST and ELISA, variant MN exhibited the best binding, closely 
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followed by CDC42 and HXB2 which bound with similar affinity to 447-52D, whereas RF 
and SF33 bound only marginally or not at all. 
 
Figure 20. Interaction of mAb 447-52D with monomeric gp120 Env/V3 chimeras in buffer, quantified by MST and 
ELISA. For MST analysis (A), gp120 Env/V3 chimeras diluted in buffer were titrated to the Alexa647-labeled 447-52D 
which was kept at constant concentration. Results of the MST measurements are presented as normalized binding curves of 
three independent experiments, error bars reflect the standard error of the mean (SEM) of the independent experiments. (B) 
Validation of MST by ELISA: Binding of 447-52D to monomeric gp120 Env/V3 chimeras was assessed by a lectin 
(Galanthus nivalis) capture-ELISA (negative control: Wells coated with lectin, incubated with PBS). 447-52D, diluted in 
binding buffer, was titrated to immobilized Env proteins at indicated concentrations and a HRP-conjugated polyclonal rabbit 
anti-human Ab was used for readout. ELISAs were performed in two independent experiments, error bars reflect the SEM of 
the independent experiments. 
 
4.1.5 Interactions between mAb 447-52D and soluble, trimeric 
gp140 Env/V3 chimeras in buffer 
The next step included the analysis of interactions between 447-52D and trimeric gp140 
Env/V3 chimeras. MST measurements were performed in buffer as described above and 
under measurement conditions summarized in 3.5, Table 5. The resulting binding curves 
(Figure 21A) showed that the affinity ranking, as determined for gp120 Env/V3 chimeras 
before, was mostly preserved also in measurements with gp140 Env/V3 chimeras. However, 
the binding affinity of variants MN, HXB2 and CDC42 to 447-52D can be considered as 
similar since binding curves were in close range to each other. Further, whereas the 
monomeric gp120 variant RF showed no saturated binding to 447-52D, this was the case for 
the trimeric version of the protein. KD-values, calculated from the MST binding curves of 
MN, HXB2, CDC42, and also RF indicate that 447-52D binds trimeric gp140 Env/V3 
chimeras with higher affinities, compared to monomeric gp120 versions of the proteins (see 
Table 8). However, the KD-values determined for gp140 Env/V3 chimeras MN, HXB2 and 
CDC42 can be only seen as an orientation as these variants bound with affinities that seemed 
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to be far beneath the concentration of the fluorescent-labeled 447-52D (0.05 nM), and thus at 
the detection limit (using lower amount of labeled 447-52D was not possible without falling 
below the required fluorescent signal). GNL capture-ELISAs (3.4.9) with gp140 Env/V3 
chimeras produced comparable results. Within ELISA of gp140 Env/V3 chimeras, variants 
MN, HXB2 and CDC42 bound with similar affinities to 447-52D, while variant RF and SF33 
showed reduced and no binding, respectively, see Figure 21B. In general, as also observed in 
MST analysis, 447-52D seems to bind with higher affinities to trimeric gp140 Env/V3 
chimeras compared to gp120 versions of the proteins. However, in ELISA this was limited to 
Env/V3 chimeras HXB2, CDC42 and RF, while gp140 MN exhibited a binding affinity 
comparable to gp120 MN (see Table 8). Importantly, the absolute KD-values calculated from 
the interactions between gp140 Env/V3 chimeras and 447-52D (throughout all following 
analyses) differed between MST and ELISA. Thus, all calculated affinity values are only 
comparable within the respective method used. 
 
Figure 21. Interaction of mAb 447-52D with trimeric gp140 Env/V3 chimeras in buffer, quantified by MST and 
ELISA. For MST analysis (A), gp140 Env/V3 chimeras diluted in buffer were titrated to the Alexa647-labeled 447-52D 
which was kept at constant concentration. Results of the MST measurements are presented as normalized binding curves of 
three independent experiments, error bars reflect the SEM of the independent experiments. (B) Validation of MST by ELISA: 
Binding of 447-52D to trimeric gp140 Env/V3 chimeras was assessed by a lectin (Galanthus nivalis) capture-ELISA 
(negative control: Wells coated with lectin, incubated with PBS). 447-52D, diluted in binding buffer, was titrated to 
immobilized Env proteins at indicated concentrations and a HRP-conjugated polyclonal rabbit anti-human Ab was used for 
readout. ELISAs were performed in two independent experiments, error bars reflect the SEM of the independent experiments. 
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4.1.6 Interactions between mAb 447-52D and VLP-presented gp145 
Env/V3 chimeras in buffer 
As described in 1.5.3, there exist several reasons to use particle-presented Env immunogens 
for vaccination. However, especially in case of particle-presented native-like trimers it has to 
be ensured that they retain their favorable antigenicity profile, which has therefore to be 
analyzed. Nevertheless, analysis of the interaction between particle-presented Env and 
antibodies is rather complex. For example, depending on the particle type, surface 
immobilization of particles may result in the disruption of particles and/or disturbance of the 
structure of presented Env proteins. Since measurements in solution avoid this kind of 
problem from the outset, it was reasonable to test if MST is capable to measure affinity 
interactions between antibodies and particle-presented Env proteins. Since VLPs are relatively 
easy to produce, HIV-1 Gag VLPs decorated with gp145 Env/V3 chimeras were chosen as a 
model system for particle-presented Env proteins. MST analysis of the interaction between 
447-52D and the VLP-presented Env/V3 chimeras in buffer was performed using VLP-
presented Env/V3 chimeras as fluorescently-labeled interaction partners while 447-52D was 
used as titrant (for measurement conditions see 3.5, Table 5). This experimental setup was 
chosen because VLPs contain -next to gp145 Env proteins- all cellular components, including 
membrane proteins present on the cell surface, which allow an efficient labeling with 
fluorescent dyes via NHS-chemistry. In turn, using the antibody as titrant allows precise 
characterization of KD-values, since antibody concentrations can be easily determined. The 
resulting binding curves (Figure 22A) with corresponding KD-values (Table 8) showed that 
the VLP variants MN, CDC42 and HXB2 bound with similar affinities to 447-52D, whereas 
marginal/no binding was detected for variants RF, SF33 and blank VLPs (Appendix Figure 
2A). This in general reflected the results of measurements with gp140 Env/V3 chimeras, with 
the difference that variant RF displayed only indicated binding to 447-52D in the VLP-
context, whereas saturated binding to 447-52D was observed for the gp140 RF trimer. To 
validate MST results, VLP-ELISA experiments were performed (3.4.9, VLP-ELISA), in 
which VLP-presented Env/V3 chimeras were adsorbed to the surface of ELISA plates and 
447-52D was used as titrant. ELISA binding curves (Figure 22B) and corresponding the KD-
values (Table 8) showed that VLP variants MN, HXB2 and CDC42 bound with comparable 
affinities to 447-52D, whereas a lower affinity was measured for VLP variant RF and no 
binding to SF33 and blank VLPs (Gag w/o). ELISA data basically reflected results obtained 
from MST measurements, with the difference that saturated binding of 447-52D to VLP 
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variant RF was only detected in ELISA. Of note, as described above, KD-values were only 
comparable within one method. Interestingly, regarding the absolute binding signal, VLP-
ELISA binding curves showed a different picture compared to ELISAs with gp120 monomers 
and gp140 trimers, see Figure 23. In ELISAs with gp120 Env/V3 chimeras, the best binding 
variant MN also showed the highest overall signal. Similar was true for MN in ELISAs with 
gp140 Env/V3 chimeras, also not as distinctly as in gp120 ELISAs. However, despite of high 
affinity binding (according to the calculated KD) in VLP-ELISA, MN exhibited the lowest 
absolute binding signal. This can most likely be explained by the fact that Env concentrations 
in VLP preparations were determined by semi-quantitative slot blot titration. Thus, the 
amount of VLP-presented Env used for coating ELISA plates slightly varied within the 
different VLP preparations, resulting in varying absolute binding signals. In summary, results 
demonstrated that MST is capable to measure the affinities of the interactions between VLP-
presented Env/V3 chimeras and 447-52D as confirmed by ELISA. In conclusion, MST 
represents a valuable tool to investigate interactions of antibodies and particle-presented Env 
molecules. 
 
Figure 22. Interaction of mAb 447-52D with VLP-presented Env/V3 chimeras in buffer, quantified by MST and 
ELISA. (A) MST analysis of VLP-presented Env/V3 chimeras in buffer. 447-52D, diluted in buffer, was titrated to DY-
647P1-labeled VLPs which were kept at constant concentration. Results of the MST measurements are presented as 
normalized binding curves of two independent experiments, error bars reflect the SEM of the independent experiments. (B) 
Validation of MST by ELISA: Binding of 447-52D to VLP-presented Env/V3 chimeras was assessed by direct-ELISA. VLPs 
were directly coated to ELISA plates (negative controls: Wells coated with blank VLPs (Gag w/o) and PBS, respectively). 
447-52D, diluted in binding buffer, was titrated to coated VLPs at indicated concentrations and a HRP-conjugated polyclonal 
rabbit anti-human Ab was used for readout. ELISAs were performed in two independent experiments, error bars reflect the 
SEM of the independent experiments. VLP-ELISA data were generated during the doctoral thesis of Tobias Fischer under my 
experimental supervision. 
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4.1.7 Summary: Interactions between Env/V3 chimeras and mAb 
447-52D in buffer 
In summary, experiments with the Env/V3 model system have shown that MST provided 
consistent data within the overall expected affinity ranking (MN≥CDC42/HXB2>RF>SF33) 
of the interactions between gp120, gp140 and VLP-presented gp145 Env/V3 chimeras and 
447-52D. Further, MST-derived data haven been successfully validated by ELISA 
experiments, see Figure 23. However, the calculated KD-values were only comparable within 
the respective measurement method used, see Table 8. In general, 447-52D bound with 
higher overall affinities to soluble trimeric gp140 Env/V3 chimeras compared to monomeric 
gp120 versions of the protein, in both, MST and ELISA analyses. VLP analyses were 
excluded from this comparison since different experimental setups were used for their 
analysis in both, MST and ELISA. These included labeling of VLPs instead of the antibody in 
MST analyses (potentially affecting the 447-52D epitope) and direct coating of VLPs (instead 
of lectin capture) in the VLP ELISA setup. 
 
Table 8. Apparent equilibrium dissociation constants of the 447-52D-Env/V3 chimera interactions in buffer. KD-values 
in nM represent the mean value, ± the SEM of n experiments. Detectable, but not saturated signals were excluded from KD-
fitting and are therefore designated as “binding indicated“. Background-level binding is designated as “no binding” (n.b.). 
ELISA KD-values were calculated by using non-linear least squares regression (one site binding, hyperbola; GraphPad Prism 
5). MST KD-values are computed by the KD-fit model of KaleidaGraph. R2-values of the respective fits are included in 
brackets. 
 gp120 monomers gp140 trimers 
VLP-presented 
gp145 
 
Env/V3 
chimera 
MST 
(n=3) 
ELISA 
(n=2) 
MST 
(n=3) 
ELISA 
(n=2) 
MST 
(n=2) 
ELISA 
(n=2) 
Affinity 
ranking 
MN 
0.14 ± 0.05 
(R2=0.9676) 
0.63 ± 0.14 
(R2=0.9743) 
0.0025± 
0.0044 
(R2=0.9021) 
0.26 ± 0.03 
(R2=0.9917) 
1.5 ± 0.9 
(R2=0.8906) 
0.053 ± 
0.018 
(R2=0.9291) 
1 
HXB2 
3.4 ± 0.8 
(R2=0.9729) 
1.6 ± 0.6 
(R2=0.9192) 
0.020 ± 
0.019 
(R2=0.8188) 
0.36 ± 0.13 
(R2=0.9409) 
8.7 ± 4.0 
(R2=0.9197) 
0.064 ± 
0.028 
(R2=0.8955) 
2/3 
CDC42 
1.6 ± 0.7 
(R2=0.9046) 
2.2 ± 0.7 
(R2=0.9404) 
0.070 ± 
0.058 
(R2=0.8350) 
0.39 ± 0.10 
(R2=0.9712) 
2.1 ± 1.5 
(R2=0.8579) 
0.11 ± 0.03 
(R2=0.9626) 2/3 
RF b.i. b.i. 
0.62 ± 0.18 
(R2=0.9581) 
11 ± 1 
(R2=0.9956) 
b.i. 
3.2 ± 0.6 
(R2=0.9812) 4 
SF33 b.i. b.i. b.i. n.b. b.i. n.b. 5 
KD (nM) 
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Figure 23. Interaction of mAb 447-52D with Env/V3 chimeras in buffer, quantified by MST and ELISA. MST (left 
panel) and ELISA analyses (right panel) of the interactions between 447-52D and monomeric gp120, trimeric gp140 and 
VLP-presented gp145 Env/V3 chimeras are shown in (A), (B) and (C), respectively. For MST analyses of gp120 and gp140 
Env/V3 chimeras, Env proteins diluted in buffer were titrated to the Alexa647-labeled 447-52D which was kept at constant 
concentration. MST analysis of VLP-presented gp145 Env/V3 chimeras was performed in an inverse setup (447-52D was 
titrated to DY-647P1-labeled VLPs). Results of the MST measurements are presented as normalized binding curves of at 
least two independent experiments, error bars reflect the SEM of the independent experiments. Validation of MST by ELISA: 
Binding of 447-52D to gp120 and gp140 Env/V3 chimeras was assessed by a lectin (Galanthus nivalis) capture-ELISA 
(negative control: Wells coated with lectin, incubated with PBS). 447-52D, diluted in binding buffer, was titrated to 
immobilized Env molecules at indicated concentrations and a HRP-conjugated polyclonal rabbit anti-human Ab was used for 
readout. Env/V3-VLPs were directly coated to ELISA plates and analyzed in the same way (negative controls: Wells coated 
with blank VLPs (Gag w/o) and PBS, respectively). All ELISAs were performed in two independent experiments, error bars 
reflect the SEM of the independent experiments. 
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4.1.8 Interactions between mAb 447-52D and soluble, monomeric 
gp120 Env/V3 chimeras in 50 % human serum  
Ideally, binding analysis of interaction partners should be performed under physiological 
conditions, since the environment of interaction potentially affects the behavior of interaction 
partners. Serum proteases, for example, are known to clip the V3 region of gp120 in subtype 
B Env proteins and thereby damaging protein structure (see 1.6). In order to test if MST is in 
principle capable to determine affinities under physiological conditions, analysis of the 
interactions between 447-52D and Env/V3 chimeras were repeated in presence of human 
serum. Initial experiments showed that measurements 100 % human serum were not possible 
due to high background signals (data not shown). However, using 50 % serum resulted in 
evaluable data. Thus, the interactions between 447-52D and gp120, gp140 and VLP-presented 
Env/V3 chimeras were investigated under this “near-physiological” condition. 
MST analyses of the interactions between gp120 Env/V3 chimeras and 447-52D in presence 
of 50 % serum (for measurement conditions see 3.5, Table 6)  showed that the binding 
profiles, see Figure 24A, were in agreement with the measurements for gp120 monomers in 
buffer (with MN depicting the best binding, followed by CDC42/HXB2 and only indicated 
binding of RF and SF33, see Figure 20A). However, the overall binding affinity of 447-52D 
seemed to be reduced in the presence of serum (compare KD-values obtained from serum, 
Table 9, and buffer measurements, Table 8). In order to validate MST results, GNL capture-
ELISAs were performed, in which biotinylated 447-52D was incubated in the presence of 50 
% serum (see 3.4.9, Serum ELISA). ELISA analysis in 50 % serum showed that the affinity 
ranking determined by MST was also preserved in ELISA analyses (Figure 24B), thereby 
validating MST derived data. Interestingly, and contrary to MST results described above, the 
presence of serum in ELISA analyses of  gp120 Env/V3 chimeras did not result in a reduced 
affinity of 447-52D (compare KD-values of gp120 Env/V3 chimeras in buffer, Table 8, and 
serum, Table 9). 
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Figure 24. Interaction of mAb 447-52D with monomeric gp120 Env/V3 chimeras in 50 % human serum, quantified by 
MST and ELISA. For MST analysis (A), gp120 Env/V3 chimeras diluted in 50 % human serum were titrated to the 
Alexa647-labeled 447-52D which was kept at constant concentration. Results of the MST measurements are presented as 
normalized binding curves of two independent experiments, error bars reflect the SEM of the independent experiments. (B) 
Validation of MST by ELISA: Binding of 447-52D to monomeric gp120 Env/V3 chimeras was assessed by a lectin 
(Galanthus nivalis) capture-ELISA (negative control: Wells coated with lectin, incubated with PBS). Biotinylated 447-52D, 
diluted in 50 % human serum, was titrated to immobilized Env proteins at indicated concentrations and streptavidin-POD 
conjugate was used for readout. ELISAs were performed in two independent experiments, error bars reflect the SEM of the 
independent experiments. 
 
4.1.9 Interactions between mAb 447-52D and soluble, trimeric 
gp140 Env/V3 chimeras in 50 % human serum 
Next, MST was used to analyze interactions between trimeric gp140 Env/V3 chimeras and 
447-52D in the presence of 50 % serum (for experimental conditions see 3.5, Table 6). The 
resulting binding curves demonstrated that variants MN, HXB2 and CDC42 bound with 
similar affinities to 447-52D, see Figure 25A. Thus, the binding profile of these three gp140 
Env/V3 chimeras in serum is comparable to the binding profile of the same proteins analyzed 
in buffer, see Figure 21A. However, the overall binding affinity of 447-52D to gp140 Env/V3 
chimeras was reduced in presence of serum, as it was already observed in the analyses of 
gp120 Env/V3 chimeras (compare MST-derived KD-values of gp120/gp140 Env/V3 chimeras 
analyzed in buffer, Table 8, and in presence of serum, Table 9). In addition, while 447-52D 
showed saturated binding to gp140 Env/V3 chimera RF in buffer measurements, this was not 
the case in presence of serum. Here, as variant SF33, RF showed only indicated/no binding.  
GNL capture-ELISAs with gp140 Env/V3 chimeras in serum demonstrated similar results. 
Within ELISA, variants MN, HXB2 and CDC42 bound with similar affinities to 447-52D 
whereas variants RF and SF33 showed reduced and no binding, respectively (Figure 25B). 
Thus, ELISA basically reflected and thereby validated MST data. Further, as previously 
observed for MST and ELISA analyses in buffer, 447-52D seems to bind with higher 
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affinities to trimeric gp140 Env/V3 chimeras than to the corresponding monomeric gp120 
versions of the protein since this was also the case in serum measurements (compare KD-
values of gp120 and gp140 Env/V3 chimeras in Table 9). Contrary to MST analyses, and in 
accordance to the results obtained from the analyses of gp120 monomers, the presence of 
serum did not reduce the affinity of 447-52D to gp140 Env/V3 chimeras in ELISA (compare 
KD-values of gp120/gp140 Env/V3 chimeras in buffer, Table 8, and serum, Table 9). 
 
 
Figure 25. Interaction of mAb 447-52D with trimeric gp140 Env/V3 chimeras in 50 % human serum, quantified by 
MST and ELISA. For MST analysis (A), gp140 Env/V3 chimeras diluted in 50 % human serum were titrated to the 
Alexa647-labeled 447-52D which was kept at constant concentration. Results of the MST measurements are presented as 
normalized binding curves of three independent experiments, error bars reflect the SEM of the independent experiments. (B) 
Validation of MST by ELISA: Binding of 447-52D to trimeric gp140 Env/V3 chimeras was assessed by a lectin (Galanthus 
nivalis) capture-ELISA (negative control: Wells coated with lectin, incubated with PBS). Biotinylated 447-52D, diluted in 50 
% human serum, was titrated to immobilized Env proteins at indicated concentrations and streptavidin-POD conjugate was 
used for readout. ELISAs were performed in two independent experiments, error bars reflect the SEM of the independent 
experiments. 
 
4.1.10 Interactions between mAb 447-52D and VLP-presented 
gp145 Env/V3 chimeras in 50 % human serum 
The last experiments within the Env/V3 model system included MST and ELISA analyses of 
VLPs in presence of 50 % serum. For MST analyses in serum, 447-52D was titrated to 
fluorescent-labeled VLPs, according to the experimental setup for the analysis of VLPs in 
buffer. For measurement conditions of VLPs in serum see 3.5, Table 6. MST analyses of the 
interactions between 447-52D and VLP-presented gp145 Env/V3 chimeras in serum revealed 
an overall binding profile (Figure 26A) that is comparable to the corresponding 
measurements of VLPs in buffer (Figure 22A).VLP-variants MN, HXB2 and CDC42 
demonstrated similar affinities to 447-52D and whereas variants RF and SF33 showed only 
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indicated/no binding. In addition, there was also no binding of 447-52D to blank VLPs in 
presence of 50 % serum, see Appendix Figure 2B. Notably, KD-values calculated from MST 
analyses of VLPs in buffer and serum were in the same range and did not drastically differ 
between buffer and serum measurements as KD-values of gp120 and gp140 Env V3 chimeras 
did (compare MST KD-values in buffer, Table 8, and serum, Table 9). VLP-ELISAs in 
presence of 50 % serum delivered comparable results. Within ELISA, VLP-variants MN, 
HXB2 and CDC42 bound with similar affinities to 447-52D while variant SF33 and blank 
VLPs (Gag w/o) demonstrated no binding (Figure 26B). However, VLP variant RF exhibited 
saturated binding to 447-52D in serum ELISA which was not observed in the corresponding 
MST analysis (Figure 26A). Of note, this was also observed in the analysis of VLPs in buffer, 
see (Figure 22). In addition, the results obtained from VLP-ELISAs in serum are in 
accordance to VLP-ELISAs in buffer, including comparable KD-values (see Table 8, and 
Table 9) and the reduced absolute binding signal for variant MN, explained in 4.1.6. 
 
 
Figure 26 Interaction of mAb 447-52D with VLP-presented Env/V3 chimeras in 50 % human serum, quantified by 
MST and ELISA. (A) MST analysis of VLP-presented Env/V3 chimeras in 50 % human serum. 447-52D, diluted in 50 % 
human serum, was titrated to DY-647P1-labeled VLPs which were kept at constant concentration. Results of the MST 
measurements are presented as normalized binding curves of two independent experiments, error bars reflect the SEM of the 
independent experiments. (B) Validation of MST by ELISA: Binding of 447-52D to VLP-presented Env/V3 chimeras was 
assessed by direct-ELISA. VLPs were directly coated to ELISA plates (negative controls: Wells coated with blank VLPs 
(Gag w/o) and PBS, respectively). Biotinylated 447-52D, diluted in 50 % human serum, was titrated to immobilized Env 
proteins at indicated concentrations and streptavidin-POD conjugate was used for readout. ELISAs were performed in two 
independent experiments, error bars reflect the SEM of the independent experiments. VLP-ELISA data were generated 
during the doctoral thesis of Tobias Fischer under my experimental supervision. 
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4.1.11 Summary: Interactions between Env/V3 chimeras and 
mAb 447-52D in 50 % human serum 
In summary, it has been demonstrated that MST provides consistent data within the overall 
expected affinity ranking (MN≥CDC42/HXB2>RF>SF33) of the interactions between gp120, 
gp140 and VLP-presented gp145 Env/V3 chimeras and 447-52D also in presence of 50 % 
human serum. Further, MST data have been successfully validated by ELISA, see Figure 27. 
However, the calculated KD-values were only comparable within the respective measurement 
method used, see Table 9. Interestingly, the presence of serum in MST analyses seemed to 
reduce the overall binding affinity of 447-52D to gp120 and gp140 Env/V3 chimeras. 
However, this was not the case in MST analyses of VLPs were binding affinities between 
buffer and serum were comparable. In addition, serum effects in terms of reduced binding 
affinities were not observed in ELISA analyses. For comparison of calculated KD-values in 
buffer and serum analyses see Table 8 and Table 9, respectively. Furthermore, as already 
observed for MST and ELISA analyses in buffer, 447-52D bound with higher overall 
affinities to soluble trimeric gp140 Env/V3 chimeras compared to the corresponding soluble 
gp120 versions of the proteins. In conclusion, data underline that MST is capable to determine 
affinities under near-physiological conditions. 
 
Table 9. Apparent equilibrium dissociation constants of the 447-52D-Env/V3 chimera interactions in 50 % human 
serum. KD-values in nM represent the mean value, ± the SEM of n experiments. Detectable, but not saturated signals were 
excluded from KD-fitting and are therefore designated as “binding indicated“. Background-level binding is designated as “no 
binding” (n.b.). ELISA KD-values were calculated by using non-linear least squares regression (one site binding, hyperbola; 
GraphPad Prism 5). MST KD-values are computed by the KD-fit model of KaleidaGraph. R2-values of the respective fits are 
included in brackets. 
 gp120 monomers gp140 trimers 
VLP-presented 
gp145 
 
Env/V3 
chimera 
MST 
(n=2) 
ELISA 
(n=2) 
MST 
(n=3) 
ELISA 
(n=2) 
MST 
(n=2) 
ELISA 
(n=2) 
Affinity 
ranking 
MN 
0.80 ± 0.42 
(R2=0.8953) 
0.20 ± 0.03 
(R2=0.9901) 
0.21 ± 0.09 
(R2=0.9228) 
0.040 ± 
0.009 
(R2=0.9742) 
5.7 ± 1.9 
(R2=0.9516) 
0.073 ± 
0.021 
(R2=0.9532) 
1 
HXB2 
75 ± 37 
(R2=0.8917) 
0.86 ± 0.11 
(R2=0.9915) 
0.23 ± 0.06 
(R2=0.9667) 
0.079 ± 
0.015 
(R2=0.9800) 
6.7 ± 4.7 
(R2=0.8701) 
0.052 ± 
0.013 
(R2=0.9681) 
2/3 
CDC42 
25 ± 10 
(R2=0.9211) 
0.80 ± 0.12 
(R2=0.9875) 
0.42 ± 0.22 
(R2=0.8821) 
0.090 ± 
0.020 
(R2=0.9729) 
11 ± 8 
(R2=0.8012) 
0.072 ± 
0.018 
(R2=0.9647) 
2/3 
RF b.i. b.i. b.i. 
5.7 ± 1.1 
(R2=0.9822) 
b.i. 
2.9 ± 0.8 
(R2=0.9630) 4 
SF33 b.i. b.i. b.i. n.b. b.i. n.b. 5 
KD (nM) 
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Figure 27. Interaction of mAb 447-52D with Env/V3 chimeras in 50 % human serum, quantified by MST and ELISA. 
MST (left panel) and ELISA analyses (right panel) of the interactions between 447-52D and monomeric gp120, trimeric 
gp140 and VLP-presented gp145 Env/V3 chimeras are shown in (A), (B) and (C), respectively. For MST analyses of gp120 
and gp140 Env/V3 chimeras, Env proteins diluted in 50 % human serum were titrated to the Alexa647-labeled 447-52D 
which was kept at constant concentration. MST analysis of VLP-presented gp145 Env/V3 chimeras was performed in an 
inverse setup (447-52D in 50 % human serum was titrated to DY-647P1-labeled VLPs). Results of the MST measurements 
are presented as normalized binding curves of at least two independent experiments, error bars reflect the SEM of the 
independent experiments. Validation of MST by ELISA: Binding of 447-52D to gp120 and gp140 Env/V3 chimeras was 
assessed by a lectin (Galanthus nivalis) capture-ELISA (negative control: Wells coated with lectin, incubated with PBS). 
Biotinylated 447-52D, diluted in 50 % human serum, was titrated to immobilized Env molecules at indicated concentrations 
and streptavidin-POD conjugate was used for readout. Env/V3-VLPs were directly coated to ELISA plates and analyzed in 
the same way (negative controls: Wells coated with blank VLPs (Gag w/o) and PBS, respectively). All ELISAs were 
performed in two independent experiments, error bars reflect the SEM of the independent experiments. 
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4.1.12 The BG505 SOSIP.664 model system 
Contrary to other biophysical or biochemical methods like SPR, BLI and ELISA, MST does 
not require surface immobilization of one interaction partner, which has the potential to 
negatively influence the structure of the immobilized interaction partner and thereby the 
outcome of an experiment. This becomes particular relevant in the analysis of the antigenicity 
profile of native-like Env immunogens. Consequently, the next step was to examine if next-
generation Env immunogens in MST analyses retain their native-like structure that is 
characterized by a favorable antigenicity profile. The previously used Env/V3 model system, 
although a valuable tool for assay establishment, cannot address this question since it includes 
uncleaved, artificial Env chimeras that very likely do not adopt a native-like conformation. 
Thus, the previously described and well-characterized native-like BG505 SOSIP.664 trimer61, 
representing the prototype of next-generation Env immunogens, and a panel of quaternary 
structure-characterizing mAbs were chosen as an alternative model system. The antibody 
panel included bNAbs PGT145178,179 and PGT151107,108 targeting epitopes in V1/V2 
(PGT145) and the gp120-g41 interface (PGT151). The special feature of these antibodies is 
that they only bind to Env trimers with an intact quaternary structure179,108,119. Further, the 
panel included the CD4-binding site directed non-neutralizing mAb F105183,184 that binds to 
monomers, open and disordered trimers but not to well-folded native-like trimers191,61. Last 
but not least, the panel included bNAbs VRC01181,182 and 2G12101,105 that target epitopes in 
the CD4-binding site (VRC01) and the N332-glycan supersite (2G12). Binding of VRC01 and 
2G12 does not depend on an intact quaternary structure, since it has been shown that both 
bNAbs similarly bind to BG505 SOSIP.664 trimers, BG505 gp120-gp41ECTO protomers and 
BG505 gp120 monomers119. Since the antibody panel described above represents a useful tool 
for structural characterization Env proteins it was used to analyze BG505 SOSIP.664 trimers 
in MST analyses. 
  
 _____________________________________________________________________ Results 
89 
 
4.1.13 Production and purification of BG505 SOSIP.664 trimers 
BG505 SOSIP.664 trimers were produced by transient cotransfection of 293F suspension 
cells with plasmids encoding for Env and Furin and purified to trimer homogeneity using 
affinity and size exclusion chromatography, as described in 3.4.2. For pooled protein fractions 
see SEC profile in Appendix Figure 1. Blue PAGE analysis, performed as described in 3.4.4, 
revealed that BG505 SOSIP.664 trimers were successfully purified to high trimer 
homogeneity, see Figure 28. 
 
 
Figure 28. BN-PAGE analysis of affinity/SEC 
purified BG505 SOSIP.664 trimers. Molecular 
weight (MW) markers are indicated. 
 
 
4.1.14 Interactions between BG505 SOSIP.664 trimers and 
quaternary structure-characterizing antibodies in buffer and 
50 % human serum 
In order to examine if native-like trimers retain their favorable antigenicity profile in MST 
measurements, BG505 SOSIP.664 trimers and a panel of quaternary structure-characterizing 
antibodies (described in 4.1.12) were subjected to MST analysis in buffer. To classify results, 
two different ELISA setups were performed for comparison. These included a His-capture 
ELISA that allows directed presentation of BG505 SOSIP.664 trimers via their His-tag, and a 
direct-ELISA setup in which the proteins were directly coated to the surface ELISA plates. 
The resulting MST binding curves (Figure 29A, left with corresponding KD-values in Table 
10) showed that bNAbs VRC01 and 2G12 bound with high affinity to BG505 SOSIP.664 
trimers which was expected since the binding of these antibodies is only marginally 
influenced by both, the oligomerization state and an intact quaternary structure. Quaternary 
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epitope-specific bNAbs PGT145 and PGT151 also bound with high affinities, whereas non-
neutralizing antibody F105 which binds to monomers, open and disordered trimers but not 
well-folded native-like trimers, demonstrated only indicated binding at high concentrations. 
Taken together, MST results demonstrated that BG505 SOSIP.664 trimers retained their well-
folded structure in MST measurements. His-capture ELISA represents a commonly used 
method for assessment of the antigenicity profile of Env vaccine candidates since this ELISA 
setup allows the directed presentation of His-tagged trimers, thereby retaining their native-like 
structure191. Thus, this ELISA format was used to further validate MST results. The results of 
the His-capture ELISA (see Figure 29B, left with corresponding KD-values in Table 10) in 
general reflected MST-derived data. All bNAbs bound with high affinities to BG505 
SOSIP.664 trimers, whereas non-neutralizing antibody F105 demonstrated only 
marginal/indicated binding. In contrast, when BG505 SOSIP.664 trimers were directly coated 
to the solid phase in the direct-ELISA setup, the binding of the quaternary structure-
depending bNAbs PGT145 and PGT151 was lost and high affinity binding of F105 was 
detected, see Figure 29C, left, with corresponding KD-values in Table 10. This indicates a 
disturbance of the native-like structure, most likely caused by hydrophobic and electrostatic 
interactions between the BG505 SOSIP.664 trimers and the solid phase of the ELISA plate. In 
summary, results demonstrate that the native-like protein structure of BG505 SOSIP.664 
trimers is preserved during MST measurements since MST results reflect data obtained from 
His-capture ELISAs, and further that the choice of the immobilization strategy in ELISA 
analyses can strongly impact the antigenicity profile of immobilized Env proteins. 
The antigenicity profile of Env vaccine candidates is mostly assessed in artificial buffer and 
not under near-physiological conditions. Since experiments within the Env/V3 system have 
shown that MST has the capacity to quantify interactions in presence of 50 % serum, MST 
was used to investigate the antigenicity profile of BG505.SOSIP.664 trimers, representing the 
prototype of next-generation Env immunogens, under near-physiological conditions. Again, 
His-capture and direct-ELISAs were performed for comparison. Results of MST analyses in 
50 % serum, shown in Figure 29A, right, with corresponding KD-values in Table 10 were in 
general comparable to results obtained in buffer analyses (Figure 29A, left) with the 
exception that saturated binding of non-neutralizing antibody F105 was detected. This 
indicates that a least a part of the BG505.SOSIP.664 trimers turned into a more open 
conformation, which allows binding of F105. However, this was not observed in the His-
capture ELISA, which demonstrated results comparable to measurements in buffer, as did 
direct-ELISA (see Figure 29B, C). Surprisingly and unexpected, in the presence of 50 % 
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human serum binding of 2G12 was substantially reduced in both, His-capture and direct-
ELISAs. This turned out to be an effect of the biotinylation of this antibody since the same 
effect was observed in a control experiment without serum (data not shown).  
 
 
Figure 29. Interactions of BG505 SOSIP.664 trimers with quaternary structure-characterizing mAbs in buffer and 50 
% human serum, quantified by MST, His-capture and direct-ELISA. For MST analyses, BG505 SOSIP.664 trimers 
diluted in buffer or 50 % human serum were titrated to Alexa647-labeled mAbs (VRC01, PGT145, PGT151, F105, 2G12) 
which were kept at constant concentration. Results in buffer (A, left) and 50 % human serum (A, right) are presented as 
normalized binding curves of two independent experiments, error bars reflect the SEM of the independent experiments. His-
capture ELISA was performed by immobilizing His-tagged BG505 SOSIP.664 trimers via coated anti-His Ab. In case of 
direct-ELISA, BG505 SOSIP.664 trimers were directly coated to the surface of ELISA plates (negative controls for His-
capture and direct-ELISA: Wells with captured/coated PBS). MAbs diluted in PBS were titrated to captured/coated BG505 
SOSIP.664 trimers at indicated concentrations. A HRP-conjugated polyclonal rabbit anti-human Ab was used for readout. 
Results of His-capture and direct-ELISAs in buffer are shown in (B, C, left). His-capture and direct-ELISAs in 50 % human 
serum (B, C, right) were performed the same way, with the differences that biotinylated mAbs were diluted in 50 % human 
serum and streptavidin-POD conjugate was used for readout. All ELISA experiments were performed in two independent 
experiments, error bars reflect the SEM of the independent experiments. 
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Table 10. Apparent equilibrium dissociation constants of BG505 SOSIP.664-antibody interactions in buffer and 50 % 
human serum. KD-values in nM represent the mean value, ± the SEM of n experiments. Detectable, but not saturated signals 
were excluded from KD-fitting and are therefore designated as “binding indicated“. Background-level binding is designated 
as “no binding” (n.b.). ELISA KD-values were calculated by using non-linear least squares regression (one site binding, 
hyperbola; GraphPad Prism 5). MST KD-values are computed by the KD-fit model of KaleidaGraph. R2-values of the 
respective fits are included in brackets. 
BG505 SOSIP.664 trimers 
 KD (nM) in buffer KD (nM) in 50 % human serum 
Antibody 
MST 
(n=2) 
His-
capture 
ELISA 
(n=2) 
Direct-
ELISA 
(n=2) 
MST 
(n=2) 
His-
capture 
ELISA 
(n=2) 
Direct-
ELISA 
(n=2) 
VRC01 
1.7 ± 1.0 
(R2=0.8758) 
1.9 ± 0.4 
(R2=0.9688) 
0.25 ± 0.08 
(R2=0.9068) 
0.39 ± 0.36 
(R2=0.7575) 
9.8 ± 2.3 
(R2=0.9623) 
0.54 ± 0.16 
(R2=0.9300) 
2G12 
0.35 ± 0.20 
(R2=0.8931) 
0.42 ± 0.06 
(R2=0.9819) 
0.13 ± 0.02 
(R2=0.9740) 
0.042 ± 0.041 
(R2=0.9071) 
b.i. 
6.7 ± 2.0 
(R2=0.9390) 
F105 b.i. b.i. 
0.53 ± 0.08 
(R2=0.9821) 
3.5 ± 2.4 
(R2=0.8108) 
b.i. 
0.43 ± 0.14 
(R2=0.9206) 
PGT145 
5.6 ± 1.3 
(R2=0.9703) 
0.54 ± 0.04 
(R2=0.9954) 
n.b. 
1.6 ± 0.9 
(R2=0.8760) 
3.4 ± 0.5 
(R2=0.9818) 
n.b. 
PGT151 
0.36 ± 0.18 
(R2=0.9085) 
0.15 ± 0.03 
(R2=0.9615) 
b.i. 
0.97 ± 0.48 
(R2=0.8935) 
0.18 ± 0.05 
(R2=0.9519) 
b.i. 
 
In conclusion, MST analyses of the interaction between BG505 SOSIP.664 trimers and the 
panel of quaternary structure-characterizing antibody panel in buffer have shown that the 
native-like Env structure is retained in MST measurements. Further, results of His-capture 
ELISAs validated MST-derived data. In addition, it has been demonstrated that direct coating 
of BG505 SOSIP.664 trimers to the surface of ELISA plates destroys the native-like structure 
of the protein. Importantly, the presence of serum had a detectable influence on the 
antigenicity profile of BG505.SOSIP.664 trimers in terms of an enhanced binding of the non-
neutralizing antibody F105, indicating that at least a proportion of BG505 SOSIP trimers 
turned into a more open conformation. However, this was only detected in MST analysis and 
not in the corresponding His-capture ELISA. 
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4.1.15 Interactions between PLA-adsorbed BG505 SOSIP.664 
trimers and quaternary structure-characterizing antibodies in 
buffer and 50 % human serum 
As described in 1.5.3, presentation of immunogens by particles conceptually offers several 
advantages over soluble proteins, like enhanced uptake of antigens into T-cells or enhanced 
B-cell activation, highlighting the potential of particles to contribute to stronger and 
potentially broader Ab responses. However, the antigenic profile of Env immunogens should 
be preserved when they are presented on particles, since this may contribute to direct antibody 
responses against vulnerable sites of the Env protein. MST has been proven useful for the 
characterization of the interactions between mAb 447-52D and VLPs in the Env/V3 model 
system, and further for the analysis of the antigenicity profile of soluble, native-like BG505 
SOSIP.664 trimers. Consequently, it was considered reasonable to use MST to investigate the 
antigenicity profile of next-generation Env immunogens, presented on a state-of-the-art 
particle system. For this purpose, poly(lactic acid) particles (PLA particles) with adsorbed 
BG505 SOSIP.664 trimers were chosen as a model system, since, as described in 1.5.3,  PLA 
particles represent well-established, biodegradable particles that allow adsorption of proteins, 
and further offer the option to incorporate immunostimulatory molecules as further adjuvants. 
Thus, PLA particles represent promising vaccine carriers. PLA particles with adsorbed 
BG505 SOSIP.664 trimers were produced in cooperation with Bernard Verrier, as described 
in 3.4.8. The resulting particles with passively adsorbed BG505 SOSIP.664 trimers were 
about 175 nm in size with a calculated amount of ~50 trimers per particle.  
For MST experiments, PLA particles were titrated to fluorescent-labeled antibodies, starting 
with a calculated concentration of ~100 nM Env in the PLA-particle solution. This setup was 
chosen in order to avoid labeling of the limited amount of BG505 SOSIP trimers present on 
the particle surface since, as described in 4.1.4 , labeling may affect antibody epitopes. 
However, due to its setup, this experiment allowed only a comparison in binding of different 
antibodies to PLA-presented BG505 SOSIP.664 trimers, which is sufficient to investigate the 
antigenicity profile, but it is not suitable to calculate precise KD-values since it is difficult to 
determine the exact concentration of PLA-adsorbed BG505 SOSIP trimers. However, results 
of MST measurements in principle demonstrated that all mAbs bound to PLA-adsorbed 
BG505 SOSIP.664 trimers in both, artificial buffer and 50 % human serum, see Figure 30A 
and B. However, it is important to mention that MST analyses, and in particular 
measurements in buffer, suffered from unspecific binding of mAbs to control particles 
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without adsorbed Env proteins, see Appendix Figure 3. Even pre-blocking of control 
particles with blocking buffers did not result in reduction of unspecific binding in buffer 
analysis (data not shown). Although it seemed that saturated binding of mAbs was only 
observed for PLA particles with adsorbed BG505 SOSIP.664 trimers, data were difficult to 
interpret. However, the presence of serum during MST analysis improved the quality of 
measurements since, despite of some unspecific binding, saturated binding curves were only 
observed for PLA particles with adsorbed BG505 SOSIP.664 trimers, see Appendix Figure 
4. Thus, the binding of all mAbs was considered as specific. The resulting antigenicity profile 
obtained from MST analyses in serum (and also inferred from analyses in buffer) indicated 
that PLA-adsorbed BG505 SOSIP.664 trimers most likely represented a mixture of trimers 
with native-like and open conformation since both was detected, binding of bNAbs including 
quaternary structure-depending PGT145 and PGT151, and binding of non-neutralizing 
antibody F105. For comparison, the antigenicity profile of PLA-adsorbed BG505 SOSIP.664 
trimers was analyzed in a direct-ELISA setup in which PLA particles were directly coated to 
the surface of ELISA plates and mAbs were used as titrants. This setup was chosen for two 
reasons: 1) it was considered that an antibody capturing approach, e.g. by 2G12 ELISA, will 
be unsuitable to capture particles with ~175 nm in size and a limited amount of protein on the 
surface; 2) it was assumed that immobilized PLA particles will serve as platform which 
avoids direct coupling of BG505 SOSIP.664 trimers to the surface of the ELISA plate. 
However, ELISA results, shown in Figure 30C, differed from the data obtained from MST 
analyses. Saturated binding was only detected for bNAbs 2G12 and VRC01 that do not 
depend on a native-like structure of the Env protein. Non-neutralizing antibody F105 
demonstrated indicated binding, whereas binding of quaternary structure-depending bNAbs 
PGT145 and PGT151 was lost (PGT151 showed somewhat marginal binding, but limited 
highest antibody concentration used). In addition, there was no detectable background binding 
of mAbs to control particles in the direct-ELISA setup, see Appendix Figure 5. Comparing 
MST results with ELISA data indicates that direct coating of PLA particles to the surface of 
ELISA plates disrupted the particle structure together with the structure of BG505 SOSIP.664 
trimers since in direct-ELISA, contrary to MST, there was no binding of quaternary structure-
depending bNAbs PGT145 and PGT151 detectable. 
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Figure 30. Interactions of PLA-adsorbed BG505 SOSIP.664 
trimers with quaternary structure-characterizing mAbs in 
buffer and 50 % human serum, quantified by MST and 
direct-ELISA. For MST analyses, PLA-adsorbed BG505 
SOSIP.664 trimers diluted in buffer or 50 % human serum were 
titrated to Alexa647-labeled mAbs (VRC01, PGT145, PGT151, 
F105, 2G12) which were kept at constant concentration. Results 
in buffer (A) and 50 % human serum (B), are presented as 
normalized binding curves of two independent experiments, error 
bars reflect the SEM of the independent experiments. Results of 
direct-ELISA in buffer are shown in (C). For direct-ELISA, 
PLA-adsorbed BG505 SOSIP.664 trimers were directly coated to 
the surface of ELISA plates (negative controls: Wells coated with 
PLA particles without adsorbed Env and PBS, respectively). 
MAbs diluted in PBS were titrated to coated PLA particles at 
indicated concentrations. A HRP-conjugated polyclonal rabbit 
anti-human Ab was used for readout. ELISA experiments were 
performed in two independent experiments, error bars reflect the 
SEM of the independent experiments. 
 
 
 
In summary, MST analyses of PLA adsorbed BG505 SOSIP.664 trimers were challenging 
since control experiments revealed unspecific binding of mAbs to PLA particles without 
adsorbed Env proteins. Thus, it could be not excluded that unspecific binding partially 
contributed to the binding of mAbs in the MST analyses of PLA-adsorbed BG505 SOSIP.664 
trimers. However, binding of mAbs to PLA-adsorbed BG505 SOSIP.664 trimers was 
considered as specific since saturated binding was only observed in this case. Interestingly, 
the presence of serum seemed to improve the quality of MST analyses. Taken together, MST 
analyses of the interactions between PLA-adsorbed BG505 SOSIP.664 trimers and quaternary 
structure-characterizing mAbs indicate that PLA-adsorbed BG505 SOSIP.664 trimers are 
present as a mixture of native-like trimers and open conformations. Notably, ELISA results 
indicate that the direct coating disrupted both, structure of PLA particles and BG505 
SOSIP.664 trimers. Thus, the analysis of this kind of particles may benefit from 
measurements in solution. 
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4.2 Generation of a BG505 SOSIP alanine substitution 
library for cell-based antibody epitope mapping 
The development of next-generation Env immunogens by rational immunogen design requires 
detailed information of the interaction between bNAbs and Env proteins. Analyses of Env-
antibody co-crystals for example provide valuable structural information60,78,192, whereas 
functional information about amino acid residues that critically contribute to antibody binding 
can be obtained from peptide screenings193,194, or mutant analyses175,195,196. Mammalian cell 
display in combination with flow cytometry offers the ability to analyze cell-membrane 
exposed Env mutant libraries in high throughput, and further provides advantages like 
mammalian glycosylation and presentation of Env proteins in their natural membrane-bound 
context. Exploiting these features, our group recently developed a mammalian cell display- 
and flow cytometry-based approach for functional mapping bNAb epitopes in high 
throughput. For this purpose, a clade C isolate 96ZM651-based alanine substitution library 
(designed to express gp145) was generated, displayed on the surface of HEK293T cells and 
subsequently screened for antibody binding via flow cytometry. Several successful mapping 
experiments highlighted the applicability of the method for functional screening (Kliche and 
Grassmann et al., manuscripts in preparation, PhD thesis Veronika Grassmann197). The 
experiments included the mapping of previously determined bNAb epitopes of HGN194194, 
HJ16194 (PDB ID: 4YE4, Chen et al., to be published), VRC01181,182, PG9175,176,177 and the 
epitope of soluble CD458. Thereby it has been demonstrated that the library properly 
displayed linear (HGN194) and conformational gp120 (HJ16, VRC01, sCD4) epitopes as well 
as the quaternary epitope of PG9. However, the library was not suitable for mapping of newly 
identified, highly quaternary structure-depending bNAbs197, such as PGT145178,179 or 
PGT151107,108. The cleavage deficiency of the 96ZM651 gp145 library, likely resulting in the 
expression of Env trimers with perturbed quaternary structure, was considered mainly 
responsible for this outcome. Hence, one objective of this thesis was the development of an 
alanine substitution library that overcomes the limitations of the 96ZM651 gp145 library and 
allows the display of Env proteins with an intact quaternary structure, enabling mapping of 
bNAbs with quaternary epitopes. 
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4.2.1 Impact of stabilizing SOSIP modifications and cytoplasmic 
tail truncation on expression levels of cell-membrane 
expressed BG505 Env 
The clade A transmitted/founder isolate BG505 (GenBank # DQ208458.1) was chosen a basis 
for the development of an alanine substitution library for several reasons: 1) this isolate is 
known to benefit from intrinsic trimer enhancing propensities in soluble proteins127, thus 
BG505 may be also superior to other isolates in terms of forming a homogenous Env trimer 
population on the cell surface; 2) the soluble, stabilized version BG505 SOSIP.664 displays a 
favorable antigenicity profile, in terms of binding to nearly all known bNAbs56, that is likely 
transferable to the membrane-exposed BG505; 3) The structure of the soluble, stabilized 
version BG505 SOSIP.664 is well characterized56,60,78. Cleavage competence was considered 
as a key feature of the new library since folding of soluble BG505 SOSIP.664 into native-like 
trimers depends on proper cleavage of the Env precursor into gp120-gp41 subunits116. 
Notably, cleavage competence is not only desirable for soluble proteins but also for 
membrane-exposed Env since it avoids binding of non-neutralizing antibodies198, nowadays 
seen as evidence for a disturbed quaternary structure. Thus, the library was planned to contain 
an optimized Furin cleavage site for cleavage enhancement (substitution of the naturally 
occurring amino acid motif REKR by R6)61. However, cleavage involves the risk of the 
dissociation of non-covalently linked gp120 and gp41 subunits (gp120 shedding87). In the 
soluble, stabilized version of BG505 (BG505 SOSIP.664) and also VLP-exposed Env 
proteins, dissociation of  gp120-gp41subunits was successfully prevented by the introduction 
of disulfide-bond forming cysteines, termed “SOS” 61,87. Thus, the introduction of SOS 
modifications at amino acid positions 501 and 605 (corresponding to soluble BG505 
SOSIP.664) was conceived as an option to prevent shedding in the new library approach. 
Further, it was considered to incorporate the helix-breaking I to P substitution at amino acid 
position 559 in gp41, since this substitution was included in BG505 SOSIP.664 to promote 
trimerization61,199 and may do so in membrane-exposed BG505. However, it was unknown if 
it is in general possible to express a membrane-bound version of BG505, containing 
modifications that were originally designed to stabilize soluble proteins. Thus, the first step 
prior to the generation of the new library was to perform a comparative analysis in order to 
investigate how stabilizing modifications (and their combination) affect expression levels of 
membrane-bound BG505, presented on the surface of mammalian cells. In addition, the effect 
of Env cytoplasmic tail truncation was also investigated in this analysis, since the truncation 
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of the CT is associated with enhanced Env expression levels145,200. In summary, eight different 
constructs based on the codon-optimized BG505 sequence (GenBank # DQ208458.1) were 
generated and cloned into the mammalian expression vector pcDNA5/FRT/TO as described in 
3.2.1. The eight constructs, all sharing the optimized Furin cleavage site (R6) and the T332N 
substitution to restore the central glycan of the V3-glycan bNAb epitope106,180, consisted of 
each, four variants with the full-length BG505 sequence (gp160 constructs, including CT), 
and four variants with truncated CT (gp145 constructs), with the following stabilizing 
modifications: 1) Wildtype (WT), no further modification; 2) SOS (disulfide-bond forming 
cysteines); 3) IP (helix-breaking amino acid substitution I559P); and 4) SOSIP (combination 
of both stabilizing modifications). To compare Env surface expression of the generated Env 
variants, HEK293T cells were transiently cotransfected with plasmids enconding for the eight 
Env variants and Furin (to promote cleavage of the proteins) as described in 3.3.2 and 
analyzed by flow cytometry, see 3.3.6. The bNAb 2G12 was used as a marker for Env surface 
expression in flow cytometry since SPR analysis of soluble BG505 variants demonstrated that 
the binding of this antibody is not affected by stabilizing modifications119. The results, shown 
in Figure 31, demonstrated that the truncation of the CT, as expected, resulted in an enhanced 
Env surface expression since all gp145 variants exhibited a higher 2G12 signal than their 
respective gp160 counterpart. Notably, the I559P substitution seemed to be beneficial in terms 
Env expression levels since all variants containing this modification (IP and SOSIP) 
demonstrated an enhanced surface expression (~factor of 2) compared to the WT in both, 
gp145 and gp160 Env variants. However, the presence of the SOS modification seemed to 
slightly reduce the beneficial effect of the I559P substitution in gp145 and gp160 SOSIP 
variants. In addition, the SOS modification alone did not alter the overall expression levels 
since the 2G12 signal in gp145 and gp160 SOS variants was always comparable to the 
corresponding WT signal. 
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Figure 31. Impact of stabilizing modifications 
and cytoplasmic tail truncation on BG505 Env 
cell-surface expression levels. HEK293T cells 
were transiently cotransfected with plasmids 
encoding for Env and Furin (control: Mock 
transfected cells, no Env/Furin DNA). 48 h post 
transfection, cells were stained with 250 nM 
Alexa647-labeled bNAb 2G12 and analyzed by 
flow cytometry. Depicted are the mean 
fluorescence intensities (MFIs) of 2G12 binding to 
gp145 (blue bars) and corresponding gp160 Env 
variants (red bars). Results represent the mean 
value of two independent experiments with error 
bars reflecting the SEM of the independent 
experiments. 
 
In conclusion, BG505 SOSIP was chosen as a basis for the development of a new alanine 
substitution library, mainly for two reasons: 1) Compared to WT, the IP modification resulted 
in enhanced surface expression, which is beneficial because antibody mapping requires robust 
antibody signals; and 2) the SOS modification, despite of slightly reducing expression-
enhancing effects of IP, could prevent shedding of gp120. Further, there was the question if 
the library should express full-length gp160 or the CT-truncated gp145 versions of the 
proteins. There were good reasons to express library variants as CT-truncated gp145 Env 
proteins. These included the enhanced surface expression and good experiences with the 
96ZM651 library that was also designed to express gp145 Env variants. However, Chen et al. 
recently reported that the truncation of the CT diminishes Env binding of trimer-specific 
bNAbs and results in the exposure non-neutralizing Env epitopes, indicating that the CT 
largely affects the antigenicity profile of the Env ectodomain145. Taking the results of this 
study in consideration, it was decided to design the library based on the full-length BG505 
SOSIP gp160, see 4.2.2. 
4.2.2 Features of BG505 SOSIP alanine substitution library 
The BG505 SOSIP gp160 alanine substitution library was generated as described in detail in 
3.2.3. Starting with amino acid position 34 (HXB2 numbering) every amino acid (with 
exception of SOSIP modifications, R6 cleavage site and naturally occurring 
alanines/cysteines) of the extracellular part of the protein, including the transmembrane 
domain (gp145, AA 34-712), was consecutively substituted for an alanine while the CT 
remained unmodified, see Figure 32B. In total, 615 alanine substitution variants were 
generated. However, it was considered that it at some point may be interesting to analyze 
gp145 or gp140 Env variants (for example to investigate the influence of alanine substitutions 
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in the context of CT-truncation or in soluble trimers). Thus, for being able to quickly 
transform the gp160 alanine substitution library into either a gp145 or a gp140 library, 
elements were implemented to allow this switching by simple molecular biology tools. These 
consisted of XhoI and SfiI restriction sites and 3´ parts of gp145 and gp140, respectively, see 
Figure 32A. Together these elements allow to convert the BG505 SOSIP gp160 alanine 
variants into the corresponding gp145 or gp140 constructs by simple restriction digest and re-
ligation. The possibility to use the library for generation of Env-expressing stable cell lines 
represents another feature of the library. Since the library bases on a modified 
pcDNA5/FRT/TO plasmid vector (pLib1.1, see 3.2.3) it can be used for generation of stable 
cell lines using the ThermoFisher Scientific Flp-In System. Here, Flp-In™ T-REx™ 293 cells 
are cotransfected with a plasmid vector containing a Flp recombination target (FRT) site (e.g. 
pLib1.1 with Env) and a plasmid encoding for the Flp recombinase (pOG44). Hence, the 
recombinase can mediate a homologous recombination event between the FRT site of the 
plasmid vector and the FRT site present in the genome of Flp-In™ T-REx™ 293 cells. This 
results in the integration of the FRT containing plasmid vector, and thus in the integration of a 
single copy env gene into the predefined FRT site of Flp-In™ T-REx™ 293 cells. Further, 
stable transfected Flp-In™ T-REx™ 293 cells offer the advantage of a doxycycline inducible 
gene expression that is regulated by the Tet operator/repressor system. This in turn enables 
cultivation of stable cell lines without potential negative effects that may be caused by Env 
cytotoxicity. 
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Figure 32. Schematic overview of the BG505 alanine substitution library. (A) Schematic representation of BG505 SOSIP 
gp160 in the library plasmid vector pLib1.1. The BG505 SOSIP alanine substitution library was generated based on the full-
length gp160 sequence (black). In this configuration BG505 SOSIP is expressed as full-length, membrane-bound gp160 with 
gp41 cytoplasmic tail (CT). In order to easily convert the BG505 SOSIP gp160 alanine substitution library into a gp145 or 
gp140 library, elements were implemented that allow this switching by simple restriction digest and re-ligation. These 
elements consisted of XhoI and SfiI restriction sites, depicted as triangles in red and blue, and 3´ parts of gp145 and gp140 
shown in red and blue, respectively. Stop codons are indicated as asterisks. Restriction digest of the gp160 constructs with 
SfiI and subsequent re-ligation results in gp145 expressing constructs (red), while XhoI digestion leads to gp140 constructs 
(blue). Of note, using XhoI digestion, gp145 constructs can be further converted into gp140 constructs. (B) Schematic 
overview of the BG505 SOSIP gp160 alanine substitution library. Starting with the first amino acid after the signal peptide 
(SP), every amino acid of the extracellular part of the protein, including the transmembrane domain (TM), was consecutively 
substituted for an alanine (AA 34-712, according to HXB2 numbering), as indicated in red for the first three amino acid 
positions. Importantly, SOSIP modifications, R6 cleavage site and naturally occurring alanines/cysteines as well as the CT 
remained unmodified. In summary, 615 alanine substitution variants were generated. Further indicated: Constant regions 
(C1-C5), variable loops (V1-V5), heptad repeats 1 and 2 (HR1, HR2), membrane-proximal external region (MPER), R6 
cleavage site, I559P substitution, disulfide-bond (S-S) forming cysteine substitutions at positions 501 (A501C) and 605 
(T605C). 
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4.2.3 Antibody epitope mapping with the BG505 SOSIP gp160 
alanine substitution library 
The in-depth characterization of the BG505 SOSIP gp160 alanine substitution library as a 
mapping tool was done by Iris Ganser in her master`s thesis201, which was supervised by Dr. 
David Peterhoff. Since some results of the master` thesis were important for this thesis, 
relevant outcomes are shortly summarized in this section. 
During the master´s thesis the BG505 SOSIP gp160 alanine substitution library was tested for 
its applicability as a mapping tool in several proof-of-principle screenings. In a typical 
mapping experiment, Env variants of the BG505 SOSIP gp160 alanine substitution library 
were expressed on the surface of HEK293T cells. To this end, HEK293T cells were 
transiently cotransfected with plasmids encoding for Env library variants and Furin in a high-
throughput 96-well format (one variant per well). After 48 h of Env expression, cells were 
stained with the Alexa647-labeled screening antibody and analyzed by flow cytometry. To 
assess the impact of alanine substitutions on antibody binding, the MFI of the alanine 
substitution variants was normalized to the signal of the WT reference (WT=BG505 SOSIP 
gp160 without alanine substitution), which was present on each plate. Data that were 
evaluated this way are further referred to as “unreferenced measurements”. Since this kind of 
evaluation does not consider Env expression effects, potentially resulting from alanine 
substitutions themselves or varying transfection efficiencies, a second evaluation method was 
applied in parallel. In this so called “referenced measurements” the WT-normalized MFI of 
the screening antibody was divided by the WT-normalized MFI of a reference antibody to 
normalize for varying Env surface expression levels between different alanine substitution 
variants. Thereby, a ratio greater than 1 indicated a gain of binding, while a ratio smaller than 
1 represented a loss of binding. To enable referenced measurements, cells were screened in a 
“multiplex” approach, which avoids co-staining of cells with two antibodies in parallel, 
involving the risk of binding interference between antibodies. For multiplexing, HEK293T 
cells in two 96-well plates were transfected with identical Env DNAs (one Env variant/well). 
After 48 h, cells expressing corresponding alanine substitution variants on each plate were 
mixed, split to equal parts and separately analyzed by screening and reference antibody, 
respectively. This procedure ensured that cells analyzed by screening and reference antibody 
were highly comparable regarding transfection efficiency and cell quality, and further avoided 
co-staining. Furthermore, the multiplexing approach allowed the direct comparison of 
unreferenced and referenced evaluation, since data for both analyses were generated within 
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one experiment. Alanine substitutions resulting in significant loss and gain of binding were 
calculated with t-tests using a false discovery rate (FDR) correction in R. Here, an FDR-
corrected p-value < 0.05 was assumed as significant change compared to WT. The first proof-
of-principle screening involved mapping of the epitope of bNAb HGN194194. This antibody 
targets a linear (conformational) epitope within the crown of the V3 loop of gp120, which was 
previously mapped by peptide screening194,202. In addition, the epitope of this antibody was 
successfully mapped using the 96ZM651 gp145 alanine substitution library (Kliche and 
Grassmann et al., manuscript in preparation). Thus, this antibody was considered useful for 
assay establishment. The HGN194 screening included all BG505 SOSIP gp160 library 
variants that encode for alanine substitutions in the V3 loop, while randomly selected library 
variants encoding for alanine substitutions in gp120 surface residues served as controls. The 
HGN194 screening was performed as described above, while MPER-targeting bNAb 
4E10101,102 was tested as a reference antibody. The unreferenced HGN194 screening identified 
four alanine substitutions that resulted significant changes of HGN194 binding, see Figure 
33A. Three of the alanine substitutions reduced HGN194 binding, while one alanine 
substitution led to enhanced HGN194 binding. Importantly, all alanine substitutions that 
significantly altered binding of HGN194 were located within the V3 loop, whereas control 
residues demonstrated no significant changes in binding. However, when the WT-normalized 
HGN194 signals were referenced to WT-normalized 4E10 signals, almost all screened alanine 
substitutions demonstrated a significant loss of HGN194 binding, irrespective of V3 loop or 
control residues, see Figure 33B. This effect can be explained by the fact that 4E10 exhibited 
enhanced binding to nearly all alanine substitution variants compared to the WT (data not 
shown). Thus, referencing the WT-normalized HGN194 signals to the WT-normalized 4E10 
signals resulted in a loss of HGN194 binding. Consequently, 4E10 was not useful as a 
reference antibody. Additional proof-of-principle screenings aiming to map more complex 
antibody epitopes (VRC01, PGT121178,203) ended up with similar results (data not shown). 
Overall, proof-of-principle screenings (unreferenced) identified alanine substitutions that 
mainly resulted in losses of binding in regions that had been described as the respective 
antibody epitopes, demonstrating that the BG505 SOSIP gp160 alanine substitution library is 
in principle a suitable tool for epitope mapping201. However, epitope-mapping of the 
quaternary structure-depending bNAb PGT145 delivered no reliable results, since no distinct 
binding site has been identified, see Appendix Figure 6. Overall, mapping conditions were 
suboptimal due to the lack of a suitable method for referencing and the low Env surface 
expression levels of BG505 SOSIP gp160. Env expression levels, next to other factors such as 
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brightness of the fluorescent dye, antibody labeling efficiency and antibody-Env binding 
affinity, essentially contribute to the flow cytometer`s limit of detection and thus to mapping 
feasibility201. In summary, results demonstrated that the BG505 SOSIP library is in principle 
applicable for epitope mapping, however further efforts are required to enhance the quality of 
mapping experiments. 
 
 
Figure 33. HGN194 preliminary screening. Gains (bars upwards) and losses of binding (bars downwards) are plotted for 
every screened variant. V3 loop residues are shown in light grey, control residues in dark grey. The logarithmically 
transformed false discovery rate (FDR)-corrected p-value of every library variant is indicated by red points. Points above the 
upper green dashed line (for gains of binding) or below the lower green dashed line (for losses of binding) correspond to a p-
value < 0.5. (A) In the unreferenced screening, three significant losses and one significant gain of binding could be identified 
in the V3 loop. (B) As the reference antibody 4E10 showed gains of binding for almost all variants, the HGN194 signals 
were calculated as losses of binding in the referenced setup. The screening was performed in five replicates, data were 
generated during the master`s thesis of Iris Ganser under experimental supervision of Dr. David Peterhoff. 
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4.2.4 Summary 
One objective of this thesis was the generation of an Env alanine substitution library that can 
be used for mapping of antibodies with quaternary epitopes in a mammalian cell display 
approach. As precursor cleavage essentially contributes to proper protein folding, cleavage 
competence was a prerequisite of the new library. Since SOSIP modifications were 
successfully used to express soluble, fully-cleaved, stabilized Env trimers, it was considered 
to implement these modifications in the library design in order to benefit from their stabilizing 
effects, regarding the expression of a homogeneous trimer population on the cell surface. 
BG505 was chosen as a library base because this isolate benefits from trimer enhancing 
propensities and was successfully used for the generation the well-characterized BG505 
SOSIP.664 trimers, binding to nearly all known bNAbs. Prior to library generation, a 
comparative analysis was performed that aimed to investigate the impact of stabilizing 
modifications and CT truncation on expression levels of cell membrane-bound BG505, see 
Figure 31. Notably, all Env variants carrying the I559P substitution demonstrated enhanced 
surface expression compared to the WT (in gp145 and gp160), whereas the SOS modification 
did not alter overall expression levels. Further, as expected, truncation of the cytoplasmic tail 
increased Env surface expression. Since expression levels seemed to be sufficient and in 
consideration of a recent publication145, BG505 SOSIP gp160 was chosen as basis for the new 
alanine substitution library. In summary, the extracellular part of BG505 SOSIP gp160 was 
consecutively substituted by an alanine, resulting in a total number of 615 generated alanine 
substitution variants, see Figure 32B. Further, elements were implemented that allow 
conversion of BG505 SOSIP gp160 alanine variants into the corresponding gp145 or gp140 
constructs by simple restriction digest and re-ligation, see Figure 32A. In addition, the 
plasmid vector utilized for library generation offers the ability to generate stable cell lines 
with doxycycline inducible Env expression via the ThermoFisher Scientific Flp-In System. 
Mapping experiments performed by Iris Ganser during her master`s thesis demonstrated that 
BG505 SOSIP gp160 library is in principle a suitable tool for epitope mapping. Overall, 
proof-of-principle screenings (e.g. HGN194, see Figure 33) identified alanine substitutions 
that mainly resulted in losses of binding in regions that had been described as the respective 
antibody epitopes. However, mapping of the PGT145 epitope remained unsuccessful. Overall, 
measurements suffered from low expression levels of gp160 Env and the lack of a suitable 
method for referencing. In summary, epitope mapping using the BG505 SOSIP alanine 
substitution library requires further optimization efforts. 
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4.3 High-throughput analysis of a cellular BG505 
SOSIP gp145 glycan-knockout library by FACS in 
combination with NGS 
Screening of mutant libraries displaying a vast diversity of cell-surface exposed Env proteins 
by FACS offers great opportunities for Env immunogen design, including the identification of 
amino acid residues that are critical for protein structure or binding of bNAbs. Further, the 
method can be used to select Env variants with distinct phenotypes, e.g. enhanced binding to 
bNAbs or reduced binding to non-neutralizing antibodies. In addition, cell sorting offers the 
ability to re-cultivate cells with desired phenotypes, and thus allows iterative selection 
processes that can be used for the development of germline-targeting immunogens and 
intermediate Env variants for sequential immunization strategies (see 1.5.2). Prior to this 
thesis, Dr. Tim-Henrik Bruun and Dr. Veronika Grassmann developed a mammalian cell 
display and FACS-based procedure that allows selection of Env variants according to their 
antibody affinity. The applicability of the method was demonstrated by enrichment analysis of 
a cell-surface expressed five-member Env/V3 chimeric model library (see 4.1.2)154. One 
objective of this thesis was to apply the selection procedure to a cellular library expressing 
membrane-exposed, cleavage-competent BG505 SOSIP alanine substitution variants that 
result in the deletion of N-linked glycosylation sites. 
4.3.1 Overview of the mammalian cell display-based FACS 
selection system 
With the exception of minor adjustments, the mammalian cell display-based FACS selection 
used in this work was identical to the procedure that was previously reported by Bruun and 
Grassmann et al.154. Thus, the latter is shortly reviewed. The previously described mammalian 
cell display and FACS-based procedure consisted of five different steps, see Figure 34. The 
first step comprises the generation of a cellular library, consisting of stable HEK293T cell 
lines that carry a single copy of a given env variant at a defined locus in the cellular genome. 
Thereby, the stable cell lines with doxycycline inducible Env expression are generated using 
the ThermoFisher Scientific Flp-In System. To this end, Flp-In™ T-REx™ 293 cells are 
cotransfected with a plasmid vector containing a Flp recombination target (FRT) site (in this 
case pQL13 encoding for Env) and a plasmid encoding for the Flp recombinase (pOG44), see 
Figure 34, step 1. The Flp recombinase can mediate a homologous recombination event 
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between the FRT site of the plasmid vector and the FRT site present in the genome of Flp-
In™ T-REx™ 293 cells. This leads to the integration of the plasmid vector into the predefined 
FRT site of Flp-In™ T-REx™ 293 cells. Since Flp-In™ T-REx™ 293 cells contain precisely 
one FRT site, integration of a single copy env gene results in linkage of genotype and 
phenotype. Further, by successful integration of the plasmid vector in to FRT site, Flp-In™ T-
REx™ 293 cells acquire a hygromycin resistance that allows selection of stable transfected 
cells. After about 25 days of selection, stable cell lines are pooled to generate a cellular Env 
library, see Figure 34, step 2. Prior to FACS, the Env expression of stable cell lines is 
induced by doxycycline as the Env expression in Flp-In™ T-REx™ 293 cells is regulated by 
the Tet operator/repressor system. After staining with a fluorescent-labeled screening 
antibody (Figure 34, step 3), Env expressing cells are subjected to FACS to select for Env 
variants with the desired antibody binding profile, see Figure 34, step 4. Thereby, Env 
expression levels were normalized to green fluorescent protein (GFP) expression as Env and 
GFP expression were genetically coupled by a "self-cleaving" TaV 2A peptide154,204 (feature 
of the pQL13 vector). To determine the genotypes of selected Env variants, and further to 
calculate the enrichment of Env variants by the FACS selection process, gDNA of input and 
output samples is recovered and analyzed by NGS, see Figure 34, step 5. Alternatively, 
selected cells can be re-expanded and applied to a second round of sorting to increase 
enrichment rates. 
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Figure 34. Schematic overview of the FACS-based selection procedure. (1) Generation of stable cell lines using the 
ThermoFisher Scientific Flp-In System. Flp-In™ T-REx™ 293 cells are cotransfected with an Env encoding plasmid vector 
(pQL13) containing a Flp recombination target (FRT) site and the helper plasmid pOG44 encoding for the Flp recombinase. 
The Flp recombinase mediates the integration of the FRT containing plasmid vector into the predefined FRT site of Flp-In™ 
T-REx™ 293 cells via homologous recombination. As Flp-In™ T-REx™ 293 cells contain precisely one FRT site, linkage of 
genotype and phenotype is achieved. Successful integration of the plasmid vector into the FRT site of Flp-In™ T-REx™ 293 
cells results in the acquisition of a hygromycin resistance, allowing antibiotic selection of stable cell lines. (2) Stable cell 
lines are pooled to generate a cellular Env library. After induction of Env expression with doxycycline (Env expression in 
Flp-In™ T-REx™ 293 cells is regulated by the Tet operator/repressor system), cells are stained with a fluorescent-labeled 
screening antibody (3). FACS is used to select for cells that display Env variants with the desired antibody binding profile 
(4), thereby Env expression levels are normalized to genetically coupled GFP expression. Genomic DNA (gDNA) of input 
and output samples is recovered and analyzed by next generation sequencing (NGS) to determine genotypes of selected Env 
variants, and further to calculate the enrichment of Env variants by the FACS selection process (5). Alternatively, to enhance 
enrichment rates, selected cells can be re-expanded and applied to a second round of sorting (indicated by dashed line). 
Figure adapted from Bruun, T.-H. et al. Mammalian cell surface display for monoclonal antibody-based FACS selection of 
viral envelope proteins. MAbs 9, 1052–1064 (2017)154. 
 
4.3.2 Comparative analysis of stable cell lines and transiently 
transfected cells regarding Env expression and antigenicity 
The initial step in the mammalian cell display-based FACS selection system comprises the 
generation of a cellular library based on Env expressing stable cell lines. Based on the 
experiences made with the BG505 SOSIP gp160 alanine substitution library in transient 
mapping experiments there were obvious reasons to use BG505 SOSIP gp145 as basis for the 
cellular library since it was expected that CT truncation likely enhances Env expression. 
However, keeping in mind that the CT might largely affect the antigenicity profile of the Env 
ectodomain145, there was again the question if the cellular library should express full-length 
gp160 or the CT-truncated gp145 version of the Env protein. In order to answer this question 
and find an optimal solution two aspects were investigated in detail, including: 1) Env 
expression levels in stable cell lines; and 2) the influence of the CT on antibody binding to 
stabilized, cell-surface presented BG505 SOSIP Env proteins. The first step consisted of the 
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generation of stable cell lines for expression BG505 SOSIP gp160 full-length and CT-
truncated gp145 Env proteins. Thereby, stable cell lines were generated based on a 
constitutive Furin overexpressing cell line to promote Env precursor cleavage. This cell line, 
termed Flp-In™ T-REx™ 293 CMV_Furin+ and further referred to as CMV F+, 
constitutively overexpresses Furin under a control of CMV promotor and was previously 
established by our group during the master`s thesis of Dominik Fiegle165. Next to constitutive 
Furin overexpression, CMV F+ cells offer all advantages of normal Flp-In™ T-REx™ 293 
cells (generation of stable cell lines with inducible Env expression, see 4.3.1) since the latter 
were used as basis for their generation. Stable cell lines for expression of BG505 SOSIP 
gp160 and gp145 Env were generated by stable transfection of CMV F+ cells with plasmids 
(pLib1.1, see 3.2.3) encoding for BG505 SOSIP gp160 or gp145, see 3.3.3. After successful 
selection, CMV F+ cell lines with stably integrated BG505 SOSIP gp145 or gp160 env genes 
were analyzed for their Env surface expression levels. To this end, stable cell lines were 
cultured in presence of doxycycline to induce Env expression (see 3.3.4) and analyzed via 
flow cytometry (see 3.3.6) using bNAb 2G12 as a marker for Env surface expression. For 
comparison, HEK293T cells transiently cotransfected with plasmids encoding for Furin and 
BG505 SOSIP gp145 or gp160 were also included in this analysis. The results, shown in 
Figure 35, demonstrated that stable cell lines were superior to transiently transfected cells 
regarding expression levels of BG505 SOSIP gp145 (~factor of 2) and gp160 Env (~factor of 
5). Further, as expected, the presence of the CT in gp160 full-length Env resulted in reduced 
expression levels also in stable cell lines. 
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Figure 35. Comparative analysis of the expression 
levels of cell-surface presented BG505 SOSIP gp145 
and gp160 Env, expressed by stable cell lines and 
transiently transfected cells. HEK293T cells were 
transiently co-transfected with plasmids encoding for 
Furin and BG505 SOSIP gp145 or gp160 Env 
(transfection in T175 flasks). Cell lines, based on 
constitutive Furin overexpressing CMV F+ cells, with 
stably integrated BG505 SOSIP gp145 or gp160 env 
genes, were cultured in T175 flasks and Env expression 
was induced with doxycycline. 48 h post 
transfection/induction, cells were stained with 250 nM 
Alexa647-labeled bNAb 2G12 and analyzed by flow 
cytometry. Depicted are MFIs of 2G12 binding to 
BG505 SOSIP gp145 and gp160 Env expressed by 
stable cell lines (CMV F+, blue and red bars) and 
transiently transfected HEK293T cells (T, purple and 
orange bars). CMV F+ cells (doxycycline induced, 
without integrated env) and mock transfected 
HEK293T cells (plasmid vector without env together 
with a Furin encoding vector) were used as negative 
controls (black bars) for stable cell lines (CMV F+ 
control) and transiently transfected cells (T control), 
respectively. Results represent the mean value of four 
independent experiments with error bars reflecting the 
SEM of the independent experiments. 
 
Next, stable cell lines were analyzed in flow cytometry-based antibody titration experiments 
to investigate the influence of the CT on the BG505 SOSIP antigenicity profile. In order to 
compare the antigenicity profile between Env expressing stable cell lines and transiently 
transfected cells, the latter were also included in the experiment. The antibody panel used for 
assessment of Env antigenicity profiles consisted of the quaternary structure-characterizing 
mAbs described in 4.1.12 and bNAb PG9175,176,177 recognizing a quaternary epitope in V1/V2 
as well as mAb 17b185,186 binding to Env with transiently sampled- or CD4-induced (CD4i) 
open conformations205. In the experiment, transiently transfected cells and stable CMV F+ 
cells expressing BG505 SOSIP gp145 or gp160 were subjected to antibody titration and 
analyzed by flow cytometry as described in 3.3.7. Thereby, binding signals of titration 
antibodies were normalized for varying Env expression levels and referred to as “relative 
MFI”. This was achieved by calculating the ratio between binding signals of titration 
antibodies and 2G12, which was used as a marker for Env surface expression (cells were 
analyzed in separate wells to avoid co-staining and potential antibody-binding interference, 
see 3.3.7. Results of the titration experiments are shown in Figure 36. With regard to BG505 
SOSIP expressing stable cell lines, all bNAbs, including quaternary-structure depending 
bNAbs PG9, PGT145 and PGT151 demonstrated comparable binding to CT-truncated gp145 
and full-length gp160, while non-neutralizing antibodies F105 and 17b exhibited no binding. 
This indicates that membrane-exposed BG505 SOSIP displays a favorable antigenicity 
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profile, which is not affected by the presence or absence of the CT. Similar was observed 
within transiently transfected cells, here BG505 SOSIP gp145 and gp160 were comparably 
bound by bNAbs and, however, also by non-neutralizing antibodies F105 and 17b. 
Interestingly, comparing antigenicity profiles of BG505 SOSIP gp145/gp160 expressed by 
stable cell lines and transiently transfected cells revealed that quaternary-structure depending 
bNAbs PG9, PGT145 and PGT151 by trend exhibited better binding to proteins expressed by 
stable cell lines. In turn, BG505 SOSIP gp145 and gp160 expressed by transiently transfected 
cells demonstrated binding to non-neutralizing antibodies F105 and 17b, which was not the 
case for corresponding proteins expressed by stable cell lines. Taken together, these 
observations indicate that stable cell lines display homogeneous BG505 SOSIP gp145 and 
gp160 trimer populations whereas transiently transfected cells likely present a mixture of 
native-like trimers and trimers with an open conformation (or Env in other oligomerization 
states e.g. dimers/monomers). BNAb 2G12, as expected, bound similar to BG505 SOSIP 
gp145 and gp160, irrespective if expressed by stable cell lines or transiently transfected cells. 
BNAb VRC01 demonstrated better binding to BG505 SOSIP gp145 and gp160 expressed by 
transiently transfected cells compared to stable cell lines. Interestingly, a previously reported 
comparative analysis of soluble BG505 SOSIP.664 and less stabilized/uncleaved versions of 
BG505 demonstrated that VRC01, although binding to all versions of BG505, exhibited the 
weakest binding to the most stabilized, native-like form BG505 SOSIP.664119. Consequently, 
more open BG505 SOSIP conformations or presence of other oligomerization states may have 
contributed to enhanced VRC01 binding in case of transiently transfected cells. The same 
reasons are likely responsible for binding of 17b (not CD4-induced) to BG505 SOSIP g145 
and gp160 expressed by transiently transfected cells. Irrespective if expressed by stable cell 
lines or transiently transfected cells, BG505 SOSIP gp145 and gp160 demonstrated binding to 
17b after incubation with soluble CD4 (sCD4) that induces the (open) CD4i Env 
conformation resulting in the exposure of the 17b epitope. This result was expected since it 
was previously reported that sCD4 induces the CD4i conformation in soluble BG505 
SOSIP.664 trimers61. However, 17b demonstrated enhanced binding to CD4-induced BG505 
SOSIP gp145 and gp160 expressed by transiently transfected cells, compared to the same 
proteins expressed by stable cell lines. 
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Figure 36. Comparative analysis of the antigenicity profile of cell-surface presented BG505 SOSIP gp145 and gp160 
Env, expressed by stable cell lines and transiently transfected cells. HEK293T cells were transiently co-transfected with 
plasmids encoding for Furin and BG505 SOSIP gp145 or gp160 Env (transfection in T175 flasks). Cell lines, based on 
constitutive Furin overexpressing CMV F+ cells, with stably integrated BG505 SOSIP gp145 or gp160 env genes, were 
cultured in T175 flasks and Env expression was induced with doxycycline. 48 h post transfection/induction, cells were split 
into two parts and analyzed by flow cytometry. Thereby, one part of cells was stained with 250 nM Alexa647-labeled bNAb 
2G12 to determine Env surface expression levels, while the other part was used for titration of Alexa647-labled mAbs. Of 
note, binding of mAb 17b (recognizes the CD4-induced Env configuration) was additionally analyzed in presence of soluble 
CD4.To this end, cells were pre-incubated with sCD4, followed by 17b titration. Doxycycline induced CMV F+ cells without 
integrated env and mock transfected HEK293T cells (plasmid vector without env together with a Furin encoding vector) were 
used as negative controls. For evaluation, MFIs of Env expressing cells were corrected for antibody background binding by 
subtracting the respective negative control signals and are further referred to as referenced MFIs. To normalize binding 
signals of titration antibodies for varying Env expression levels, the respective referenced MFIs obtained from titration 
experiments were divided by the corresponding referenced 2G12 signals and are further referred to as relative MFIs. Shown 
are binding curves (relative MFI) of antibody titrations to BG505 SOSIP gp145 and gp160 Env expressed by stable cell lines 
(CMV F+, in blue and red) and transiently transfected HEK293T cells (T, in purple and orange). Binding curves of 17b in 
presence of sCD4 (+CD4) are depicted as dashed curves. Results represent the mean value of two independent experiments 
with error bars reflecting the SEM of the independent experiments. 
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In summary, the constitutive Furin overexpressing cell line CMV F+ was used for the 
generation of stable cell lines with integrated BG505 SOSIP gp145 or gp160 env genes. A 
comparative analysis between the generated stable cell lines and transiently transfected cells 
revealed that stable cell lines are superior to transiently transfected cells regarding BG505 
SOSIP gp145 and gp160 expression levels. Further, the antigenicity profiles of BG505 SOSIP 
gp145 and gp160 expressed by stable cell lines and transiently transfected cells were analyzed 
in titration experiments, using a panel of quaternary structure-characterizing mAbs. Here, it 
has been demonstrated that the favorable antigenicity profile of membrane-exposed BG505 
SOSIP is not affected by presence or absence of the CT in both, stable cell lines and 
transiently transfected cells. Notably, stable cell lines were superior to transiently transfected 
cells regarding the Env antigenicity profile. Whereas binding of bNAbs and some binding of 
non-neutralizing antibodies was detected for BG505 SOSIP gp145 and gp160 expressed by 
transiently transfected cells, corresponding Env proteins expressed by stable cell lines were 
exclusively bound by bNAbs and not by non-neutralizing antibodies. This indicates that stable 
cell lines display homogeneous BG505 SOSIP gp145 and gp160 trimer populations. 
4.3.3 Generation and quality control of a cellular BG505 SOSIP 
gp145 glycan-knockout library  
The extensive glycosylation of Env, acting as a “shield” to prevent binding of neutralizing 
antibodies, essentially contributes to HIV immune evasion, see 1.3.3. However, structural 
analyses revealed that a proportion of bNAbs does not only bind to gp120 protein residues but 
also recognizes glycans attached to gp120206,176,207,180,208,209. Based on these findings, the 
analysis of the Env glycan shield became increasingly important in HIV-1 Env vaccine 
design. Thus, this thesis focused on the generation of a cellular BG505 SOSIP glycan-
knockout library that can be used to analyze the impact of single glycan deletions on antibody 
binding via a mammalian cell display and FACS-based selection procedure, see 4.3.1. Since 
antibody titration experiments (see 4.3.2) demonstrated that the truncation of the CT does not 
negatively affect the antigenicity profile of membrane-exposed BG505 SOSIP, the cellular 
library was generated based on gp145 to benefit from high expression levels. 
The already existing BG505 SOSIP gp160 alanine substitution library was used as a template 
for the generation of the cellular BG505 SOSIP gp145 glycan-knockout library (for details see 
3.3.5). Briefly, the following pLib1.1 plasmid vectors of the BG505 SOSIP gp160 alanine 
substitution library were cloned into gp145 expressing constructs: 1) all plasmid vectors that 
encode for alanine substitutions in the 28 NXT/S glycosylation sequons (alanine substitutions 
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of N and T/S, since it was expected that both alanine substitutions equally prevent the 
glycosylation of the asparagine in the sequon); 2) two plasmid vectors that encode for alanine 
substitutions at two potential O-linked glycosylation sites50,51 (positions T499 and T606, 
HXB2 numbering). The resulting 58 pLib1.1 plasmids were used for stable transfection of 
CMV F+ cells to generate 58 individual stable cell lines. Finally, 56 out 58 stable 
transfections resulted in the successful generation and selection of stable cell lines. Next, 
stable cell lines were tested for their Env expression levels. For this purpose, stable cell lines 
with induced Env expression were analyzed via flow cytometry (see 3.3.6) using bNAbs 
2G12 and VRC01 as markers for Env surface expression. VRC01 was chosen a second 
marker since binding this bNAb does not depend on the presence of glycans210. At a first 
glance, all stable cell lines demonstrated Env expression when analyzed by 2G12 and VRC01, 
see Figure 37A. Further, there was a good correlation between expression levels quantified 
by 2G12 and VRC01, see Figure 37B, indicating that both antibodies are suitable for the 
quantification of Env surface expression. Overall, expression levels between stable cell lines 
and the WT (no glycan deletion) varied by approximately a factor of 2 or less. Thereby most 
variants demonstrated a slightly reduced expression compared to the WT. However, some 
stable cell lines including variants N262A, N448A and T450A exhibited very low Env 
expression levels. Repeating the analysis for these particular cell lines confirmed low 
expression levels, except for variant T450A which demonstrated negligible expression (data 
not shown). In addition, N and T/S alanine substitutions in a particular sequon tended to result 
in comparable expression levels. Taking a closer look to glycans in the proximity of VRC01 
and 2G12 epitopes lead to interesting results. VRC01 for example demonstrated enhanced 
binding (compared to WT) to stable cell lines expressing Env variants with a glycan deletion 
at AA position N276 (N276A and T278A), which was not observed for 2G12.This 
observation can be explained by the critical role of the N276 glycan regarding the 
accessibility of the CD4bs. It has been previously reported that the presence of this glycan 
likely prevents interaction between germline VRC01 and Env due to a steric clash135. Further, 
as demonstrated in the PhD thesis of Veronika Grassmann, the removal of this glycan also 
improves binding of the mature VRC01197. Interestingly, the comparison of VRC01 and 2G12 
expression levels revealed the glycan deletion at AA position N332 (N332A, S334A) resulted 
in WT-like 2G12 binding, despite the fact that the N332 glycan is part of the 2G12105 epitope. 
 
 
 _____________________________________________________________________ Results 
115 
 
 
 
 
Figure 37. Expression analysis of stable cell lines 
displaying BG505 SOSIP gp145 Env variants with single 
glycan deletions. Stable cell lines were cultured in 96-well 
plates (all 56 variants in one plate, six plates in total) and 
Env expression was induced with doxycycline. Stable cell 
lines expressing BG505 SOSIP gp145 WT (WT=no glycan 
knockout) and CMV F+ cells without integrated env were 
present on each plate as positive and negative controls, 
respectively. 48 h post induction, cells were stained with 
250 nM Alexa647-labeled bNAbs 2G12 or VRC01 (three 
plates for each antibody) and analyzed by flow cytometry. 
To compare expression levels between library variants and 
WT and between different antibodies used for their 
quantification, data were processed as follows. MFIs of Env 
expressing cells were corrected for the respective antibody background binding by subtracting negative control signals 
(resulting in referenced MFIs) and set into relation to the WT signal (relative MFIs). Relative MFIs were separately 
calculated for each plate (n=3 for each antibody). (A) Env expression levels of library variants compared to the WT (WT=1, 
indicated by the dashed line) measured by 2G12 (red) and VRC01 (blue). Shown are mean values and SEM of the three 
replicates. Further illustrated: Positions of glycans within Env regions and proximity to the CD4 binding site (CD4bs). (B) 
Linear regression analysis of Env expression levels, quantified by 2G12 and VRC01. Alanine substitution variants N276A 
and T278A resulting in enhanced binding of VRC01 compared to WT (not observed for 2G12) are highlighted. Linear 
regression analysis was performed using GraphPad Prism 5. 
 
 
In summary, the BG505 SOSIP gp160 alanine substitution library was used as a template to 
generate stable cell lines expressing gp145 Env variants with alanine substitutions in NXT/S 
glycosylation sequons. Thereby, stable cell lines were individually generated and tested for 
Env expression. Finally, individual stable cell lines were pooled to equal parts to generate the 
cellular BG505 SOSIP gp145 glycan-knockout library. 
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4.3.4 FACS of the BG505 SOSIP gp145 glycan-knockout library 
with bNAb PGT135 
The bNAb PGT135178,180,106 recognizes the V3-glycan epitope of Env (see 1.4.2) and its 
binding depends on the presence of the glycan at AA position N332. Due to its glycan- 
dependency PGT135 was chosen as a model antibody for an initial FACS analysis with the 
BG505 SOSIP gp145 glycan-knockout library. Thereby, to get a first glance, the FACS-based 
methodology focused on the identification of glycans that result in a loss of PGT135 binding. 
FACS was performed as described in 3.3.8. In the first step, a freshly thawed aliquot of the 
BG505 SOSIP gp145 glycan knockout library (generated by pooling of independently 
generated stable cell lines) was grown to sufficient cell numbers (18 days). After induction 
with doxycycline, cells were grown for further 48 h and co-stained with PGT135 (100 nM, 
linear binding range) and VRC01 (250 nM) which was used as expression marker. VRC01 
was chosen as a reference antibody because a control experiment demonstrated that VRC01 
does not compete with PGT135 binding as 2G12 did (data not shown). Finally, approximately 
2 x 107 cells were subjected to FACS selection. To select for cells that exhibit a loss of 
PGT135 binding in relation to their Env expression level, cells were sorted for the lowest 
PGT135 signal in relation to the VRC01 signal (gate P3), see Figure 38. In summary, from 
approximately 1.5 x 107 analyzed cells about 3 x 105 cells were sorted in to the final gate P4 
(living cells). 
 
 
Figure 38. Gating strategy of the FACS-based selection procedure. The sorting procedure of 1 x 104 cells is exemplarily 
shown. Cells were gated for living, single cells (P1 and P2). Cells separated into uninduced (low FITC-A / low APC-A) and 
induced populations (higher APC-A). Induced cells were gated for lowest (P3) FITC-A signals (PGT135) in relation to their 
APC-A signal (VRC01, surface expression marker). Finally, sorted cells were again gated for living cells (P4). Gating 
hierarchy: All events (black) → P1 (red) → P2 (blue) → P3 (green) → P4 (purple). 
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Subsequently, gDNA samples of sorted cells and input material were analyzed by NGS, see 
3.2.5. This enabled the identification of Env variants present in the input material and sorted 
cells, and further allowed to calculate the fold-enrichment of variants displaying a PGT135 
low-affinity phenotype. The frequency of alanine substitution variants in sorted cells 
compared to the input material is shown in Figure 39A. Variant N332A, knocking out the 
essential glycan required for PGT135 binding, accounted for ~82 % of the sorted population, 
corresponding to a 35-fold enrichment of this variant in the sorted cells, see Figure 39B. Env 
variant S334A, also expected to knockout the glycosylation of N332, however, was only 
enriched by a factor of 2. All other Env variants demonstrated no enrichment in the sorted 
population.  
 
Figure 39. Single-round FACS selection of the BG505 SOSIP gp145 glycan-knockout library with bNAb PGT135. 48 h 
post induction, the BG505 SOSIP gp145 glycan-knockout library was subjected to one round of FACS selection with 
PGT135 as screening antibody. Cells were sorted for the lowest PGT135 signal in relation to Env surface expression. After 
sorting, gDNA of input control (drawn prior to sorting) and sorted cells was recovered and analyzed by NGS. The 
frequencies of alanine substitution variants in input control and sorted cells in % are shown in (A). All variants which were 
not present in the library are designated as not available (N/A). (B) Enrichment of stable cell lines in the sorted population. 
Enrichment is represented as log2-fold change in the number (n) of alanine substitutions for each variant compared to the 
input control. Calculations were made according to the formula from Bruun et al.154. 
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Besides, NGS was used to analyze the variability of the cellular library in the initial stage 
(frozen library stock), after cultivation for 18 days (time to get sufficient cell numbers for 
sorting), and further, after cultivation for additional 2 days in presence of doxycycline 
(induction of Env expression). The results shown in Appendix Figure 7 demonstrated a 
varying distribution between library stock and cultured/induced cells. Importantly, however, 
all cell lines present in the library stock were also present in the input material which was 
subjected to sorting. 
Taken together, the previously described FACS selection system in combination with NGS 
was successfully used to enrich and identify PGT135 low-affinity variants out of 54-member 
BG505 SOSIP gp145 glycan knockout library.  
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4.3.5 Summary 
Recently, our group reported a mammalian cell display and FACS-based methodology that 
allows selection of Env variants according to their antibody affinity. Thereby, the 
applicability of the method was demonstrated using a cell-surface expressed five-member 
Env/V3 chimeric model library154. One objective of this thesis was to apply the selection 
procedure to a cellular library that can be used to investigate the impact of single glycan 
deletions on antibody binding. To this end, the BG505 SOSIP gp160 alanine substitution 
library, described in 4.2.2, was used as template for the generation of a glycan-knockout 
library, comprising plasmids that encode for alanine substitutions in N-linked and O-linked 
glycosylation sites of BG505 SOSIP, see 4.3.3. Since comparative analyses demonstrated that 
truncation of the CT enhanced Env expression levels without negative effects on the favorable 
antigenicity profile of membrane-exposed BG505 SOSIP (see 4.3.2), variants of the BG505 
SOSIP glycan-knockout library were cloned to express gp145 Env. Subsequently, constructs 
were stably transfected in constitutive Furin overexpressing CMV F+ cells to generate stable 
cell lines. Stable cell lines were individually tested for Env expression and pooled to generate 
the cellular BG505 SOSIP gp145 glycan-knockout library, see 4.3.3. After successful 
generation, the cellular library was applied to FACS selection using the N332 glycan-
dependent bNAb PGT135 as screening antibody. Thereby, FACS in combination with NGS 
was successfully used to enrich PGT135 low-affinity variants, see 4.3.4.  
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5. Discussion 
A protective HIV vaccine could essentially contribute to end the HIV-1 pandemic. During the 
last years, the field focused on rational Env vaccine design with the aim to elicit bNAbs, 
targeting vulnerable sites of the HIV Env protein. Although induction of bNAbs by active 
immunization remained unsuccessful so far, major progress has been made. Since 2009, new 
screening procedures and technologies led to the identification of a huge number of bNAbs 
(see 1.4.2) with some of them defining new vulnerable sites on the highly variable and heavily 
glycosylated Env protein (see 1.3). A hallmark in HIV-vaccine design was the development of 
the soluble, stabilized native-like BG505 SOSIP.664 trimers, displaying a favorable 
antigenicity profile in terms of binding to bNAbs but no or reduced binding to non-
neutralizing antibodies, as determined by several biochemical and biophysical assays (see 
1.5.1). These trimers essentially contributed to the identification/characterization of many of 
the newly identified bNAbs (see 1.4.2), and further gave valuable insights into the highly 
dynamic, metastable nature of the Env protein (see 1.3). Within the last few years, binding 
characteristics of bNAbs and structural knowledge were used to generate a multitude of 
stabilized Env immunogens (see 1.5.1). When tested in animal models, several stabilized 
immunogens (including BG505 SOSIP.664) induced autologous neutralizing antibody 
responses, considered as first success on the road towards broader neutralizing antibody 
responses. Based on these promising results, efforts have been made to improve the quality 
and breadth of antibody responses, including particle-based delivery of (stabilized) Env 
immunogens (see 1.5.3). However, as particle immobilization of Env immunogens may affect 
their antigenicity profile, the latter has to be investigated by suitable methods. Furthermore, 
analysis of the antigenicity profile of Env immunogens, soluble or particle-presented, should 
be ideally performed under physiological conditions as the environment may affect their 
structural integrity. MicroScale Thermophoresis represents a relatively new and powerful 
technique which offers the ability to measure affinities in solution and under physiological 
conditions (see 1.6). Thereby, the method is in principle not limited in respect to molecule 
size. As MST offers great opportunities for the investigation of the Env antigenicity profile, 
one objective of this thesis was to test whether MST is a useful technique for the 
characterization of soluble and particle-presented Env proteins in buffer and under 
physiological conditions. In addition, this thesis focused on the development of a BG505 
SOSIP-based alanine substitution library for functional mapping of bNAb epitopes using 
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mammalian cell display. A third objective of this thesis was the generation of a BG505 SOSIP 
gp145 glycan knockout library to investigate antibody-glycan interactions via a previously 
described cell sorting based approach154. 
5.1 MicroScale Thermophoresis and ELISA analysis of 
Env proteins 
One objective of this thesis was to investigate if MicroScale Thermophoresis is a useful 
technique for the characterization of soluble and particle-presented Env proteins in buffer and 
under physiological conditions. A model system consisting of five chimeric Env variants 
(Env/V3 chimeras) with distinct binding capacities to mAb 447-52D was used to address this 
question step-by-step. Experiments with soluble (gp120 monomers/gp140 trimers) and VLP-
presented Env/V3 chimeras have shown that MST in general can meet the criteria mentioned 
above, albeit with the minor restrictions that measurement in presence of 100 % serum was 
not possible. However, MST tolerated presence of 50 % serum, and thus enabled the 
investigation Env-antibody interactions under near-physiological conditions. Noteworthy, 
MST results were in general agreement with ELISA data that were collected in parallel, 
although measured affinities were only comparable within the respective method used. 
Further, MST analyses of the interactions between BG505 SOSIP.664 trimers and a panel of 
quaternary structure-characterizing mAbs demonstrated that the favorable antigenicity profile 
of BG505 SOSIP.664 trimers was preserved in MST measurements in buffer, as validated by 
His-capture ELISA. From this starting point and with the ability to measure affinities in 
presence of 50 % serum, MST was successfully used to investigate the antigenicity profile of 
BG505 SOSIP.664 trimers under near-physiological conditions. Further, MST was useful to 
assess the antigenicity profile of PLA particle-adsorbed BG505.SOSIP.664 trimers. 
5.1.1 Interactions between Env/V3 chimeras and mAb 447-52D in 
buffer and 50 % human serum 
MST analyses within the Env/V3 model system in buffer and 50 % serum demonstrated that 
MST provided consistent data within the overall expected affinity ranking 
(MN≥CDC42/HXB2>RF>SF33) of the interactions between gp120, gp140 and VLP-
presented gp145 Env/V3 chimeras and 447-52D, as confirmed by ELISA, see Figure 23 and 
Figure 27. Interestingly, it was observed that mAb 447-52D bound with higher overall 
affinities to trimeric gp140 Env/V3 chimeras than to respective gp120 versions of the 
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proteins. This was for the case for both, ELISA and MST analyses, in buffer as well as in 
presence of 50 % serum, see Table 8 and Table 9. 447-52D targets a linear conformational 
epitope in the crown of the V3 loop of gp120202,160,188 meaning that the epitope this antibody 
is three-times present within an Env trimer. Thus, one could consider that avidity effects, 
mediated by bivalent binding of the antibody within an Env trimer, were responsible for the 
enhanced affinity of 447-52D towards trimeric gp140 Env/V3 chimeras. However, this is an 
unlikely explanation since the architecture of Env trimers in general impedes intra-spike 
crosslinking211,212. A possible reason for the enhanced binding to trimeric Env/V3 chimeras 
may be that gp140 trimers seemed to be more stable than their monomeric counterparts. The 
instability of gp120 monomers was already observed during the protein purification process. 
Here, gp120 monomers did not tolerate addition of a His-tag and were highly sensitive to 
further concentration after SEC purification (both resulted in aggregation of the proteins), 
which was not observed for gp140 trimers. Thus, the instability of gp120 monomers may have 
negatively affected the presentation of the linear, but conformationally influenced 447-52D 
epitope, which may explain the reduced overall binding affinity of 447-52D to gp120 Env/V3 
monomers. 
As mentioned in the summary of the analysis of Env/V3 chimeras in buffer, it was waived to 
directly compare affinity data of VLPs measurements with the corresponding affinity data of 
soluble gp120 and gp140 Env/V3 chimeras since different assay setups were used for their 
analysis in both, MST and ELISA. For example, whereas 447-52D was labeled for the 
analysis of soluble Env/V3 chimeras, an inversed setup was used for the analysis of VLPs. 
Since fluorescent labeling has the potential to influence either the binding affinity of 447-52D 
or the 447-52D epitope present on labeled VLPs, a valid comparison of overall binding 
affinities is only possible within the respective assay setup. This holds also true for ELISA 
were soluble Env/V3 chimeras were analyzed by lectin capture and VLPs by direct-ELISA. In 
conclusion, comparing absolute affinities between VLP-presented and soluble proteins would 
require that the affinities are determined in within one assay setup. For ELISA, one could try 
if VLPs can be captured by lectin. In case of MST, a conceivable scenario would be to use 
Env proteins (soluble and VLP-presented) as fluorescent-labeled interaction partners and use 
antibodies as titrants. The fluorescent labeling of soluble and VLP-presented Env could be 
achieved by adding suitable tags (e.g. Flag- or Avi-tag) that are accessible in both, VLP-
presented and soluble Env proteins. This would allow site-directed labeling of Env proteins, 
and thus avoid disturbance of antibody epitopes as it might be the case in unspecific labeling 
via NHS-chemistry. However, a C-terminal tag, like it is often used for the purification of 
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soluble proteins, is not an option for VLP-presented Env proteins since the C-terminus in this 
case is buried within the particle, and thus no accessible for antibody-directed labeling. 
Interestingly, flow cytometry analyses previously performed in our group have shown that is 
possible to express BG505 SOSIP gp145 Env proteins with a N-terminal Flag-tag on the 
surface of mammalian cells. Further, analyses of the antigenicity profile, assessed by flow 
cytometry-based titration experiments with a panel of quaternary structure-characterizing 
antibodies revealed that the N-terminal Flag-tag had no negative effects on the protein 
structure. In conclusion, expression of Env proteins with N-terminal tags would allow site 
directed labeling of soluble and VLP-presented Env proteins and thus, offers an option to 
analyze soluble and VLP-presented Env proteins within one assay setup.  
Comparison of MST-derived KD-values demonstrated that the presence of serum during MST 
analyses seemed to reduce the overall binding affinity of 447-52D to soluble monomeric 
gp120 and trimeric gp140 Env/V3 chimeras. However, this was not the case in MST analyses 
with VLPs, in which binding affinities between buffer and serum analyses were comparable. 
Interestingly, serum effects were not observed in ELISA analyses (compare KD-values of 
MST and ELISA analyses in buffer and serum in Table 8 and Table 9, respectively). As 
described in 1.6, Env proteins and in particular Env proteins of subtype B, are susceptible to 
serum proteases-mediated proteolytical damage of the V3 region (V3-clipping). Since all V3-
loops of Env/V3 chimeras were derived from subytype B-isolates213,214,215,216,217, V3 clipping 
has to be considered as a factor that may have contributed to the reduced binding of 447-52D, 
because this antibody binds a V3 epitope. However, V3-clipping of soluble Env/V3 chimeras 
by serum proteases seems to be an unlikely reason for the MST-measured reduced binding 
affinity of 447-52D for several reasons: 1) the reduced affinity of 447-52D was only detected 
for soluble proteins and not for VLP-presented Env/V3 chimeras, although one would expect 
clipping also for VLPs; 2) it is assumed that V3-clipping would have also reduced the binding 
affinities of 447-52D in ELISA analyses. A possible explanation for the reduced affinity of 
447-52D could be that soluble Env/V3 chimeras, gp120 monomers as well as gp140 trimers, 
are less stable in the presence of serum. Similar, as discussed above for gp120 monomers, this 
may have negatively influenced the linear conformational epitope, and thus the binding 
affinity of 447-52D. Interestingly, the reduced binding affinity was only observed in MST 
analysis and there may be (a combination of) two reasons why this was the case: 1) MST, 
based on the thermophorectic effect which is influenced by multiple parameters (size, charge, 
hydration shell or conformation of a molecule150,149) is exceptional sensitive; and 2) that 
serum was present during the measurement itself, which was not the case in ELISA analyses. 
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Here, serum was only present during the incubation of the primary Ab (447-52D), while the 
final detection was done after several washing steps. However, the question why VLPs in 
MST analyses were not affected by presence of serum remains elusive. It is known that the 
transmembrane domain and the cytoplasmic tail contribute to the stability of membrane-
exposed Env proteins which may explain why truncated soluble Env proteins without 
stabilizing modifications are unstable and conformationally heterogeneous218,219. In line with 
the arguments that instability of soluble Env/V3 chimeras probably contributed to the reduced 
affinity of 447-52D in MST serum analyses, one could consider that Env/V3 chimeras were 
more stable when they are presented in the membrane exposed context, and thus not affected 
by presence of serum. However, to what extent this may have contributed to the experimental 
outcome of MST analyses is unknown since VLPs that expose C-terminal tail truncated 
Env/V3 chimeras are a highly artificial system. In summary, the Env/V3 system represents a 
valuable tool for assay establishment, but since it is a highly artificial system it is difficult to 
draw final conclusions how presence of serum affected antibody binding in this case. This 
was one reason why MST experiments were expanded to the well-characterized, native-like 
BG505 SOSIP.664 trimers as their structure can be nicely analyzed by quaternary structure-
characterizing antibodies. 
5.1.2 Interactions between BG505 SOSIP.664 trimers and 
quaternary structure-characterizing antibodies in buffer and 
50 % human serum 
With the intention to investigate a relevant next-generation Env immunogen, MST was used 
to analyze the interaction of native-like BG505 SOSIP.664 trimers and set of quaternary 
structure-characterizing mAbs in buffer and 50 % human serum. Thereby, MST-derived data 
were compared to results from direct and His-capture ELISAs. Measurements in buffer 
demonstrated that the native-like structure of the BG505 SOSIP.664 trimers was preserved in 
MST analysis since all bNAbs (PGT145, PGT151, VRC01, 2G12) bound with high affinities, 
whereas non-neutralizing mAb F105 exhibited only marginal binding. His-capture ELISAs 
produced comparable results and thereby validated MST-derived data, see Figure 29. 
Importantly, comparing results of MST and His-capture ELISA with data obtained from 
direct-ELISA nicely demonstrated that direct coating of BG505 SOSIP.664 trimers destroys 
the native-like structure of the protein, which has been previously reported by Schiffner et 
al.125. Noteworthy, His- and direct ELISA results measured within this thesis were general in 
good agreement with ELISA data reported in this publication. Further, MST was used to 
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investigate if the presence of serum affects the antigenicity profile of BG505 SOSIP.664 
trimers. Results showed that the antigenicity profile of BG505 SOSIP.664 trimers was in 
general agreement to measurements in buffer, with the exception that saturated binding of 
non-neutralizing antibody F105 was detected, see Figure 29. This indicated that in presence 
of serum at least a small proportion of the trimers turned into a more open conformation. 
However, this was not detected in His-capture ELISA, likely for reasons already described in 
5.1.1 (high sensitivity of MST, presence of serum during analysis). In addition, the results 
obtained from the MST analyses of BG505 SOSIP.664 trimers nicely demonstrated that 
presence of serum can affect the stability of Env proteins as it was discussed for soluble 
Env/V3 chimeras. The reasons why BG505 SOSIP.664 trimers partially turned into an open 
conformation, as indicated by binding of mAb F105, remain elusive. V3-clipping can be 
excluded since the V3 sequence of BG505 is not particularly vulnerable to this kind of 
proteolytical damage220. 
5.1.3 Interactions between PLA-adsorbed BG505 SOSIP.664 
trimers and quaternary structure-characterizing antibodies in 
buffer and 50 % human serum 
PLA particles with adsorbed BG505 SOSIP.664 trimers were generated in collaboration with 
Bernard Verrier and analyzed by MST and ELISA in order to test if MST is useful to assess 
the antigenicity profile of native-like Env trimers presented in the context of a state-of-the art 
particle-based vaccine delivery system. Contrary to MST analyses with VLPs, measurements 
of PLA particles suffered from background binding of the mAbs to control particles (without 
adsorbed Env), see Appendix Figure 3. This can be explained by passive adsorption of mAbs 
to the positively charged surface of PLA particles, which also enabled adsorption of BG505 
SOSIP.664 trimers. Notably, MST analyses of control PLA particles did benefit from the 
presence of 50 % serum, since serum components reduced unspecific binding of mAbs, most 
likely by blocking the particle surface, see Appendix Figure 4. In summary, it could not be 
excluded that unspecific binding, at least partially, contributed to the binding of mAbs to PLA 
particles with adsorbed BG505 SOSIP.664 trimers in MST analyses, since the calculated 
amount of ~50 trimers per particle (175 nm in size) is likely not sufficient block the complete 
particle surface from unspecific adsorption of mAbs. However, binding of all mAbs was 
considered as specific since saturated binding curves were only observed for PLA particles 
with adsorbed BG505 SOSIP.664 trimers, see Appendix Figure 3, Appendix Figure 4. MST 
analyses of PLA-adsorbed BG505 SOSIP.664 trimers in buffer and 50 % serum revealed 
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binding of bNAbs including quaternary structure-depending PGT145/PGT151, and binding of 
non-neutralizing antibody F105, see Figure 30. Consequently, MST results suggested that 
PLA-adsorbed BG505 SOSIP.664 trimers were present on particles surfaces as a mixture of 
native-like trimers and trimers with disturbed quaternary structure. It is likely that the mixed 
trimer population resulted from the immobilization strategy used for particle decoration 
(passive adsorption) since direct-ELISA experiments with BG505 SOSIP.664 trimers have 
shown that passive adsorption negatively influenced the protein structure, see Figure 29. In 
order to validate MST data, direct-ELISAs with PLA-adsorbed BG505 SOSIP trimers were 
performed with the assumption that PLA particles would serve as a platform for the 
presentation of BG505 SOSIP.664 trimers. Thus, it was expected to detect an antigenicity 
profile comparable to MST results, including binding of all bNAbs and non-neutralizing 
antibody F105. However, results of the direct-ELISA, contrary to MST results, indicated that 
the native-like structure of the BG505 SOSIP.664 trimers was completely disturbed. Whereas 
binding of bNAbs VRC01 and 2G12 (no quaternary structure dependency) and also non-
neutralizing F105 was detected, binding of quaternary structure-depending PGT145 was 
completely lost and PGT151 demonstrated some marginal signal limited to the highest 
antibody concentration used, see Figure 30. Taken together, results indicated the disruption of 
both, PLA particles and BG505 SOSIP.664 trimers due to coating to ELISA plates.  
5.1.4 Conclusion and potential applications for MST 
In summary, experiments have demonstrated that MST represents useful tool for the analysis 
of (stabilized) Env proteins for various reasons: 
1) MST is capable to determine affinities of interactions, starting from very simple to 
complex ligand presentations, as it was demonstrated in an exemplary way for soluble 
and VLP-presented Env/V3 chimeras and also in measurements with BG505 
SOSIP.664 trimers in soluble or PLA-adsorbed state. This, in principle, allows the 
antigenic characterization of soluble Env vaccines or particle-presented Env vaccines, 
using a single technology. This is from particular interest for particle-presented Env 
vaccines, as it became clear that they are more effective in B-cell stimulation 
compared to soluble versions of the protein221,222,143. However inherent properties of 
particles and the experimental design strongly influence if it is possible to determine 
binding affinities (like in case of VLPs) or if the measurement is restricted to allow 
characterization of the antigenicity profile by comparing antibody binding profiles 
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rather than by precise determination of binding affinities, like in case of PLA-adsorbed 
BG505 SOSIP.664 trimers. 
2) MST is in principle applicable to nearly any kind of buffer, and thus offers the option 
to investigate Env-antibody interactions under near-physiological conditions as it was 
shown for experiments in the presence of 50 % human serum. This is of particular 
interest for HIV vaccine design, since the antigenic profile of Env vaccine candidates 
is, as state-of-the-art, mostly assessed in artificial buffer and not under near-
physiological conditions that could affect the antigenicity profile as demonstrated in 
the analysis of the antigenicity profile of BG505 SOSIP.664 trimers in the presence of 
serum. MST thereby offers the advantage that binding of antibodies can be directly 
detected in presence of serum and not indirectly as it was the case in ELISA 
experiments. A nice experiment would be to incubate BG505 SOSIP.664 trimers or 
other stabilized Env immunogens in 20 % human serum as surrogate for lymphatic 
fluid (lymphatic fluid generally exhibits lower protein content than complete serum222) 
and analyze the antigenicity profile over different periods of time. This would maybe 
give a hint to what extent the antigenicity profile is already affected by serum 
components when proteins reach B-cells in the draining lymph nodes (parentally 
injected proteins are typically detectable in lymph nodes within minutes to a few 
hours223). Another possible application for MST would be to analyze how different 
kinds of immunostimulatory adjuvants influence the antigenic profile of next 
generation Env immunogens since only few studies addressed this issue in detail191,140. 
3) The main advantage of MST over ELISA and other methods which depend on surface-
immobilization of one interaction partner is that measurement takes place in solution. 
This might be important since immobilization of one interaction partner might 
interfere with the binding event or negatively influence the structure of the 
immobilized protein, like it was demonstrated in direct-ELISA experiments with 
BG505 SOSIP.664 trimers. Further, as it was assumed for direct-ELISA experiments 
with PLA-adsorbed BG505 SOSIP.664 trimers, immobilization of particles may have 
resulted in particle-disruption. Since analysis takes place in solution, MST avoids 
these kinds of problems from the outset. However, it is worth mentioning that also 
other methods can be used for analyses of Env-carrying particles. BLI for example 
was successfully used to characterize the Env-carrying liposomes143 mentioned in 
1.5.3. In general, surface immobilization of particles by direct coating or capturing 
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approaches may be not applicable to every type of particle, thus MST could represent 
a more universal approach to analyze interactions between particle-presented proteins 
and interaction partners. 
4) Other benefits of MST are fast assay development, short hands-on time as well as 
rapid measurements. Measurement of monomers, trimers VLPs and PLAs in buffer 
and serum were performed under comparable conditions with only minor adjustments 
(except for VLPs, were an inverse assay setup was used), see 3.5. Furthermore, in 
comparison to ELISA, MST consumed only small amounts of sample material and 
was faster, see Appendix Table 1. 
In conclusion, MST combines the advantages of low sample consumption, fast assay 
development and fast readout with high sensitivity and the possibility to analyze 
interactions in artificial as well as near-physiological environments with only minor 
adjustments in the assay conditions. Therefore, MST is considered as a valuable tool, not 
only for the analysis of soluble or particle-presented Env immunogens, but as a universal 
method to investigate the antigenicity profiles of also other immunogens like influenza 
hemagglutinin or ebola glycoprotein.  
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5.2 Generation of a BG505 SOSIP alanine substitution 
library for cell-based antibody epitope mapping 
Since 2009, new screening procedures and technologies, including high-throughput 
neutralization screenings of single B-cell cultures and antibody isolation by antigen-specific 
single B-cell FACS, led to the identification of a huge number of bNAbs44. Such antibodies 
provide insight into the development of HIV specific B cell responses and at the same time 
represent valuable tools for rational immunogen design. For both, the precise mapping of 
bNAb binding specificities is mandatory. This thesis focused on the development of an 
alanine substitution library that should enable mapping of bNAbs with quaternary epitopes, as 
this was only possible to a limited extent with the already existing 96ZM651 gp145 alanine 
library (see 4.2). The cleavage deficiency of the 96ZM651 gp145 library, likely resulting in 
the expression of trimers with perturbed quaternary structure, was considered mainly 
responsible that mapping of highly quaternary structure-depending bNAbs remained 
unsuccessful197. Hence, cleavage competence was a prerequisite of the new library which was 
generated based on the cleavage-competent BG505 SOSIP gp160, see 4.2. 
5.2.1 Antibody epitope mapping with the BG505 SOSIP gp160 
alanine substitution library 
The in-depth characterization of the BG505 SOSIP gp160 alanine substitution library, 
including proof-of-principle screenings, was performed by Iris Ganser during her master`s 
thesis201. Here, proof-of-principle screenings with bNAbs HGN194, VRC01 and PGT121 
identified alanine substitutions that mainly resulted in losses of binding in regions that had 
been described as their respective epitopes (exemplarily shown for HGN194, see Figure 33) 
demonstrating that the library in principle is a suitable tool for epitope mapping. However, 
epitope mapping using the BG505 SOSIP gp160 alanine substitution library faced several 
challenges including the low surface expression levels of BG505 SOSIP gp160. Env 
expression levels, next to other factors such as brightness of the fluorescent dye, antibody 
labeling efficiency and antibody-Env binding affinity, essentially contribute to the flow 
cytometer`s limit of detection. The interplay of low Env expression levels with the factors 
described above could have been responsible that in some cases signals were too low to 
distinguish small differences in binding affinities, thereby impeding mapping quality and 
reliability. However, there are several options to improve signals and thereby the quality and 
reliability of future mapping experiments as discussed in detail in the master`s thesis201. 
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Noteworthy, the truncation of the Env CT offers a very promising approach for signal 
enhancement by improving Env expression levels, see Figure 31. The truncation of the CT 
was initially avoided in the library design when a study reported that CT truncation can 
negatively influence the Env structure145. However, during this thesis it turned out that this 
seemed to be not the case in the context of membrane-exposed BG505 SOSIP, see Figure 36. 
A reason for this could be that SOSIP modifications can provide stabilizing effects that 
counteract potential destabilizing effects resulting from CT truncation. However, if this theory 
holds true has to be tested. The comparison of the antigenicity profile of BG505 WT gp145 
and gp160 without stabilizing modifications would be a likely starting point to address this 
question. Taken together, in case of the BG505 SOSIP alanine substitution library, the 
truncation of the Env CT represents a very likely starting point for future improvements since 
experiments with the previously described 96ZM651 gp145 library demonstrated that Env CT 
truncation provides sufficient expression levels for robust epitope mapping197. Notably, due to 
the library design (see 4.2.2), the conversion of the gp160 library into a gp145 library can be 
achieved rather quickly. The lack of suitable method for referencing Env surface expression 
levels represented another major issue in mapping experiments with the BG505 SOSIP gp160 
alanine scanning library. Signal referencing is considered crucial to obtain reliable and high-
quality mapping results as it offers the advantage to normalize binding signals of the 
screening antibody for varying expression levels between different library variants. Proof-of-
principle screenings (e.g. HGN194, see Figure 33) with the BG505 SOSIP gp160 alanine 
library were conducted in multiplex approach, allowing for a direct comparison between 
referenced and unreferenced measurements, see 4.2.3. Thereby, the MPER targeting bNAb 
4E10 was chosen as reference antibody as the analyzed subset of library variants did not 
contain alanine substitutions within this region. Hence, it was assumed that the antibody binds 
comparably to all variants of the subset. At this point it has to be mentioned that it was 
initially planned to apply a co-staining strategy as soon as suitable reference was identified 
since this approach was successfully used in mapping experiments with the 96ZM651 gp145 
library197, (Kliche and Grassmann et al., manuscript in preparation). Therefore, gp41 
antibodies were preferred over gp120 targeting reference antibodies, simply for the reason 
that binding interference is more likely when the reference antibody targets the same Env 
subunit as the screening antibody. However, while unreferenced HGN194 measurements 
detected losses of binding in the V3 loop, representing the HGN194 epitope, 4E10 referenced 
measurements resulted in loss of HGN194 binding for almost all screened variants, 
irrespective of V3 loop or control residues. This resulted from the fact that 4E10 exhibited 
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enhanced binding to nearly all alanine substitution variants compared to the WT, meaning that 
4E10 is not suitable for surface referencing. Notably, bNAbs 2G12 and VRC01 have been 
proven useful for quantifying Env surface expression levels in case of the cellular BG505 
SOSIP gp145 glycan-knockout library, see Figure 37. Thus, these antibodies could be 
considered as an option for referencing Env expression levels in future mapping experiments. 
However, when used in a co-staining approach (e.g. Alexa488-labeled screening Ab and 
Alexa647-labeled reference Ab) binding interference has to be tested. Otherwise, library 
screening has to be conducted in a multiplex approach, see 4.2.3. Another option that may 
help to solve the referencing problem would be the addition of an N-terminal Flag-tag to the 
library variants. Experiments previously performed in group already demonstrated the 
applicability of this strategy, see 5.1.1. The expression of Flag-tagged Env would allow 
quantification of Env expression levels via an anti-Flag antibody. This setup would be 
beneficial since the Flag-tag is not affected by alanine substitutions, which might be the case 
when an Env-targeting antibody is used for referencing. Further, this setup likely excludes 
binding interferences with the screening antibody. However this strategy would require re-
design and re-cloning of the library, but has to be considered for future library approaches. 
5.2.2 Conclusion 
In summary, stabilizing SOSIP modifications were successfully implemented into membrane-
exposed BG505 and a BG505 SOSIP gp160 alanine substitution library was generated (see 
4.2.2). Initial proof-of-principle mapping experiments with antibodies HGN194, VRC01 and 
PGT121 demonstrated that the library is in principle a suitable tool for epitope mapping. 
However, the quality of mapping experiments suffered from low Env expression levels and 
the lack of a suitable method for referencing (see 4.2.3). Notably, there are options to 
overcome these limitations in future mapping experiments. These include the possibility to 
convert the gp160 into a gp145 expressing library using the cloning features of the library (see 
4.2.2). This strategy is recommended as titration experiments with BG505 SOSIP trimers 
demonstrated that their structural integrity does not depend on the presence of the Env CT 
(see 4.3.2). In addition, bNAbs 2G12 and VRC01 represent likely candidates to address the 
problem of surface referencing since they were successfully used to quantify Env expression 
levels in the cellular BG505 SOSIP gp145 glycan-knockout library approach (see 4.3.3). In 
conclusion, enhanced Env surface expression levels together with a robust method for surface 
referencing have the potential to greatly improve the overall mapping quality. Such 
improvements also represent first steps towards the mapping of quaternary structure 
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depending antibodies (e.g. PGT145), which remained unsuccessful under the given 
conditions. In conclusion, future experiments under optimized conditions are required to 
explore the full potential of the library. 
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5.3 High-throughput analysis of a cellular BG505 
SOSIP gp145 glycan-knockout library by FACS in 
combination with NGS 
Recently, our group reported a mammalian cell surface display and FACS based methodology 
that enables the selection of Env variants with improved or reduced affinity towards a 
screening antibody154. The methodology involves a cellular library of stable cell lines with 
inducible Env expression, providing advantages such as mammalian glycosylation and 
presentation of Env proteins in their natural membrane-exposed context. For selection the 
library is applied to FACS, thereby, Env expressing cells are selected towards their affinity to 
a screening antibody and subsequently identified using NGS. This procedure was successfully 
utilized to enrich low and high affinity Env variants from a five-member Env/V3 chimeric 
model library154, demonstrating its opportunities for selection and analysis of Env 
immunogens. Within last years the analysis of the Env glycan shield (see 1.3.3) became 
increasingly important in HIV-1 Env vaccine design since structural analyses revealed that a 
proportion of bNAbs (see 1.4.2) does not only bind to gp120 protein residues but also 
recognizes glycans attached to gp120206,176,207,180,208,209. Hence, the third objective of this 
thesis focused to apply the procedure described above to a library that can be used to analyze 
the impact of single glycan deletions on antibody binding. For this purpose a 54-member 
cellular BG505 SOSIP gp145 glycan-knockout library was generated and subjected to 
screening with bNAb PGT135178,180,106 recognizing a V3-glycan epitope. The initial 
screening, aiming to select for Env variants with low PGT135 affinity, demonstrated the N332 
glycan essentially contributes to the binding of this antibody, as previously described180,106. 
5.3.1 Advantages of the applied stable cell line based mammalian 
cell display system and comparison to the previously reported 
approach 
The mammalian cell surface display which was previously reported by our group provides 
several advantages over other currently used methods. Contrary to yeast224,225 or phage226 
display approaches, it enables the presentation Env trimers in their natural membrane-exposed 
environment, and further provides mammalian glycosylation154. In addition, the Flp-In™ T-
REx™ system supports the integration of a single copy env gene at a pre-defined locus. This 
provides an advantage over stable cell lines that were generated by random integration 
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methods (e.g. lentiviral transduction) since it reduces the risk of varying expression levels 
between different cell lines that may result from the genomic context of the integration locus. 
In addition, Flp-In™ T-REx™ 293 cells provide an inducible Env expression via the Tet 
operator/repressor system, eliminating Env cytotoxicity effects during stable cell line 
generation and cultivation. The stable cell line based BG505 SOSIP glycan-knockout library 
that was developed during this thesis benefits from all advantages described above. However, 
there were two major differences between the previously described and the newly developed 
library system. First, although proven useful to normalize Env expression levels in the proof-
of concept study with the five-member Env/V3 library, GFP expression was excluded as 
normalization method in the BG505 glycan-knockout library system. Here, a reference 
antibody was used to normalize Env expression levels (see 4.3.4). This option was chosen for 
two reasons: 1) although genetically coupled to GFP expression, the amount of GFP 
remaining in the cytoplasm has not necessarily to correlate with the Env level on the cell 
surface as both proteins may deviate in their turnover; and 2) it was considered to avoid the 
risk of a potential insufficient TaV 2A “cleavage” which would result in GFP-Env fusion 
proteins with likely disturbed Env quaternary structure. The second major difference regards 
the cell line that was used for the generation of stable cell lines. In the proof-of principle study 
with the Env/V3 chimera library commercially available Flp-In™ T-REx™ 293 cells were 
used for generation of stable cell lines. However, the endogenous Furin expression of  
mammalian cells including HEK293T cells is not sufficient to confer proper protein cleavage 
when Env proteins are expressed at high levels227,228. This was no issue in the proof-of-
principle study with Env/V3 chimeras but considered as a major obstacle for a library that was 
designed to express fully-cleaved Env with intact quaternary structure. To avoid limitations in 
Env cleavage that could potentially arise from insufficient endogenous Furin expression a 
Furin overexpressing cell line, termed CMV F+, was used for stable cell line generation in 
case of the BG505 SOSIP gp145 glycan knockout library. This cell line was generated based 
on Flp-In™ T-REx™ 293 cells and constitutively expresses Furin under a control of CMV 
promotor, thereby providing all advantages of normal Flp-In™ T-REx™ 293 cells. The 
advantages of this cell line over normal Flp-In™ T-REx™ 293 cells was impressively 
demonstrated in the master`s thesis of Dominik Fiegle during which CMV F+ cells were 
developed. Here, CMV F+ cells demonstrated expression of fully-cleaved BG505 SOSIP.664 
while parental Flp-In™ T-REx™ 293 cells achieved only partial protein cleavage165. In a 
comparative analysis BG505 SOSIP gp145 and gp160 expressed by CMV F+ cells were 
exclusively bound by bNAbs and not by non-neutralizing antibodies, see Figure 36. This 
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demonstrates the capacity of the CMV F+ cells to express fully-cleaved Env with intact 
quaternary structure, assuming that partial cleavage would have resulted in detectable binding 
of non-neutralizing antibodies. 
5.3.2 FACS of the BG505 SOSIP gp145 glycan-knockout library 
with bNAb PGT135 
An initial FACS experiment with the BG505 SOSIP glycan-knockout library and bNAb 
PGT135 demonstrated that the previously described mammalian cell display and FACS-based 
selection procedure154 can be successfully used for the analysis of bNAb glycan-
dependencies. The screening procedure successfully identified Env variant N332A as crucial 
for PGT135 binding, since this variant accounted for approximately for 82 % of the cells in 
the sorted population, which corresponds to 35-fold enrichment by the sorting procedure (see 
Figure 39). Interestingly, Env variant T334A which also prevents the glycosylation of the 
asparagine at position 332 was only 2-fold enriched in the sorted population. This is an 
interesting observation since it indicates that not only N332 glycan residues essentially 
contribute to PGT135 binding, as previously described180, but also the asparagine itself. 
However, this observation has to be investigated in detail by further experiments, including 
PGT135 titration experiments with the respective cell lines. Notably, next to several protein 
contact residues, three additional glycans at AA positions 295, 386 and 392 are associated 
with binding of PGT135180. However, the FACS selection did not result in a considerable 
fold-enrichment for the respective glycan-knockout variants. The stringent gating strategy 
might be an explanation for this observation since there were still several events protruding 
from the main population towards the low affinity gate (see Figure 38) which were not sorted 
in this first analysis. It may be that this “intermediate” population included glycan-knockout 
variants for the glycan positions described above. This theory is supported by a recent 
publication in which capture-ELISA was used to analyze the interaction between PGT135 and 
soluble glycan-knockout variants229. Here, it has been demonstrated that the alanine 
substitution of the asparagine at AA position 392 also reduces binding of PGT135, however, 
not as drastically as the N332A variant. Further, it has been shown that the N386A glycan 
deletion only slightly decreased PGT135 binding, whereas the N295A variant exhibited WT-
like binding. Taken together, the results that were reported in this publication may partially 
explain the outcomes of the PGT135 sorting experiment which successfully demonstrated the 
potential of the library for the analysis of bNAb glycan-dependencies. However, for future 
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experiments a less stringent gating strategy would be desirable to enable detection of Env-
glycan-knockouts with less pronounced effects on antibody binding. 
5.3.3 Future directions 
The first screening experiment with the bNAb PGT135 demonstrated that the BG505 SOSIP 
gp145 glycan-knockout library is a useful tool for the investigation of antibody-glycan 
interactions, offering the option to identify glycan-dependencies of already known or newly 
identified bNAbs. However, there are remaining questions and potential applications that 
could be addressed by future experiments. These include the in-depth characterization of the 
relationship between glycan deletions and Env cell surface expression levels. When single cell 
lines were tested for Env expression most cell lines varied within a factor of 2 compared to 
the WT. However, some cell lines exhibited very low Env expression levels, see Figure 37. 
The deletion of the glycan at AA position 448 for example reduced Env expression close to 
the background level. Of course one could consider that this could be an artefact but it is 
interesting that both glycan knockout variants, N448A and T450A, exhibited the same 
phenotype. This has to be further investigated since it was reported that glycan knockouts can 
affect incorporation of Env into virions230. A first step to validate observations for the 448 
glycan deletion could be the re-sequencing of genomic DNA samples to exclude mutations in 
the env sequences. In addition, quantitative real-time PCR could be used to analyze the 
relation between mRNA and Env surface expression levels. This would provide first insights 
if the reduced surface expression is associated with the transcription level or later processes in 
protein expression. Notably, this kind of analysis would be highly desirable not only for 
variants mentioned above , but for the whole library to better understand varying Env 
expression levels between stable cell lines.  
Future applications of this library could include screenings to identify glycan-dependencies of 
antibodies as described for PGT135. However there are also other considerable applications. 
Env immunogens, including BG505 and other SOSIP.664 stabilized Env trimers react only 
very weakly with germline-reverted bNAbs121,231,134,232. For this reason they likely fail to 
engage B-cells that carry receptors of bNAbs precursors. The Env glycan shield seems to play 
an important role in this context since it masks conserved epitopes from recognition by bNAb 
germline precursors233. In conclusion, the library could be used to screen for glycan deletions 
that result in enhanced binding of germline bNAbs to gain knowledge for germline-targeting 
immunogen design. However, also worth a try, it is likely that a single glycan deletion is not 
sufficient to enable detectable binding of germline bNAbs. Alternatively, mature bNAbs 
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could be screened for enhanced binding since enhanced binding in such a case would likely 
result from removal of a steric clash by the respective glycan deletion. This could be an 
indirect hint that the removal of the glycan may contribute to access binding of the germline 
version of the particular antibody. There are observations that support the likelihood of such a 
scenario. By applying bNAb VRC01to a screening with the 96ZM651 alanine substitution 
library, Veronika Grassmann identified the N276A alanine substitution as variant with 
enhanced binding towards VRC01197. Similar was observed in the context of the BG505 
SOSIP gp145 glycan-knockout library when stable cell lines were analyzed for their Env 
expression via VRC01 and 2G12. Here, VRC01 demonstrated enhanced binding to the 
variants that result in the knockout of the glycan at position N276 (T276A, T278A), whereas 
2G12 indicated an expression below the WT reference for the respective variants, see Figure 
37. Interestingly, the deletion of the N276 glycan restored binding of germline reverted 
versions of VRC01-class antibodies to the clade C Env 426c234 and is nowadays included in 
germline-targeting Env immunogens138,135. Hence, taking observations from the VRC01 
screening with the 96ZM951libary, this thesis, and results from literature in consideration, 
mature bNAbs can be used for sorting of glycan deletion variants with enhanced binding since 
potentially identified variants may be interesting for germline-targeting Env vaccine design. 
In addition, the experiences and results that were generated during this thesis could be used to 
develop more advanced cellular libraries, including for example permutation libraries in 
which every amino acid is substituted by every possible natural amino acid. The feasibility of 
such a library approach was recently demonstrated by our group which developed and 
characterized a permutation library that based on the clade C 16055 Env (PhD thesis Julia 
Koop164). However, similar to the 96ZM651 library, the permutation library expressed 
cleavage-defective Env, excluding experiments with highly quaternary structure-depending 
bNAbs. Such limitations could be avoided using a stabilized, fully-cleaved Env and the Furin 
overexpressing CMV F+ cell line as bases for future libraries. Potential applications of such a 
library could for example involve the selection and development of germline-targeting 
immunogens. Recently, Steichen et al. demonstrated that cell-surface presented Env libraries 
in combination with FACS can be used for the design of germline targeting Env immunogens, 
highlighting the applicability of a FACS-based selection strategy. Here, different libraries, 
based on BG505 SOSIP gp140 fused to a platelet-derived growth factor receptor (PDGFR), 
were generated by lentiviral transgene integration and used for engineering of Env trimers 
with affinity to PGT121-class antibodies210. Contrary to the strategy that was applied by 
Steichen et al. the here described approach would also allow screenings with MPER-directed 
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(germline) bNAbs and does not require Furin transfection prior to the induction of the Env 
expression. In addition, it allows the integration of a single copy env gene at a predefined 
locus, minimizing effects that may result from random integration events or multiple 
infections that may occur when transgenes are introduced via lentiviral transduction. 
5.3.4 Conclusion 
In summary, CMV F+ cells allowing for presentation of fully-cleaved Env were used to 
generate a BG505 SOSIP gp145 glycan-knockout library (see 4.3.3). Appling the library to a 
screening with glycan-dependent bNAb PGT135 led to the enrichment and identification of 
PGT135 low-affinity variants (see 4.3.4). This demonstrated the applicability of a previously 
described FACS-based selection procedure that was developed with a five-member Env/V3 
chimera library154. Although further experiments are required to characterize the glycan-
knockout library in more detail it offers several options for future applications. These include 
mapping of bNAb glycan dependencies, identification of glycans that may play a critical role 
in binding of bNAb germline precursors, or to investigate the influence of glycans on the Env 
surface expression. In addition, the successful presentation of fully-cleaved Env with intact 
quaternary structure via CMV F+ cells laid the foundation for the generation of advanced 
cellular libraries e.g. permutation libraries of membrane-exposed stabilized trimers. 
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7. Appendix 
 
 
 
Appendix Figure 1. Preparative size 
exclusion profiles of affinity purified gp120 
and gp140 Env/V3 chimeras and BG505 
SOSIP.664. Proteins were expressed by 
transiently transfected 293-F suspension 
cells. In case of BG505 SOSIP.664 
expression, plasmids encoding for Env and 
Furin were cotransfected in a 3:1 (w/w) 
ratio to promote cleavage of the protein. 
Fractions between red lines represent 
pooled protein fractions. 
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Appendix Figure 2. MST: Binding of mAb 447-52D to blank VLPs (Gag w/o) in buffer and 50 % serum. To determine 
potential background binding of 447-52D to blank VLPs (without surface-presented Env), 447-52D was titrated to DY-
647P1-labeled VLPs, which were kept at constant concentration. (A) and (B) show the normalized fluorescence (FNorm) of 
two independent experiments in buffer and 50 % human serum, respectively. Error bars reflect the SEM of the independent 
experiments. In summary, 447-52D exhibited no binding to blank VLPs. 
 
 
Appendix Figure 3. MST: Binding of quaternary structure-characterizing mAbs to PLA particles without adsorbed 
Env proteins in buffer. To determine background binding, PLA particles without adsorbed Env proteins (control particles) 
diluted in buffer were titrated to Alexa647-labeled mAbs (VRC01, PGT145, PGT151, F105, 2G12) which were kept at 
constant concentration. The upper panel shows the normalized fluorescence (FNorm) of control particle titrations to mAbs. 
Depicted are technical repeats (blue and red, respectively) within one MST analysis. Titration curves of PLA-adsorbed 
BG505 SOSIP.664 trimers in buffer are shown for comparison (lower panel). Results are presented as normalized binding 
curves of two independent experiments with error bars reflecting the SEM of the independent experiments. In summary, there 
was background binding detectable. 
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Appendix Figure 4. MST: Binding of quaternary structure-characterizing mAbs to PLA particles without adsorbed 
Env proteins in 50 % human serum. To determine background binding, PLA particles without adsorbed Env proteins 
(control particles) diluted in 50 % human serum were titrated to Alexa647-labeled mAbs (VRC01, PGT145, PGT151, F105, 
2G12) which were kept at constant concentration. The upper panel shows the normalized binding curves of control particle 
titrations to mAbs. Error bars reflect the SEM of two technical repeats within one experiment. Titration curves of PLA-
adsorbed BG505 SOSIP.664 trimers in 50 % serum are shown for comparison (lower panel). Results are presented as 
normalized binding curves of two independent experiments with error bars reflecting the SEM of the independent 
experiments. In summary, there was also background binding detectable. However, binding of PLA-adsorbed BG505 
SOSIP.664 trimers can be considered as specific since saturation was only reached when particle-adsorbed BG505 
SOSIP.664 trimers were present. 
 
 
 
Appendix Figure 5. ELISA: Binding of quaternary structure-characterizing mAbs to PLA particles without adsorbed 
Env proteins in buffer. For direct-ELISA, PLA-adsorbed BG505 SOSIP.664 trimers and PLA particles without adsorbed 
Env (control particles, indicated as PLA w/o) were directly coated to the surface of ELISA plates (negative control: Wells 
coated PBS). MAbs diluted in PBS were titrated to coated PLA particles at indicated concentrations. A HRP-conjugated 
polyclonal rabbit anti-human Ab was used for readout. ELISA experiments were performed in two independent experiments, 
error bars reflect the SEM of the independent experiments. This figure presents the titration curves of mAbs which are 
summarized in Figure 30C with the difference that the background signal of control particles (PLA w/o) is not subtracted. In 
summary, there was no detectable background binding of mAbs to control particles in direct ELISA.  
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Appendix Figure 6. PGT145 alanine library screening under optimized conditions. (Left) The second PGT145 mapping 
was carried out with changed conditions such as a screening concentration of 5 nM PGT145, controlled quality of all 
transfected DNAs and screening of surface-exposed gp120 residues. The gains and losses of binding of every residue 
normalized on BG505 SOSIP gp160 WT and the respective false discovery rate (FDR)-corrected p-values are shown for 
amino acid residues 33-174. Eight significant losses and 15 significant gains of binding were recognized, yet no distinct 
patches of losses could be identified. (Right) WT-normalized PGT145 signals were referenced on the WT-normalized 
PGT151 signals and plotted as gains or losses of binding. Former significant gains or losses of binding from the unreferenced 
screening were calculated as non-significant in the referenced setup. The screening was performed in five replicates, data 
were generated during the master`s thesis of Iris Ganser under experimental supervision of Dr. David Peterhoff. 
 
 
Appendix Figure 7. Frequency of alanine substitution variants in the BG505 SOSIP gp145 glycan-knockout library. 
NGS was used to investigate the variability of the cellular library over time. To this end, the frequency of alanine substitution 
variants in the library was analyzed at three different points of time: 1) directly after pooling of stable cell lines (frozen 
library stock); 2) non-induced cells, cultured for 18 days; and 3) induced cells (input material for sort, cultured for further 48 
h in presence of doxycycline). The NGS analysis revealed that four stable cell lines were missing in the library stock 
(N197A, S199A, N355A, N386A). Despite a varying distribution, all variants detected in the library stock were present in the 
input sample. Variant N355A (indicated by an asterisk) seemed to be only apparent in the non-induced sample. However, as 
N355A was not present in the library stock, the variant was considered as not available (N/A) as were N197A, S199A and 
N386A. 
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Appendix Table 1. Comparison of MST and ELISA regarding consumables and experimental effort. MST calculations 
are based on 16 dilutions (1:2 dilution series, starting with 1000 nM) with a volume of 6 μl/capillary. ELISA calculations are 
based on 8 dilutions (1:10 dilution series, starting with 1000 nM) and a volume of 50 μl/well. 
 MST ELISA 
Amount titrant 
Antibody: ~2 μg 
Env: ~3 μg 
Antibody: ~9 μg 
Amount labeled interaction 
partner MST/solid phase 
ELISA 
Antibody: ~0.7 – 7 ng 
VLPs: < 100 ng Env 
Env: ~400 ng 
VLPs: ~200 ng Env 
Hands on time ~15 min ~ 60 min 
Duration experiment 
~ 20 min for measurement of 
16 capillaries 
~ 5 h 
 
Appendix Table 2. Oligonucleotide sequences used for cloning/sequencing of envelope variants in pQL13 and 
pcDNA5/FRT/TO. 
Name Sequence 5´→3´ 
Primer for cloning envelope variants into pQL13 (addition of Esp3I restriction sites) 
THB-5I3-fwd-QL-ZM96 
ATAATACGTCTCGCTAGCATGGGAGTGCGGGAGATCCTGCGGAACTG
GCAGCGGTGGTGG 
RevZM96gp140TagQL 
ATATTCGTCTCCTCGAGCTATCAGTGGTGATGGTGGTGGTGCTTGTCGT
CGTCGTCCTTGTAGTCGCTGCCGCCTCCGCCGCTCTTGATGTACCACAG
CCACTTGG 
Rev-96zm651-gp120-
QL 
ATATTCGTCTCCTCGAGCTACTACTAACTCTTCTCCCGCTCCACCACCC
GCCGCTTGGCCTCGG 
Primer for cloning envelope variants into pcDNA5/FRT/TO (addition of HindIII and XhoI restriction sites) 
p X BG505_Ala fw GATCAAGCTTGCCACCATGAGAGTGATGGGCATCCAGCGG 
BG505 gp145 rev  GATCCTCGAGTTATCAGTAGCCCTGCCGCACTCTGTGG 
BG505 gp160 rev GATCCTCGAGTTATCACAGCAGTGCTCTTTCCAGGCCC 
Primer for overlap extension PCR (REKR to REKS substitution) for cloning of gp140 96ZM651 Env/V3 
chimeras 
FusPrim-synZM96-
cleav-mut-For 
GGGTGGTGGAGCGGGAGAAGAGCGCCGTGGGCATCGG 
FusPrim-synZM96-
cleav-mut-Rev 
CCGATGCCCACGGCGCTCTTCTCCCGCTCCACCACCC 
Primer for overlap extension PCR (insertion of I to P substitution at AA position 559 and R6 site in the 
BG505 envelope sequence, stop codon deletion for cloning of gp160 constructs) 
BG505 6x Arginin mut 
for 
GGCCAAGAGAAGAGTCGTGGGACGGCGGAGAAGGCGGAGAGCCGTG
GGCATCGGAGCCGTGTTTCTGG 
BG505 6x Arginin mut 
rev 
CCAGAAACACGGCTCCGATGCCCACGGCTCTCCGCCTTCTCCGCCGTC
CCACGACTCTTCTCTTGGCC 
BG505 I559P for GCAATCTGCTCAGAGCCCCTGAGGCCCAGCAG 
BG505 I559P rev CTGCTGGGCCTCAGGGGCTCTGAGCAGATTGC 
BG505 gp145 Stop 
deletion 
GTAGCCCTGCCGCACTCTGTGGATC 
Sequencing primer for 96ZM651 Env/V3 chimeras in pQL13 
pQL13_seq_for CTGAGCACCCAGTCCGCCCTGAGC 
THB ZM96 seq-1-fwd ATCCCCATCCACTACTGCG 
THB ZM96 seq-2-fwd AGCACCAACGACAGCACC 
pcDNA3.1seq r3191 
BGHpA rev 
CCCCCAGAATAGAATGACACC 
Sequencing primer for BG505 envelope variants in pcDNA5/FRT/TO 
pC-CMV-For GTAGGCGTGTACGGTGGGAGG 
 ___________________________________________________________________ Appendix 
159 
 
BG505 SOSIP Seq1 GGACAAGAAGTTCAACGG 
BG505 SOSIP Seq2 AGAGAAGAGTCGTGGGACG 
pcDNA3.1seq r3191 
BGHpA rev 
CCCCCAGAATAGAATGACACC 
 
Appendix Table 3. Plasmid vectors used in this thesis. 
Description Selectable marker Specification 
pcDNA3.1(+) AmpR, NeoR 
Mammalian expression vector (ThermoFisher Scientific, 
Waltham, USA, # V79020); expression of TeeGag1 for VLP 
production. 
pcDNA3.1(+) QL  AmpR, NeoR 
Derivative of pcDNA3.1(+), including a CcdB cloning 
cassette at the MCS; expression of Furin; cotransfected  with 
BG505 R6 envelope variants to promote protein cleavage. 
pcDNA5/FRT/TO 
AmpR, HygroR (no 
ATG) 
Tetracycline inducible mammalian expression vector. 
Designed for generation of stable cell lines using Flp-In™ T-
REx™ system (ThermoFisher Scientific, # V652020). 
pLib1.1 
AmpR, HygroR (no 
ATG) 
Derivative of pcDNA5/FRT/TO, for details see 3.2.3; used 
for cloning of the BG505 alanine substitution library. 
pQL13 
AmpR, HygroR (no 
ATG) 
Derivative of pcDNA5/FRT/TO, including a CcdB cloning 
cassette and eGFP154; used for expression of gp120, gp140 
and gp145 Env/V3 chimeras. 
pOG44 AmpR 
Mammalian expression vector for transient expression of the 
Flp recombinase235; (ThermoFisher Scientific, # V600520); 
used for generation of stable cell lines. 
pSEVA silent KanR 
Derivative of pSEVA241 (GenBank # JX560329), including 
a CcdB cloning cassette at the MCS; used for generation of 
exchange cassettes, see 3.2.3. 
CMVR VRC01 mAb 
heavy/light chain 
expression vectors 
KanR 
Mammalian expression vector (NIH AIDS Reagent Program, 
Germantown, Maryland, USA, # 12035, # 12036); used for 
antibody expression. 
 
Appendix Table 4. Oligonucleotide, DNA linker and gBlock sequences used for cloning of the BG505 SOSIP alanine 
substitution library. 
Oligonucleotides 
Name Sequence 5´→3´ 
Primer for cloning of BG505 gp145/gp160 constructs into pcDNA5/FRT/TO (addition of HindIII restriction site) 
p X BG505_Ala fw GATCAAGCTTGCCACCATGAGAGTGATGGGCATCCAGCGG 
Primer for cloning of BG505 gp145/gp160 constructs into pcDNA5/FRT/TO (addition of stop codon and XhoI restriction 
site) 
BG505 gp145 rev  GATCCTCGAGTTATCAGTAGCCCTGCCGCACTCTGTGG 
BG505 gp160 rev GATCCTCGAGTTATCACAGCAGTGCTCTTTCCAGGCCC 
Primer for adding NotI, NheI and AarI restriction sites as well as a stop codon to BG505 gp145 
BG505-gp145+X-
rev 
GTGCGCTAGCGCGGCCGCTTATCACCTGCCTCAGTAGCCCTGCCGCACTCTGTGGATC 
Primer for gBlockCT amplification, attachment of a glycine-serine linker and a hexa histidine-tag 
gBlock_CT+X_am
pli_fw 
AGGGCTACTGAGGCAGGTGATAAGC 
BG505_Ala_His_re
v 
GGGCCCTTATCAGTGGTGATGGTGGTGGTGGCTGCCATCCAGAGCCAGCAGATCCTG 
Primer for gBlockXhoI amplification 
gBlock-Xho_fw  GGCAAAGCTTTCTAGACCATGGGCGCTG 
gBlock-Xho_rev 
GTGCGCTAGCGCGGCCGCTTATCACC 
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Primer to remove a BsaI site in the ampicillin resistance of pcDNA5/FRT/TO by silent mutation 
pcDNA5_no_BsaI_
fw  
GCGGGTCTCTACCGCGAGAgCCACGCTCACCGGCTCCAGATTTATC 
pC-BGH-Rev GCAACTAGAAGGCACAGTCGAGG 
Sequencing primer for pcDNA5/FRT/TO 
pcDNA5/FRT/TO 
seq 1 fw 
TCTCCCGATCCCCTATGGT 
pcDNA5/FRT/TO 
seq 2 fw 
GTACGGTGGGAGGTCTATAT 
pcDNA5/FRT/TO 
seq 3 fw 
ACTTGATTAGGGTGATGGTT 
pcDNA5/FRT/TO 
seq 4 fw 
CAACATCTTCTTCTGGAGGC 
pcDNA5/FRT/TO 
seq 5 fw 
GTGCCAGCTGCATTAATGA 
pcDNA5/FRT/TO 
seq 6 fw 
GCGGTGGTTTTTTTGTTTGC 
pcDNA5/FRT/TO 
seq 7 fw 
GAGAATAGTGTATGCGGCGA 
Sequencing primer pLib1.1 
BG505_gp160rev AGAAAGCCGGACACCAGT 
DNA linker (annealed oligonucleotide pairs) 
Name Sequence 5´→3´ 
Cloning of 3´gp145 part with SfiI restriction site in pLib1.1 (via KpnI and XhoI) 
lig-p145_fw 
CGGCCTGATCGGCCTCCGCATTGTCTTCGCTGTCCTCTCCGTCATTCATAGCGTACGCC
AAGGATATTAATGAGC 
lig-p145_rev 
TCGAGCTCATTAATATCCTTGGCGTACGCTATGAATGACGGAGAGGACAGCGAAGAC
AATGCGGAGGCCGATCAGGCCGGTAC 
Linker pair to remove a KpnI restriction site in the MCS of pcDNA5/FRT/TO (via BamHI and HindIII) 
pcDNA5-Kpn-del-
li-fw 
AGCTTGGTAGCGAGCTCG  
pcDNA5-Kpn-del-
li-rev  
GATCCGAGCTCGCTACCA 
Linker pair to remove a KpnI restriction site in the MCS of pSEVA silent (via BamHI and EcoRI) 
pSEVA-
KpnI_del_li_fw 
AATTCGAGCTCAGTACCCGGG 
pSEVA-
KpnI_del_li_rev 
GATCCCCGGGTACTGAGCTCG 
gBlock sequences 
Name Sequence 5´→3´ 
gBlockCT 
DP_BG505_CT-X 
AGGGCTACTGAGGCAGGTGATAAGCGGCCGCGCTAGCGCACACCTGCTAGGCTACAG
CCCCCTGAGCTTTCAGACCCACACCCCCAACCCCAGAGGCCTGGACAGACCCGAGAG
AATCGAGGAAGAGGACGGCGAGCAGGACCGGGGCAGATCTACCAGACTGGTGTCCG
GCTTTCTGGCCCTGGCCTGGGACGATCTGAGAAGCCTGTGCCTGTTCTGCTACCACCG
GCTGCGGGACTTCATCCTGATCGCCGCCAGAATCGTGGAACTGCTGGGCCACAGCTCC
CTGAAGGGCCTGAGACTGGGATGGGAGGGCCTGAAGTACCTGTGGAACCTGCTGGCC
TACTGGGGCAGAGAGCTGAAGATCAGCGCCATCAACCTGTTCGACACAATCGCCATT
GCCGTGGCCGAGTGGACCGACAGAGTGATCGAGATCGGCCAGCGGCTGTGCAGAGCC
TTCCTGCACATCCCCAGACGCATCCGGCAGGGCCTGGAAAGAGCACTGCTGTAATGA
GGTACCCTCGAGGAGAGTCAGAATCAGCAGGAGAAAAATGAACAGGATCTGCTGGCT
CTGGATTGATAAGGGCCCGATCCGATC 
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gBlockXhoI 
BG505_SOSIP_R6
_145-
3'part+exobox 
GGCAAAGCTTTCTAGACCATGGGCGCTGCCAGCATGACACTGACCGTGCAGGCCCGG
AACCTGCTGAGCGGCATCGTGCAGCAGCAGAGCAATCTGCTCAGAGCCCCTGAGGCC
CAGCAGCATCTGCTGAAACTGACCGTGTGGGGCATCAAGCAGCTGCAGGCCAGAGTG
CTGGCCGTGGAAAGATACCTGCGGGATCAGCAGCTCCTGGGCATCTGGGGATGCAGC
GGCAAGCTGATCTGCTGCACCAATGTGCCCTGGAACAGCAGCTGGTCCAACCGGAAC
CTGAGCGAGATCTGGGACAACATGACCTGGCTGCAGTGGGACAAAGAGATCAGCAAC
TACACCCAGATCATCTACGGCCTGCTCGAGGAGAGCCAGAACCAGCAGGAAAAGAAC
GAGCAGGACCTGCTGGCCCTGGACAAGTGGGCCAGCCTGTGGAATTGGTTCGACATC
AGCAACTGGCTGTGGTACATCAAGATCTTCATCATGATCGTGGGCGGCCTGATCGGCC
TGCGGATCGTGTTTGCCGTGCTGAGCGTGATCCACAGAGTGCGGCAGGGCTACTGAGG
CAGGTGATAAGCGGCCGCGCTAGCGCAC 
 
Appendix Table 5. Oligonucleotide pairs for cloning of sequence segment exchange cassettes in pSEVA silent 
containing the BG505 SOSIP R6 library template. 
Exchange 
cassette 
Forward primer 5´→3´ Reverse primer 5´→3´ 
1 
GTAGGTACCGGTCTCACTGTTCTGCGCCA
GCGACGC 
GTAGGTACCGGTCTCGGTTCTCGGCGGCA
GAGCAGA 
2 
GTAGGTACCGGTCTCAGCCACCCACGCCT
GCGTGCC 
GTAGGTACCGGTCTCGGGTTGTCTCGGCGT
CCTTCC 
3 
GTAGGTACCGGTCTCAAACGTGACCGAAG
AGTTCAA 
GTAGGTACCGGTCTCGCCACACGTTGTGC
TTCTCTG 
4 
GTAGGTACCGGTCTCAACCGACATCATCA
GCCTGTG 
GTAGGTACCGGTCTCGTTCCAGGTGGATTT
CCTGGG 
5 
GTAGGTACCGGTCTCACCCCTGTGCGTGA
CCCTGCA 
GTAGGTACCGGTCTCGGTGCATCTGTTCCA
CCATGT 
6 
GTAGGTACCGGTCTCAATGCGGGGCGAGC
TGAAGAA 
GTAGGTACCGGTCTCGGGTCAGCTTCACG
CAGGGCT 
7 
GTAGGTACCGGTCTCAAAGAAACAGAAGG
TGTACAG 
GTAGGTACCGGTCTCGGTCGTCGGTGATG
TTGTTGG 
8 
GTAGGTACCGGTCTCAGAGAACCAGGGCA
ACAGAAG 
GTAGGTACCGGTCTCGGTCCCGCAGCTCG
GTGGTCA 
9 
GTAGGTACCGGTCTCATGCAACACCAGCG
CCATCAC 
GTAGGTACCGGTCTCGGTTGATCTGCACC
ACGTCCA 
10 
GTAGGTACCGGTCTCACCCATCCACTACT
GCGCCCC 
GTAGGTACCGGTCTCGGTTGATCAGCCGG
TACTCTT 
11 
GTAGGTACCGGTCTCAAAGTTCAACGGCA
CCGGCCC 
GTAGGTACCGGTCTCGGATGGGCTCGAAG
GACACCT 
12 
GTAGGTACCGGTCTCAGGCATCAAGCCCG
TGGTGTC 
GTAGGTACCGGTCTCGCTTGTCCTTGCACT
TCAGGA 
13 
GTAGGTACCGGTCTCAGAGGAAGTGATGA
TCAGAAG 
GTAGGTACCGGTCTCGGTGGGTACACTGC
ACGGTGG 
14 
GTAGGTACCGGTCTCAGTGCAGTTCAACA
CCCCCGT 
GTAGGTACCGGTCTCGTTCGGCGAGGCTG
CCGTTCA 
15 
GTAGGTACCGGTCTCAAGAAAGAGCATCC
GGATCGG 
GTAGGTACCGGTCTCGCAGGATGTTCTTG
GCGTTGT 
16 
GTAGGTACCGGTCTCAATCGGCGACATCC
GGCAGGC 
GTAGGTACCGGTCTCGGGTGTTGTTGTTGG
GCCGGG 
17 
GTAGGTACCGGTCTCAACACTGGGCAAGG
TGGTGAA 
GTAGGTACCGGTCTCGGATGTCGCCGGTG
GCGTAGA 
18 
GTAGGTACCGGTCTCAATCAGATTCGCCA
ACAGCTC 
GTAGGTACCGGTCTCGCTCGTTCCAGGTG
GCCTTGG 
19 
GTAGGTACCGGTCTCAAACTGTGGCGGCG
AGTTCTT 
GTAGGTACCGGTCTCGGATGGTGTTGTTCC
CGAAGT 
20 
GTAGGTACCGGTCTCATGGATCAGCAATA
CCAGCGT 
GTAGGTACCGGTCTCGGAAGCTGTGGGTG
GTCACTT 
21 
GTAGGTACCGGTCTCAATCACCCTGCCCT
GCCGGAT 
GTAGGTACCGGTCTCGGGTGCTGTTGAAC
AGGCCGG 
22 
GTAGGTACCGGTCTCACAGGCTATGTACG
CCCCACC 
GTAGGTACCGGTCTCGGCTGTCGTTGCTGC
CGGTGC 
23 
GTAGGTACCGGTCTCAACCGGCCTGATCC
TGACCCG 
GTAGGTACCGGTCTCGGCCGATCCGCTGC
CACATAT 
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24 
GTAGGTACCGGTCTCATTCAGACCCGGCG
GAGGCGA 
GTAGGTACCGGTCTCGGATATTGGACACG
CATCTGA 
25 
GTAGGTACCGGTCTCATACAAAGTGGTGA
AAATCGA 
GTAGGTACCGGTCTCGGGTTTCGGTGGTG
CTGTTGG 
26 
GTAGGTACCGGTCTCAAGAGTCGTGGGAC
GGCGGAG 
GTAGGTACCGGTCTCGCTTGTACAGCTCG
CTCCGCC 
27 
GTAGGTACCGGTCTCACTGGGCTTTCTGGG
AGCCGC 
GTAGGTACCGGTCTCGTCTCTTGCACCGG
GTGGGGG 
28 
GTAGGTACCGGTCTCAACCGTGCAGGCCC
GGAACCT 
GTAGGTACCGGTCTCGAAACACGGCTCCG
ATGCCCA 
29 
GTAGGTACCGGTCTCACTCAGAGCCCCTG
AGGCCCA 
GTAGGTACCGGTCTCGCAGTGTCATGCTG
GCAGCGC 
30 
GTAGGTACCGGTCTCAAAGCAGCTGCAGG
CCAGAGT 
GTAGGTACCGGTCTCGCAGATTGCTCTGCT
GCTGCA 
31 
GTAGGTACCGGTCTCACTCCTGGGCATCT
GGGGATG 
GTAGGTACCGGTCTCGGATGCCCCACACG
GTCAGTT 
32 
GTAGGTACCGGTCTCATGGAACAGCAGCT
GGTCCAA 
GTAGGTACCGGTCTCGCTGCTGATCCCGC
AGGTATC 
33 
GTAGGTACCGGTCTCATGGCTGCAGTGGG
ACAAAGA 
GTAGGTACCGGTCTCGGGGCACATTGGTG
CAGCAGA 
34 
GTAGGTACCGGTCTCACTCGAGGAGAGCC
AGAACCA 
GTAGGTACCGGTCTCGGGTCATGTTGTCCC
AGATCT 
35 
GTAGGTACCGGTCTCAGACAAGTGGGCCA
GCCTGTG 
GTAGGTACCGGTCTCGCAGGCCGTAGATG
ATCTGGG 
36 
GTAGGTACCGGTCTCAATCAAGATCTTCAT
CATGAT 
GTAGGTACCGGTCTCGCAGGGCCAGCAGG
TCCTGCT 
37 
GTAGGTACCGGTCTCAGCCGTGCTGAGCG
TGATCCA 
GTAGGTACCGGTCTCGGTACCACAGCCAG
TTGCTGA 
38 
GTAGGTACCGGTCTCATGAGGCAGGTGAT
AAGCGGC 
GTAGGTACCGGTCTCGAAACACGATCCGC
AGGCCGA 
 
Appendix Table 6. DNA linker sequences encoding for alanine substitutions at indicated positions. 
Residue 
HXB2 
Amino acid 
BG505 
Linker with alanine substitution 
(forward sequence 5´→3´) 
Linker with alanine substitution 
(reverse sequence 5´→3´) 
34 L 
GAACGCCTGGGTGACAGTGTACTACGGCGT
GCCCGTGTGGAAGGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCCTTCCACACGG
GCACGCCGTAGTACACTGTCACCCAGGC 
35 W 
GAACCTGGCCGTGACAGTGTACTACGGCGT
GCCCGTGTGGAAGGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCCTTCCACACGG
GCACGCCGTAGTACACTGTCACGGCCAG 
36 V 
GAACCTGTGGGCCACAGTGTACTACGGCGT
GCCCGTGTGGAAGGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCCTTCCACACGG
GCACGCCGTAGTACACTGTGGCCCACAG 
37 T 
GAACCTGTGGGTGGCCGTGTACTACGGCGT
GCCCGTGTGGAAGGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCCTTCCACACGG
GCACGCCGTAGTACACGGCCACCCACAG 
38 V 
GAACCTGTGGGTGACAGCCTACTACGGCGT
GCCCGTGTGGAAGGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCCTTCCACACGG
GCACGCCGTAGTAGGCTGTCACCCACAG 
39 Y 
GAACCTGTGGGTGACAGTGGCCTACGGCGT
GCCCGTGTGGAAGGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCCTTCCACACGG
GCACGCCGTAGGCCACTGTCACCCACAG 
40 Y 
GAACCTGTGGGTGACAGTGTACGCCGGCGT
GCCCGTGTGGAAGGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCCTTCCACACGG
GCACGCCGGCGTACACTGTCACCCACAG 
41 G 
GAACCTGTGGGTGACAGTGTACTACGCCGT
GCCCGTGTGGAAGGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCCTTCCACACGG
GCACGGCGTAGTACACTGTCACCCACAG 
42 V 
GAACCTGTGGGTGACAGTGTACTACGGCGC
CCCCGTGTGGAAGGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCCTTCCACACGG
GGGCGCCGTAGTACACTGTCACCCACAG 
43 P 
GAACCTGTGGGTGACAGTGTACTACGGCGT
GGCCGTGTGGAAGGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCCTTCCACACGG
CCACGCCGTAGTACACTGTCACCCACAG 
44 V 
GAACCTGTGGGTGACAGTGTACTACGGCGT
GCCCGCCTGGAAGGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCCTTCCAGGCGG
GCACGCCGTAGTACACTGTCACCCACAG 
45 W 
GAACCTGTGGGTGACAGTGTACTACGGCGT
GCCCGTGGCCAAGGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCCTTGGCCACGG
GCACGCCGTAGTACACTGTCACCCACAG 
46 K 
GAACCTGTGGGTGACAGTGTACTACGGCGT
GCCCGTGTGGGCCGACGCCGAGACAACC 
ACAGGGTTGTCTCGGCGTCGGCCCACACGG
GCACGCCGTAGTACACTGTCACCCACAG 
47 D 
GAACCTGTGGGTGACAGTGTACTACGGCGT
GCCCGTGTGGAAGGCCGCCGAGACAACC 
ACAGGGTTGTCTCGGCGGCCTTCCACACGG
GCACGCCGTAGTACACTGTCACCCACAG 
49 E 
GAACCTGTGGGTGACAGTGTACTACGGCGT
GCCCGTGTGGAAGGACGCCGCCACAACC 
ACAGGGTTGTGGCGGCGTCCTTCCACACGG
GCACGCCGTAGTACACTGTCACCCACAG 
50 T 
GAACCTGTGGGTGACAGTGTACTACGGCGT
GCCCGTGTGGAAGGACGCCGAGGCCACC 
ACAGGGTGGCCTCGGCGTCCTTCCACACGG
GCACGCCGTAGTACACTGTCACCCACAG 
51 T 
GAACCTGTGGGTGACAGTGTACTACGGCGT
GCCCGTGTGGAAGGACGCCGAGACAGCC 
ACAGGGCTGTCTCGGCGTCCTTCCACACGG
GCACGCCGTAGTACACTGTCACCCACAG 
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52 L 
AACCGCCTTCTGCGCCAGCGACGCCAAGGC
CTACGAGACAGAGAAGCACAACGTGTGG 
TGGCCCACACGTTGTGCTTCTCTGTCTCGTA
GGCCTTGGCGTCGCTGGCGCAGAAGGC 
53 F 
AACCCTGGCCTGCGCCAGCGACGCCAAGGC
CTACGAGACAGAGAAGCACAACGTGTGG 
TGGCCCACACGTTGTGCTTCTCTGTCTCGTA
GGCCTTGGCGTCGCTGGCGCAGGCCAG 
56 S 
AACCCTGTTCTGCGCCGCCGACGCCAAGGC
CTACGAGACAGAGAAGCACAACGTGTGG 
TGGCCCACACGTTGTGCTTCTCTGTCTCGTA
GGCCTTGGCGTCGGCGGCGCAGAACAG 
57 D 
AACCCTGTTCTGCGCCAGCGCCGCCAAGGC
CTACGAGACAGAGAAGCACAACGTGTGG 
TGGCCCACACGTTGTGCTTCTCTGTCTCGTA
GGCCTTGGCGGCGCTGGCGCAGAACAG 
59 K 
AACCCTGTTCTGCGCCAGCGACGCCGCCGC
CTACGAGACAGAGAAGCACAACGTGTGG 
TGGCCCACACGTTGTGCTTCTCTGTCTCGTA
GGCGGCGGCGTCGCTGGCGCAGAACAG 
61 Y 
AACCCTGTTCTGCGCCAGCGACGCCAAGGC
CGCCGAGACAGAGAAGCACAACGTGTGG 
TGGCCCACACGTTGTGCTTCTCTGTCTCGGC
GGCCTTGGCGTCGCTGGCGCAGAACAG 
62 E 
AACCCTGTTCTGCGCCAGCGACGCCAAGGC
CTACGCCACAGAGAAGCACAACGTGTGG 
TGGCCCACACGTTGTGCTTCTCTGTGGCGTA
GGCCTTGGCGTCGCTGGCGCAGAACAG 
63 T 
AACCCTGTTCTGCGCCAGCGACGCCAAGGC
CTACGAGGCCGAGAAGCACAACGTGTGG 
TGGCCCACACGTTGTGCTTCTCGGCCTCGTA
GGCCTTGGCGTCGCTGGCGCAGAACAG 
64 E 
AACCCTGTTCTGCGCCAGCGACGCCAAGGC
CTACGAGACAGCCAAGCACAACGTGTGG 
TGGCCCACACGTTGTGCTTGGCTGTCTCGTA
GGCCTTGGCGTCGCTGGCGCAGAACAG 
65 K 
AACCCTGTTCTGCGCCAGCGACGCCAAGGC
CTACGAGACAGAGGCCCACAACGTGTGG 
TGGCCCACACGTTGTGGGCCTCTGTCTCGTA
GGCCTTGGCGTCGCTGGCGCAGAACAG 
66 H 
AACCCTGTTCTGCGCCAGCGACGCCAAGGC
CTACGAGACAGAGAAGGCCAACGTGTGG 
TGGCCCACACGTTGGCCTTCTCTGTCTCGTA
GGCCTTGGCGTCGCTGGCGCAGAACAG 
67 N 
AACCCTGTTCTGCGCCAGCGACGCCAAGGC
CTACGAGACAGAGAAGCACGCCGTGTGG 
TGGCCCACACGGCGTGCTTCTCTGTCTCGTA
GGCCTTGGCGTCGCTGGCGCAGAACAG 
68 V 
AACCCTGTTCTGCGCCAGCGACGCCAAGGC
CTACGAGACAGAGAAGCACAACGCCTGG 
TGGCCCAGGCGTTGTGCTTCTCTGTCTCGTA
GGCCTTGGCGTCGCTGGCGCAGAACAG 
69 W 
AACCCTGTTCTGCGCCAGCGACGCCAAGGC
CTACGAGACAGAGAAGCACAACGTGGCC 
TGGCGGCCACGTTGTGCTTCTCTGTCTCGTA
GGCCTTGGCGTCGCTGGCGCAGAACAG 
71 T 
GTGGGCCGCCCACGCCTGCGTGCCCACCGA
CCCCAACCCCCAGGAAATCCACCTGGAA 
CGTTTTCCAGGTGGATTTCCTGGGGGTTGGG
GTCGGTGGGCACGCAGGCGTGGGCGGC 
72 H 
GTGGGCCACCGCCGCCTGCGTGCCCACCGA
CCCCAACCCCCAGGAAATCCACCTGGAA 
CGTTTTCCAGGTGGATTTCCTGGGGGTTGGG
GTCGGTGGGCACGCAGGCGGCGGTGGC 
75 V 
GTGGGCCACCCACGCCTGCGCCCCCACCGA
CCCCAACCCCCAGGAAATCCACCTGGAA 
CGTTTTCCAGGTGGATTTCCTGGGGGTTGGG
GTCGGTGGGGGCGCAGGCGTGGGTGGC 
76 P 
GTGGGCCACCCACGCCTGCGTGGCCACCGA
CCCCAACCCCCAGGAAATCCACCTGGAA 
CGTTTTCCAGGTGGATTTCCTGGGGGTTGGG
GTCGGTGGCCACGCAGGCGTGGGTGGC 
77 T 
GTGGGCCACCCACGCCTGCGTGCCCGCCGA
CCCCAACCCCCAGGAAATCCACCTGGAA 
CGTTTTCCAGGTGGATTTCCTGGGGGTTGGG
GTCGGCGGGCACGCAGGCGTGGGTGGC 
78 D 
GTGGGCCACCCACGCCTGCGTGCCCACCGC
CCCCAACCCCCAGGAAATCCACCTGGAA 
CGTTTTCCAGGTGGATTTCCTGGGGGTTGGG
GGCGGTGGGCACGCAGGCGTGGGTGGC 
79 P 
GTGGGCCACCCACGCCTGCGTGCCCACCGA
CGCCAACCCCCAGGAAATCCACCTGGAA 
CGTTTTCCAGGTGGATTTCCTGGGGGTTGGC
GTCGGTGGGCACGCAGGCGTGGGTGGC 
80 N 
GTGGGCCACCCACGCCTGCGTGCCCACCGA
CCCCGCCCCCCAGGAAATCCACCTGGAA 
CGTTTTCCAGGTGGATTTCCTGGGGGGCGG
GGTCGGTGGGCACGCAGGCGTGGGTGGC 
81 P 
GTGGGCCACCCACGCCTGCGTGCCCACCGA
CCCCAACGCCCAGGAAATCCACCTGGAA 
CGTTTTCCAGGTGGATTTCCTGGGCGTTGGG
GTCGGTGGGCACGCAGGCGTGGGTGGC 
82 Q 
GTGGGCCACCCACGCCTGCGTGCCCACCGA
CCCCAACCCCGCCGAAATCCACCTGGAA 
CGTTTTCCAGGTGGATTTCGGCGGGGTTGG
GGTCGGTGGGCACGCAGGCGTGGGTGGC 
83 E 
GTGGGCCACCCACGCCTGCGTGCCCACCGA
CCCCAACCCCCAGGCCATCCACCTGGAA 
CGTTTTCCAGGTGGATGGCCTGGGGGTTGG
GGTCGGTGGGCACGCAGGCGTGGGTGGC 
84 I 
GTGGGCCACCCACGCCTGCGTGCCCACCGA
CCCCAACCCCCAGGAAGCCCACCTGGAA 
CGTTTTCCAGGTGGGCTTCCTGGGGGTTGGG
GTCGGTGGGCACGCAGGCGTGGGTGGC 
85 H 
GTGGGCCACCCACGCCTGCGTGCCCACCGA
CCCCAACCCCCAGGAAATCGCCCTGGAA 
CGTTTTCCAGGGCGATTTCCTGGGGGTTGGG
GTCGGTGGGCACGCAGGCGTGGGTGGC 
86 L 
GTGGGCCACCCACGCCTGCGTGCCCACCGA
CCCCAACCCCCAGGAAATCCACGCCGAA 
CGTTTTCGGCGTGGATTTCCTGGGGGTTGGG
GTCGGTGGGCACGCAGGCGTGGGTGGC 
87 E 
GTGGGCCACCCACGCCTGCGTGCCCACCGA
CCCCAACCCCCAGGAAATCCACCTGGCC 
CGTTGGCCAGGTGGATTTCCTGGGGGTTGG
GGTCGGTGGGCACGCAGGCGTGGGTGGC 
88 N 
GGAAGCCGTGACCGAAGAGTTCAACATGTG
GAAGAACAACATGGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACCATGTTGTTCTT
CCACATGTTGAACTCTTCGGTCACGGC 
89 V 
GGAAAACGCCACCGAAGAGTTCAACATGTG
GAAGAACAACATGGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACCATGTTGTTCTT
CCACATGTTGAACTCTTCGGTGGCGTT 
90 T 
GGAAAACGTGGCCGAAGAGTTCAACATGTG
GAAGAACAACATGGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACCATGTTGTTCTT
CCACATGTTGAACTCTTCGGCCACGTT 
91 E 
GGAAAACGTGACCGCCGAGTTCAACATGTG
GAAGAACAACATGGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACCATGTTGTTCTT
CCACATGTTGAACTCGGCGGTCACGTT 
92 E 
GGAAAACGTGACCGAAGCCTTCAACATGTG
GAAGAACAACATGGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACCATGTTGTTCTT
CCACATGTTGAAGGCTTCGGTCACGTT 
93 F 
GGAAAACGTGACCGAAGAGGCCAACATGT
GGAAGAACAACATGGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACCATGTTGTTCTT
CCACATGTTGGCCTCTTCGGTCACGTT 
94 N 
GGAAAACGTGACCGAAGAGTTCGCCATGTG
GAAGAACAACATGGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACCATGTTGTTCTT
CCACATGGCGAACTCTTCGGTCACGTT 
95 M 
GGAAAACGTGACCGAAGAGTTCAACGCCTG
GAAGAACAACATGGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACCATGTTGTTCTT
CCAGGCGTTGAACTCTTCGGTCACGTT 
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96 W 
GGAAAACGTGACCGAAGAGTTCAACATGGC
CAAGAACAACATGGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACCATGTTGTTCTT
GGCCATGTTGAACTCTTCGGTCACGTT 
97 K 
GGAAAACGTGACCGAAGAGTTCAACATGTG
GGCCAACAACATGGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACCATGTTGTTGGC
CCACATGTTGAACTCTTCGGTCACGTT 
98 N 
GGAAAACGTGACCGAAGAGTTCAACATGTG
GAAGGCCAACATGGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACCATGTTGGCCTT
CCACATGTTGAACTCTTCGGTCACGTT 
99 N 
GGAAAACGTGACCGAAGAGTTCAACATGTG
GAAGAACGCCATGGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACCATGGCGTTCTT
CCACATGTTGAACTCTTCGGTCACGTT 
100 M 
GGAAAACGTGACCGAAGAGTTCAACATGTG
GAAGAACAACGCCGTGGAACAGATGCAC 
CGGTGTGCATCTGTTCCACGGCGTTGTTCTT
CCACATGTTGAACTCTTCGGTCACGTT 
101 V 
GGAAAACGTGACCGAAGAGTTCAACATGTG
GAAGAACAACATGGCCGAACAGATGCAC 
CGGTGTGCATCTGTTCGGCCATGTTGTTCTT
CCACATGTTGAACTCTTCGGTCACGTT 
102 E 
GGAAAACGTGACCGAAGAGTTCAACATGTG
GAAGAACAACATGGTGGCCCAGATGCAC 
CGGTGTGCATCTGGGCCACCATGTTGTTCTT
CCACATGTTGAACTCTTCGGTCACGTT 
103 Q 
GGAAAACGTGACCGAAGAGTTCAACATGTG
GAAGAACAACATGGTGGAAGCCATGCAC 
CGGTGTGCATGGCTTCCACCATGTTGTTCTT
CCACATGTTGAACTCTTCGGTCACGTT 
104 M 
GGAAAACGTGACCGAAGAGTTCAACATGTG
GAAGAACAACATGGTGGAACAGGCCCAC 
CGGTGTGGGCCTGTTCCACCATGTTGTTCTT
CCACATGTTGAACTCTTCGGTCACGTT 
105 H 
GGAAAACGTGACCGAAGAGTTCAACATGTG
GAAGAACAACATGGTGGAACAGATGGCC 
CGGTGGCCATCTGTTCCACCATGTTGTTCTT
CCACATGTTGAACTCTTCGGTCACGTT 
106 T 
GCACGCCGACATCATCAGCCTGTGGGACCA
GAGCCTGAAGCCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGGCTTCAGGC
TCTGGTCCCACAGGCTGATGATGTCGGC 
107 D 
GCACACCGCCATCATCAGCCTGTGGGACCA
GAGCCTGAAGCCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGGCTTCAGGC
TCTGGTCCCACAGGCTGATGATGGCGGT 
108 I 
GCACACCGACGCCATCAGCCTGTGGGACCA
GAGCCTGAAGCCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGGCTTCAGGC
TCTGGTCCCACAGGCTGATGGCGTCGGT 
109 I 
GCACACCGACATCGCCAGCCTGTGGGACCA
GAGCCTGAAGCCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGGCTTCAGGC
TCTGGTCCCACAGGCTGGCGATGTCGGT 
110 S 
GCACACCGACATCATCGCCCTGTGGGACCA
GAGCCTGAAGCCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGGCTTCAGGC
TCTGGTCCCACAGGGCGATGATGTCGGT 
111 L 
GCACACCGACATCATCAGCGCCTGGGACCA
GAGCCTGAAGCCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGGCTTCAGGC
TCTGGTCCCAGGCGCTGATGATGTCGGT 
112 W 
GCACACCGACATCATCAGCCTGGCCGACCA
GAGCCTGAAGCCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGGCTTCAGGC
TCTGGTCGGCCAGGCTGATGATGTCGGT 
113 D 
GCACACCGACATCATCAGCCTGTGGGCCCA
GAGCCTGAAGCCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGGCTTCAGGC
TCTGGGCCCACAGGCTGATGATGTCGGT 
114 Q 
GCACACCGACATCATCAGCCTGTGGGACGC
CAGCCTGAAGCCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGGCTTCAGGC
TGGCGTCCCACAGGCTGATGATGTCGGT 
115 S 
GCACACCGACATCATCAGCCTGTGGGACCA
GGCCCTGAAGCCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGGCTTCAGGG
CCTGGTCCCACAGGCTGATGATGTCGGT 
116 L 
GCACACCGACATCATCAGCCTGTGGGACCA
GAGCGCCAAGCCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGGCTTGGCGC
TCTGGTCCCACAGGCTGATGATGTCGGT 
117 K 
GCACACCGACATCATCAGCCTGTGGGACCA
GAGCCTGGCCCCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGGGGCCAGGC
TCTGGTCCCACAGGCTGATGATGTCGGT 
118 P 
GCACACCGACATCATCAGCCTGTGGGACCA
GAGCCTGAAGGCCTGCGTGAAGCTGACC 
GGGGGGTCAGCTTCACGCAGGCCTTCAGGC
TCTGGTCCCACAGGCTGATGATGTCGGT 
120 V 
GCACACCGACATCATCAGCCTGTGGGACCA
GAGCCTGAAGCCCTGCGCCAAGCTGACC 
GGGGGGTCAGCTTGGCGCAGGGCTTCAGGC
TCTGGTCCCACAGGCTGATGATGTCGGT 
121 K 
GCACACCGACATCATCAGCCTGTGGGACCA
GAGCCTGAAGCCCTGCGTGGCCCTGACC 
GGGGGGTCAGGGCCACGCAGGGCTTCAGGC
TCTGGTCCCACAGGCTGATGATGTCGGT 
122 L 
GCACACCGACATCATCAGCCTGTGGGACCA
GAGCCTGAAGCCCTGCGTGAAGGCCACC 
GGGGGGTGGCCTTCACGCAGGGCTTCAGGC
TCTGGTCCCACAGGCTGATGATGTCGGT 
123 T 
GCACACCGACATCATCAGCCTGTGGGACCA
GAGCCTGAAGCCCTGCGTGAAGCTGGCC 
GGGGGGCCAGCTTCACGCAGGGCTTCAGGC
TCTGGTCCCACAGGCTGATGATGTCGGT 
124 P 
GACCGCCCTGTGCGTGACCCTGCAGTGCAC
CAACGTGACCAACAACATCACCGACGAC 
GCATGTCGTCGGTGATGTTGTTGGTCACGTT
GGTGCACTGCAGGGTCACGCACAGGGC 
125 L 
GACCCCCGCCTGCGTGACCCTGCAGTGCAC
CAACGTGACCAACAACATCACCGACGAC 
GCATGTCGTCGGTGATGTTGTTGGTCACGTT
GGTGCACTGCAGGGTCACGCAGGCGGG 
127 V 
GACCCCCCTGTGCGCCACCCTGCAGTGCAC
CAACGTGACCAACAACATCACCGACGAC 
GCATGTCGTCGGTGATGTTGTTGGTCACGTT
GGTGCACTGCAGGGTGGCGCACAGGGG 
128 T 
GACCCCCCTGTGCGTGGCCCTGCAGTGCAC
CAACGTGACCAACAACATCACCGACGAC 
GCATGTCGTCGGTGATGTTGTTGGTCACGTT
GGTGCACTGCAGGGCCACGCACAGGGG 
129 L 
GACCCCCCTGTGCGTGACCGCCCAGTGCAC
CAACGTGACCAACAACATCACCGACGAC 
GCATGTCGTCGGTGATGTTGTTGGTCACGTT
GGTGCACTGGGCGGTCACGCACAGGGG 
130 Q 
GACCCCCCTGTGCGTGACCCTGGCCTGCAC
CAACGTGACCAACAACATCACCGACGAC 
GCATGTCGTCGGTGATGTTGTTGGTCACGTT
GGTGCAGGCCAGGGTCACGCACAGGGG 
132 T 
GACCCCCCTGTGCGTGACCCTGCAGTGCGC
CAACGTGACCAACAACATCACCGACGAC 
GCATGTCGTCGGTGATGTTGTTGGTCACGTT
GGCGCACTGCAGGGTCACGCACAGGGG 
133 N 
GACCCCCCTGTGCGTGACCCTGCAGTGCAC
CGCCGTGACCAACAACATCACCGACGAC 
GCATGTCGTCGGTGATGTTGTTGGTCACGGC
GGTGCACTGCAGGGTCACGCACAGGGG 
134 V 
GACCCCCCTGTGCGTGACCCTGCAGTGCAC
CAACGCCACCAACAACATCACCGACGAC 
GCATGTCGTCGGTGATGTTGTTGGTGGCGTT
GGTGCACTGCAGGGTCACGCACAGGGG 
135 T 
GACCCCCCTGTGCGTGACCCTGCAGTGCAC
CAACGTGGCCAACAACATCACCGACGAC 
GCATGTCGTCGGTGATGTTGTTGGCCACGTT
GGTGCACTGCAGGGTCACGCACAGGGG 
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136 N 
GACCCCCCTGTGCGTGACCCTGCAGTGCAC
CAACGTGACCGCCAACATCACCGACGAC 
GCATGTCGTCGGTGATGTTGGCGGTCACGTT
GGTGCACTGCAGGGTCACGCACAGGGG 
137 N 
GACCCCCCTGTGCGTGACCCTGCAGTGCAC
CAACGTGACCAACGCCATCACCGACGAC 
GCATGTCGTCGGTGATGGCGTTGGTCACGTT
GGTGCACTGCAGGGTCACGCACAGGGG 
138 I 
GACCCCCCTGTGCGTGACCCTGCAGTGCAC
CAACGTGACCAACAACGCCACCGACGAC 
GCATGTCGTCGGTGGCGTTGTTGGTCACGTT
GGTGCACTGCAGGGTCACGCACAGGGG 
139 T 
GACCCCCCTGTGCGTGACCCTGCAGTGCAC
CAACGTGACCAACAACATCGCCGACGAC 
GCATGTCGTCGGCGATGTTGTTGGTCACGTT
GGTGCACTGCAGGGTCACGCACAGGGG 
140 D 
GACCCCCCTGTGCGTGACCCTGCAGTGCAC
CAACGTGACCAACAACATCACCGCCGAC 
GCATGTCGGCGGTGATGTTGTTGGTCACGTT
GGTGCACTGCAGGGTCACGCACAGGGG 
141 D 
GACCCCCCTGTGCGTGACCCTGCAGTGCAC
CAACGTGACCAACAACATCACCGACGCC 
GCATGGCGTCGGTGATGTTGTTGGTCACGTT
GGTGCACTGCAGGGTCACGCACAGGGG 
150 M 
CGACGCCCGGGGCGAGCTGAAGAACTGCAG
CTTCAACATGACCACCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGTGGTCATGTTGAA
GCTGCAGTTCTTCAGCTCGCCCCGGGC 
151 R 
CGACATGGCCGGCGAGCTGAAGAACTGCAG
CTTCAACATGACCACCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGTGGTCATGTTGAA
GCTGCAGTTCTTCAGCTCGCCGGCCAT 
152 G 
CGACATGCGGGCCGAGCTGAAGAACTGCAG
CTTCAACATGACCACCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGTGGTCATGTTGAA
GCTGCAGTTCTTCAGCTCGGCCCGCAT 
153 E 
CGACATGCGGGGCGCCCTGAAGAACTGCAG
CTTCAACATGACCACCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGTGGTCATGTTGAA
GCTGCAGTTCTTCAGGGCGCCCCGCAT 
154 L 
CGACATGCGGGGCGAGGCCAAGAACTGCA
GCTTCAACATGACCACCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGTGGTCATGTTGAA
GCTGCAGTTCTTGGCCTCGCCCCGCAT 
155 K 
CGACATGCGGGGCGAGCTGGCCAACTGCAG
CTTCAACATGACCACCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGTGGTCATGTTGAA
GCTGCAGTTGGCCAGCTCGCCCCGCAT 
156 N 
CGACATGCGGGGCGAGCTGAAGGCCTGCAG
CTTCAACATGACCACCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGTGGTCATGTTGAA
GCTGCAGGCCTTCAGCTCGCCCCGCAT 
158 S 
CGACATGCGGGGCGAGCTGAAGAACTGCGC
CTTCAACATGACCACCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGTGGTCATGTTGAA
GGCGCAGTTCTTCAGCTCGCCCCGCAT 
159 F 
CGACATGCGGGGCGAGCTGAAGAACTGCAG
CGCCAACATGACCACCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGTGGTCATGTTGGC
GCTGCAGTTCTTCAGCTCGCCCCGCAT 
160 N 
CGACATGCGGGGCGAGCTGAAGAACTGCAG
CTTCGCCATGACCACCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGTGGTCATGGCGA
AGCTGCAGTTCTTCAGCTCGCCCCGCAT 
161 M 
CGACATGCGGGGCGAGCTGAAGAACTGCAG
CTTCAACGCCACCACCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGTGGTGGCGTTGAA
GCTGCAGTTCTTCAGCTCGCCCCGCAT 
162 T 
CGACATGCGGGGCGAGCTGAAGAACTGCAG
CTTCAACATGGCCACCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGTGGCCATGTTGAA
GCTGCAGTTCTTCAGCTCGCCCCGCAT 
163 T 
CGACATGCGGGGCGAGCTGAAGAACTGCAG
CTTCAACATGACCGCCGAGCTGCGGGAC 
TCTTGTCCCGCAGCTCGGCGGTCATGTTGAA
GCTGCAGTTCTTCAGCTCGCCCCGCAT 
164 E 
CGACATGCGGGGCGAGCTGAAGAACTGCAG
CTTCAACATGACCACCGCCCTGCGGGAC 
TCTTGTCCCGCAGGGCGGTGGTCATGTTGA
AGCTGCAGTTCTTCAGCTCGCCCCGCAT 
165 L 
CGACATGCGGGGCGAGCTGAAGAACTGCAG
CTTCAACATGACCACCGAGGCCCGGGAC 
TCTTGTCCCGGGCCTCGGTGGTCATGTTGAA
GCTGCAGTTCTTCAGCTCGCCCCGCAT 
166 R 
CGACATGCGGGGCGAGCTGAAGAACTGCAG
CTTCAACATGACCACCGAGCTGGCCGAC 
TCTTGTCGGCCAGCTCGGTGGTCATGTTGAA
GCTGCAGTTCTTCAGCTCGCCCCGCAT 
167 D 
CGACATGCGGGGCGAGCTGAAGAACTGCAG
CTTCAACATGACCACCGAGCTGCGGGCC 
TCTTGGCCCGCAGCTCGGTGGTCATGTTGAA
GCTGCAGTTCTTCAGCTCGCCCCGCAT 
168 K 
GGACGCCAAACAGAAGGTGTACAGCCTGTT
CTACCGGCTGGACGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGTCCAGCCGGTA
GAACAGGCTGTACACCTTCTGTTTGGC 
169 K 
GGACAAGGCCCAGAAGGTGTACAGCCTGTT
CTACCGGCTGGACGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGTCCAGCCGGTA
GAACAGGCTGTACACCTTCTGGGCCTT 
170 Q 
GGACAAGAAAGCCAAGGTGTACAGCCTGTT
CTACCGGCTGGACGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGTCCAGCCGGTA
GAACAGGCTGTACACCTTGGCTTTCTT 
171 K 
GGACAAGAAACAGGCCGTGTACAGCCTGTT
CTACCGGCTGGACGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGTCCAGCCGGTA
GAACAGGCTGTACACGGCCTGTTTCTT 
172 V 
GGACAAGAAACAGAAGGCCTACAGCCTGTT
CTACCGGCTGGACGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGTCCAGCCGGTA
GAACAGGCTGTAGGCCTTCTGTTTCTT 
173 Y 
GGACAAGAAACAGAAGGTGGCCAGCCTGTT
CTACCGGCTGGACGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGTCCAGCCGGTA
GAACAGGCTGGCCACCTTCTGTTTCTT 
174 S 
GGACAAGAAACAGAAGGTGTACGCCCTGTT
CTACCGGCTGGACGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGTCCAGCCGGTA
GAACAGGGCGTACACCTTCTGTTTCTT 
175 L 
GGACAAGAAACAGAAGGTGTACAGCGCCTT
CTACCGGCTGGACGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGTCCAGCCGGTA
GAAGGCGCTGTACACCTTCTGTTTCTT 
176 F 
GGACAAGAAACAGAAGGTGTACAGCCTGG
CCTACCGGCTGGACGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGTCCAGCCGGTA
GGCCAGGCTGTACACCTTCTGTTTCTT 
177 Y 
GGACAAGAAACAGAAGGTGTACAGCCTGTT
CGCCCGGCTGGACGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGTCCAGCCGGGC
GAACAGGCTGTACACCTTCTGTTTCTT 
178 R 
GGACAAGAAACAGAAGGTGTACAGCCTGTT
CTACGCCCTGGACGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGTCCAGGGCGTA
GAACAGGCTGTACACCTTCTGTTTCTT 
179 L 
GGACAAGAAACAGAAGGTGTACAGCCTGTT
CTACCGGGCCGACGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGTCGGCCCGGTA
GAACAGGCTGTACACCTTCTGTTTCTT 
180 D 
GGACAAGAAACAGAAGGTGTACAGCCTGTT
CTACCGGCTGGCCGTGGTGCAGATCAAC 
TCTCGTTGATCTGCACCACGGCCAGCCGGT
AGAACAGGCTGTACACCTTCTGTTTCTT 
181 V 
GGACAAGAAACAGAAGGTGTACAGCCTGTT
CTACCGGCTGGACGCCGTGCAGATCAAC 
TCTCGTTGATCTGCACGGCGTCCAGCCGGTA
GAACAGGCTGTACACCTTCTGTTTCTT 
 ___________________________________________________________________ Appendix 
166 
 
182 V 
GGACAAGAAACAGAAGGTGTACAGCCTGTT
CTACCGGCTGGACGTGGCCCAGATCAAC 
TCTCGTTGATCTGGGCCACGTCCAGCCGGTA
GAACAGGCTGTACACCTTCTGTTTCTT 
183 Q 
GGACAAGAAACAGAAGGTGTACAGCCTGTT
CTACCGGCTGGACGTGGTGGCCATCAAC 
TCTCGTTGATGGCCACCACGTCCAGCCGGT
AGAACAGGCTGTACACCTTCTGTTTCTT 
184 I 
GGACAAGAAACAGAAGGTGTACAGCCTGTT
CTACCGGCTGGACGTGGTGCAGGCCAAC 
TCTCGTTGGCCTGCACCACGTCCAGCCGGTA
GAACAGGCTGTACACCTTCTGTTTCTT 
185 N 
GGACAAGAAACAGAAGGTGTACAGCCTGTT
CTACCGGCTGGACGTGGTGCAGATCGCC 
TCTCGGCGATCTGCACCACGTCCAGCCGGT
AGAACAGGCTGTACACCTTCTGTTTCTT 
186 E 
CAACGCCAACCAGGGCAACAGAAGCAACA
ACAGCAACAAAGAGTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTACTCTTTGTTGCT
GTTGTTGCTTCTGTTGCCCTGGTTGGC 
N/A N 
CAACGAGGCCCAGGGCAACAGAAGCAACA
ACAGCAACAAAGAGTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTACTCTTTGTTGCT
GTTGTTGCTTCTGTTGCCCTGGGCCTC 
N/A Q 
CAACGAGAACGCCGGCAACAGAAGCAACA
ACAGCAACAAAGAGTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTACTCTTTGTTGCT
GTTGTTGCTTCTGTTGCCGGCGTTCTC 
N/A G 
CAACGAGAACCAGGCCAACAGAAGCAACA
ACAGCAACAAAGAGTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTACTCTTTGTTGCT
GTTGTTGCTTCTGTTGGCCTGGTTCTC 
N/A N 
CAACGAGAACCAGGGCGCCAGAAGCAACA
ACAGCAACAAAGAGTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTACTCTTTGTTGCT
GTTGTTGCTTCTGGCGCCCTGGTTCTC 
N/A R 
CAACGAGAACCAGGGCAACGCCAGCAACA
ACAGCAACAAAGAGTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTACTCTTTGTTGCT
GTTGTTGCTGGCGTTGCCCTGGTTCTC 
N/A S 
CAACGAGAACCAGGGCAACAGAGCCAACA
ACAGCAACAAAGAGTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTACTCTTTGTTGCT
GTTGTTGGCTCTGTTGCCCTGGTTCTC 
N/A N 
CAACGAGAACCAGGGCAACAGAAGCGCCA
ACAGCAACAAAGAGTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTACTCTTTGTTGCT
GTTGGCGCTTCTGTTGCCCTGGTTCTC 
N/A N 
CAACGAGAACCAGGGCAACAGAAGCAACG
CCAGCAACAAAGAGTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTACTCTTTGTTGCT
GGCGTTGCTTCTGTTGCCCTGGTTCTC 
187 S 
CAACGAGAACCAGGGCAACAGAAGCAACA
ACGCCAACAAAGAGTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTACTCTTTGTTGGC
GTTGTTGCTTCTGTTGCCCTGGTTCTC 
188 N 
CAACGAGAACCAGGGCAACAGAAGCAACA
ACAGCGCCAAAGAGTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTACTCTTTGGCGCT
GTTGTTGCTTCTGTTGCCCTGGTTCTC 
189 K 
CAACGAGAACCAGGGCAACAGAAGCAACA
ACAGCAACGCCGAGTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTACTCGGCGTTGCT
GTTGTTGCTTCTGTTGCCCTGGTTCTC 
190 E 
CAACGAGAACCAGGGCAACAGAAGCAACA
ACAGCAACAAAGCCTACCGGCTGATCAAC 
TGCAGTTGATCAGCCGGTAGGCTTTGTTGCT
GTTGTTGCTTCTGTTGCCCTGGTTCTC 
191 Y 
CAACGAGAACCAGGGCAACAGAAGCAACA
ACAGCAACAAAGAGGCCCGGCTGATCAAC 
TGCAGTTGATCAGCCGGGCCTCTTTGTTGCT
GTTGTTGCTTCTGTTGCCCTGGTTCTC 
192 R 
CAACGAGAACCAGGGCAACAGAAGCAACA
ACAGCAACAAAGAGTACGCCCTGATCAAC 
TGCAGTTGATCAGGGCGTACTCTTTGTTGCT
GTTGTTGCTTCTGTTGCCCTGGTTCTC 
193 L 
CAACGAGAACCAGGGCAACAGAAGCAACA
ACAGCAACAAAGAGTACCGGGCCATCAAC 
TGCAGTTGATGGCCCGGTACTCTTTGTTGCT
GTTGTTGCTTCTGTTGCCCTGGTTCTC 
194 I 
CAACGAGAACCAGGGCAACAGAAGCAACA
ACAGCAACAAAGAGTACCGGCTGGCCAAC 
TGCAGTTGGCCAGCCGGTACTCTTTGTTGCT
GTTGTTGCTTCTGTTGCCCTGGTTCTC 
195 N 
CAACGAGAACCAGGGCAACAGAAGCAACA
ACAGCAACAAAGAGTACCGGCTGATCGCC 
TGCAGGCGATCAGCCGGTACTCTTTGTTGCT
GTTGTTGCTTCTGTTGCCCTGGTTCTC 
197 N 
CAACTGCGCCACCAGCGCCATCACCCAGGC
CTGCCCCAAGGTGTCCTTCGAGCCCATC 
TGGGGATGGGCTCGAAGGACACCTTGGGGC
AGGCCTGGGTGATGGCGCTGGTGGCGCA 
198 T 
CAACTGCAACGCCAGCGCCATCACCCAGGC
CTGCCCCAAGGTGTCCTTCGAGCCCATC 
TGGGGATGGGCTCGAAGGACACCTTGGGGC
AGGCCTGGGTGATGGCGCTGGCGTTGCA 
199 S 
CAACTGCAACACCGCCGCCATCACCCAGGC
CTGCCCCAAGGTGTCCTTCGAGCCCATC 
TGGGGATGGGCTCGAAGGACACCTTGGGGC
AGGCCTGGGTGATGGCGGCGGTGTTGCA 
201 I 
CAACTGCAACACCAGCGCCGCCACCCAGGC
CTGCCCCAAGGTGTCCTTCGAGCCCATC 
TGGGGATGGGCTCGAAGGACACCTTGGGGC
AGGCCTGGGTGGCGGCGCTGGTGTTGCA 
202 T 
CAACTGCAACACCAGCGCCATCGCCCAGGC
CTGCCCCAAGGTGTCCTTCGAGCCCATC 
TGGGGATGGGCTCGAAGGACACCTTGGGGC
AGGCCTGGGCGATGGCGCTGGTGTTGCA 
203 Q 
CAACTGCAACACCAGCGCCATCACCGCCGC
CTGCCCCAAGGTGTCCTTCGAGCCCATC 
TGGGGATGGGCTCGAAGGACACCTTGGGGC
AGGCGGCGGTGATGGCGCTGGTGTTGCA 
206 P 
CAACTGCAACACCAGCGCCATCACCCAGGC
CTGCGCCAAGGTGTCCTTCGAGCCCATC 
TGGGGATGGGCTCGAAGGACACCTTGGCGC
AGGCCTGGGTGATGGCGCTGGTGTTGCA 
207 K 
CAACTGCAACACCAGCGCCATCACCCAGGC
CTGCCCCGCCGTGTCCTTCGAGCCCATC 
TGGGGATGGGCTCGAAGGACACGGCGGGG
CAGGCCTGGGTGATGGCGCTGGTGTTGCA 
208 V 
CAACTGCAACACCAGCGCCATCACCCAGGC
CTGCCCCAAGGCCTCCTTCGAGCCCATC 
TGGGGATGGGCTCGAAGGAGGCCTTGGGGC
AGGCCTGGGTGATGGCGCTGGTGTTGCA 
209 S 
CAACTGCAACACCAGCGCCATCACCCAGGC
CTGCCCCAAGGTGGCCTTCGAGCCCATC 
TGGGGATGGGCTCGAAGGCCACCTTGGGGC
AGGCCTGGGTGATGGCGCTGGTGTTGCA 
210 F 
CAACTGCAACACCAGCGCCATCACCCAGGC
CTGCCCCAAGGTGTCCGCCGAGCCCATC 
TGGGGATGGGCTCGGCGGACACCTTGGGGC
AGGCCTGGGTGATGGCGCTGGTGTTGCA 
211 E 
CAACTGCAACACCAGCGCCATCACCCAGGC
CTGCCCCAAGGTGTCCTTCGCCCCCATC 
TGGGGATGGGGGCGAAGGACACCTTGGGGC
AGGCCTGGGTGATGGCGCTGGTGTTGCA 
212 P 
CAACTGCAACACCAGCGCCATCACCCAGGC
CTGCCCCAAGGTGTCCTTCGAGGCCATC 
TGGGGATGGCCTCGAAGGACACCTTGGGGC
AGGCCTGGGTGATGGCGCTGGTGTTGCA 
213 I 
CAACTGCAACACCAGCGCCATCACCCAGGC
CTGCCCCAAGGTGTCCTTCGAGCCCGCC 
TGGGGGCGGGCTCGAAGGACACCTTGGGGC
AGGCCTGGGTGATGGCGCTGGTGTTGCA 
214 P 
CATCGCCATCCACTACTGCGCCCCTGCCGGC
TTCGCCATCCTGAAGTGCAAGGACAAG 
ACTTCTTGTCCTTGCACTTCAGGATGGCGAA
GCCGGCAGGGGCGCAGTAGTGGATGGC 
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215 I 
CATCCCCGCCCACTACTGCGCCCCTGCCGGC
TTCGCCATCCTGAAGTGCAAGGACAAG 
ACTTCTTGTCCTTGCACTTCAGGATGGCGAA
GCCGGCAGGGGCGCAGTAGTGGGCGGG 
216 H 
CATCCCCATCGCCTACTGCGCCCCTGCCGGC
TTCGCCATCCTGAAGTGCAAGGACAAG 
ACTTCTTGTCCTTGCACTTCAGGATGGCGAA
GCCGGCAGGGGCGCAGTAGGCGATGGG 
217 Y 
CATCCCCATCCACGCCTGCGCCCCTGCCGGC
TTCGCCATCCTGAAGTGCAAGGACAAG 
ACTTCTTGTCCTTGCACTTCAGGATGGCGAA
GCCGGCAGGGGCGCAGGCGTGGATGGG 
220 P 
CATCCCCATCCACTACTGCGCCGCCGCCGG
CTTCGCCATCCTGAAGTGCAAGGACAAG 
ACTTCTTGTCCTTGCACTTCAGGATGGCGAA
GCCGGCGGCGGCGCAGTAGTGGATGGG 
222 G 
CATCCCCATCCACTACTGCGCCCCTGCCGCC
TTCGCCATCCTGAAGTGCAAGGACAAG 
ACTTCTTGTCCTTGCACTTCAGGATGGCGAA
GGCGGCAGGGGCGCAGTAGTGGATGGG 
223 F 
CATCCCCATCCACTACTGCGCCCCTGCCGGC
GCCGCCATCCTGAAGTGCAAGGACAAG 
ACTTCTTGTCCTTGCACTTCAGGATGGCGGC
GCCGGCAGGGGCGCAGTAGTGGATGGG 
225 I 
CATCCCCATCCACTACTGCGCCCCTGCCGGC
TTCGCCGCCCTGAAGTGCAAGGACAAG 
ACTTCTTGTCCTTGCACTTCAGGGCGGCGAA
GCCGGCAGGGGCGCAGTAGTGGATGGG 
226 L 
CATCCCCATCCACTACTGCGCCCCTGCCGGC
TTCGCCATCGCCAAGTGCAAGGACAAG 
ACTTCTTGTCCTTGCACTTGGCGATGGCGAA
GCCGGCAGGGGCGCAGTAGTGGATGGG 
227 K 
CATCCCCATCCACTACTGCGCCCCTGCCGGC
TTCGCCATCCTGGCCTGCAAGGACAAG 
ACTTCTTGTCCTTGCAGGCCAGGATGGCGA
AGCCGGCAGGGGCGCAGTAGTGGATGGG 
229 K 
CATCCCCATCCACTACTGCGCCCCTGCCGGC
TTCGCCATCCTGAAGTGCGCCGACAAG 
ACTTCTTGTCGGCGCACTTCAGGATGGCGA
AGCCGGCAGGGGCGCAGTAGTGGATGGG 
230 D 
CATCCCCATCCACTACTGCGCCCCTGCCGGC
TTCGCCATCCTGAAGTGCAAGGCCAAG 
ACTTCTTGGCCTTGCACTTCAGGATGGCGAA
GCCGGCAGGGGCGCAGTAGTGGATGGG 
231 K 
CATCCCCATCCACTACTGCGCCCCTGCCGGC
TTCGCCATCCTGAAGTGCAAGGACGCC 
ACTTGGCGTCCTTGCACTTCAGGATGGCGA
AGCCGGCAGGGGCGCAGTAGTGGATGGG 
232 K 
CAAGGCCTTCAACGGCACCGGCCCCTGCCC
CAGCGTGTCCACCGTGCAGTGTACCCAC 
TGCCGTGGGTACACTGCACGGTGGACACGC
TGGGGCAGGGGCCGGTGCCGTTGAAGGC 
233 F 
CAAGAAGGCCAACGGCACCGGCCCCTGCCC
CAGCGTGTCCACCGTGCAGTGTACCCAC 
TGCCGTGGGTACACTGCACGGTGGACACGC
TGGGGCAGGGGCCGGTGCCGTTGGCCTT 
234 N 
CAAGAAGTTCGCCGGCACCGGCCCCTGCCC
CAGCGTGTCCACCGTGCAGTGTACCCAC 
TGCCGTGGGTACACTGCACGGTGGACACGC
TGGGGCAGGGGCCGGTGCCGGCGAACTT 
235 G 
CAAGAAGTTCAACGCCACCGGCCCCTGCCC
CAGCGTGTCCACCGTGCAGTGTACCCAC 
TGCCGTGGGTACACTGCACGGTGGACACGC
TGGGGCAGGGGCCGGTGGCGTTGAACTT 
236 T 
CAAGAAGTTCAACGGCGCCGGCCCCTGCCC
CAGCGTGTCCACCGTGCAGTGTACCCAC 
TGCCGTGGGTACACTGCACGGTGGACACGC
TGGGGCAGGGGCCGGCGCCGTTGAACTT 
237 G 
CAAGAAGTTCAACGGCACCGCCCCCTGCCC
CAGCGTGTCCACCGTGCAGTGTACCCAC 
TGCCGTGGGTACACTGCACGGTGGACACGC
TGGGGCAGGGGGCGGTGCCGTTGAACTT 
238 P 
CAAGAAGTTCAACGGCACCGGCGCCTGCCC
CAGCGTGTCCACCGTGCAGTGTACCCAC 
TGCCGTGGGTACACTGCACGGTGGACACGC
TGGGGCAGGCGCCGGTGCCGTTGAACTT 
240 P 
CAAGAAGTTCAACGGCACCGGCCCCTGCGC
CAGCGTGTCCACCGTGCAGTGTACCCAC 
TGCCGTGGGTACACTGCACGGTGGACACGC
TGGCGCAGGGGCCGGTGCCGTTGAACTT 
241 S 
CAAGAAGTTCAACGGCACCGGCCCCTGCCC
CGCCGTGTCCACCGTGCAGTGTACCCAC 
TGCCGTGGGTACACTGCACGGTGGACACGG
CGGGGCAGGGGCCGGTGCCGTTGAACTT 
242 V 
CAAGAAGTTCAACGGCACCGGCCCCTGCCC
CAGCGCCTCCACCGTGCAGTGTACCCAC 
TGCCGTGGGTACACTGCACGGTGGAGGCGC
TGGGGCAGGGGCCGGTGCCGTTGAACTT 
243 S 
CAAGAAGTTCAACGGCACCGGCCCCTGCCC
CAGCGTGGCCACCGTGCAGTGTACCCAC 
TGCCGTGGGTACACTGCACGGTGGCCACGC
TGGGGCAGGGGCCGGTGCCGTTGAACTT 
244 T 
CAAGAAGTTCAACGGCACCGGCCCCTGCCC
CAGCGTGTCCGCCGTGCAGTGTACCCAC 
TGCCGTGGGTACACTGCACGGCGGACACGC
TGGGGCAGGGGCCGGTGCCGTTGAACTT 
245 V 
CAAGAAGTTCAACGGCACCGGCCCCTGCCC
CAGCGTGTCCACCGCCCAGTGTACCCAC 
TGCCGTGGGTACACTGGGCGGTGGACACGC
TGGGGCAGGGGCCGGTGCCGTTGAACTT 
246 Q 
CAAGAAGTTCAACGGCACCGGCCCCTGCCC
CAGCGTGTCCACCGTGGCCTGTACCCAC 
TGCCGTGGGTACAGGCCACGGTGGACACGC
TGGGGCAGGGGCCGGTGCCGTTGAACTT 
248 T 
CAAGAAGTTCAACGGCACCGGCCCCTGCCC
CAGCGTGTCCACCGTGCAGTGTGCCCAC 
TGCCGTGGGCACACTGCACGGTGGACACGC
TGGGGCAGGGGCCGGTGCCGTTGAACTT 
249 H 
CAAGAAGTTCAACGGCACCGGCCCCTGCCC
CAGCGTGTCCACCGTGCAGTGTACCGCC 
TGCCGGCGGTACACTGCACGGTGGACACGC
TGGGGCAGGGGCCGGTGCCGTTGAACTT 
250 G 
CCACGCCATCAAGCCCGTGGTGTCCACCCA
GCTGCTGCTGAACGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGTTCAGCAGCA
GCTGGGTGGACACCACGGGCTTGATGGC 
251 I 
CCACGGCGCCAAGCCCGTGGTGTCCACCCA
GCTGCTGCTGAACGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGTTCAGCAGCA
GCTGGGTGGACACCACGGGCTTGGCGCC 
252 K 
CCACGGCATCGCCCCCGTGGTGTCCACCCA
GCTGCTGCTGAACGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGTTCAGCAGCA
GCTGGGTGGACACCACGGGGGCGATGCC 
253 P 
CCACGGCATCAAGGCCGTGGTGTCCACCCA
GCTGCTGCTGAACGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGTTCAGCAGCA
GCTGGGTGGACACCACGGCCTTGATGCC 
254 V 
CCACGGCATCAAGCCCGCCGTGTCCACCCA
GCTGCTGCTGAACGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGTTCAGCAGCA
GCTGGGTGGACACGGCGGGCTTGATGCC 
255 V 
CCACGGCATCAAGCCCGTGGCCTCCACCCA
GCTGCTGCTGAACGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGTTCAGCAGCA
GCTGGGTGGAGGCCACGGGCTTGATGCC 
256 S 
CCACGGCATCAAGCCCGTGGTGGCCACCCA
GCTGCTGCTGAACGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGTTCAGCAGCA
GCTGGGTGGCCACCACGGGCTTGATGCC 
257 T 
CCACGGCATCAAGCCCGTGGTGTCCGCCCA
GCTGCTGCTGAACGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGTTCAGCAGCA
GCTGGGCGGACACCACGGGCTTGATGCC 
258 Q 
CCACGGCATCAAGCCCGTGGTGTCCACCGC
CCTGCTGCTGAACGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGTTCAGCAGCA
GGGCGGTGGACACCACGGGCTTGATGCC 
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259 L 
CCACGGCATCAAGCCCGTGGTGTCCACCCA
GGCCCTGCTGAACGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGTTCAGCAGGG
CCTGGGTGGACACCACGGGCTTGATGCC 
260 L 
CCACGGCATCAAGCCCGTGGTGTCCACCCA
GCTGGCCCTGAACGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGTTCAGGGCCA
GCTGGGTGGACACCACGGGCTTGATGCC 
261 L 
CCACGGCATCAAGCCCGTGGTGTCCACCCA
GCTGCTGGCCAACGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGTTGGCCAGCA
GCTGGGTGGACACCACGGGCTTGATGCC 
262 N 
CCACGGCATCAAGCCCGTGGTGTCCACCCA
GCTGCTGCTGGCCGGCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGCCGGCCAGCAGCA
GCTGGGTGGACACCACGGGCTTGATGCC 
263 G 
CCACGGCATCAAGCCCGTGGTGTCCACCCA
GCTGCTGCTGAACGCCAGCCTCGCCGAA 
CCTCTTCGGCGAGGCTGGCGTTCAGCAGCA
GCTGGGTGGACACCACGGGCTTGATGCC 
264 S 
CCACGGCATCAAGCCCGTGGTGTCCACCCA
GCTGCTGCTGAACGGCGCCCTCGCCGAA 
CCTCTTCGGCGAGGGCGCCGTTCAGCAGCA
GCTGGGTGGACACCACGGGCTTGATGCC 
265 L 
CCACGGCATCAAGCCCGTGGTGTCCACCCA
GCTGCTGCTGAACGGCAGCGCCGCCGAA 
CCTCTTCGGCGGCGCTGCCGTTCAGCAGCA
GCTGGGTGGACACCACGGGCTTGATGCC 
267 E 
CCACGGCATCAAGCCCGTGGTGTCCACCCA
GCTGCTGCTGAACGGCAGCCTCGCCGCC 
CCTCGGCGGCGAGGCTGCCGTTCAGCAGCA
GCTGGGTGGACACCACGGGCTTGATGCC 
268 E 
CGAAGCCGAAGTGATGATCAGAAGCGAGA
ACATCACCAACAACGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGTTGTTGGTGAT
GTTCTCGCTTCTGATCATCACTTCGGC 
269 E 
CGAAGAGGCCGTGATGATCAGAAGCGAGA
ACATCACCAACAACGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGTTGTTGGTGAT
GTTCTCGCTTCTGATCATCACGGCCTC 
270 V 
CGAAGAGGAAGCCATGATCAGAAGCGAGA
ACATCACCAACAACGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGTTGTTGGTGAT
GTTCTCGCTTCTGATCATGGCTTCCTC 
271 M 
CGAAGAGGAAGTGGCCATCAGAAGCGAGA
ACATCACCAACAACGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGTTGTTGGTGAT
GTTCTCGCTTCTGATGGCCACTTCCTC 
272 I 
CGAAGAGGAAGTGATGGCCAGAAGCGAGA
ACATCACCAACAACGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGTTGTTGGTGAT
GTTCTCGCTTCTGGCCATCACTTCCTC 
273 R 
CGAAGAGGAAGTGATGATCGCCAGCGAGA
ACATCACCAACAACGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGTTGTTGGTGAT
GTTCTCGCTGGCGATCATCACTTCCTC 
274 S 
CGAAGAGGAAGTGATGATCAGAGCCGAGA
ACATCACCAACAACGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGTTGTTGGTGAT
GTTCTCGGCTCTGATCATCACTTCCTC 
275 E 
CGAAGAGGAAGTGATGATCAGAAGCGCCA
ACATCACCAACAACGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGTTGTTGGTGAT
GTTGGCGCTTCTGATCATCACTTCCTC 
276 N 
CGAAGAGGAAGTGATGATCAGAAGCGAGG
CCATCACCAACAACGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGTTGTTGGTGAT
GGCCTCGCTTCTGATCATCACTTCCTC 
277 I 
CGAAGAGGAAGTGATGATCAGAAGCGAGA
ACGCCACCAACAACGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGTTGTTGGTGGC
GTTCTCGCTTCTGATCATCACTTCCTC 
278 T 
CGAAGAGGAAGTGATGATCAGAAGCGAGA
ACATCGCCAACAACGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGTTGTTGGCGAT
GTTCTCGCTTCTGATCATCACTTCCTC 
279 N 
CGAAGAGGAAGTGATGATCAGAAGCGAGA
ACATCACCGCCAACGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGTTGGCGGTGA
TGTTCTCGCTTCTGATCATCACTTCCTC 
280 N 
CGAAGAGGAAGTGATGATCAGAAGCGAGA
ACATCACCAACGCCGCCAAGAACATCCTG 
GCACCAGGATGTTCTTGGCGGCGTTGGTGA
TGTTCTCGCTTCTGATCATCACTTCCTC 
282 K 
CGAAGAGGAAGTGATGATCAGAAGCGAGA
ACATCACCAACAACGCCGCCAACATCCTG 
GCACCAGGATGTTGGCGGCGTTGTTGGTGA
TGTTCTCGCTTCTGATCATCACTTCCTC 
283 N 
CGAAGAGGAAGTGATGATCAGAAGCGAGA
ACATCACCAACAACGCCAAGGCCATCCTG 
GCACCAGGATGGCCTTGGCGTTGTTGGTGA
TGTTCTCGCTTCTGATCATCACTTCCTC 
284 I 
CGAAGAGGAAGTGATGATCAGAAGCGAGA
ACATCACCAACAACGCCAAGAACGCCCTG 
GCACCAGGGCGTTCTTGGCGTTGTTGGTGAT
GTTCTCGCTTCTGATCATCACTTCCTC 
285 L 
CGAAGAGGAAGTGATGATCAGAAGCGAGA
ACATCACCAACAACGCCAAGAACATCGCC 
GCACGGCGATGTTCTTGGCGTTGTTGGTGAT
GTTCTCGCTTCTGATCATCACTTCCTC 
286 V 
CCTGGCCCAGTTCAACACCCCCGTGCAGAT
TAACTGCACCCGGCCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGGCCGGGTGCAGTT
AATCTGCACGGGGGTGTTGAACTGGGC 
287 Q 
CCTGGTGGCCTTCAACACCCCCGTGCAGATT
AACTGCACCCGGCCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGGCCGGGTGCAGTT
AATCTGCACGGGGGTGTTGAAGGCCAC 
288 F 
CCTGGTGCAGGCCAACACCCCCGTGCAGAT
TAACTGCACCCGGCCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGGCCGGGTGCAGTT
AATCTGCACGGGGGTGTTGGCCTGCAC 
289 N 
CCTGGTGCAGTTCGCCACCCCCGTGCAGATT
AACTGCACCCGGCCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGGCCGGGTGCAGTT
AATCTGCACGGGGGTGGCGAACTGCAC 
290 T 
CCTGGTGCAGTTCAACGCCCCCGTGCAGAT
TAACTGCACCCGGCCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGGCCGGGTGCAGTT
AATCTGCACGGGGGCGTTGAACTGCAC 
291 P 
CCTGGTGCAGTTCAACACCGCCGTGCAGAT
TAACTGCACCCGGCCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGGCCGGGTGCAGTT
AATCTGCACGGCGGTGTTGAACTGCAC 
292 V 
CCTGGTGCAGTTCAACACCCCCGCCCAGAT
TAACTGCACCCGGCCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGGCCGGGTGCAGTT
AATCTGGGCGGGGGTGTTGAACTGCAC 
293 Q 
CCTGGTGCAGTTCAACACCCCCGTGGCCATT
AACTGCACCCGGCCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGGCCGGGTGCAGTT
AATGGCCACGGGGGTGTTGAACTGCAC 
294 I 
CCTGGTGCAGTTCAACACCCCCGTGCAGGC
CAACTGCACCCGGCCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGGCCGGGTGCAGTT
GGCCTGCACGGGGGTGTTGAACTGCAC 
295 N 
CCTGGTGCAGTTCAACACCCCCGTGCAGAT
TGCCTGCACCCGGCCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGGCCGGGTGCAGGC
AATCTGCACGGGGGTGTTGAACTGCAC 
297 T 
CCTGGTGCAGTTCAACACCCCCGTGCAGAT
TAACTGCGCCCGGCCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGGCCGGGCGCAGTT
AATCTGCACGGGGGTGTTGAACTGCAC 
298 R 
CCTGGTGCAGTTCAACACCCCCGTGCAGAT
TAACTGCACCGCCCCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGGGGCGGTGCAGTT
AATCTGCACGGGGGTGTTGAACTGCAC 
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299 P 
CCTGGTGCAGTTCAACACCCCCGTGCAGAT
TAACTGCACCCGGGCCAACAACAACACC 
TTCTGGTGTTGTTGTTGGCCCGGGTGCAGTT
AATCTGCACGGGGGTGTTGAACTGCAC 
300 N 
CCTGGTGCAGTTCAACACCCCCGTGCAGAT
TAACTGCACCCGGCCCGCCAACAACACC 
TTCTGGTGTTGTTGGCGGGCCGGGTGCAGTT
AATCTGCACGGGGGTGTTGAACTGCAC 
301 N 
CCTGGTGCAGTTCAACACCCCCGTGCAGAT
TAACTGCACCCGGCCCAACGCCAACACC 
TTCTGGTGTTGGCGTTGGGCCGGGTGCAGTT
AATCTGCACGGGGGTGTTGAACTGCAC 
302 N 
CCTGGTGCAGTTCAACACCCCCGTGCAGAT
TAACTGCACCCGGCCCAACAACGCCACC 
TTCTGGTGGCGTTGTTGGGCCGGGTGCAGTT
AATCTGCACGGGGGTGTTGAACTGCAC 
303 T 
CCTGGTGCAGTTCAACACCCCCGTGCAGAT
TAACTGCACCCGGCCCAACAACAACGCC 
TTCTGGCGTTGTTGTTGGGCCGGGTGCAGTT
AATCTGCACGGGGGTGTTGAACTGCAC 
304 R 
CACCGCCAAGAGCATCCGGATCGGGCCTGG
GCAGGCCTTCTACGCCACCGGCGACATC 
CGATGATGTCGCCGGTGGCGTAGAAGGCCT
GCCCAGGCCCGATCCGGATGCTCTTGGC 
305 K 
CACCAGAGCCAGCATCCGGATCGGGCCTGG
GCAGGCCTTCTACGCCACCGGCGACATC 
CGATGATGTCGCCGGTGGCGTAGAAGGCCT
GCCCAGGCCCGATCCGGATGCTGGCTCT 
306 S 
CACCAGAAAGGCCATCCGGATCGGGCCTGG
GCAGGCCTTCTACGCCACCGGCGACATC 
CGATGATGTCGCCGGTGGCGTAGAAGGCCT
GCCCAGGCCCGATCCGGATGGCCTTTCT 
307 I 
CACCAGAAAGAGCGCCCGGATCGGGCCTGG
GCAGGCCTTCTACGCCACCGGCGACATC 
CGATGATGTCGCCGGTGGCGTAGAAGGCCT
GCCCAGGCCCGATCCGGGCGCTCTTTCT 
308 R 
CACCAGAAAGAGCATCGCCATCGGGCCTGG
GCAGGCCTTCTACGCCACCGGCGACATC 
CGATGATGTCGCCGGTGGCGTAGAAGGCCT
GCCCAGGCCCGATGGCGATGCTCTTTCT 
309 I 
CACCAGAAAGAGCATCCGGGCCGGGCCTGG
GCAGGCCTTCTACGCCACCGGCGACATC 
CGATGATGTCGCCGGTGGCGTAGAAGGCCT
GCCCAGGCCCGGCCCGGATGCTCTTTCT 
312 G 
CACCAGAAAGAGCATCCGGATCGCCCCTGG
GCAGGCCTTCTACGCCACCGGCGACATC 
CGATGATGTCGCCGGTGGCGTAGAAGGCCT
GCCCAGGGGCGATCCGGATGCTCTTTCT 
313 P 
CACCAGAAAGAGCATCCGGATCGGGGCCGG
GCAGGCCTTCTACGCCACCGGCGACATC 
CGATGATGTCGCCGGTGGCGTAGAAGGCCT
GCCCGGCCCCGATCCGGATGCTCTTTCT 
314 G 
CACCAGAAAGAGCATCCGGATCGGGCCTGC
CCAGGCCTTCTACGCCACCGGCGACATC 
CGATGATGTCGCCGGTGGCGTAGAAGGCCT
GGGCAGGCCCGATCCGGATGCTCTTTCT 
315 Q 
CACCAGAAAGAGCATCCGGATCGGGCCTGG
GGCCGCCTTCTACGCCACCGGCGACATC 
CGATGATGTCGCCGGTGGCGTAGAAGGCGG
CCCCAGGCCCGATCCGGATGCTCTTTCT 
317 F 
CACCAGAAAGAGCATCCGGATCGGGCCTGG
GCAGGCCGCCTACGCCACCGGCGACATC 
CGATGATGTCGCCGGTGGCGTAGGCGGCCT
GCCCAGGCCCGATCCGGATGCTCTTTCT 
318 Y 
CACCAGAAAGAGCATCCGGATCGGGCCTGG
GCAGGCCTTCGCCGCCACCGGCGACATC 
CGATGATGTCGCCGGTGGCGGCGAAGGCCT
GCCCAGGCCCGATCCGGATGCTCTTTCT 
320 T 
CACCAGAAAGAGCATCCGGATCGGGCCTGG
GCAGGCCTTCTACGCCGCCGGCGACATC 
CGATGATGTCGCCGGCGGCGTAGAAGGCCT
GCCCAGGCCCGATCCGGATGCTCTTTCT 
321 G 
CACCAGAAAGAGCATCCGGATCGGGCCTGG
GCAGGCCTTCTACGCCACCGCCGACATC 
CGATGATGTCGGCGGTGGCGTAGAAGGCCT
GCCCAGGCCCGATCCGGATGCTCTTTCT 
N/A D 
CACCAGAAAGAGCATCCGGATCGGGCCTGG
GCAGGCCTTCTACGCCACCGGCGCCATC 
CGATGATGGCGCCGGTGGCGTAGAAGGCCT
GCCCAGGCCCGATCCGGATGCTCTTTCT 
322 I 
CACCAGAAAGAGCATCCGGATCGGGCCTGG
GCAGGCCTTCTACGCCACCGGCGACGCC 
CGATGGCGTCGCCGGTGGCGTAGAAGGCCT
GCCCAGGCCCGATCCGGATGCTCTTTCT 
323 I 
CATCGCCGGCGACATCCGGCAGGCCCACTG
CAACGTGTCCAAGGCCACCTGGAACGAG 
GTGTCTCGTTCCAGGTGGCCTTGGACACGTT
GCAGTGGGCCTGCCGGATGTCGCCGGC 
324 G 
CATCATCGCCGACATCCGGCAGGCCCACTG
CAACGTGTCCAAGGCCACCTGGAACGAG 
GTGTCTCGTTCCAGGTGGCCTTGGACACGTT
GCAGTGGGCCTGCCGGATGTCGGCGAT 
325 D 
CATCATCGGCGCCATCCGGCAGGCCCACTG
CAACGTGTCCAAGGCCACCTGGAACGAG 
GTGTCTCGTTCCAGGTGGCCTTGGACACGTT
GCAGTGGGCCTGCCGGATGGCGCCGAT 
326 I 
CATCATCGGCGACGCCCGGCAGGCCCACTG
CAACGTGTCCAAGGCCACCTGGAACGAG 
GTGTCTCGTTCCAGGTGGCCTTGGACACGTT
GCAGTGGGCCTGCCGGGCGTCGCCGAT 
327 R 
CATCATCGGCGACATCGCCCAGGCCCACTG
CAACGTGTCCAAGGCCACCTGGAACGAG 
GTGTCTCGTTCCAGGTGGCCTTGGACACGTT
GCAGTGGGCCTGGGCGATGTCGCCGAT 
328 Q 
CATCATCGGCGACATCCGGGCCGCCCACTG
CAACGTGTCCAAGGCCACCTGGAACGAG 
GTGTCTCGTTCCAGGTGGCCTTGGACACGTT
GCAGTGGGCGGCCCGGATGTCGCCGAT 
330 H 
CATCATCGGCGACATCCGGCAGGCCGCCTG
CAACGTGTCCAAGGCCACCTGGAACGAG 
GTGTCTCGTTCCAGGTGGCCTTGGACACGTT
GCAGGCGGCCTGCCGGATGTCGCCGAT 
332 N 
CATCATCGGCGACATCCGGCAGGCCCACTG
CGCCGTGTCCAAGGCCACCTGGAACGAG 
GTGTCTCGTTCCAGGTGGCCTTGGACACGG
CGCAGTGGGCCTGCCGGATGTCGCCGAT 
333 V 
CATCATCGGCGACATCCGGCAGGCCCACTG
CAACGCCTCCAAGGCCACCTGGAACGAG 
GTGTCTCGTTCCAGGTGGCCTTGGAGGCGTT
GCAGTGGGCCTGCCGGATGTCGCCGAT 
334 S 
CATCATCGGCGACATCCGGCAGGCCCACTG
CAACGTGGCCAAGGCCACCTGGAACGAG 
GTGTCTCGTTCCAGGTGGCCTTGGCCACGTT
GCAGTGGGCCTGCCGGATGTCGCCGAT 
335 K 
CATCATCGGCGACATCCGGCAGGCCCACTG
CAACGTGTCCGCCGCCACCTGGAACGAG 
GTGTCTCGTTCCAGGTGGCGGCGGACACGT
TGCAGTGGGCCTGCCGGATGTCGCCGAT 
337 T 
CATCATCGGCGACATCCGGCAGGCCCACTG
CAACGTGTCCAAGGCCGCCTGGAACGAG 
GTGTCTCGTTCCAGGCGGCCTTGGACACGTT
GCAGTGGGCCTGCCGGATGTCGCCGAT 
338 W 
CATCATCGGCGACATCCGGCAGGCCCACTG
CAACGTGTCCAAGGCCACCGCCAACGAG 
GTGTCTCGTTGGCGGTGGCCTTGGACACGTT
GCAGTGGGCCTGCCGGATGTCGCCGAT 
339 N 
CATCATCGGCGACATCCGGCAGGCCCACTG
CAACGTGTCCAAGGCCACCTGGGCCGAG 
GTGTCTCGGCCCAGGTGGCCTTGGACACGT
TGCAGTGGGCCTGCCGGATGTCGCCGAT 
340 E 
CATCATCGGCGACATCCGGCAGGCCCACTG
CAACGTGTCCAAGGCCACCTGGAACGCC 
GTGTGGCGTTCCAGGTGGCCTTGGACACGT
TGCAGTGGGCCTGCCGGATGTCGCCGAT 
341 T 
CGAGGCCCTGGGCAAGGTGGTGAAACAGCT
GCGGAAGCACTTCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGAAGTGCTTCCG
CAGCTGTTTCACCACCTTGCCCAGGGC 
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342 L 
CGAGACAGCCGGCAAGGTGGTGAAACAGCT
GCGGAAGCACTTCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGAAGTGCTTCCG
CAGCTGTTTCACCACCTTGCCGGCTGT 
343 G 
CGAGACACTGGCCAAGGTGGTGAAACAGCT
GCGGAAGCACTTCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGAAGTGCTTCCG
CAGCTGTTTCACCACCTTGGCCAGTGT 
344 K 
CGAGACACTGGGCGCCGTGGTGAAACAGCT
GCGGAAGCACTTCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGAAGTGCTTCCG
CAGCTGTTTCACCACGGCGCCCAGTGT 
345 V 
CGAGACACTGGGCAAGGCCGTGAAACAGCT
GCGGAAGCACTTCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGAAGTGCTTCCG
CAGCTGTTTCACGGCCTTGCCCAGTGT 
346 V 
CGAGACACTGGGCAAGGTGGCCAAACAGCT
GCGGAAGCACTTCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGAAGTGCTTCCG
CAGCTGTTTGGCCACCTTGCCCAGTGT 
347 K 
CGAGACACTGGGCAAGGTGGTGGCCCAGCT
GCGGAAGCACTTCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGAAGTGCTTCCG
CAGCTGGGCCACCACCTTGCCCAGTGT 
348 Q 
CGAGACACTGGGCAAGGTGGTGAAAGCCCT
GCGGAAGCACTTCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGAAGTGCTTCCG
CAGGGCTTTCACCACCTTGCCCAGTGT 
349 L 
CGAGACACTGGGCAAGGTGGTGAAACAGG
CCCGGAAGCACTTCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGAAGTGCTTCCG
GGCCTGTTTCACCACCTTGCCCAGTGT 
350 R 
CGAGACACTGGGCAAGGTGGTGAAACAGCT
GGCCAAGCACTTCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGAAGTGCTTGGC
CAGCTGTTTCACCACCTTGCCCAGTGT 
351 K 
CGAGACACTGGGCAAGGTGGTGAAACAGCT
GCGGGCCCACTTCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGAAGTGGGCCC
GCAGCTGTTTCACCACCTTGCCCAGTGT 
352 H 
CGAGACACTGGGCAAGGTGGTGAAACAGCT
GCGGAAGGCCTTCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGAAGGCCTTCCG
CAGCTGTTTCACCACCTTGCCCAGTGT 
353 F 
CGAGACACTGGGCAAGGTGGTGAAACAGCT
GCGGAAGCACGCCGGGAACAACACCATC 
TGATGATGGTGTTGTTCCCGGCGTGCTTCCG
CAGCTGTTTCACCACCTTGCCCAGTGT 
354 G 
CGAGACACTGGGCAAGGTGGTGAAACAGCT
GCGGAAGCACTTCGCCAACAACACCATC 
TGATGATGGTGTTGTTGGCGAAGTGCTTCCG
CAGCTGTTTCACCACCTTGCCCAGTGT 
355 N 
CGAGACACTGGGCAAGGTGGTGAAACAGCT
GCGGAAGCACTTCGGGGCCAACACCATC 
TGATGATGGTGTTGGCCCCGAAGTGCTTCC
GCAGCTGTTTCACCACCTTGCCCAGTGT 
356 N 
CGAGACACTGGGCAAGGTGGTGAAACAGCT
GCGGAAGCACTTCGGGAACGCCACCATC 
TGATGATGGTGGCGTTCCCGAAGTGCTTCC
GCAGCTGTTTCACCACCTTGCCCAGTGT 
357 T 
CGAGACACTGGGCAAGGTGGTGAAACAGCT
GCGGAAGCACTTCGGGAACAACGCCATC 
TGATGATGGCGTTGTTCCCGAAGTGCTTCCG
CAGCTGTTTCACCACCTTGCCCAGTGT 
358 I 
CGAGACACTGGGCAAGGTGGTGAAACAGCT
GCGGAAGCACTTCGGGAACAACACCGCC 
TGATGGCGGTGTTGTTCCCGAAGTGCTTCCG
CAGCTGTTTCACCACCTTGCCCAGTGT 
359 I 
CATCGCCAGATTCGCCAACAGCTCTGGCGG
CGACCTGGAAGTGACCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGTCACTTCCAGGT
CGCCGCCAGAGCTGTTGGCGAATCTGGC 
360 R 
CATCATCGCCTTCGCCAACAGCTCTGGCGG
CGACCTGGAAGTGACCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGTCACTTCCAGGT
CGCCGCCAGAGCTGTTGGCGAAGGCGAT 
361 F 
CATCATCAGAGCCGCCAACAGCTCTGGCGG
CGACCTGGAAGTGACCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGTCACTTCCAGGT
CGCCGCCAGAGCTGTTGGCGGCTCTGAT 
363 N 
CATCATCAGATTCGCCGCCAGCTCTGGCGG
CGACCTGGAAGTGACCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGTCACTTCCAGGT
CGCCGCCAGAGCTGGCGGCGAATCTGAT 
364 S 
CATCATCAGATTCGCCAACGCCTCTGGCGG
CGACCTGGAAGTGACCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGTCACTTCCAGGT
CGCCGCCAGAGGCGTTGGCGAATCTGAT 
365 S 
CATCATCAGATTCGCCAACAGCGCCGGCGG
CGACCTGGAAGTGACCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGTCACTTCCAGGT
CGCCGCCGGCGCTGTTGGCGAATCTGAT 
366 G 
CATCATCAGATTCGCCAACAGCTCTGCCGG
CGACCTGGAAGTGACCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGTCACTTCCAGGT
CGCCGGCAGAGCTGTTGGCGAATCTGAT 
367 G 
CATCATCAGATTCGCCAACAGCTCTGGCGC
CGACCTGGAAGTGACCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGTCACTTCCAGGT
CGGCGCCAGAGCTGTTGGCGAATCTGAT 
368 D 
CATCATCAGATTCGCCAACAGCTCTGGCGG
CGCCCTGGAAGTGACCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGTCACTTCCAGGG
CGCCGCCAGAGCTGTTGGCGAATCTGAT 
369 L 
CATCATCAGATTCGCCAACAGCTCTGGCGG
CGACGCCGAAGTGACCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGTCACTTCGGCGT
CGCCGCCAGAGCTGTTGGCGAATCTGAT 
370 E 
CATCATCAGATTCGCCAACAGCTCTGGCGG
CGACCTGGCCGTGACCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGTCACGGCCAGGT
CGCCGCCAGAGCTGTTGGCGAATCTGAT 
371 V 
CATCATCAGATTCGCCAACAGCTCTGGCGG
CGACCTGGAAGCCACCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGTGGCTTCCAGGT
CGCCGCCAGAGCTGTTGGCGAATCTGAT 
372 T 
CATCATCAGATTCGCCAACAGCTCTGGCGG
CGACCTGGAAGTGGCCACCCACAGCTTC 
AGTTGAAGCTGTGGGTGGCCACTTCCAGGT
CGCCGCCAGAGCTGTTGGCGAATCTGAT 
373 T 
CATCATCAGATTCGCCAACAGCTCTGGCGG
CGACCTGGAAGTGACCGCCCACAGCTTC 
AGTTGAAGCTGTGGGCGGTCACTTCCAGGT
CGCCGCCAGAGCTGTTGGCGAATCTGAT 
374 H 
CATCATCAGATTCGCCAACAGCTCTGGCGG
CGACCTGGAAGTGACCACCGCCAGCTTC 
AGTTGAAGCTGGCGGTGGTCACTTCCAGGT
CGCCGCCAGAGCTGTTGGCGAATCTGAT 
375 S 
CATCATCAGATTCGCCAACAGCTCTGGCGG
CGACCTGGAAGTGACCACCCACGCCTTC 
AGTTGAAGGCGTGGGTGGTCACTTCCAGGT
CGCCGCCAGAGCTGTTGGCGAATCTGAT 
376 F 
CATCATCAGATTCGCCAACAGCTCTGGCGG
CGACCTGGAAGTGACCACCCACAGCGCC 
AGTTGGCGCTGTGGGTGGTCACTTCCAGGT
CGCCGCCAGAGCTGTTGGCGAATCTGAT 
377 N 
CTTCGCCTGTGGCGGCGAGTTCTTCTACTGC
AATACCTCCGGCCTGTTCAACAGCACC 
TCCAGGTGCTGTTGAACAGGCCGGAGGTAT
TGCAGTAGAAGAACTCGCCGCCACAGGC 
379 G 
CTTCAACTGTGCCGGCGAGTTCTTCTACTGC
AATACCTCCGGCCTGTTCAACAGCACC 
TCCAGGTGCTGTTGAACAGGCCGGAGGTAT
TGCAGTAGAAGAACTCGCCGGCACAGTT 
380 G 
CTTCAACTGTGGCGCCGAGTTCTTCTACTGC
AATACCTCCGGCCTGTTCAACAGCACC 
TCCAGGTGCTGTTGAACAGGCCGGAGGTAT
TGCAGTAGAAGAACTCGGCGCCACAGTT 
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381 E 
CTTCAACTGTGGCGGCGCCTTCTTCTACTGC
AATACCTCCGGCCTGTTCAACAGCACC 
TCCAGGTGCTGTTGAACAGGCCGGAGGTAT
TGCAGTAGAAGAAGGCGCCGCCACAGTT 
382 F 
CTTCAACTGTGGCGGCGAGGCCTTCTACTGC
AATACCTCCGGCCTGTTCAACAGCACC 
TCCAGGTGCTGTTGAACAGGCCGGAGGTAT
TGCAGTAGAAGGCCTCGCCGCCACAGTT 
383 F 
CTTCAACTGTGGCGGCGAGTTCGCCTACTGC
AATACCTCCGGCCTGTTCAACAGCACC 
TCCAGGTGCTGTTGAACAGGCCGGAGGTAT
TGCAGTAGGCGAACTCGCCGCCACAGTT 
384 Y 
CTTCAACTGTGGCGGCGAGTTCTTCGCCTGC
AATACCTCCGGCCTGTTCAACAGCACC 
TCCAGGTGCTGTTGAACAGGCCGGAGGTAT
TGCAGGCGAAGAACTCGCCGCCACAGTT 
386 N 
CTTCAACTGTGGCGGCGAGTTCTTCTACTGC
GCCACCTCCGGCCTGTTCAACAGCACC 
TCCAGGTGCTGTTGAACAGGCCGGAGGTGG
CGCAGTAGAAGAACTCGCCGCCACAGTT 
387 T 
CTTCAACTGTGGCGGCGAGTTCTTCTACTGC
AATGCCTCCGGCCTGTTCAACAGCACC 
TCCAGGTGCTGTTGAACAGGCCGGAGGCAT
TGCAGTAGAAGAACTCGCCGCCACAGTT 
388 S 
CTTCAACTGTGGCGGCGAGTTCTTCTACTGC
AATACCGCCGGCCTGTTCAACAGCACC 
TCCAGGTGCTGTTGAACAGGCCGGCGGTAT
TGCAGTAGAAGAACTCGCCGCCACAGTT 
389 G 
CTTCAACTGTGGCGGCGAGTTCTTCTACTGC
AATACCTCCGCCCTGTTCAACAGCACC 
TCCAGGTGCTGTTGAACAGGGCGGAGGTAT
TGCAGTAGAAGAACTCGCCGCCACAGTT 
390 L 
CTTCAACTGTGGCGGCGAGTTCTTCTACTGC
AATACCTCCGGCGCCTTCAACAGCACC 
TCCAGGTGCTGTTGAAGGCGCCGGAGGTAT
TGCAGTAGAAGAACTCGCCGCCACAGTT 
391 F 
CTTCAACTGTGGCGGCGAGTTCTTCTACTGC
AATACCTCCGGCCTGGCCAACAGCACC 
TCCAGGTGCTGTTGGCCAGGCCGGAGGTAT
TGCAGTAGAAGAACTCGCCGCCACAGTT 
392 N 
CTTCAACTGTGGCGGCGAGTTCTTCTACTGC
AATACCTCCGGCCTGTTCGCCAGCACC 
TCCAGGTGCTGGCGAACAGGCCGGAGGTAT
TGCAGTAGAAGAACTCGCCGCCACAGTT 
393 S 
CTTCAACTGTGGCGGCGAGTTCTTCTACTGC
AATACCTCCGGCCTGTTCAACGCCACC 
TCCAGGTGGCGTTGAACAGGCCGGAGGTAT
TGCAGTAGAAGAACTCGCCGCCACAGTT 
394 T 
CTTCAACTGTGGCGGCGAGTTCTTCTACTGC
AATACCTCCGGCCTGTTCAACAGCGCC 
TCCAGGCGCTGTTGAACAGGCCGGAGGTAT
TGCAGTAGAAGAACTCGCCGCCACAGTT 
395 W 
CACCGCCATCAGCAATACCAGCGTGCAGGG
GAGCAACAGCACCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGTGCTGTTGCT
CCCCTGCACGCTGGTATTGCTGATGGC 
396 I 
CACCTGGGCCAGCAATACCAGCGTGCAGGG
GAGCAACAGCACCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGTGCTGTTGCT
CCCCTGCACGCTGGTATTGCTGGCCCA 
397 S 
CACCTGGATCGCCAATACCAGCGTGCAGGG
GAGCAACAGCACCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGTGCTGTTGCT
CCCCTGCACGCTGGTATTGGCGATCCA 
398 N 
CACCTGGATCAGCGCCACCAGCGTGCAGGG
GAGCAACAGCACCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGTGCTGTTGCT
CCCCTGCACGCTGGTGGCGCTGATCCA 
399 T 
CACCTGGATCAGCAATGCCAGCGTGCAGGG
GAGCAACAGCACCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGTGCTGTTGCT
CCCCTGCACGCTGGCATTGCTGATCCA 
401 S 
CACCTGGATCAGCAATACCGCCGTGCAGGG
GAGCAACAGCACCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGTGCTGTTGCT
CCCCTGCACGGCGGTATTGCTGATCCA 
402 V 
CACCTGGATCAGCAATACCAGCGCCCAGGG
GAGCAACAGCACCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGTGCTGTTGCT
CCCCTGGGCGCTGGTATTGCTGATCCA 
403 Q 
CACCTGGATCAGCAATACCAGCGTGGCCGG
GAGCAACAGCACCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGTGCTGTTGCT
CCCGGCCACGCTGGTATTGCTGATCCA 
404 G 
CACCTGGATCAGCAATACCAGCGTGCAGGC
CAGCAACAGCACCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGTGCTGTTGCT
GGCCTGCACGCTGGTATTGCTGATCCA 
405 S 
CACCTGGATCAGCAATACCAGCGTGCAGGG
GGCCAACAGCACCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGTGCTGTTGGC
CCCCTGCACGCTGGTATTGCTGATCCA 
406 N 
CACCTGGATCAGCAATACCAGCGTGCAGGG
GAGCGCCAGCACCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGTGCTGGCGCT
CCCCTGCACGCTGGTATTGCTGATCCA 
407 S 
CACCTGGATCAGCAATACCAGCGTGCAGGG
GAGCAACGCCACCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGTGGCGTTGCT
CCCCTGCACGCTGGTATTGCTGATCCA 
408 T 
CACCTGGATCAGCAATACCAGCGTGCAGGG
GAGCAACAGCGCCGGCAGCAACGACAGC 
TGATGCTGTCGTTGCTGCCGGCGCTGTTGCT
CCCCTGCACGCTGGTATTGCTGATCCA 
409 G 
CACCTGGATCAGCAATACCAGCGTGCAGGG
GAGCAACAGCACCGCCAGCAACGACAGC 
TGATGCTGTCGTTGCTGGCGGTGCTGTTGCT
CCCCTGCACGCTGGTATTGCTGATCCA 
410 S 
CACCTGGATCAGCAATACCAGCGTGCAGGG
GAGCAACAGCACCGGCGCCAACGACAGC 
TGATGCTGTCGTTGGCGCCGGTGCTGTTGCT
CCCCTGCACGCTGGTATTGCTGATCCA 
411 N 
CACCTGGATCAGCAATACCAGCGTGCAGGG
GAGCAACAGCACCGGCAGCGCCGACAGC 
TGATGCTGTCGGCGCTGCCGGTGCTGTTGCT
CCCCTGCACGCTGGTATTGCTGATCCA 
412 D 
CACCTGGATCAGCAATACCAGCGTGCAGGG
GAGCAACAGCACCGGCAGCAACGCCAGC 
TGATGCTGGCGTTGCTGCCGGTGCTGTTGCT
CCCCTGCACGCTGGTATTGCTGATCCA 
413 S 
CACCTGGATCAGCAATACCAGCGTGCAGGG
GAGCAACAGCACCGGCAGCAACGACGCC 
TGATGGCGTCGTTGCTGCCGGTGCTGTTGCT
CCCCTGCACGCTGGTATTGCTGATCCA 
414 I 
CAGCGCCACCCTGCCCTGCCGGATCAAGCA
GATCATCAATATGTGGCAGCGGATCGGC 
CCTGGCCGATCCGCTGCCACATATTGATGAT
CTGCTTGATCCGGCAGGGCAGGGTGGC 
415 T 
CAGCATCGCCCTGCCCTGCCGGATCAAGCA
GATCATCAATATGTGGCAGCGGATCGGC 
CCTGGCCGATCCGCTGCCACATATTGATGAT
CTGCTTGATCCGGCAGGGCAGGGCGAT 
416 L 
CAGCATCACCGCCCCCTGCCGGATCAAGCA
GATCATCAATATGTGGCAGCGGATCGGC 
CCTGGCCGATCCGCTGCCACATATTGATGAT
CTGCTTGATCCGGCAGGGGGCGGTGAT 
417 P 
CAGCATCACCCTGGCCTGCCGGATCAAGCA
GATCATCAATATGTGGCAGCGGATCGGC 
CCTGGCCGATCCGCTGCCACATATTGATGAT
CTGCTTGATCCGGCAGGCCAGGGTGAT 
419 R 
CAGCATCACCCTGCCCTGCGCCATCAAGCA
GATCATCAATATGTGGCAGCGGATCGGC 
CCTGGCCGATCCGCTGCCACATATTGATGAT
CTGCTTGATGGCGCAGGGCAGGGTGAT 
420 I 
CAGCATCACCCTGCCCTGCCGGGCCAAGCA
GATCATCAATATGTGGCAGCGGATCGGC 
CCTGGCCGATCCGCTGCCACATATTGATGAT
CTGCTTGGCCCGGCAGGGCAGGGTGAT 
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421 K 
CAGCATCACCCTGCCCTGCCGGATCGCCCA
GATCATCAATATGTGGCAGCGGATCGGC 
CCTGGCCGATCCGCTGCCACATATTGATGAT
CTGGGCGATCCGGCAGGGCAGGGTGAT 
422 Q 
CAGCATCACCCTGCCCTGCCGGATCAAGGC
CATCATCAATATGTGGCAGCGGATCGGC 
CCTGGCCGATCCGCTGCCACATATTGATGAT
GGCCTTGATCCGGCAGGGCAGGGTGAT 
423 I 
CAGCATCACCCTGCCCTGCCGGATCAAGCA
GGCCATCAATATGTGGCAGCGGATCGGC 
CCTGGCCGATCCGCTGCCACATATTGATGG
CCTGCTTGATCCGGCAGGGCAGGGTGAT 
424 I 
CAGCATCACCCTGCCCTGCCGGATCAAGCA
GATCGCCAATATGTGGCAGCGGATCGGC 
CCTGGCCGATCCGCTGCCACATATTGGCGA
TCTGCTTGATCCGGCAGGGCAGGGTGAT 
425 N 
CAGCATCACCCTGCCCTGCCGGATCAAGCA
GATCATCGCCATGTGGCAGCGGATCGGC 
CCTGGCCGATCCGCTGCCACATGGCGATGA
TCTGCTTGATCCGGCAGGGCAGGGTGAT 
426 M 
CAGCATCACCCTGCCCTGCCGGATCAAGCA
GATCATCAATGCCTGGCAGCGGATCGGC 
CCTGGCCGATCCGCTGCCAGGCATTGATGA
TCTGCTTGATCCGGCAGGGCAGGGTGAT 
427 W 
CAGCATCACCCTGCCCTGCCGGATCAAGCA
GATCATCAATATGGCCCAGCGGATCGGC 
CCTGGCCGATCCGCTGGGCCATATTGATGA
TCTGCTTGATCCGGCAGGGCAGGGTGAT 
428 Q 
CAGCATCACCCTGCCCTGCCGGATCAAGCA
GATCATCAATATGTGGGCCCGGATCGGC 
CCTGGCCGATCCGGGCCCACATATTGATGA
TCTGCTTGATCCGGCAGGGCAGGGTGAT 
429 R 
CAGCATCACCCTGCCCTGCCGGATCAAGCA
GATCATCAATATGTGGCAGGCCATCGGC 
CCTGGCCGATGGCCTGCCACATATTGATGA
TCTGCTTGATCCGGCAGGGCAGGGTGAT 
430 I 
CAGCATCACCCTGCCCTGCCGGATCAAGCA
GATCATCAATATGTGGCAGCGGGCCGGC 
CCTGGCCGGCCCGCTGCCACATATTGATGA
TCTGCTTGATCCGGCAGGGCAGGGTGAT 
431 G 
CAGCATCACCCTGCCCTGCCGGATCAAGCA
GATCATCAATATGTGGCAGCGGATCGCC 
CCTGGGCGATCCGCTGCCACATATTGATGA
TCTGCTTGATCCGGCAGGGCAGGGTGAT 
432 Q 
CGGCGCCGCTATGTACGCCCCACCCATCCA
GGGCGTGATCAGATGCGTGTCCAATATC 
CGGTGATATTGGACACGCATCTGATCACGC
CCTGGATGGGTGGGGCGTACATAGCGGC 
434 M 
CGGCCAGGCTGCCTACGCCCCACCCATCCA
GGGCGTGATCAGATGCGTGTCCAATATC 
CGGTGATATTGGACACGCATCTGATCACGC
CCTGGATGGGTGGGGCGTAGGCAGCCTG 
435 Y 
CGGCCAGGCTATGGCCGCCCCACCCATCCA
GGGCGTGATCAGATGCGTGTCCAATATC 
CGGTGATATTGGACACGCATCTGATCACGC
CCTGGATGGGTGGGGCGGCCATAGCCTG 
437 P 
CGGCCAGGCTATGTACGCCGCCCCCATCCA
GGGCGTGATCAGATGCGTGTCCAATATC 
CGGTGATATTGGACACGCATCTGATCACGC
CCTGGATGGGGGCGGCGTACATAGCCTG 
438 P 
CGGCCAGGCTATGTACGCCCCAGCCATCCA
GGGCGTGATCAGATGCGTGTCCAATATC 
CGGTGATATTGGACACGCATCTGATCACGC
CCTGGATGGCTGGGGCGTACATAGCCTG 
439 I 
CGGCCAGGCTATGTACGCCCCACCCGCCCA
GGGCGTGATCAGATGCGTGTCCAATATC 
CGGTGATATTGGACACGCATCTGATCACGC
CCTGGGCGGGTGGGGCGTACATAGCCTG 
440 Q 
CGGCCAGGCTATGTACGCCCCACCCATCGC
CGGCGTGATCAGATGCGTGTCCAATATC 
CGGTGATATTGGACACGCATCTGATCACGC
CGGCGATGGGTGGGGCGTACATAGCCTG 
441 G 
CGGCCAGGCTATGTACGCCCCACCCATCCA
GGCCGTGATCAGATGCGTGTCCAATATC 
CGGTGATATTGGACACGCATCTGATCACGG
CCTGGATGGGTGGGGCGTACATAGCCTG 
442 V 
CGGCCAGGCTATGTACGCCCCACCCATCCA
GGGCGCCATCAGATGCGTGTCCAATATC 
CGGTGATATTGGACACGCATCTGATGGCGC
CCTGGATGGGTGGGGCGTACATAGCCTG 
443 I 
CGGCCAGGCTATGTACGCCCCACCCATCCA
GGGCGTGGCCAGATGCGTGTCCAATATC 
CGGTGATATTGGACACGCATCTGGCCACGC
CCTGGATGGGTGGGGCGTACATAGCCTG 
444 R 
CGGCCAGGCTATGTACGCCCCACCCATCCA
GGGCGTGATCGCCTGCGTGTCCAATATC 
CGGTGATATTGGACACGCAGGCGATCACGC
CCTGGATGGGTGGGGCGTACATAGCCTG 
446 V 
CGGCCAGGCTATGTACGCCCCACCCATCCA
GGGCGTGATCAGATGCGCCTCCAATATC 
CGGTGATATTGGAGGCGCATCTGATCACGC
CCTGGATGGGTGGGGCGTACATAGCCTG 
447 S 
CGGCCAGGCTATGTACGCCCCACCCATCCA
GGGCGTGATCAGATGCGTGGCCAATATC 
CGGTGATATTGGCCACGCATCTGATCACGC
CCTGGATGGGTGGGGCGTACATAGCCTG 
448 N 
CGGCCAGGCTATGTACGCCCCACCCATCCA
GGGCGTGATCAGATGCGTGTCCGCCATC 
CGGTGATGGCGGACACGCATCTGATCACGC
CCTGGATGGGTGGGGCGTACATAGCCTG 
449 I 
CGGCCAGGCTATGTACGCCCCACCCATCCA
GGGCGTGATCAGATGCGTGTCCAATGCC 
CGGTGGCATTGGACACGCATCTGATCACGC
CCTGGATGGGTGGGGCGTACATAGCCTG 
450 T 
TATCGCCGGCCTGATCCTGACCCGGGACGG
CGGCAGCACCAACAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGTTGGTGCTGCC
GCCGTCCCGGGTCAGGATCAGGCCGGC 
451 G 
TATCACCGCCCTGATCCTGACCCGGGACGG
CGGCAGCACCAACAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGTTGGTGCTGCC
GCCGTCCCGGGTCAGGATCAGGGCGGT 
452 L 
TATCACCGGCGCCATCCTGACCCGGGACGG
CGGCAGCACCAACAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGTTGGTGCTGCC
GCCGTCCCGGGTCAGGATGGCGCCGGT 
453 I 
TATCACCGGCCTGGCCCTGACCCGGGACGG
CGGCAGCACCAACAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGTTGGTGCTGCC
GCCGTCCCGGGTCAGGGCCAGGCCGGT 
454 L 
TATCACCGGCCTGATCGCCACCCGGGACGG
CGGCAGCACCAACAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGTTGGTGCTGCC
GCCGTCCCGGGTGGCGATCAGGCCGGT 
455 T 
TATCACCGGCCTGATCCTGGCCCGGGACGG
CGGCAGCACCAACAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGTTGGTGCTGCC
GCCGTCCCGGGCCAGGATCAGGCCGGT 
456 R 
TATCACCGGCCTGATCCTGACCGCCGACGG
CGGCAGCACCAACAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGTTGGTGCTGCC
GCCGTCGGCGGTCAGGATCAGGCCGGT 
457 D 
TATCACCGGCCTGATCCTGACCCGGGCCGG
CGGCAGCACCAACAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGTTGGTGCTGCC
GCCGGCCCGGGTCAGGATCAGGCCGGT 
458 G 
TATCACCGGCCTGATCCTGACCCGGGACGC
CGGCAGCACCAACAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGTTGGTGCTGCC
GGCGTCCCGGGTCAGGATCAGGCCGGT 
459 G 
TATCACCGGCCTGATCCTGACCCGGGACGG
CGCCAGCACCAACAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGTTGGTGCTGGC
GCCGTCCCGGGTCAGGATCAGGCCGGT 
460 S 
TATCACCGGCCTGATCCTGACCCGGGACGG
CGGCGCCACCAACAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGTTGGTGGCGC
CGCCGTCCCGGGTCAGGATCAGGCCGGT 
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461 T 
TATCACCGGCCTGATCCTGACCCGGGACGG
CGGCAGCGCCAACAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGTTGGCGCTGCC
GCCGTCCCGGGTCAGGATCAGGCCGGT 
462 N 
TATCACCGGCCTGATCCTGACCCGGGACGG
CGGCAGCACCGCCAGCACCACCGAAACC 
TGAAGGTTTCGGTGGTGCTGGCGGTGCTGC
CGCCGTCCCGGGTCAGGATCAGGCCGGT 
463 S 
TATCACCGGCCTGATCCTGACCCGGGACGG
CGGCAGCACCAACGCCACCACCGAAACC 
TGAAGGTTTCGGTGGTGGCGTTGGTGCTGC
CGCCGTCCCGGGTCAGGATCAGGCCGGT 
464 T 
TATCACCGGCCTGATCCTGACCCGGGACGG
CGGCAGCACCAACAGCGCCACCGAAACC 
TGAAGGTTTCGGTGGCGCTGTTGGTGCTGCC
GCCGTCCCGGGTCAGGATCAGGCCGGT 
465 T 
TATCACCGGCCTGATCCTGACCCGGGACGG
CGGCAGCACCAACAGCACCGCCGAAACC 
TGAAGGTTTCGGCGGTGCTGTTGGTGCTGCC
GCCGTCCCGGGTCAGGATCAGGCCGGT 
466 E 
TATCACCGGCCTGATCCTGACCCGGGACGG
CGGCAGCACCAACAGCACCACCGCCACC 
TGAAGGTGGCGGTGGTGCTGTTGGTGCTGC
CGCCGTCCCGGGTCAGGATCAGGCCGGT 
467 T 
TATCACCGGCCTGATCCTGACCCGGGACGG
CGGCAGCACCAACAGCACCACCGAAGCC 
TGAAGGCTTCGGTGGTGCTGTTGGTGCTGCC
GCCGTCCCGGGTCAGGATCAGGCCGGT 
468 F 
AACCGCCAGACCCGGCGGAGGCGACATGA
GAGACAACTGGCGGAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTCCGCCAGTTGTC
TCTCATGTCGCCTCCGCCGGGTCTGGC 
469 R 
AACCTTCGCCCCCGGCGGAGGCGACATGAG
AGACAACTGGCGGAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTCCGCCAGTTGTC
TCTCATGTCGCCTCCGCCGGGGGCGAA 
470 P 
AACCTTCAGAGCCGGCGGAGGCGACATGAG
AGACAACTGGCGGAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTCCGCCAGTTGTC
TCTCATGTCGCCTCCGCCGGCTCTGAA 
471 G 
AACCTTCAGACCCGCCGGAGGCGACATGAG
AGACAACTGGCGGAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTCCGCCAGTTGTC
TCTCATGTCGCCTCCGGCGGGTCTGAA 
472 G 
AACCTTCAGACCCGGCGCCGGCGACATGAG
AGACAACTGGCGGAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTCCGCCAGTTGTC
TCTCATGTCGCCGGCGCCGGGTCTGAA 
473 G 
AACCTTCAGACCCGGCGGAGCCGACATGAG
AGACAACTGGCGGAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTCCGCCAGTTGTC
TCTCATGTCGGCTCCGCCGGGTCTGAA 
474 D 
AACCTTCAGACCCGGCGGAGGCGCCATGAG
AGACAACTGGCGGAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTCCGCCAGTTGTC
TCTCATGGCGCCTCCGCCGGGTCTGAA 
475 M 
AACCTTCAGACCCGGCGGAGGCGACGCCAG
AGACAACTGGCGGAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTCCGCCAGTTGTC
TCTGGCGTCGCCTCCGCCGGGTCTGAA 
476 R 
AACCTTCAGACCCGGCGGAGGCGACATGGC
CGACAACTGGCGGAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTCCGCCAGTTGTC
GGCCATGTCGCCTCCGCCGGGTCTGAA 
477 D 
AACCTTCAGACCCGGCGGAGGCGACATGAG
AGCCAACTGGCGGAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTCCGCCAGTTGGC
TCTCATGTCGCCTCCGCCGGGTCTGAA 
478 N 
AACCTTCAGACCCGGCGGAGGCGACATGAG
AGACGCCTGGCGGAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTCCGCCAGGCGTC
TCTCATGTCGCCTCCGCCGGGTCTGAA 
479 W 
AACCTTCAGACCCGGCGGAGGCGACATGAG
AGACAACGCCCGGAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTCCGGGCGTTGTC
TCTCATGTCGCCTCCGCCGGGTCTGAA 
480 R 
AACCTTCAGACCCGGCGGAGGCGACATGAG
AGACAACTGGGCCAGCGAGCTGTACAAG 
TGTACTTGTACAGCTCGCTGGCCCAGTTGTC
TCTCATGTCGCCTCCGCCGGGTCTGAA 
481 S 
AACCTTCAGACCCGGCGGAGGCGACATGAG
AGACAACTGGCGGGCCGAGCTGTACAAG 
TGTACTTGTACAGCTCGGCCCGCCAGTTGTC
TCTCATGTCGCCTCCGCCGGGTCTGAA 
482 E 
AACCTTCAGACCCGGCGGAGGCGACATGAG
AGACAACTGGCGGAGCGCCCTGTACAAG 
TGTACTTGTACAGGGCGCTCCGCCAGTTGTC
TCTCATGTCGCCTCCGCCGGGTCTGAA 
483 L 
AACCTTCAGACCCGGCGGAGGCGACATGAG
AGACAACTGGCGGAGCGAGGCCTACAAG 
TGTACTTGTAGGCCTCGCTCCGCCAGTTGTC
TCTCATGTCGCCTCCGCCGGGTCTGAA 
484 Y 
AACCTTCAGACCCGGCGGAGGCGACATGAG
AGACAACTGGCGGAGCGAGCTGGCCAAG 
TGTACTTGGCCAGCTCGCTCCGCCAGTTGTC
TCTCATGTCGCCTCCGCCGGGTCTGAA 
485 K 
AACCTTCAGACCCGGCGGAGGCGACATGAG
AGACAACTGGCGGAGCGAGCTGTACGCC 
TGTAGGCGTACAGCTCGCTCCGCCAGTTGTC
TCTCATGTCGCCTCCGCCGGGTCTGAA 
486 Y 
CAAGGCCAAAGTGGTGAAAATCGAGCCCCT
GGGCGTGGCCCCCACCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGTGGGGGCCACGCC
CAGGGGCTCGATTTTCACCACTTTGGC 
487 K 
CAAGTACGCCGTGGTGAAAATCGAGCCCCT
GGGCGTGGCCCCCACCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGTGGGGGCCACGCC
CAGGGGCTCGATTTTCACCACGGCGTA 
488 V 
CAAGTACAAAGCCGTGAAAATCGAGCCCCT
GGGCGTGGCCCCCACCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGTGGGGGCCACGCC
CAGGGGCTCGATTTTCACGGCTTTGTA 
489 V 
CAAGTACAAAGTGGCCAAAATCGAGCCCCT
GGGCGTGGCCCCCACCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGTGGGGGCCACGCC
CAGGGGCTCGATTTTGGCCACTTTGTA 
490 K 
CAAGTACAAAGTGGTGGCCATCGAGCCCCT
GGGCGTGGCCCCCACCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGTGGGGGCCACGCC
CAGGGGCTCGATGGCCACCACTTTGTA 
491 I 
CAAGTACAAAGTGGTGAAAGCCGAGCCCCT
GGGCGTGGCCCCCACCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGTGGGGGCCACGCC
CAGGGGCTCGGCTTTCACCACTTTGTA 
492 E 
CAAGTACAAAGTGGTGAAAATCGCCCCCCT
GGGCGTGGCCCCCACCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGTGGGGGCCACGCC
CAGGGGGGCGATTTTCACCACTTTGTA 
493 P 
CAAGTACAAAGTGGTGAAAATCGAGGCCCT
GGGCGTGGCCCCCACCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGTGGGGGCCACGCC
CAGGGCCTCGATTTTCACCACTTTGTA 
494 L 
CAAGTACAAAGTGGTGAAAATCGAGCCCGC
CGGCGTGGCCCCCACCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGTGGGGGCCACGCC
GGCGGGCTCGATTTTCACCACTTTGTA 
495 G 
CAAGTACAAAGTGGTGAAAATCGAGCCCCT
GGCCGTGGCCCCCACCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGTGGGGGCCACGG
CCAGGGGCTCGATTTTCACCACTTTGTA 
496 V 
CAAGTACAAAGTGGTGAAAATCGAGCCCCT
GGGCGCCGCCCCCACCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGTGGGGGCGGCGC
CCAGGGGCTCGATTTTCACCACTTTGTA 
498 P 
CAAGTACAAAGTGGTGAAAATCGAGCCCCT
GGGCGTGGCCGCCACCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGTGGCGGCCACGCC
CAGGGGCTCGATTTTCACCACTTTGTA 
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499 T 
CAAGTACAAAGTGGTGAAAATCGAGCCCCT
GGGCGTGGCCCCCGCCCGGTGCAAGAGA 
CTCTTCTCTTGCACCGGGCGGGGGCCACGC
CCAGGGGCTCGATTTTCACCACTTTGTA 
500 R 
CAAGTACAAAGTGGTGAAAATCGAGCCCCT
GGGCGTGGCCCCCACCGCCTGCAAGAGA 
CTCTTCTCTTGCAGGCGGTGGGGGCCACGC
CCAGGGGCTCGATTTTCACCACTTTGTA 
502 K 
CAAGTACAAAGTGGTGAAAATCGAGCCCCT
GGGCGTGGCCCCCACCCGGTGCGCCAGA 
CTCTTCTGGCGCACCGGGTGGGGGCCACGC
CCAGGGGCTCGATTTTCACCACTTTGTA 
503 R 
CAAGTACAAAGTGGTGAAAATCGAGCCCCT
GGGCGTGGCCCCCACCCGGTGCAAGGCC 
CTCTGGCCTTGCACCGGGTGGGGGCCACGC
CCAGGGGCTCGATTTTCACCACTTTGTA 
504 R 
GAGAGCCGTCGTGGGACGGCGGAGAAGGC
GGAGAGCCGTGGGCATCGGAGCCGTGTTT 
CCAGAAACACGGCTCCGATGCCCACGGCTC
TCCGCCTTCTCCGCCGTCCCACGACGGC 
505 V 
GAGAAGAGCCGTGGGACGGCGGAGAAGGC
GGAGAGCCGTGGGCATCGGAGCCGTGTTT 
CCAGAAACACGGCTCCGATGCCCACGGCTC
TCCGCCTTCTCCGCCGTCCCACGGCTCT 
506 V 
GAGAAGAGTCGCCGGACGGCGGAGAAGGC
GGAGAGCCGTGGGCATCGGAGCCGTGTTT 
CCAGAAACACGGCTCCGATGCCCACGGCTC
TCCGCCTTCTCCGCCGTCCGGCGACTCT 
507 G 
GAGAAGAGTCGTGGCCCGGCGGAGAAGGC
GGAGAGCCGTGGGCATCGGAGCCGTGTTT 
CCAGAAACACGGCTCCGATGCCCACGGCTC
TCCGCCTTCTCCGCCGGGCCACGACTCT 
513 V 
GAGAAGAGTCGTGGGACGGCGGAGAAGGC
GGAGAGCCGCCGGCATCGGAGCCGTGTTT 
CCAGAAACACGGCTCCGATGCCGGCGGCTC
TCCGCCTTCTCCGCCGTCCCACGACTCT 
514 G 
GAGAAGAGTCGTGGGACGGCGGAGAAGGC
GGAGAGCCGTGGCCATCGGAGCCGTGTTT 
CCAGAAACACGGCTCCGATGGCCACGGCTC
TCCGCCTTCTCCGCCGTCCCACGACTCT 
515 I 
GAGAAGAGTCGTGGGACGGCGGAGAAGGC
GGAGAGCCGTGGGCGCCGGAGCCGTGTTT 
CCAGAAACACGGCTCCGGCGCCCACGGCTC
TCCGCCTTCTCCGCCGTCCCACGACTCT 
516 G 
GAGAAGAGTCGTGGGACGGCGGAGAAGGC
GGAGAGCCGTGGGCATCGCCGCCGTGTTT 
CCAGAAACACGGCGGCGATGCCCACGGCTC
TCCGCCTTCTCCGCCGTCCCACGACTCT 
518 V 
GAGAAGAGTCGTGGGACGGCGGAGAAGGC
GGAGAGCCGTGGGCATCGGAGCCGCCTTT 
CCAGAAAGGCGGCTCCGATGCCCACGGCTC
TCCGCCTTCTCCGCCGTCCCACGACTCT 
519 F 
GAGAAGAGTCGTGGGACGGCGGAGAAGGC
GGAGAGCCGTGGGCATCGGAGCCGTGGCC 
CCAGGGCCACGGCTCCGATGCCCACGGCTC
TCCGCCTTCTCCGCCGTCCCACGACTCT 
520 L 
GTTTGCCGGCTTTCTGGGAGCCGCCGGAAG
CACCATGGGCGCTGCCAGCATGACACTG 
CGGTCAGTGTCATGCTGGCAGCGCCCATGG
TGCTTCCGGCGGCTCCCAGAAAGCCGGC 
521 G 
GTTTCTGGCCTTTCTGGGAGCCGCCGGAAG
CACCATGGGCGCTGCCAGCATGACACTG 
CGGTCAGTGTCATGCTGGCAGCGCCCATGG
TGCTTCCGGCGGCTCCCAGAAAGGCCAG 
522 F 
GTTTCTGGGCGCCCTGGGAGCCGCCGGAAG
CACCATGGGCGCTGCCAGCATGACACTG 
CGGTCAGTGTCATGCTGGCAGCGCCCATGG
TGCTTCCGGCGGCTCCCAGGGCGCCCAG 
523 L 
GTTTCTGGGCTTTGCCGGAGCCGCCGGAAG
CACCATGGGCGCTGCCAGCATGACACTG 
CGGTCAGTGTCATGCTGGCAGCGCCCATGG
TGCTTCCGGCGGCTCCGGCAAAGCCCAG 
524 G 
GTTTCTGGGCTTTCTGGCCGCCGCCGGAAGC
ACCATGGGCGCTGCCAGCATGACACTG 
CGGTCAGTGTCATGCTGGCAGCGCCCATGG
TGCTTCCGGCGGCGGCCAGAAAGCCCAG 
527 G 
GTTTCTGGGCTTTCTGGGAGCCGCCGCCAGC
ACCATGGGCGCTGCCAGCATGACACTG 
CGGTCAGTGTCATGCTGGCAGCGCCCATGG
TGCTGGCGGCGGCTCCCAGAAAGCCCAG 
528 S 
GTTTCTGGGCTTTCTGGGAGCCGCCGGAGC
CACCATGGGCGCTGCCAGCATGACACTG 
CGGTCAGTGTCATGCTGGCAGCGCCCATGG
TGGCTCCGGCGGCTCCCAGAAAGCCCAG 
529 T 
GTTTCTGGGCTTTCTGGGAGCCGCCGGAAG
CGCCATGGGCGCTGCCAGCATGACACTG 
CGGTCAGTGTCATGCTGGCAGCGCCCATGG
CGCTTCCGGCGGCTCCCAGAAAGCCCAG 
530 M 
GTTTCTGGGCTTTCTGGGAGCCGCCGGAAG
CACCGCCGGCGCTGCCAGCATGACACTG 
CGGTCAGTGTCATGCTGGCAGCGCCGGCGG
TGCTTCCGGCGGCTCCCAGAAAGCCCAG 
531 G 
GTTTCTGGGCTTTCTGGGAGCCGCCGGAAG
CACCATGGCCGCTGCCAGCATGACACTG 
CGGTCAGTGTCATGCTGGCAGCGGCCATGG
TGCTTCCGGCGGCTCCCAGAAAGCCCAG 
534 S 
GTTTCTGGGCTTTCTGGGAGCCGCCGGAAG
CACCATGGGCGCTGCCGCCATGACACTG 
CGGTCAGTGTCATGGCGGCAGCGCCCATGG
TGCTTCCGGCGGCTCCCAGAAAGCCCAG 
535 M 
GTTTCTGGGCTTTCTGGGAGCCGCCGGAAG
CACCATGGGCGCTGCCAGCGCCACACTG 
CGGTCAGTGTGGCGCTGGCAGCGCCCATGG
TGCTTCCGGCGGCTCCCAGAAAGCCCAG 
536 T 
GTTTCTGGGCTTTCTGGGAGCCGCCGGAAG
CACCATGGGCGCTGCCAGCATGGCCCTG 
CGGTCAGGGCCATGCTGGCAGCGCCCATGG
TGCTTCCGGCGGCTCCCAGAAAGCCCAG 
537 L 
GTTTCTGGGCTTTCTGGGAGCCGCCGGAAG
CACCATGGGCGCTGCCAGCATGACAGCC 
CGGTGGCTGTCATGCTGGCAGCGCCCATGG
TGCTTCCGGCGGCTCCCAGAAAGCCCAG 
538 T 
ACTGGCCGTGCAGGCCCGGAACCTGCTGAG
CGGCATCGTGCAGCAGCAGAGCAATCTG 
TGAGCAGATTGCTCTGCTGCTGCACGATGC
CGCTCAGCAGGTTCCGGGCCTGCACGGC 
539 V 
ACTGACCGCCCAGGCCCGGAACCTGCTGAG
CGGCATCGTGCAGCAGCAGAGCAATCTG 
TGAGCAGATTGCTCTGCTGCTGCACGATGC
CGCTCAGCAGGTTCCGGGCCTGGGCGGT 
540 Q 
ACTGACCGTGGCCGCCCGGAACCTGCTGAG
CGGCATCGTGCAGCAGCAGAGCAATCTG 
TGAGCAGATTGCTCTGCTGCTGCACGATGC
CGCTCAGCAGGTTCCGGGCGGCCACGGT 
542 R 
ACTGACCGTGCAGGCCGCCAACCTGCTGAG
CGGCATCGTGCAGCAGCAGAGCAATCTG 
TGAGCAGATTGCTCTGCTGCTGCACGATGC
CGCTCAGCAGGTTGGCGGCCTGCACGGT 
543 N 
ACTGACCGTGCAGGCCCGGGCCCTGCTGAG
CGGCATCGTGCAGCAGCAGAGCAATCTG 
TGAGCAGATTGCTCTGCTGCTGCACGATGC
CGCTCAGCAGGGCCCGGGCCTGCACGGT 
544 L 
ACTGACCGTGCAGGCCCGGAACGCCCTGAG
CGGCATCGTGCAGCAGCAGAGCAATCTG 
TGAGCAGATTGCTCTGCTGCTGCACGATGC
CGCTCAGGGCGTTCCGGGCCTGCACGGT 
545 L 
ACTGACCGTGCAGGCCCGGAACCTGGCCAG
CGGCATCGTGCAGCAGCAGAGCAATCTG 
TGAGCAGATTGCTCTGCTGCTGCACGATGC
CGCTGGCCAGGTTCCGGGCCTGCACGGT 
546 S 
ACTGACCGTGCAGGCCCGGAACCTGCTGGC
CGGCATCGTGCAGCAGCAGAGCAATCTG 
TGAGCAGATTGCTCTGCTGCTGCACGATGC
CGGCCAGCAGGTTCCGGGCCTGCACGGT 
547 G 
ACTGACCGTGCAGGCCCGGAACCTGCTGAG
CGCCATCGTGCAGCAGCAGAGCAATCTG 
TGAGCAGATTGCTCTGCTGCTGCACGATGG
CGCTCAGCAGGTTCCGGGCCTGCACGGT 
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548 I 
ACTGACCGTGCAGGCCCGGAACCTGCTGAG
CGGCGCCGTGCAGCAGCAGAGCAATCTG 
TGAGCAGATTGCTCTGCTGCTGCACGGCGC
CGCTCAGCAGGTTCCGGGCCTGCACGGT 
549 V 
ACTGACCGTGCAGGCCCGGAACCTGCTGAG
CGGCATCGCCCAGCAGCAGAGCAATCTG 
TGAGCAGATTGCTCTGCTGCTGGGCGATGC
CGCTCAGCAGGTTCCGGGCCTGCACGGT 
550 Q 
ACTGACCGTGCAGGCCCGGAACCTGCTGAG
CGGCATCGTGGCCCAGCAGAGCAATCTG 
TGAGCAGATTGCTCTGCTGGGCCACGATGC
CGCTCAGCAGGTTCCGGGCCTGCACGGT 
551 Q 
ACTGACCGTGCAGGCCCGGAACCTGCTGAG
CGGCATCGTGCAGGCCCAGAGCAATCTG 
TGAGCAGATTGCTCTGGGCCTGCACGATGC
CGCTCAGCAGGTTCCGGGCCTGCACGGT 
552 Q 
ACTGACCGTGCAGGCCCGGAACCTGCTGAG
CGGCATCGTGCAGCAGGCCAGCAATCTG 
TGAGCAGATTGCTGGCCTGCTGCACGATGC
CGCTCAGCAGGTTCCGGGCCTGCACGGT 
553 S 
ACTGACCGTGCAGGCCCGGAACCTGCTGAG
CGGCATCGTGCAGCAGCAGGCCAATCTG 
TGAGCAGATTGGCCTGCTGCTGCACGATGC
CGCTCAGCAGGTTCCGGGCCTGCACGGT 
554 N 
ACTGACCGTGCAGGCCCGGAACCTGCTGAG
CGGCATCGTGCAGCAGCAGAGCGCCCTG 
TGAGCAGGGCGCTCTGCTGCTGCACGATGC
CGCTCAGCAGGTTCCGGGCCTGCACGGT 
555 L 
ACTGACCGTGCAGGCCCGGAACCTGCTGAG
CGGCATCGTGCAGCAGCAGAGCAATGCC 
TGAGGGCATTGCTCTGCTGCTGCACGATGC
CGCTCAGCAGGTTCCGGGCCTGCACGGT 
556 L 
TCTGGCCAGAGCCCCTGAGGCCCAGCAGCA
TCTGCTGAAACTGACCGTGTGGGGCATC 
GCTTGATGCCCCACACGGTCAGTTTCAGCA
GATGCTGCTGGGCCTCAGGGGCTCTGGC 
557 R 
TCTGCTCGCCGCCCCTGAGGCCCAGCAGCA
TCTGCTGAAACTGACCGTGTGGGGCATC 
GCTTGATGCCCCACACGGTCAGTTTCAGCA
GATGCTGCTGGGCCTCAGGGGCGGCGAG 
560 E 
TCTGCTCAGAGCCCCTGCCGCCCAGCAGCA
TCTGCTGAAACTGACCGTGTGGGGCATC 
GCTTGATGCCCCACACGGTCAGTTTCAGCA
GATGCTGCTGGGCGGCAGGGGCTCTGAG 
562 Q 
TCTGCTCAGAGCCCCTGAGGCCGCCCAGCA
TCTGCTGAAACTGACCGTGTGGGGCATC 
GCTTGATGCCCCACACGGTCAGTTTCAGCA
GATGCTGGGCGGCCTCAGGGGCTCTGAG 
563 Q 
TCTGCTCAGAGCCCCTGAGGCCCAGGCCCA
TCTGCTGAAACTGACCGTGTGGGGCATC 
GCTTGATGCCCCACACGGTCAGTTTCAGCA
GATGGGCCTGGGCCTCAGGGGCTCTGAG 
564 H 
TCTGCTCAGAGCCCCTGAGGCCCAGCAGGC
CCTGCTGAAACTGACCGTGTGGGGCATC 
GCTTGATGCCCCACACGGTCAGTTTCAGCA
GGGCCTGCTGGGCCTCAGGGGCTCTGAG 
565 L 
TCTGCTCAGAGCCCCTGAGGCCCAGCAGCA
TGCCCTGAAACTGACCGTGTGGGGCATC 
GCTTGATGCCCCACACGGTCAGTTTCAGGG
CATGCTGCTGGGCCTCAGGGGCTCTGAG 
566 L 
TCTGCTCAGAGCCCCTGAGGCCCAGCAGCA
TCTGGCCAAACTGACCGTGTGGGGCATC 
GCTTGATGCCCCACACGGTCAGTTTGGCCA
GATGCTGCTGGGCCTCAGGGGCTCTGAG 
567 K 
TCTGCTCAGAGCCCCTGAGGCCCAGCAGCA
TCTGCTGGCCCTGACCGTGTGGGGCATC 
GCTTGATGCCCCACACGGTCAGGGCCAGCA
GATGCTGCTGGGCCTCAGGGGCTCTGAG 
568 L 
TCTGCTCAGAGCCCCTGAGGCCCAGCAGCA
TCTGCTGAAAGCCACCGTGTGGGGCATC 
GCTTGATGCCCCACACGGTGGCTTTCAGCA
GATGCTGCTGGGCCTCAGGGGCTCTGAG 
569 T 
TCTGCTCAGAGCCCCTGAGGCCCAGCAGCA
TCTGCTGAAACTGGCCGTGTGGGGCATC 
GCTTGATGCCCCACACGGCCAGTTTCAGCA
GATGCTGCTGGGCCTCAGGGGCTCTGAG 
570 V 
TCTGCTCAGAGCCCCTGAGGCCCAGCAGCA
TCTGCTGAAACTGACCGCCTGGGGCATC 
GCTTGATGCCCCAGGCGGTCAGTTTCAGCA
GATGCTGCTGGGCCTCAGGGGCTCTGAG 
571 W 
TCTGCTCAGAGCCCCTGAGGCCCAGCAGCA
TCTGCTGAAACTGACCGTGGCCGGCATC 
GCTTGATGCCGGCCACGGTCAGTTTCAGCA
GATGCTGCTGGGCCTCAGGGGCTCTGAG 
572 G 
TCTGCTCAGAGCCCCTGAGGCCCAGCAGCA
TCTGCTGAAACTGACCGTGTGGGCCATC 
GCTTGATGGCCCACACGGTCAGTTTCAGCA
GATGCTGCTGGGCCTCAGGGGCTCTGAG 
573 I 
TCTGCTCAGAGCCCCTGAGGCCCAGCAGCA
TCTGCTGAAACTGACCGTGTGGGGCGCC 
GCTTGGCGCCCCACACGGTCAGTTTCAGCA
GATGCTGCTGGGCCTCAGGGGCTCTGAG 
574 K 
CATCGCCCAGCTGCAGGCCAGAGTGCTGGC
CGTGGAAAGATACCTGCGGGATCAGCAG 
GGAGCTGCTGATCCCGCAGGTATCTTTCCAC
GGCCAGCACTCTGGCCTGCAGCTGGGC 
575 Q 
CATCAAGGCCCTGCAGGCCAGAGTGCTGGC
CGTGGAAAGATACCTGCGGGATCAGCAG 
GGAGCTGCTGATCCCGCAGGTATCTTTCCAC
GGCCAGCACTCTGGCCTGCAGGGCCTT 
576 L 
CATCAAGCAGGCCCAGGCCAGAGTGCTGGC
CGTGGAAAGATACCTGCGGGATCAGCAG 
GGAGCTGCTGATCCCGCAGGTATCTTTCCAC
GGCCAGCACTCTGGCCTGGGCCTGCTT 
577 Q 
CATCAAGCAGCTGGCCGCCAGAGTGCTGGC
CGTGGAAAGATACCTGCGGGATCAGCAG 
GGAGCTGCTGATCCCGCAGGTATCTTTCCAC
GGCCAGCACTCTGGCGGCCAGCTGCTT 
579 R 
CATCAAGCAGCTGCAGGCCGCCGTGCTGGC
CGTGGAAAGATACCTGCGGGATCAGCAG 
GGAGCTGCTGATCCCGCAGGTATCTTTCCAC
GGCCAGCACGGCGGCCTGCAGCTGCTT 
580 V 
CATCAAGCAGCTGCAGGCCAGAGCCCTGGC
CGTGGAAAGATACCTGCGGGATCAGCAG 
GGAGCTGCTGATCCCGCAGGTATCTTTCCAC
GGCCAGGGCTCTGGCCTGCAGCTGCTT 
581 L 
CATCAAGCAGCTGCAGGCCAGAGTGGCCGC
CGTGGAAAGATACCTGCGGGATCAGCAG 
GGAGCTGCTGATCCCGCAGGTATCTTTCCAC
GGCGGCCACTCTGGCCTGCAGCTGCTT 
583 V 
CATCAAGCAGCTGCAGGCCAGAGTGCTGGC
CGCCGAAAGATACCTGCGGGATCAGCAG 
GGAGCTGCTGATCCCGCAGGTATCTTTCGG
CGGCCAGCACTCTGGCCTGCAGCTGCTT 
584 E 
CATCAAGCAGCTGCAGGCCAGAGTGCTGGC
CGTGGCCAGATACCTGCGGGATCAGCAG 
GGAGCTGCTGATCCCGCAGGTATCTGGCCA
CGGCCAGCACTCTGGCCTGCAGCTGCTT 
585 R 
CATCAAGCAGCTGCAGGCCAGAGTGCTGGC
CGTGGAAGCCTACCTGCGGGATCAGCAG 
GGAGCTGCTGATCCCGCAGGTAGGCTTCCA
CGGCCAGCACTCTGGCCTGCAGCTGCTT 
586 Y 
CATCAAGCAGCTGCAGGCCAGAGTGCTGGC
CGTGGAAAGAGCCCTGCGGGATCAGCAG 
GGAGCTGCTGATCCCGCAGGGCTCTTTCCA
CGGCCAGCACTCTGGCCTGCAGCTGCTT 
587 L 
CATCAAGCAGCTGCAGGCCAGAGTGCTGGC
CGTGGAAAGATACGCCCGGGATCAGCAG 
GGAGCTGCTGATCCCGGGCGTATCTTTCCAC
GGCCAGCACTCTGGCCTGCAGCTGCTT 
588 R 
CATCAAGCAGCTGCAGGCCAGAGTGCTGGC
CGTGGAAAGATACCTGGCCGATCAGCAG 
GGAGCTGCTGATCGGCCAGGTATCTTTCCA
CGGCCAGCACTCTGGCCTGCAGCTGCTT 
589 D 
CATCAAGCAGCTGCAGGCCAGAGTGCTGGC
CGTGGAAAGATACCTGCGGGCCCAGCAG 
GGAGCTGCTGGGCCCGCAGGTATCTTTCCA
CGGCCAGCACTCTGGCCTGCAGCTGCTT 
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590 Q 
CATCAAGCAGCTGCAGGCCAGAGTGCTGGC
CGTGGAAAGATACCTGCGGGATGCCCAG 
GGAGCTGGGCATCCCGCAGGTATCTTTCCA
CGGCCAGCACTCTGGCCTGCAGCTGCTT 
591 Q 
CATCAAGCAGCTGCAGGCCAGAGTGCTGGC
CGTGGAAAGATACCTGCGGGATCAGGCC 
GGAGGGCCTGATCCCGCAGGTATCTTTCCA
CGGCCAGCACTCTGGCCTGCAGCTGCTT 
592 L 
GCAGGCCCTGGGCATCTGGGGATGCAGCGG
CAAGCTGATCTGCTGCACCAATGTGCCC 
TCCAGGGCACATTGGTGCAGCAGATCAGCT
TGCCGCTGCATCCCCAGATGCCCAGGGC 
593 L 
GCAGCTCGCCGGCATCTGGGGATGCAGCGG
CAAGCTGATCTGCTGCACCAATGTGCCC 
TCCAGGGCACATTGGTGCAGCAGATCAGCT
TGCCGCTGCATCCCCAGATGCCGGCGAG 
594 G 
GCAGCTCCTGGCCATCTGGGGATGCAGCGG
CAAGCTGATCTGCTGCACCAATGTGCCC 
TCCAGGGCACATTGGTGCAGCAGATCAGCT
TGCCGCTGCATCCCCAGATGGCCAGGAG 
595 I 
GCAGCTCCTGGGCGCCTGGGGATGCAGCGG
CAAGCTGATCTGCTGCACCAATGTGCCC 
TCCAGGGCACATTGGTGCAGCAGATCAGCT
TGCCGCTGCATCCCCAGGCGCCCAGGAG 
596 W 
GCAGCTCCTGGGCATCGCCGGATGCAGCGG
CAAGCTGATCTGCTGCACCAATGTGCCC 
TCCAGGGCACATTGGTGCAGCAGATCAGCT
TGCCGCTGCATCCGGCGATGCCCAGGAG 
597 G 
GCAGCTCCTGGGCATCTGGGCCTGCAGCGG
CAAGCTGATCTGCTGCACCAATGTGCCC 
TCCAGGGCACATTGGTGCAGCAGATCAGCT
TGCCGCTGCAGGCCCAGATGCCCAGGAG 
599 S 
GCAGCTCCTGGGCATCTGGGGATGCGCCGG
CAAGCTGATCTGCTGCACCAATGTGCCC 
TCCAGGGCACATTGGTGCAGCAGATCAGCT
TGCCGGCGCATCCCCAGATGCCCAGGAG 
600 G 
GCAGCTCCTGGGCATCTGGGGATGCAGCGC
CAAGCTGATCTGCTGCACCAATGTGCCC 
TCCAGGGCACATTGGTGCAGCAGATCAGCT
TGGCGCTGCATCCCCAGATGCCCAGGAG 
601 K 
GCAGCTCCTGGGCATCTGGGGATGCAGCGG
CGCCCTGATCTGCTGCACCAATGTGCCC 
TCCAGGGCACATTGGTGCAGCAGATCAGGG
CGCCGCTGCATCCCCAGATGCCCAGGAG 
602 L 
GCAGCTCCTGGGCATCTGGGGATGCAGCGG
CAAGGCCATCTGCTGCACCAATGTGCCC 
TCCAGGGCACATTGGTGCAGCAGATGGCCT
TGCCGCTGCATCCCCAGATGCCCAGGAG 
603 I 
GCAGCTCCTGGGCATCTGGGGATGCAGCGG
CAAGCTGGCCTGCTGCACCAATGTGCCC 
TCCAGGGCACATTGGTGCAGCAGGCCAGCT
TGCCGCTGCATCCCCAGATGCCCAGGAG 
606 T 
GCAGCTCCTGGGCATCTGGGGATGCAGCGG
CAAGCTGATCTGCTGCGCCAATGTGCCC 
TCCAGGGCACATTGGCGCAGCAGATCAGCT
TGCCGCTGCATCCCCAGATGCCCAGGAG 
607 N 
GCAGCTCCTGGGCATCTGGGGATGCAGCGG
CAAGCTGATCTGCTGCACCGCCGTGCCC 
TCCAGGGCACGGCGGTGCAGCAGATCAGCT
TGCCGCTGCATCCCCAGATGCCCAGGAG 
608 V 
GCAGCTCCTGGGCATCTGGGGATGCAGCGG
CAAGCTGATCTGCTGCACCAATGCCCCC 
TCCAGGGGGCATTGGTGCAGCAGATCAGCT
TGCCGCTGCATCCCCAGATGCCCAGGAG 
609 P 
GCAGCTCCTGGGCATCTGGGGATGCAGCGG
CAAGCTGATCTGCTGCACCAATGTGGCC 
TCCAGGCCACATTGGTGCAGCAGATCAGCT
TGCCGCTGCATCCCCAGATGCCCAGGAG 
610 W 
GCCCGCCAACAGCAGCTGGTCCAACCGGAA
CCTGAGCGAGATCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGATCTCGCTCAG
GTTCCGGTTGGACCAGCTGCTGTTGGC 
611 N 
GCCCTGGGCCAGCAGCTGGTCCAACCGGAA
CCTGAGCGAGATCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGATCTCGCTCAG
GTTCCGGTTGGACCAGCTGCTGGCCCA 
612 S 
GCCCTGGAACGCCAGCTGGTCCAACCGGAA
CCTGAGCGAGATCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGATCTCGCTCAG
GTTCCGGTTGGACCAGCTGGCGTTCCA 
613 S 
GCCCTGGAACAGCGCCTGGTCCAACCGGAA
CCTGAGCGAGATCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGATCTCGCTCAG
GTTCCGGTTGGACCAGGCGCTGTTCCA 
614 W 
GCCCTGGAACAGCAGCGCCTCCAACCGGAA
CCTGAGCGAGATCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGATCTCGCTCAG
GTTCCGGTTGGAGGCGCTGCTGTTCCA 
615 S 
GCCCTGGAACAGCAGCTGGGCCAACCGGAA
CCTGAGCGAGATCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGATCTCGCTCAG
GTTCCGGTTGGCCCAGCTGCTGTTCCA 
616 N 
GCCCTGGAACAGCAGCTGGTCCGCCCGGAA
CCTGAGCGAGATCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGATCTCGCTCAG
GTTCCGGGCGGACCAGCTGCTGTTCCA 
617 R 
GCCCTGGAACAGCAGCTGGTCCAACGCCAA
CCTGAGCGAGATCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGATCTCGCTCAG
GTTGGCGTTGGACCAGCTGCTGTTCCA 
618 N 
GCCCTGGAACAGCAGCTGGTCCAACCGGGC
CCTGAGCGAGATCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGATCTCGCTCAG
GGCCCGGTTGGACCAGCTGCTGTTCCA 
619 L 
GCCCTGGAACAGCAGCTGGTCCAACCGGAA
CGCCAGCGAGATCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGATCTCGCTGGC
GTTCCGGTTGGACCAGCTGCTGTTCCA 
620 S 
GCCCTGGAACAGCAGCTGGTCCAACCGGAA
CCTGGCCGAGATCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGATCTCGGCCA
GGTTCCGGTTGGACCAGCTGCTGTTCCA 
621 E 
GCCCTGGAACAGCAGCTGGTCCAACCGGAA
CCTGAGCGCCATCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGATGGCGCTCA
GGTTCCGGTTGGACCAGCTGCTGTTCCA 
622 I 
GCCCTGGAACAGCAGCTGGTCCAACCGGAA
CCTGAGCGAGGCCTGGGACAACATGACC 
GCCAGGTCATGTTGTCCCAGGCCTCGCTCA
GGTTCCGGTTGGACCAGCTGCTGTTCCA 
623 W 
GCCCTGGAACAGCAGCTGGTCCAACCGGAA
CCTGAGCGAGATCGCCGACAACATGACC 
GCCAGGTCATGTTGTCGGCGATCTCGCTCA
GGTTCCGGTTGGACCAGCTGCTGTTCCA 
624 D 
GCCCTGGAACAGCAGCTGGTCCAACCGGAA
CCTGAGCGAGATCTGGGCCAACATGACC 
GCCAGGTCATGTTGGCCCAGATCTCGCTCA
GGTTCCGGTTGGACCAGCTGCTGTTCCA 
625 N 
GCCCTGGAACAGCAGCTGGTCCAACCGGAA
CCTGAGCGAGATCTGGGACGCCATGACC 
GCCAGGTCATGGCGTCCCAGATCTCGCTCA
GGTTCCGGTTGGACCAGCTGCTGTTCCA 
626 M 
GCCCTGGAACAGCAGCTGGTCCAACCGGAA
CCTGAGCGAGATCTGGGACAACGCCACC 
GCCAGGTGGCGTTGTCCCAGATCTCGCTCA
GGTTCCGGTTGGACCAGCTGCTGTTCCA 
627 T 
GCCCTGGAACAGCAGCTGGTCCAACCGGAA
CCTGAGCGAGATCTGGGACAACATGGCC 
GCCAGGCCATGTTGTCCCAGATCTCGCTCA
GGTTCCGGTTGGACCAGCTGCTGTTCCA 
628 W 
GACCGCCCTGCAGTGGGACAAAGAGATCAG
CAACTACACCCAGATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATCTGGGTGTAGT
TGCTGATCTCTTTGTCCCACTGCAGGGC 
629 L 
GACCTGGGCCCAGTGGGACAAAGAGATCAG
CAACTACACCCAGATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATCTGGGTGTAGT
TGCTGATCTCTTTGTCCCACTGGGCCCA 
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630 Q 
GACCTGGCTGGCCTGGGACAAAGAGATCAG
CAACTACACCCAGATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATCTGGGTGTAGT
TGCTGATCTCTTTGTCCCAGGCCAGCCA 
631 W 
GACCTGGCTGCAGGCCGACAAAGAGATCAG
CAACTACACCCAGATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATCTGGGTGTAGT
TGCTGATCTCTTTGTCGGCCTGCAGCCA 
632 D 
GACCTGGCTGCAGTGGGCCAAAGAGATCAG
CAACTACACCCAGATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATCTGGGTGTAGT
TGCTGATCTCTTTGGCCCACTGCAGCCA 
633 K 
GACCTGGCTGCAGTGGGACGCCGAGATCAG
CAACTACACCCAGATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATCTGGGTGTAGT
TGCTGATCTCGGCGTCCCACTGCAGCCA 
634 E 
GACCTGGCTGCAGTGGGACAAAGCCATCAG
CAACTACACCCAGATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATCTGGGTGTAGT
TGCTGATGGCTTTGTCCCACTGCAGCCA 
635 I 
GACCTGGCTGCAGTGGGACAAAGAGGCCAG
CAACTACACCCAGATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATCTGGGTGTAGT
TGCTGGCCTCTTTGTCCCACTGCAGCCA 
636 S 
GACCTGGCTGCAGTGGGACAAAGAGATCGC
CAACTACACCCAGATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATCTGGGTGTAGT
TGGCGATCTCTTTGTCCCACTGCAGCCA 
637 N 
GACCTGGCTGCAGTGGGACAAAGAGATCAG
CGCCTACACCCAGATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATCTGGGTGTAGG
CGCTGATCTCTTTGTCCCACTGCAGCCA 
638 Y 
GACCTGGCTGCAGTGGGACAAAGAGATCAG
CAACGCCACCCAGATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATCTGGGTGGCGT
TGCTGATCTCTTTGTCCCACTGCAGCCA 
639 T 
GACCTGGCTGCAGTGGGACAAAGAGATCAG
CAACTACGCCCAGATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATCTGGGCGTAGT
TGCTGATCTCTTTGTCCCACTGCAGCCA 
640 Q 
GACCTGGCTGCAGTGGGACAAAGAGATCAG
CAACTACACCGCCATCATCTACGGCCTG 
CGAGCAGGCCGTAGATGATGGCGGTGTAGT
TGCTGATCTCTTTGTCCCACTGCAGCCA 
641 I 
GACCTGGCTGCAGTGGGACAAAGAGATCAG
CAACTACACCCAGGCCATCTACGGCCTG 
CGAGCAGGCCGTAGATGGCCTGGGTGTAGT
TGCTGATCTCTTTGTCCCACTGCAGCCA 
642 I 
GACCTGGCTGCAGTGGGACAAAGAGATCAG
CAACTACACCCAGATCGCCTACGGCCTG 
CGAGCAGGCCGTAGGCGATCTGGGTGTAGT
TGCTGATCTCTTTGTCCCACTGCAGCCA 
643 Y 
GACCTGGCTGCAGTGGGACAAAGAGATCAG
CAACTACACCCAGATCATCGCCGGCCTG 
CGAGCAGGCCGGCGATGATCTGGGTGTAGT
TGCTGATCTCTTTGTCCCACTGCAGCCA 
644 G 
GACCTGGCTGCAGTGGGACAAAGAGATCAG
CAACTACACCCAGATCATCTACGCCCTG 
CGAGCAGGGCGTAGATGATCTGGGTGTAGT
TGCTGATCTCTTTGTCCCACTGCAGCCA 
645 L 
GACCTGGCTGCAGTGGGACAAAGAGATCAG
CAACTACACCCAGATCATCTACGGCGCC 
CGAGGGCGCCGTAGATGATCTGGGTGTAGT
TGCTGATCTCTTTGTCCCACTGCAGCCA 
646 L 
CCTGGCCGAGGAGAGCCAGAACCAGCAGG
AAAAGAACGAGCAGGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCCTGCTCGTTCTT
TTCCTGCTGGTTCTGGCTCTCCTCGGC 
647 E 
CCTGCTCGCCGAGAGCCAGAACCAGCAGGA
AAAGAACGAGCAGGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCCTGCTCGTTCTT
TTCCTGCTGGTTCTGGCTCTCGGCGAG 
648 E 
CCTGCTCGAGGCCAGCCAGAACCAGCAGGA
AAAGAACGAGCAGGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCCTGCTCGTTCTT
TTCCTGCTGGTTCTGGCTGGCCTCGAG 
649 S 
CCTGCTCGAGGAGGCCCAGAACCAGCAGGA
AAAGAACGAGCAGGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCCTGCTCGTTCTT
TTCCTGCTGGTTCTGGGCCTCCTCGAG 
650 Q 
CCTGCTCGAGGAGAGCGCCAACCAGCAGGA
AAAGAACGAGCAGGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCCTGCTCGTTCTT
TTCCTGCTGGTTGGCGCTCTCCTCGAG 
651 N 
CCTGCTCGAGGAGAGCCAGGCCCAGCAGGA
AAAGAACGAGCAGGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCCTGCTCGTTCTT
TTCCTGCTGGGCCTGGCTCTCCTCGAG 
652 Q 
CCTGCTCGAGGAGAGCCAGAACGCCCAGGA
AAAGAACGAGCAGGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCCTGCTCGTTCTT
TTCCTGGGCGTTCTGGCTCTCCTCGAG 
653 Q 
CCTGCTCGAGGAGAGCCAGAACCAGGCCGA
AAAGAACGAGCAGGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCCTGCTCGTTCTT
TTCGGCCTGGTTCTGGCTCTCCTCGAG 
654 E 
CCTGCTCGAGGAGAGCCAGAACCAGCAGGC
CAAGAACGAGCAGGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCCTGCTCGTTCTT
GGCCTGCTGGTTCTGGCTCTCCTCGAG 
655 K 
CCTGCTCGAGGAGAGCCAGAACCAGCAGGA
AGCCAACGAGCAGGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCCTGCTCGTTGG
CTTCCTGCTGGTTCTGGCTCTCCTCGAG 
656 N 
CCTGCTCGAGGAGAGCCAGAACCAGCAGGA
AAAGGCCGAGCAGGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCCTGCTCGGCCT
TTTCCTGCTGGTTCTGGCTCTCCTCGAG 
657 E 
CCTGCTCGAGGAGAGCCAGAACCAGCAGGA
AAAGAACGCCCAGGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCCTGGGCGTTCT
TTTCCTGCTGGTTCTGGCTCTCCTCGAG 
658 Q 
CCTGCTCGAGGAGAGCCAGAACCAGCAGGA
AAAGAACGAGGCCGACCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGTCGGCCTCGTTCTT
TTCCTGCTGGTTCTGGCTCTCCTCGAG 
659 D 
CCTGCTCGAGGAGAGCCAGAACCAGCAGGA
AAAGAACGAGCAGGCCCTGCTGGCCCTG 
TGTCCAGGGCCAGCAGGGCCTGCTCGTTCTT
TTCCTGCTGGTTCTGGCTCTCCTCGAG 
660 L 
CCTGCTCGAGGAGAGCCAGAACCAGCAGGA
AAAGAACGAGCAGGACGCCCTGGCCCTG 
TGTCCAGGGCCAGGGCGTCCTGCTCGTTCTT
TTCCTGCTGGTTCTGGCTCTCCTCGAG 
661 L 
CCTGCTCGAGGAGAGCCAGAACCAGCAGGA
AAAGAACGAGCAGGACCTGGCCGCCCTG 
TGTCCAGGGCGGCCAGGTCCTGCTCGTTCTT
TTCCTGCTGGTTCTGGCTCTCCTCGAG 
663 L 
CCTGCTCGAGGAGAGCCAGAACCAGCAGGA
AAAGAACGAGCAGGACCTGCTGGCCGCC 
TGTCGGCGGCCAGCAGGTCCTGCTCGTTCTT
TTCCTGCTGGTTCTGGCTCTCCTCGAG 
664 D 
CCTGGCCAAGTGGGCCAGCCTGTGGAATTG
GTTCGACATCAGCAACTGGCTGTGGTAC 
TGATGTACCACAGCCAGTTGCTGATGTCGA
ACCAATTCCACAGGCTGGCCCACTTGGC 
665 K 
CCTGGACGCCTGGGCCAGCCTGTGGAATTG
GTTCGACATCAGCAACTGGCTGTGGTAC 
TGATGTACCACAGCCAGTTGCTGATGTCGA
ACCAATTCCACAGGCTGGCCCAGGCGTC 
666 W 
CCTGGACAAGGCCGCCAGCCTGTGGAATTG
GTTCGACATCAGCAACTGGCTGTGGTAC 
TGATGTACCACAGCCAGTTGCTGATGTCGA
ACCAATTCCACAGGCTGGCGGCCTTGTC 
668 S 
CCTGGACAAGTGGGCCGCCCTGTGGAATTG
GTTCGACATCAGCAACTGGCTGTGGTAC 
TGATGTACCACAGCCAGTTGCTGATGTCGA
ACCAATTCCACAGGGCGGCCCACTTGTC 
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669 L 
CCTGGACAAGTGGGCCAGCGCCTGGAATTG
GTTCGACATCAGCAACTGGCTGTGGTAC 
TGATGTACCACAGCCAGTTGCTGATGTCGA
ACCAATTCCAGGCGCTGGCCCACTTGTC 
670 W 
CCTGGACAAGTGGGCCAGCCTGGCCAATTG
GTTCGACATCAGCAACTGGCTGTGGTAC 
TGATGTACCACAGCCAGTTGCTGATGTCGA
ACCAATTGGCCAGGCTGGCCCACTTGTC 
671 N 
CCTGGACAAGTGGGCCAGCCTGTGGGCCTG
GTTCGACATCAGCAACTGGCTGTGGTAC 
TGATGTACCACAGCCAGTTGCTGATGTCGA
ACCAGGCCCACAGGCTGGCCCACTTGTC 
672 W 
CCTGGACAAGTGGGCCAGCCTGTGGAATGC
CTTCGACATCAGCAACTGGCTGTGGTAC 
TGATGTACCACAGCCAGTTGCTGATGTCGA
AGGCATTCCACAGGCTGGCCCACTTGTC 
673 F 
CCTGGACAAGTGGGCCAGCCTGTGGAATTG
GGCCGACATCAGCAACTGGCTGTGGTAC 
TGATGTACCACAGCCAGTTGCTGATGTCGG
CCCAATTCCACAGGCTGGCCCACTTGTC 
674 D 
CCTGGACAAGTGGGCCAGCCTGTGGAATTG
GTTCGCCATCAGCAACTGGCTGTGGTAC 
TGATGTACCACAGCCAGTTGCTGATGGCGA
ACCAATTCCACAGGCTGGCCCACTTGTC 
675 I 
CCTGGACAAGTGGGCCAGCCTGTGGAATTG
GTTCGACGCCAGCAACTGGCTGTGGTAC 
TGATGTACCACAGCCAGTTGCTGGCGTCGA
ACCAATTCCACAGGCTGGCCCACTTGTC 
676 S 
CCTGGACAAGTGGGCCAGCCTGTGGAATTG
GTTCGACATCGCCAACTGGCTGTGGTAC 
TGATGTACCACAGCCAGTTGGCGATGTCGA
ACCAATTCCACAGGCTGGCCCACTTGTC 
677 N 
CCTGGACAAGTGGGCCAGCCTGTGGAATTG
GTTCGACATCAGCGCCTGGCTGTGGTAC 
TGATGTACCACAGCCAGGCGCTGATGTCGA
ACCAATTCCACAGGCTGGCCCACTTGTC 
678 W 
CCTGGACAAGTGGGCCAGCCTGTGGAATTG
GTTCGACATCAGCAACGCCCTGTGGTAC 
TGATGTACCACAGGGCGTTGCTGATGTCGA
ACCAATTCCACAGGCTGGCCCACTTGTC 
679 L 
CCTGGACAAGTGGGCCAGCCTGTGGAATTG
GTTCGACATCAGCAACTGGGCCTGGTAC 
TGATGTACCAGGCCCAGTTGCTGATGTCGA
ACCAATTCCACAGGCTGGCCCACTTGTC 
680 W 
CCTGGACAAGTGGGCCAGCCTGTGGAATTG
GTTCGACATCAGCAACTGGCTGGCCTAC 
TGATGTAGGCCAGCCAGTTGCTGATGTCGA
ACCAATTCCACAGGCTGGCCCACTTGTC 
681 Y 
CCTGGACAAGTGGGCCAGCCTGTGGAATTG
GTTCGACATCAGCAACTGGCTGTGGGCC 
TGATGGCCCACAGCCAGTTGCTGATGTCGA
ACCAATTCCACAGGCTGGCCCACTTGTC 
682 I 
GTACGCCAAGATCTTCATCATGATCGTGGG
CGGCCTGATCGGCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGCCGATCAGGC
CGCCCACGATCATGATGAAGATCTTGGC 
683 K 
GTACATCGCCATCTTCATCATGATCGTGGGC
GGCCTGATCGGCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGCCGATCAGGC
CGCCCACGATCATGATGAAGATGGCGAT 
684 I 
GTACATCAAGGCCTTCATCATGATCGTGGG
CGGCCTGATCGGCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGCCGATCAGGC
CGCCCACGATCATGATGAAGGCCTTGAT 
685 F 
GTACATCAAGATCGCCATCATGATCGTGGG
CGGCCTGATCGGCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGCCGATCAGGC
CGCCCACGATCATGATGGCGATCTTGAT 
686 I 
GTACATCAAGATCTTCGCCATGATCGTGGG
CGGCCTGATCGGCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGCCGATCAGGC
CGCCCACGATCATGGCGAAGATCTTGAT 
687 M 
GTACATCAAGATCTTCATCGCCATCGTGGG
CGGCCTGATCGGCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGCCGATCAGGC
CGCCCACGATGGCGATGAAGATCTTGAT 
688 I 
GTACATCAAGATCTTCATCATGGCCGTGGG
CGGCCTGATCGGCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGCCGATCAGGC
CGCCCACGGCCATGATGAAGATCTTGAT 
689 V 
GTACATCAAGATCTTCATCATGATCGCCGG
CGGCCTGATCGGCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGCCGATCAGGC
CGCCGGCGATCATGATGAAGATCTTGAT 
690 G 
GTACATCAAGATCTTCATCATGATCGTGGCC
GGCCTGATCGGCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGCCGATCAGGC
CGGCCACGATCATGATGAAGATCTTGAT 
691 G 
GTACATCAAGATCTTCATCATGATCGTGGG
CGCCCTGATCGGCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGCCGATCAGGG
CGCCCACGATCATGATGAAGATCTTGAT 
692 L 
GTACATCAAGATCTTCATCATGATCGTGGG
CGGCGCCATCGGCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGCCGATGGCGC
CGCCCACGATCATGATGAAGATCTTGAT 
693 I 
GTACATCAAGATCTTCATCATGATCGTGGG
CGGCCTGGCCGGCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGCCGGCCAGGC
CGCCCACGATCATGATGAAGATCTTGAT 
694 G 
GTACATCAAGATCTTCATCATGATCGTGGG
CGGCCTGATCGCCCTGCGGATCGTGTTT 
CGGCAAACACGATCCGCAGGGCGATCAGGC
CGCCCACGATCATGATGAAGATCTTGAT 
695 L 
GTACATCAAGATCTTCATCATGATCGTGGG
CGGCCTGATCGGCGCCCGGATCGTGTTT 
CGGCAAACACGATCCGGGCGCCGATCAGGC
CGCCCACGATCATGATGAAGATCTTGAT 
696 R 
GTACATCAAGATCTTCATCATGATCGTGGG
CGGCCTGATCGGCCTGGCCATCGTGTTT 
CGGCAAACACGATGGCCAGGCCGATCAGGC
CGCCCACGATCATGATGAAGATCTTGAT 
697 I 
GTACATCAAGATCTTCATCATGATCGTGGG
CGGCCTGATCGGCCTGCGGGCCGTGTTT 
CGGCAAACACGGCCCGCAGGCCGATCAGGC
CGCCCACGATCATGATGAAGATCTTGAT 
698 V 
GTACATCAAGATCTTCATCATGATCGTGGG
CGGCCTGATCGGCCTGCGGATCGCCTTT 
CGGCAAAGGCGATCCGCAGGCCGATCAGGC
CGCCCACGATCATGATGAAGATCTTGAT 
699 F 
GTACATCAAGATCTTCATCATGATCGTGGG
CGGCCTGATCGGCCTGCGGATCGTGGCC 
CGGCGGCCACGATCCGCAGGCCGATCAGGC
CGCCCACGATCATGATGAAGATCTTGAT 
701 V 
GTTTGCCGCCCTGAGCGTGATCCACAGAGT
GCGGCAGGGCTAC 
CTCAGTAGCCCTGCCGCACTCTGTGGATCAC
GCTCAGGGCGGC 
702 L 
GTTTGCCGTGGCCAGCGTGATCCACAGAGT
GCGGCAGGGCTAC 
CTCAGTAGCCCTGCCGCACTCTGTGGATCAC
GCTGGCCACGGC 
703 S 
GTTTGCCGTGCTGGCCGTGATCCACAGAGT
GCGGCAGGGCTAC 
CTCAGTAGCCCTGCCGCACTCTGTGGATCAC
GGCCAGCACGGC 
704 V 
GTTTGCCGTGCTGAGCGCCATCCACAGAGT
GCGGCAGGGCTAC 
CTCAGTAGCCCTGCCGCACTCTGTGGATGG
CGCTCAGCACGGC 
705 I 
GTTTGCCGTGCTGAGCGTGGCCCACAGAGT
GCGGCAGGGCTAC 
CTCAGTAGCCCTGCCGCACTCTGTGGGCCA
CGCTCAGCACGGC 
706 H 
GTTTGCCGTGCTGAGCGTGATCGCCAGAGT
GCGGCAGGGCTAC 
CTCAGTAGCCCTGCCGCACTCTGGCGATCA
CGCTCAGCACGGC 
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707 R 
GTTTGCCGTGCTGAGCGTGATCCACGCCGT
GCGGCAGGGCTAC 
CTCAGTAGCCCTGCCGCACGGCGTGGATCA
CGCTCAGCACGGC 
708 V 
GTTTGCCGTGCTGAGCGTGATCCACAGAGC
CCGGCAGGGCTAC 
CTCAGTAGCCCTGCCGGGCTCTGTGGATCA
CGCTCAGCACGGC 
709 R 
GTTTGCCGTGCTGAGCGTGATCCACAGAGT
GGCCCAGGGCTAC 
CTCAGTAGCCCTGGGCCACTCTGTGGATCA
CGCTCAGCACGGC 
710 Q 
GTTTGCCGTGCTGAGCGTGATCCACAGAGT
GCGGGCCGGCTAC 
CTCAGTAGCCGGCCCGCACTCTGTGGATCA
CGCTCAGCACGGC 
711 G 
GTTTGCCGTGCTGAGCGTGATCCACAGAGT
GCGGCAGGCCTAC 
CTCAGTAGGCCTGCCGCACTCTGTGGATCA
CGCTCAGCACGGC 
712 Y 
GTTTGCCGTGCTGAGCGTGATCCACAGAGT
GCGGCAGGGCGCC 
CTCAGGCGCCCTGCCGCACTCTGTGGATCA
CGCTCAGCACGGC 
 
 
 
Appendix Table 7. Oligonucleotides for NGS library preparation (PCR1). 
Name Forward primer 5´→3´ Name Reverse primer 5´→3´ 
IL-fw1-GL 
AGTTCTACAGTCCGACGATCC
TGTGGGTGACAGTGTACTACG 
IL-rev1-GL 
CTTGGCACCCGAGAATTCCAG
ATGATGTCGGTGTGCATC 
IL-fw2-GL 
AGTTCTACAGTCCGACGATCG
TGACCGAAGAGTTCAACATG 
IL-rev2-GL 
CTTGGCACCCGAGAATTCCAG
AACAGGCTGTACACCTTCTG 
IL-fw3-GL 
AGTTCTACAGTCCGACGATCC
TTCAACATGACCACCGAG 
IL-rev3-GL 
CTTGGCACCCGAGAATTCCAT
GTCCTTGCACTTCAGGATG 
IL-fw4-GL 
AGTTCTACAGTCCGACGATCC
AAGGTGTCCTTCGAGCC 
IL-rev4-GL 
CTTGGCACCCGAGAATTCCAA
CTGCACCAGGATGTTCTTG 
IL-fw5-GL 
AGTTCTACAGTCCGACGATCG
CGAGAACATCACCAACAAC 
IL-rev5-GL 
CTTGGCACCCGAGAATTCCAA
GCTGTTTCACCACCTTGC 
IL-fw6-GL 
AGTTCTACAGTCCGACGATCC
ACCTGGAACGAGACACTG 
IL-rev6-GL 
CTTGGCACCCGAGAATTCCAG
TGATGCTGTCGTTGCTG 
IL-fw7-GL 
AGTTCTACAGTCCGACGATCG
ATCAGCAATACCAGCGTG 
IL-rev7-GL 
CTTGGCACCCGAGAATTCCAG
TTGTCTCTCATGTCGCCTC 
IL-fw8-GL 
AGTTCTACAGTCCGACGATCC
AGCACCAACAGCACCAC 
IL-rev8-GL 
CTTGGCACCCGAGAATTCCAT
GCACGGTCAGTGTCATG 
IL-fw9-GL 
AGTTCTACAGTCCGACGATCA
TCGGAGCCGTGTTTCTG 
IL-rev9-GL 
CTTGGCACCCGAGAATTCCAG
CTGATCCCGCAGGTATC 
IL-fw10-GL 
AGTTCTACAGTCCGACGATCG
AGCAATCTGCTCAGAGCC 
IL-rev10-GL 
CTTGGCACCCGAGAATTCCAG
CAGCCAGGTCATGTTGTC 
IL-fw11-GL 
AGTTCTACAGTCCGACGATCG
ATCTGCTGCACCAATGTG 
IL-rev11-GL 
CTTGGCACCCGAGAATTCCAT
GATGTCGAACCAATTCCAC 
IL-fw12-GL 
AGTTCTACAGTCCGACGATCA
TCTACGGCCTGCTCGAG 
IL-rev12-GL 
CTTGGCACCCGAGAATTCCAA
TATCCTTGGCGTACGCTATG 
 
Appendix Table 8. Oligonucleotides for NGS library preparation (PCR2). 
Name Sequence 5´→3´ 
ILLUMINAseq_fwd 
AATGATACGGCGACCACCGAGATCTACACGTTCAGAGTTCTACAG
TCCGACGATC 
ILLUMINAseq_rev_Index2 
CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTTCCT
TGGCACCCGAGAATTCCA 
ILLUMINAseq_rev_Index9 
CAAGCAGAAGACGGCATACGAGATCTGATCGTGACTGGAGTTCCT
TGGCACCCGAGAATTCCA 
ILLUMINAseq_rev_Index10 
CAAGCAGAAGACGGCATACGAGATAAGCTAGTGACTGGAGTTCC
TTGGCACCCGAGAATTCCA 
ILLUMINAseq_rev_Index11 
CAAGCAGAAGACGGCATACGAGATGTAGCCGTGACTGGAGTTCCT
TGGCACCCGAGAATTCCA 
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Abbreviations 
AA Amino acid GC Germinal center  
Ad5 Adenovirus type 5  gDNA Genomic DNA 
ADCC Antibody-dependent cellular 
cytotoxicity  
GFP Green fluorescent protein 
ADCVI Antibody-dependent cell-mediated 
virus inhibition  
GNL Galanthus nivalis lectin  
AIDS Acquired immunodeficiency syndrome gp Glycoprotein 
BLI Biolayer interferometry GS Glycine-serine  
BN-PAGE Blue native polyacrylamide gel 
electrophoresis 
HCDR3 Heavy chain complementarity-
determining region 3  
bNAb Broadly neutralizing antibody HEK Human Embryonic Kidney 
BSA Bovine serum albumin  HIV-1 Human immunodeficiency virus-1  
C1-C5 Constant regions 1-5  HR1/HR2 Heptad repeat 1 and 2  
CcdB Control of cell death toxin B HRP Horseradish peroxidase  
CCR5 C-C chemokine receptor type 5  HVTN HIV Vaccine Trials Network  
CD4 Cluster of differentiation 4   IFN Interferon 
CD4bs CD4 binding site IgG Immunoglobuline G 
CD4i CD4-induced IL Interleukin 
CD40L CD40 ligand  ITC Isothermal titration calorimetry  
CDR Complementarity determining region  KD Equilibrium dissociation constant 
CMV F+ Flp-In™ T-REx™ 293 CMV_Furin+  LB Lysogeny broth 
CRF Circulating recombinant form  mAb Monoclonal antibody  
CTL Cytotoxic T-lymphocyte  MCS Multiple cloning site  
CT Cytoplasmic tail  MFI Mean fluorescence intensity 
CV Column volume  MPER Membrane-proximal external region 
CXCR4 C-X-C chemokine receptor type 4 MST MicroScale Thermophoresis  
DLS Dynamic light scattering  MW Molecular weight  
DMEM Dulbecco`s Modified Eagle`s Medium  NAb Neutralizing antibody 
DPBS Dulbecco`s phosphate-buffered saline nef Negative regulatory factor 
DSL Disulfide loop  NFL Native-flexible linker  
E. coli Escherichia coli NGS Next generation sequencing  
ELISA Enzyme-linked immunosorbent assay NIH National Institutes of Health  
Env Envelope glycoprotein  OD Outer domain  
eOD Engineered outer domain  OD 450 
nm 
Optical density at 450 nm 
ER Endoplasmatic reticulum  PBS Phosphate buffered saline  
FACS Fluorescence-activated cell sorting  PCR Polymerase chain reaction  
FBS Fetal bovine serum  PEI Polyethyleneimine 
FDA Food and Drug Administration  Pen/Strep Penicillin/Streptomycin  
FDR False discovery rate  PLA 
particle 
Poly(lactic acid) particle  
FNorm Normalized fluorescence  PDGFR Platelet-derived growth factor receptor 
FP Fusion peptide  Pol Polymerase 
FRT Flp recombination target  QL QuickLigation 
FWR Framework region R6 RRRRRR 
Gag Group-specific antigen  RCI Regensburg Center for Interventional 
Immunology  
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RT Room temperature    
sCD4 Soluble CD4 receptor    
SDS-
PAGE 
Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis 
  
SEC Size exclusion chromatography   
SEM Standard error of the mean    
SHIV Simian-human immunodeficiency 
virus  
  
SHM Somatic hypermutation    
SIV Simian immunodeficiency viruses   
SOSIP SOS: Disulfide-bond forming 
cysteines, connecting gp120 and gp41; 
IP: I559P substitution in gp41 
  
SP Signal peptide   
SPR Surface plasmon resonance 
spectroscopy  
  
TBS Tris-buffered saline   
Tfh T-follicular helper    
Th T-helper    
TM Transmembrane domain    
TMB 3,3′,5,5′-tetramethylbenzidine    
TNF Tumor necrosis factor   
UNAIDS Joint United Nations Programme on 
HIV/AIDS  
  
URF Unique recombinant form    
V1-V5 Variable loops 1-5   
v/v  Volume per volume   
VLP Virus-like particle   
WHO World Health Organisation    
WT Wildtype   
w/v Weight per volume   
293-F cells  FreeStyle™ 293-F suspension cells    
6HB Six-helix bundle    
ΔFNorm Baseline corrected normalized 
fluorescence 
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